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SECTION I 
GENERAL INTRODUCTION 
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CHAPTER 1 
DIURETIC AGENTS AND PHARMACOKINETICS 
SULFONAMIDE DIURETICS 
In principle, diuretics might be called all agents which promote the excre-
tion of salt and water in the urine. Mercurous chloride was applied as a 
diuretic already by Paracelsus and its use remained quite popular until 
nearly 1900 (Heidenreich, 1969). This compound, however, and the 
organomercurial diuretics which originate from it have now become ob-
solete. Also the xanthine derivatives, e.g. aminophyllin, which were in-
troduced about 100 years ago (Füllgraff, 1969) have largely been abandon-
ed and serve only as adjunctive agents in certain resistant cases of oedema. 
This study will be confined to the diuretics of the sulfonamide-type. 
Together with a few compounds of different chemical nature, e.g. 
ethacrynic acid, triamterene, amiloride or spironolactone, these drugs con-
stitute the mainstay of diuretic therapy nowadays. They have the advan-
tage of low toxicity and oral effectiveness over the organomercurials, and 
can exert a greater natriuretic effect than the xanthine diuretics. The 
history of the sulfonamide diuretics begins with a side-effect of an-
tibacterial therapy. After the observation that sulfanilamide was capable of 
producing a metabolic acidosis together with alkalinization of the urine 
and an increase of sodium bicarbonate excretion (Southworth, 1937), it 
was shown that renal carbonic anhydrase was inhibited, suggesting that 
this enzyme was involved in the tubular reabsorption of bicarbonate (Mann 
and Keilin, 1940). The inhibition of carbonic anhydrase derived from red 
blood cells was used subsequently as an in vitro test system to develop more 
effective diuretic agents. This led to the synthesis of acetazolamide (Roblin 
and Clapp, 1950), upon which many pharmacological studies have been 
centered (Maren, 1967). 
The efforts of Beyer and Baer (1961), however, concentrated on the 
search for drugs which promoted the excretion of chloride rather than that 
of bicarbonate, because they realized that there was no consistent correla-
tion between in vitro carbonic anhydrase inhibition and in vivo natriuretic 
potency. Molecular modification of sulfonamide compounds resulted 
eventually in the introduction of chlorothiazide, hydrochlorothiazide and 
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many other benzothiadiazines with an unsubstituted sulfonamide group 
(Fig. 1.1 .)· The structure-activity relationships within this group have been 
reviewed by Peters and Roch-Ramel (1969a). 
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Figure I.l 
Structural formulae of sulfonamide diuretics. Among the "thiazides", chlorothiazide has -H 
at R2 and R3, and -CI at Rg. Flumethiazide has -H at R2 and R3, and -CF3 at Rg. Among the 
"hydrothiazides", hydrochlorothiazide has -H at R2 and R3, and -CI at R^. 
Hydroflumethiazide has -H at R2 and R3, and -CF3 at Rg. Bendroflumethiazide has -H at R2, 
-CH2-C6H5 at R3, -CF3, and CF3 at Rg. Cyclopenthiazide has -H at R2, -CH2-(cyclo)C5Hg 
at R3, and -CI at Rg. Polythiazide has -CH3 at R2. -CH2-S-CH3-CF3 at R3, and -CI at Rg. 
Trichlormethiazide has -H at R2, -CHCI2 at R3 and -CI at Rfr Thiabutazide has -H at R2, 
-(iso)C4H9 at R3. and -CI at R5. 
The individual thiazides differ largely in natriuretic potency (i.e. the dose 
needed to produce a similar effect), but their log dose-response curves are 
parallel (Fig. 1.2) and the maximum diuretic effect that can be achieved is 
within the experimental error the same (Peters and Roch-Ramel 1969a; 
Meng and Loew, 1974). The same holds true for the so-called heterocyclic 
variants of the benzothiadiazines. These variants include phtalimidines 
(chlorthalidone (Fig. 1.1); clorexolone), quinazolinones (quinethazone; 
metolazone), benzenedisulfonamides (mefruside, Fig. 1.1) and chloroben-
zamides (clopamide) (Davies and Wilson, 1975; Wilson and Kirkendall, 
1970; Suki et al., 1965). 
In contrast with the above group of compounds, furosemide and 
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bumetanide (Fig. 1.1) can induce much larger losses of sodium chloride. 
Expressed as a fraction of the total sodium load filtered through the 
glomeruli, as much as 15-25% can be excreted in the urine, compared with 
a 5-8% loss of sodium chloride after maximum doses of the thiazides and 
their heterocyclic variants (Davies and Wilson, 1975; Goldberg 1973). To 
understand the differences in the pattern and extent of action between the 
primary carbonic anhydrase inhibitors, like acetazolamide, the moderately 
potent thiazides, including chlorthalidone and mefruside, and the very po­
tent drugs furosemide and bumetanide, a brief description of the normal 
physiological events in the kidney should be of value and will be presented 
in the next section. 
1,1 ·,ι ι ι η M «О ЗМ WM я м 
гжгиаЧж кі mg 
Figure 1.2 
Log-dose response curves of diuretic drugs in normal human subjects. Reproduced, with per­
mission, from Meng and Loew (1974). 
RENAL SITES OF ACTION OF SULFONAMIDE DIURETICS 
A standard human subject forms about 170 liters of glomerular filtrate 
each day, of which only 1-2 liters are excreted as urine. The reabsorption of 
filtered solutes and water is clearly the main physiological task of the 
kidney, and this demands the largest part of its available metabolic energy 
(Maude, 1974). During the past three decades, numerous efforts have been 
made to unravel the specific mechanisms of reabsorption within the neph­
ron and the sites where diuretics act. The resulting insights have been sum­
marized in several reviews (Goldberg, 1973; Suki et al., 1973; Davies and 
Wilson, 1975; Jacobson and Kokko, 1976): under normal circumstances, 
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50-60% of salt and water reabsorption occurs isosmotically in the proximal 
tubules, i.e. the fluid at the end of the tubule has the same osmolality as 
plasma (Fig. 1.3). In the descending limb of the loop of Henle, water is lost 
to the hypertonic medullary interstitium and finally the fluid is hypertonic 
at the tip of the loop. At or near the bend of the loop the tubular cells 
begins to reabsorb sodium chloride: this process continues throughout the 
entire length of the thick ascending limb of Henle and removes about 25% 
of the filtered load. Although classical experiments had indicated that ac-
tive sodium transport was the driving force behind this net transport of 
sodium chloride (see Goldberg, 1973; Fig. 1.3), recent studies provided 
evidence rather that active chloride transport is involved in this part of the 
nephron (Jacobson and Kokko, 1976). Irrespective of this controversy on 
the mechanism, dilute urine is generated at the end, because the ascending 
limb of the loop of Henle is practically impermeable to water. In the distal 
convoluted tubule another 5% of the filtered sodium load is reabsorbed in 
exchange for hydrogen and potassium ions, mainly under control of 
aldosterone. The fluid leaving the distal tubule is hypotonic, but can 
become isotonic and even hypertonic in the collecting duct under influence 
of the antidiuretic hormone. This hormone regulates the water-
permeability of the collecting ducts; under conditions of hydropenia, fluid 
is reabsorbed into the hypertonic medulla, so that a concentrated final 
urine results (see Fig. 1.3). Under conditions of a large water intake, this 
segment of the nephron is impermeable to water and a dilute urine is ex-
creted. 
The sites of action of diuretic drugs within the nephron have been local-
ized mainly by means of osmolar clearance studies and micropuncture 
techniques. An excellent review of the reasoning which led to a definite 
assessment of these sites has been given by Goldberg (1973). This informa-
tion is summarized in Table 1.1. Carbonic anhydrase inhibitors diminish 
hydrogen ion secretion and bicarbonate reabsorption in both the proximal 
tubule and in the distal nephron. The thiazides, including chlorthalidone 
and mefruside, are not entirely devoid of carbonic anhydrase inhibition, 
but exert their major natriuretic and chloruretic effects in the cortical por-
tion of the ascending limb of the loop of Henle. The most potent diuretic 
agents - furosemide, bumetanide, the new drug piretanide (Teredesai and 
Puschett, 1979) and also ethacrynic acid and the afore-mentioned 
organomercurials - inhibit sodium chloride reabsorption over the entire 
length of the ascending limb of the loop of Henle. Due to their action in the 
medullary segment the medulla is made less hypertonic than normal, so 
that also the driving force for water reabsorption in the collecting duct is 
drastically reduced. 
Compared to the information on the sites of action of diuretic drugs, still 
little is known about the molecular modes of action of these agents. The 
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Figure 1 3 
Diagram of sites of sodium and water reabsorption in the nephron Solid arrows denote active 
transport, broken arrows passive transport, and the angulated arrow indicates water im­
permeability Site 1 · paired sodium chloride reabsorption in proximal tubule; site 2 proximal 
hydrogen ion secretion and sodium bicarbonate reabsorption, site 3° sodium chloride reab-
sorption (without water) m the medullary portion of ascending limb of Henle's loop, site 4· 
sodium chloride reabsorption (without water) in the cortical portion of the ascending limb; 
site 5; distal hydrogen and potassium secretion in exchange for sodium, regulated by 
aldosterone; site 6. aldosterone-independent distal cation secretion and sodium reabsorption. 
The water-permeability of the collecting duct is regulated by the antidiuretic hormone 
Reproduced, with permission, from Goldberg (1973). 
TABLE 1.1 
Sites of action of sulfonamide diuretics3 in the nephron^ 
Diuretic drug 
Acetazolamide 
Chlorothiazide 
Furosemide 
Proximal 
tubule 
+ (2) 
( + )(2) 
( + )(1,2) 
Ascending limb 
of loop of Henle 
medullary 
segment 
+ (3) 
cortical 
segment 
+ (4) 
( + )(3) 
Distal 
tubule 
( + ) c 
( + ) c 
( + ) c 
a A representative compound of each class has been taken; 
^Numbers in parentheses refer to functional sites indicated in Fig 1.3; + , major site of 
action; ( + ) minor site of action; с = possible distal inhibitory effect on hydrogen secretion 
via inhibition of carbonic anhydrase Data obtained from references quoted in the text. 
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early concept of direct inhibition of renal carbonic anhydrase as the 
primary working mechanism has almost completely been set aside for other 
sulfonamide diuretics than acetazolamide and congeners because of: 1) the 
poor correlation of in vitro carbonic anhydrase inhibitory activity with in 
vivo natriuretic potency within the thiazide group, 2) the mainly chloruretic 
properties of the thiazides in contrast with the elevated bicarbonate excre­
tion observed after administration of acetazolamide (Meng and Loew, 
1974; Peters and Roch-Ramel, 1969a). Several other mechanisms have 
been proposed. Interferences with Na + , К + -ATPase, with glycolysis, ox­
idative metabolism, plasma membrane adenylate cyclase, and enzymatic 
prostaglandin degradation, have been demonstrated to be involved under 
various in vitro conditions, but no common mechanism has emerged 
(Jacobson and Kokko, 1976; Meng and Loew, 1974; Peters and Roch-
Ramel, 1969a, Benet, 1979). 
RENAL TRANSPORT OF SULFONAMIDE DIURETICS 
Sulfonamide diuretics concentrate in renal tissue to a manyfold of their 
plasma concentration (Peters and Roch-Ramel, 1969a; Pulver et al., 1959; 
Beisenherz et al., 1966; Duhm et al., 1967; Taugner and Iravani, 1965; 
Cohen et al., 1976). In vitro incubations of the drugs with kidney slices 
showed that only the cortical part and not the medullary tissue is responsi­
ble for this uptake (Beyer and Baer, 1975; Peters and Roch-Ramel, 1969a; 
Weiner, 1973). It is generally accepted that the organic anion transport 
system of the kidney, by which well-known substrates as para-
aminohippuric acid, phenol red, penicillin, probenecid and many other 
acidic compounds are secreted, is used also for the elimination of 
acetazolamide, the thiazides and the potent diuretics furosemide and 
bumetanide (Beyer and Baer, 1961, 1975; Despopoulos, 1965; Deetjen, 
1966; Hook and Williamson, 1965; Olsen, 1977; Peters and Roch-Ramel, 
1969a; Weiner, 1973). The site of accumulation and secretion into the 
lumen has been localized exclusively in the proximal part of the nephron, 
especially the pars recta (Beyer and Baer, 1961; Bowman, 1975; Deetjen, 
1966; Taugner and Iravani, 1965; Weiner, 1973). 
Relationship between the effect of diuretic drugs and their own urinary 
excretion. 
In the first years after the introduction of the benzothiadiazines, this site 
of accumulation - the proximal tubular cells - was supposed to be identical 
with the site of natriuretic action of these drugs. This hypothesis seemed to 
be strengthened by a good correlation between the rate and extent of prox-
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¡mal uptake and natriuretic potency in a series of thiazides of varying 
lipophilicity (Beyer and Baer, 1961). However, as discussed in the previous 
section, there is overwhelming evidence now that the major sites of action 
of both the thiazides and the loop diuretics are not localized in the prox-
imal, but in the distal part of the nephron. Furthermore, studies with 
isolated kidney tubules have demonstrated that rather the intratubular con-
centration than that at the peritubular membrane is decisive for the inhibi-
tion of sodium chloride reabsorption by furosemide in the thick ascending 
limb of Henle (Deetjen, 1966; Burg et al. 1973; Bowman, 1975). Also 
bumetanide and ethacrynic acid have been demonstrated to exert their 
diuretic effects from the luminal side of this nephron segment (Burg and 
Green, 1973; Imai, 1977). So, it appears that the proximal tubular secretion 
of these diuretics is merely a prerequisite for the diuretic effect that follows 
in a later part of the nephron. It can be visualized then that the urinary ex-
cretion rate of these drugs, which is a function of tubular secretion, reflects 
the amount of drug in the tubule lumen and thus might be a measure for 
the natriuretic response. This view is supported by the finding that changes 
Urinary excretion rate (log. scale) 
2 
1 
0.1 
Creatinine excretion (mmol/hr) 
/ 1 1 1 1 1 1 1 ' 
0 10 20 30 40 50 60 70 
Time after dose (hours) 
Figure 1 4 
Following administration of a single dose of chlorthalidone to a healthy human subject, the 
excretion rates of urinary sodium and the diuretic itself change in almost identical direction. 
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Dose: 200mg chlorthalidone 
orally,subject Н.Р,2 уг, 69Kg 
chlorthalidone (mg/hr) 
in the urinary excretion rate of furosemide or bumetanide run closely 
parallel with changes in the urinary excretion of sodium. On the contrary, 
very poor correlations have been found between the plasma concentration 
and the diuretic effects of these drugs (Andreasen et al., 1978; Davies et al., 
1974; Feit et al., 1973; Rose et al., 1976; Sörgel et al., 1979). The lack of a 
direct relationship between plasma concentration and natriuresis is in-
dicated further by the way probenecid interacts with the diuretic response 
to furosemide and bumetanide administered as single doses. Probenecid 
competes for tubular secretion, so that the urinary excretion rate of both 
diuretics is reduced and the plasma concentration increases. Under these 
conditions a clear reduction of the diuretic effect has been reported (Hook 
and Williamson, 1965; Homeida et al., 1977; Honari et al., 1977; Lant, 
1975). 
Although direct proof for the dependence of natriuresis upon luminal 
concentration is still lacking for the diuretics of the thiazide class, there is a 
good agreement between the changes in urinary excretion rate of chlor-
thalidone and urinary sodium in man, see Fig. 1.4 (Fleuren and Boomkens, 
1979). Furthermore, a reduction of the diuretic effects of chlorothiazide 
Na+excretion rate (mEq/day) 
500 π 
4 0 0 -
3 0 0 -
200-
100-
200 mg 
100 mg 
50 mg 
- 3 - 2 - 1 0 1 2 4 5 6 
Time (days) 
Figure 1.5 
Typical patterns of salt excretion during 5 days after single doses of chlorthalidone in man. 
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and hydrochlorothiazide in dogs after previous treatment with probenecid 
has been described (Beyer and Baer, 1961, 1975). 
For a proper understanding of the interaction of probenecid with the 
natriuresis caused by the long-acting drug chlorthalidone, some informa­
tion on the time course of action of the latter has to be given. A typical pat­
tern of salt excretion after therapeutic doses of this drug in man is shown in 
Fig. 1.5. Three different single doses were administered on different occa­
sions to the same healthy human subject, who had a controlled dietary in­
take of 10 gram sodium chloride (172 mEq Na) each day (during the trial 
and a preceding control period of 5 days). There was a dose-dependent in­
crease of sodium excretion lasting for up to two days. Hereafter, net excre­
tion became negative: such a "rebound-phase" is generally observed with 
diuretics if the losses of salt are not replaced during the experiment (Meng 
and Loew, 1974; Peters and Roch-Ramel, 1969a). This retention is due to a 
homeostatic maintainance of the sodium balance, which is controlled by 
hormonal factors (Laragh and Sealy, 1973). It can be discerned therefore 
from Fig. 1.5 that the extent of sodium retention in the rebound-phase is 
proportional to the magnitude of the preceding natriuretic effect. 
Fig. 1.6 compares the time course of the plasma concentration and the 
urinary excretion rate of chlorthalidone with the pattern of urinary sodium 
excretion after single 100 mg doses of chlorthalidone to a human subject, 
without and with simultaneous administration of probenecid (Fleuren and 
Boomkens, 1979). There was a strong depression of the renal plasma 
clearance of chlorthalidone during the two days of a high probenecid 
plasma concentration and on the following day*. The average renal 
clearance in this period was only 27.5 ±4.6 ml/min (mean ± S.D., η = 9), 
compared to 52.2± 13.4 ml/min (mean ± S.D., n= 17) in the experiment 
without probenecid. The resulting smaller amount of chlorthalidone ex­
creted into urine was accompanied by a drastic reduction of the urinary 
sodium excretion. Correspondingly, also the rebound-retention of sodium 
on following days was much less marked than that seen without probenecid 
(Fig. 1.6, cf. Fig. 1.5). 
Wether and to what extent such situation applies to all thiazides remains 
to be confirmed. Despite the fact that a considerable number of publica­
tions has appeared recently on the single dose kinetics of hydrochloro­
thiazide, no close correlation between urinary excretion rate and sodium 
losses has apparently been recognized (Beermann and Groschinsky-Grind, 
1977, 1978; Beermann et al., 1976, 1977b). It is obvious, however, that 
such a correlation could easily be overlooked if the urine portions are not 
separately collected and assayed, but pooled instead. 
* Probenecid concentration analysed by high-pressure liquid chromatography according to 
Hekman et al., 1979. 
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Figure 1.6 
Effect of probenecid on the pharmacokinetics and the natriuretic effect of chlorthalidone in a 
healthy human subject. The two experiments were performed 1 month apart, each with 100 
mg of the diuretic. The broken lines in the lower graphs indicate the average salt excretion 
during previous control periods. 
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For many drugs the plasma concentration is considered as an ap-
propriate measure of drug response and several clear-cut relationships be-
tween plasma levels and biological effects have been established (Sjöqvist 
et al., 1976). On the contrary, however, as outlined above, it appears that 
for the sulfonamide diuretics investigated the amount of drug excreted with 
the urine instead of the plasma concentration is well correlated with the 
diuretic effect. This conclusion is not invalidated by the observation by 
Brater (1978), who reported a paradoxical increase in the 8-hours diuretic 
effect of a single dose of chlorothiazide in human subjects after pretreat-
ment with probenecid. The dose administered, 0.5-1 gram intravenously, 
was fairly high so that the supra-maximal amounts of drug which would 
otherwise rapidly be eliminated were longer available now, because pro-
benecid retarded their tubular secretion. Larger doses of sulfonamide 
diuretics apparently deliver sufficient amounts of drug at their site of ac-
tion, so that the natriuresis is not reduced by probenecid, despite a lesser 
drug clearance. This has been confirmed for hydrochlorothiazide (Beyer 
and Baer, 1961, 1975). Also the well-known observation that probenecid 
does not interfere with the long-term treatment of hypertension by 
diuretics (e.g. Freis and Sappington, 1966; Garcia and Yendt, 1970) is in 
agreement with this concept. 
PHARMACOKINETICS: GENERAL REMARKS 
Several barriers must be passed by a drug before it can exert a biological 
effect. Three main phases can be discerned in this process as shown in the 
following scheme (cf. Ariens and Simonis, 1974): 
I Pharmaceutical phase II Pharmacokinetic phase III Pharmacodynamic phase 
dose 
disintegration of 
dosage form 
dissolution of 
active substance 
absorption 
distr ibut ion 
metabolism 
excretion 
drug-receptor 
interaction 
in target tissue • effect 
In the pharmaceutical phase the active principle has to be released from 
its dosage form, e.g. tablet, capsule or potion. The rate and extent of 
liberation are influenced by crystal structure, particle size and coating of 
the drug formulation. 
The pharmacokinetic phase includes the absorption, distribution, 
biotransformation and excretion of drugs. These events proceed generally 
with a small rate compared with the very fast formation of drug-receptor 
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complexes in the later pharmacodynamic phase (van Ginneken, 1977). 
Therefore, the onset and time course of action of a drug will in many cases 
depend on the rate-limiting kinetic characteristics of that substance. 
The use of open compartment models in pharmacokinetic studies is 
widely accepted and many textbooks and other readings on this matter are 
available (Teorell, 1937; Dost, 1953, 1968; Rescigno and Segre, 1966; 
Gibaldi and Perrier, 1975; van Rossum, 1971; van Rossum et al., 1977; 
Wagner, 1971, 1976; van Ginneken, 1976). When exclusively first-order 
processes are considered the plasma concentration of a drug can be written 
as a function of time in an integrated form. For any linear n-compartment 
model the plasma concentration curve can be fitted to a sum of exponential 
terms (Reversely, however, this does obviously not prove that a compart­
ment model is involved. Stochastic processes may lead as well to a sum of 
exponentials). As a matter of fact, the plasma curve depends also on the in­
put function (dose, dosage form). After administration of a single dose, 
the following general equations are valid: 
In case of intravenous injection (pulse input): 
η - t / τ . 
С = Σ д . e
 1 
i=l 1 (Eq. 1.1) 
In case of intravenous infusion during 0-T (step function): 
η - t / T . 
C = Σ Α . . τ . / Τ (1-е 1 ) fort < Τ (Eq. 1.2a) 
and 
i = l 
η - ( t - T ) / T . - t / τ . 
С = Σ Α 1 . τ /Τ (e 1 - e 1 ) for t > Τ 
i = l 
In case of oral administration (first-order input) 
(Eq. 1.2b) 
η - t / τ . - t / τ 
С = Σ A. (e 1 - e a ) (Eq. 1.3) 
i = l 
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In these equations С represents the concentration in plasma, t is the time 
after the start of the infusion or after intake of the oral dose, Τ is the dura­
tion of the infusion, TJ are the time constants corresponding to the various 
decay phases visible in a semi-logarithmic plot of the plasma concentration 
against time (i = 1 η ; the largest time constant is equal to 1.44 times the 
terminal half-life), and т
а
 is the time constant of first-order absorption into 
the central compartment. In case of i.v. administration, the coefficients Aj 
are the hypothetical intercepts with the ordinate for an intravenous bolus 
injection of the same amount of drug. The intercepts after oral administra­
tion (AjPO) and those after i.v. administration (AjP0) are for equal doses 
related as follows: AjP0 = A¡ i v . τ[/(τ[—т
а
). 
The search for the parameters Aj and т\ best fitting to the experimental 
concentration-time data is facilitated by a suitable computer curve-fitting 
program. The weighed least-squares regression analysis program FARM-
FIT, used in our investigations, approaches the model function as a set of 
linear (Aj) and non-linear (TJ) parameters. Non-linear parameter estimates 
are optimized by means of an iterative Gauss-Newton procedure and the 
linear parameters are calculated analytically. A full description of the 
FARMFIT program has been given elsewhere (Breimer, 1974) and a listing 
of the main routine and current subroutines is available (Klok, 1979). Once 
the constants A[ and TJ have been found, they may serve to calculate direct­
ly two important pharmacokinetic parameters: the plasma clearance (k
c e
i) 
and the total volume of distribution at steady-state ( ^ ) (van Rossum, 
1971; Wagner, 1976): 
In case of intravenous administration: 
к C e l η (Eq. 1.4) 
Σ Α . . τ . 
i = l ι ι 
and 
η 
D. Σ Α . . τ ? 
·=ι
 1 1 
V d s s = " T Í " (Eq. 1.5) 
( Σ Α . . τ . Γ 
І - 1 1 1 
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In case of oral administration: 
C e l η 
Σ 
i = l 
— (Eq. 1.6) 
Σ ( 1 - τ / τ . ) . Α . . τ . 
a i 1 1 
and 
η 
F.D Σ (1-τ / τ . ) . Α . . τ ? 
. _ a i 1 1 
V = — ( E q j 7ч 
dss η ν ч > 
( Σ (1-τ / τ . ) . Α . . τ . 
. « a i ι ι 1=1 
2 
where D denotes the dose, and F the fraction of dose coming into the gen­
eral circulation after oral administration. The plasma clearance (k
c e
i), 
which equals the total body clearance if the elimination of the drug occurs 
from the central compartment only, is in fact an abstract parameter. It 
represents that volume of fluid which is entirely cleared of drug per unit 
time. The clearance concept is very useful because it provides a link bet­
ween pharmacokinetics and the underlying physiological processes, e.g. the 
capacity of liver enzymes to metabolize foreign compounds or that of the 
kidney to excrete them (van Rossum et al., 1977). Thus, for instance, the 
total plasma clearance of a hypothetical drug that is not metabolized and 
only excreted by the kidneys will in general not be able to exceed the renal 
plasma flow. 
The volume of distribution (Vjss) is defined as that hypothetical volume 
over which the total amount of drug in the body would be distributed at 
steady-state if we assumed that this volume would contain a concentration 
equal to that measured in plasma. Because in reality very unequal tissue 
over plasma concentration ratios occur, it will be clear that this volume is a 
purely operational parameter: a large V^ss implies low plasma concentra­
tions and extensive localization of the drug outside the plasma. 
The equations 1.1 - 1.7 can also be formulated in terms of rate constants 
instead of their reciprocals - the time constants - (cf. e.g. Chapter 9). 
Although both ways of expression are mathematically entirely equivalent, 
there are certain arguments in favour of the time constants in relation to 
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the concept of the mean residence time of a drug (van Rossum, 1979). The 
mean residence time (r) is defined as: 
ao CD 
τ = J t . C . d t / ƒ C.dt, which is equivalent to 
о о 
η η 
Σ Α . . τ ? / Σ Α . . τ . 
. , 1 1 . , 1 1 
1=1 ι=1 
It follows then from the equations 1.4 and 1.5 that Vdss = T'-kCel-
Until now, however, preference is given in current pharmacokinetic 
literature to the notation with rate constants. We will conform to this con­
vention in the following chapters (see e.g. Chapter 9), so that a rapid com­
parison can be made of the pharmacokinetic parameters from our studies 
with those from the literature. 
No explicit expression for the plasma concentration as a function of time 
can be derived in general if non-linear, i.e. not first-order, processes are in­
volved. Non-linear pharmacokinetics considers capacity-limited clearance 
pathways and/or saturable tissue binding phenomena. Only for a very sim­
ple model an integrated form of the model equation can be obtained (van 
Ginneken et al., 1974), but in other cases use has to be made of differential 
equations to describe the individual steps of drug transport between com­
partments. Solutions can then be found numerically by means of a com­
puter program such as FARMFIT (e.g. van Rossum et al., 1977; Fleuren 
and van Rossum, 1977; Chapter 7). 
The aim of any pharmacokinetic model should be more than an efficient 
reduction of experimental data to a few essential parameters. Insight 
should be obtained in the underlying biological processes. For this purpose, 
human kinetic studies always need additional information derived from, 
for instance, whole-body distribution studies in animals. Attempts to in­
tegrate real physiological entities like organ blood flows and tissue over 
plasma concentration ratios of drugs to a multicompartment drug disposi­
tion model have been described (Bischoff et al., 1971; Dedrick, 1973; Har­
rison and Gibaldi, 1977; Chen and Gross, 1979.) Such system-dynamic ap­
proach seems very promising but requires exact filling-in of all individual 
elements. Until that situation has been accomplished, the compartment 
model concept and related parameters as clearance and volumes of 
distribution can be assumed to remain most adequate for an overall 
characterization of the processes of absorption, distribution and elimina­
tion of drugs. 
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HUMAN PHARMACOKINETICS OF SULFONAMIDE DIURETICS 
Despite the bewildering number of sulfonamide diuretics available since 
1960 pertinent information on the pharmacokinetics of these drugs is bare-
ly at hand. As is outlined in Chapter 2 this may be ascribed to the use of 
unselective methods of analysis in the earliest investigations, while specific 
and sensitive assays were only recently developed. In this context, Benet 
(1979) has addressed himself to the problem of conflicting kinetic data 
reported on furosemide and concluded that part of these discrepancies was 
due to unspecificity of the older analytical methods. 
Volumes of distribution 
Those data from normal humans available today, which were selected 
from the literature under the condition that they were based on methods of 
determination specific for the parent drugs, are presented in Table 1.2*. 
Two subgroups can be discerned. Compared with the thiazides the loop 
diuretics bumetanide and furosemide have relatively small volumes of 
distribution. This can readily be explained from the pKa difference be-
tween these two drugs and the other sulfonamide diuretics (see Chapter 2). 
So, at physiological pH bumetanide and furosemide are largely in anionic 
form which will limit their passage across cell membranes. The finding that 
both drugs accumulate less than the thiazides in proximal tubular cells 
(Peters and Roch-Ramel, 1969b; Duggan, 1966; Cohen et al., 1976) in-
dicates that this physico-chemical characteristic is certainly relevant, not-
withstanding the occurrence of active tubular secretion for all sulfonamide 
diuretics. Moreover, furosemide and bumetanide are not stored in liver 
cells to the extent known from the thiazides (Pulver et al., 1959; Taugner 
and Iravani, 1965; Peters and Roch-Ramel, 1969a; Duhm et al., 1967). It 
has been reported also that bumetanide does not enter into red blood cells 
(Pentikainen et al., 1977) and the same would be expected to occur for 
furosemide. 
Uptake in red blood cells 
Besides the accumulation of the thiazides - including chlorthalidone and 
mefruside - in kidney and liver tissue, these drugs are taken up also by red 
blood cells to a variable extent. This factor obviously makes another con-
tribution to establish a large apparent volume of distribution, if its calcula-
tion is based on plasma concentration measurement. Thus, after ad-
ministration of single doses of these drugs to humans, an erythrocyte over 
plasma concentration ratio of ca. 2.5 has been reported for hydroflume-
* This part of the manuscript was completed 1st May, 1979. 
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TABLE 1.2 
Pharmacokinetic parameters of sulfonamide diuretics in man3 
r-
Generic nameb 
Bumetamde 
(Burinex®) 
Furosemide 
(Lasix®) 
Bendroflumethiazide 
(Pluryl®) 
Chlorthalidone 
(Hygroton®) 
Hydrochlorothiazide 
(Dichlotride® , Esidrex®) 
Hydroflumethiazide 
(Ronlyl®, Hydroflumethiazidum) 
Mefruside 
(Baycaron®) 
Active metabolites of mefruside 
Total volume of 
distribution 
(I) 
ca. 12.5 
12.5-15 
a: 100 
200-350 
ca. 250 
ca. 250 
300-500 
— 
Plasma clearance 
(l /h) 
ca. 12 
ca. 12 
< 20 
5-9 
ca. 12 5 
ca. 12.5 
20-135 
— 
(ml/mm) 
ca. 200 
ca 200 
£ 350 
80- 150 
ca. 200 
ca. 200 
350-2250 
— 
Renal clearance 
(% of total 
plasma clearance) 
•N-60 
•^60 
г 30 
•ν 70 
> 90 
> 90 
< 1 
> 60 
Terminal 
t'/2 
(h) 
1.2-1.8 
0.8-1.2 
a 2 4-3.8 
25-50 
13.6 
12 5-25 
2.9-12 5 
10-14 
Ref 
с 
d 
e 
f 
g 
h 
i 
i 
aTaken or recalculated from the references indicated. Some of these contain only partial information on a particular drug 
^Names of proprietary products marketed in the Netherlands in parentheses 
cDavies et al., 1974; Halladay et al., 1977, Pentikainen et al., 1977 
tlAndreasen and Mikkelsen, 1977; Beermann et al , 1977a, Benet, 1979 
eBeermann et al., 1977c. Note: plasma concentration followed only for 10 hr 
fFleuren et al., 1979a; Chapter 9 
KBeermann et al., 1976. Note- sufficient data for calculation from 1 subject only 
hBrors et al., 1978. 
'Fleuren et al., 1979c; Chapter 14. Note: parameters calculated under assumption of complete oral bioavailability 
thiazide (Brors et al., 1978), a ratio of ca. 3.5 for hydrochlorothiazide 
(Beermann et al., 1976), a ratio of 20-40 for mefruside (Fleuren et al., 
1979c; Chapter 14) and a ratio of 50-100 for chlorthalidone (Collste et al., 
1976; Beermann et al., 1975b; Fleuren and van Rossum, 1975, 1977; 
Fleuren et al., 1979a, 1979b; Chapters 7, 9 and 10; Riess et al., 1977). As all 
sulfonamide diuretics are in vitro inhibitors of red cell carbonic anhydrase, 
though to a weaker extent than acetazolamide (Beyer and Baer, 1961; 
Meng and Loew, 1974), binding to this intracellular protein might be in-
volved. As is discussed in Chapter 8, this has definitely been established in 
case of chlorthalidone, while some evidence for binding of mefruside to red 
blood cell carbonic anhydrase is given in Chapter 14. Interestingly, the red 
cell over plasma concentration ratio of the four above-mentioned com-
pounds increases in exactly the same order as the carbonic anhydrase in-
hibitory potency of these drugs (the actual drug concentrations at 50% in-
hibition can be found in the reports by Beyer and Baer (1961) and Meng 
and Loew (1974)). 
Plasma protein binding 
Not only binding to intracellular components but also the extent of 
plasma protein binding determines of course such a distribution ratio. The 
red cell over plasma concentration ratio in the above series of compounds 
can, however, be expected to be a true reflection of the extent of red blood 
cell binding if plasma protein binding would be the same. This appears 
roughly to be the case. Hydroflumethiazide is for 75% bound to human 
serum albumin (Agren and Back, 1973), chlorthalidone is also for 75% 
protein-bound (Collste et al., 1976; Dieterle et al., 1976). For mefruside 
70-80% binding has been reported to plasma proteins of dogs (Schlossman, 
1967). No data are available for hydrochlorothiazide, but due to its struc-
tural similarity to hydroflumethiazide a similar figure may be anticipated. 
The other sulfonamide compounds appearing in Table 1.2 occur even 
more protein-bound in human plasma. For bumetanide a figure of 96% 
has been reported (Pentikainen, 1977), for furosemide 96-98% (Andreasen 
and Mikkelsen, 1977; Andreasen et al., 1978) and for bendroflumethiazide 
94% (Agren and Back, 1973). 
Glomerular filtration, tubular secretion and reabsorption 
A high plasma protein binding means that the fraction of drug available 
for glomerular filtration is very low, as it may be assumed that only un-
bound drug can be filtered into the proximal renal tubules. Therefore, the 
maximum renal clearance that would theoretically be possible if glomerular 
filtration were the only route of elimination would equal glomerular filtra-
tion rate (120 ml/min for a normal human subject) times the free fraction 
of each drug. From Table 1.2 it can be seen that the actual renal clearance 
values of most drugs are much larger, which confirms the presence of an 
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additional way of elimination, i.e. tubular secretion by the organic acid 
transport system described in a previous section of this chapter. 
So, a renal clearance higher than that attributable to glomerular filtra-
tion alone is a prima facie argument for tubular secretion. The absence of 
such a clear circumstance, however, does not allow the conclusion that no 
secretion is involved because of the possibility that the net renal excretion 
of a drug is diminished by reabsorption into the blood capillaries around 
the renal tubules. The probability of such a process would be expected to 
increase with increasing lipophilicity in a series of chemically related 
substances. Cyclopenthiazide and polythiazide (Fig. 1.1) are very lipophilic 
benzothiadiazines (Schlossmann, 1974) and the older literature suggests 
that their renal clearances are smaller than those of the more hydrophilic 
compounds (Peters and Roch-Ramel, 1969a). However, as mentioned in 
the first passage of this section, unspecific and also highly unsensitive 
methods (see Chapter 2) were used for these studies, so that exact inter-
pretation is difficult. The same caution is in place with respect to recent 
data from Hobbs and Twomey (1978), who developed a very sensitive 
GLC assay for polythiazide, the specificity of which could, however, not 
be warranted. Nevertheless, the rather small renal plasma clearance of 
about 30 ml/min which can be calculated for polythiazide from their data 
could be in agreement with occurrence of tubular reabsorption of this 
relatively lipophilic diuretic. For mefruside, which has an even larger ether-
water partition coefficient than polythiazide and cyclopenthiazide 
(Schlossmann, 1974), a very low renal plasma clearance, 2.5-5 ml/min, has 
been established (Fleuren et al., 1979c; Chapter 14). Further support for 
reabsorption in more distal parts of the nephron can be borrowed from a 
slight dependence of the renal clearance of several thiazides including 
chlorthalidone upon urine pH (Beyer and Baer, 1975; Chapter 10). 
Plasma clearance 
Contrary to the difference in the apparent total volume of distribution, 
the total plasma clearance of furosemide and bumetanide does not differ 
markedly from that shown by the diuretics of the thiazide group (Table 
1.2). So, the conclusion seems justified that short half-lives of diuretics are 
just the consequence of small volumes of distribution and not due to a 
large affinity for renal (and non-renal) elimination mechanisms. 
The plots of plasma concentration and urinary excretion rate against 
time were reported to run parallel for all drugs quoted in Table 1.2. This 
implies that no saturation of the tubular transport system has become ap-
parent after single doses of these drugs (such statement cannot be made, 
however, about the kinetics during chronic administration, because suffi-
cient data about this situation have not yet been published). The linear 
relationship between the plasma concentration and urinary excretion rate 
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of diuretics in single dose studies might constitute an analytical advantage. 
As is outlined in Chapter 2, the concentrations of the thiazide diuretics in 
urine are very high compared to those in plasma, so that future determina-
tion of individual half-lives of these drugs may be performed much more 
easily by assay of urine instead of plasma. 
Pharmacokinetics and diuretic effects 
The half-life values of the diuretics quoted in Table 1.2 are approximate-
ly proportional to the duration of the natriuretic effects after single doses 
of these drugs. So, furosemide and bumetanide are known as short-acting 
diuretics with an effect that is over after 3-4 hours, bendroflumethiazide 
acts for about 10 hours,chlorthalidone for up to 48-72 hours, and the ef-
fects of hydrochlorothiazide, hydroflumethiazide and mefruside last dur-
ing 12-24 hours (Beermann et al., 1977c; Brors et al., 1977; Davies and 
Wilson, 1975). Mefruside shows considerable intersubject variation in 
elimination half-life, but forms metabolites which must be considered to be 
responsible for its diuretic activity (Fleuren et al., 1979c; Chapters 14 and 
15). As is outlined before in this Chapter, the natriuretic effect of sulfon-
amide diuretics appears to correlate better with the amount of drug 
reaching the urine than with the height of the plasma concentration. This 
conclusion is supported by the observation that all diuretic drugs, for 
which at present sufficient data are available, are characterized by a con-
siderable extent of urinary excretion. A survey of the literature is presented 
in Table 1.3. This table contains only those figures, which were based upon 
analytical methods which assayed the unchanged drugs specifically. (So, 
we assumed that these species represented the active principles and, 
therefore, would be relevant for a correlation with diuretic effect.) For this 
reason, data on, for instance, chlorothiazide after intravenous administra-
tion, which indicated that all radioactivity was excreted into human urine 
(Brettell et al., 1960), were not included because the reported method 
(Beyer, 1958; Brettell et al., 1960) did not sufficiently justify the assump-
tion that unchanged drug alone had been analysed. Similarly a definite 
range of half-life values of hydrochlorothiazide could not yet be given in 
Table 1.3, because there is reason to suspect that the actual t'/i is longer 
than most figures available to date. Thus, usually a tVi value of 3-5 hours 
has been reported for hydrochlorothiazide (Meyer and Whyatt, 1976; 
Cooper et al., 1976), but incidentally, when analytical measurement was 
sufficiently sensitive, t'/i values tended to be larger, up to 15 hours (Beer-
mann and Groschinsky-Grind, 1977; Beermann et al., 1976; Redalieu et 
al., 1978). For most drugs quoted in Table 1.3 the length of the assay 
period is sufficiently in excess of the half-life. So, the cumulative urinary 
amounts shown must be a reasonable approximation of the total amounts 
excreted at infinite time. 
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TABLE 1.3 
Urinary excretion data of some diuretic drugs in normal human subjects following single doses 
Drug name 
Bendroflumethiazide 
Bumetanide 
Chlorthalidone 
Furosemide 
Hydrochlorothiazide 
Hydroflumethiazide 
Mefruside metabolites 
Metolazone 
Xipamide 
Dose and mode 
o P 
administration 
10 mg, р.о. (9) 
0.5 mg, i.v. (4) 
0.5 mg, р.о. (4) 
1 mg, р.о. (6) 
2 mg, р.о. (3) 
50 mg, i.v. (7) 
50 mg, р.о. (6) 
50 rag, р.о. (6) 
40 mg, i.v. (6) 
4-10 mg, р.о. (2) 
7 mg, i.v. (2) 
1-35 mg, i.v. (2) 
12.5-75 mg, р.о. (8) 
150 mg, р.о. (5) 
50 mg, р.о. (4) 
2.5 mg, i.v. (6) 
42 mg, i.v. (5) 
Elimination'' 
half-life 
(h) 
2.4-3.8 
1.3-1.7 
1.2-1.6 
1.2-1.8 
25-50 
43-51 
37-59 
ca. 1 
12.4-26.9 
10-14 
— 
— 
Urinec 
assay period 
48 h 
6 h 
6 h 
24 h 
24 h 
oo 
OD 
192 h 
24 h 
24 h 
3 h 
4-7 d 
48 h 
OD 
OO 
144 h 
24 h 
Cumulative amount 
excreted unchanged 
(% of dose) 
21-37 
ca. 60 
ca. 50 
ca. 45 
50-60 
50-78 
32-51 
41-63 
38-88 
ca. 30 
ca. 50 
ca. 90 
65-72 
41-59 
48-67 
ca. 70 
50-60 
Ref. 
m 
η 
о 
Ρ 
q 
г 
aNumber of subjects in parentheses; ^Based upon plasma concentration in all cases, except for hydroflumethiazide and tnefruside-metabolites (urine 
assay); COD indicates at infinite time, calculated by extrapolation of actual data; ^Beermann et al., 1977c; ePentikainenetal., 1977; fpeitetal., 1973 
SHalladay et al., 1977; hFleuren et al., 1979a; Chapter 9; 'Fleuren et al., 1979b; Chapter 10; JRiess et al., 1977; kAndreasen and Mikkelsen, 1977 
'Beermann et al., 1975a; mBeermann et al., 1976; "Beermann and Groschinsky-Grind, 1977; 0Brors et al., 1978; PFleuren et al., 1979c; Chapter 14 
dose administered as mefruside; QTilstone et al., 1974; rHempelman and Dieker, 1977 
THE INVESTIGATIONS DESCRIBED IN THIS THESIS 
The qualitative effect of a drug is determined by its interaction with a 
receptor in the target organ. The intensity and duration of that effect are 
modified by pharmacokinetic factors. The sulfonamide diuretics chlor-
thalidone and mefruside were selected for the present studies, because they 
are used by large numbers of patients in antihypertensive therapy, while 
very little was known about the disposition of these drugs in man. As 
discussed in this introductory chapter, some general insight has now been 
acquired in the relationship between the pharmacokinetics and the phar-
macodynamics of sulfonamide diuretics. For this purpose, literature data 
on the kinetics of some benzothiadiazines and furosemide and bumetanide 
were compared with the observations, described in the following chapters 
of this thesis. 
Prior to these pharmacokinetic studies considerable efforts were made, 
as evident from section II, to realize selective and sensitive methods for the 
assay of chlorthalidone, mefruside and its metabolites in human body 
fluids. The circumstance that both drugs bind to a large extent to 
erythrocytes has made high demands to the analytical methodology, 
because no artifacts in the distribution between red cells and plasma should 
be introduced. 
Section III deals with the human kinetics of chlorthalidone. The main 
issues of interest are: the time course of plasma concentration, red blood 
cell concentration, and urinary excretion rate both after single and multiple 
doses, furthermore the contribution of the routes of renal and biliary ex-
cretion, and metabolism, to overall elimination, and the absolute 
bioavailability of oral doses as determined by reference to the intravenous 
dosage form. 
Section IV describes the pharmacokinetic characteristics of mefruside in 
man. Much attention is paid to two of its metabolites, because there are 
good reasons to assume that these metabolites constitute the really active 
principles of mefruside. 
It is hoped that the studies, described in this thesis, will provide a refer-
ence for future work with the above substances as well as other diuretic 
drugs. 
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CHAPTER 2 
GENERAL INTRODUCTION TO ANALYSIS OF 
DIURETIC DRUGS IN BIOLOGICAL FLUIDS 
INTRODUCTION 
Many drugs cannot be assayed directly in the biological fluid, due to in-
terferences by numerous endogenous substances. A commonly employed 
purification step involves extraction from the aqueous phase into a 
suitable organic solvent. Distribution of weak acids and bases between 
organic and water phases is governed, besides by lipophilicity, by the 
degree of ionization of the compound under study. Therefore, the acid or 
base dissociation constant (pKa) is an important parameter in partitioning 
studies. The pKaj values of the frequently used sulfonamide diuretics 
range between 3.6 and 9.5, as can be seen from the survey of Table 2.1. 
Apart from furosemide and bumetanide, which contain each a carboxylic 
acid moiety, most thiazides possess two weakly acidic sulfonamide groups. 
In order to distinguish one from the other, Mollica et al. (1971) replaced 
the ring-sulfonamide proton of hydrochlorothiazide by an ethylgroup and 
observed for that compound only one pKa, at 9.5. Obviously, therefore, 
the lower pKai value belonged to the sulfonamide proton in the thiazide 
ring. In agreement with this, chlorthalidone and mefruside, which possess 
only the free sulfamoyl group, showed pKai values above 9, see Table 2.1. 
As a consequence, most sulfonamide diuretics including chlorthalidone 
and mefruside, except the first three of the survey of Table 2.1, can be ex-
tracted up to high pH values. See e.g. the plot of extraction recovery of 
chlorthalidone vs pH of the aqueous phase in Fig. 2.1. It should be noticed 
from this plot that the pH value where half the maximal amount of drug is 
extracted does not coincide with the pKa value of that drug. The curve has 
been shifted to the right because of contributions from the lipophilicity of 
the drug and the ratio of the phase volumes used: 
pHo.5 = pKai + log ( T P C . V o r g / V a q - l ) 
In this equation, derived in Appendix 2.1 at the end of this chapter, pHo.5 
denotes the pH at which half maximal extraction recovery occurs, TPC the 
true partition coefficient of the drug, and Vorg and Vaq represent the 
volumes of the organic and aqueous phase respectively. The TPC depends 
on the choice of the organic solvent, so the TPC = 35 when partitioning of 
51 
TABLE 2.1. 
Acid dissociation constants of sulfonamide diuretics8 
Drug name Structural formula pKaj pKa2 Reference 
NH-CiH, 
Bumetanide " ^ ì ò l 3 · 6 7'7 0 r i t a e t al" 1 9 7 6 
Furosemide >rr*ìf о-" ^ Г 0 3.8 7.5 Orita et al., 1976 
Η,Ν-ΒΟ,'^-^ΟΟΟΗ 3.9 Hajdû and Haussier, 1964 
Chlorothiazide H ^ - S O , ' 1 ^ * - 4 " б·7 9 · 5 Charnicki et al., 1959 
о» 
HjN-SO,' 
Bendroflume- ^ γ γ ν » , - ^ 
thiazide ttN-sOj-^^S'"4 8.5 Agren and Back, 1973 
Oj 
Cl H 
Hydrochloro- YVN > i 8 · 6 9 · 9 Mollica et al., 1971 
thiazide H^-SOÍ^^^S-*1" 8.7 Mollica et al., 1971 
Hydroflume- ^ ί Ο Λ « 
thiazide Η^-βο,^4-^^"" 8.9 10.5 Smith et al., 1976 
ci 
Chlorthalidone " jNsoj^Sf^l 9 · 3 5 ^ 1 1 Fleuren et al., 1979с 
- ^ Chapter 6 
Mefruside HjN-S0a'^"^S0i-N-CH,-^-ö 9.5 — Schlossmann, 1974 
CHj 
aDetermined at 25,C by various methods. Original references should be consulted. 
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traction of chlorthalidone 
in organic phase 
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Figure 2.1 
Fraction of chlorthalidone in organic phase after equilibration with equal volumes of aqueous 
buffers of varying pH (citrate-phosphate-borate, 0.1 M, Teorell and Stenhagen). Computer 
fitting according to Eq. 2.9 yielded a TPC = 35 by use of methyl isobutyl ketone and a TPC 
= 1 5 by use of diethylether. 
chlorthalidone is carried out with methyl isobutyl ketone, whereas the TPC 
= 1.5 if diethylether is employed (calculation of TPC by use of Eq. 2.9 in 
Appendix 2.1). Therefore, when an appropriate organic solvent has been 
chosen, almost complete extraction recovery of diuretic drugs can be 
achieved at a pH just below their pKa value. An extraction pH around 8 is 
more advantageous than a lower one, because it avoids co-extraction of en­
dogenous substances which are often of acidic nature (e.g. fatty acids) and 
of many acidic drugs. 
SEPARATION AND DETECTION OF DIURETIC DRUGS: 
REVIEW AND DISCUSSION 
Detection methods without chromatographic separation 
The first methods of assay of the modern thiazide diuretics came into use 
around 1960 and were based upon the Bratton-Marshall reaction for 
primary aromatic amines (Bratton and Marshall, 1939). After organic sol-
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vent extraction, the thiazides were hydrolysed by acid or alkali to liberate 
the amino group, followed by diazotation with nitrous acid and coupling 
with N-(l-naphtyl)ethylenediamine to yield a red colour. Such colorimetrie 
analyses have been reported for, for instance, chlorothiazide (Baer et al., 
1959), hydrochlorothiazide (Sheppard et al., 1960a), furosemide (Hajdû 
and Haussier, 1964) and mefruside, the latter after substitution of an 
amino group for its chlorine atom (Schlossmann, 1967). Although these 
methods were of value for obtaining a first impression of the relative im-
portance of the various routes of elimination of these diuretic agents, very 
high doses, i.e. far above the therapeutic amounts, had to be administered 
in order to reach measurable blood levels (above ca. 10 /¿g/ml.). Besides 
this apparent unsensitivity, unselectivity too, e.g. with regard to 
discrimination between the parent drug and its possible metabolites, ob-
viously forms a limitation for use of this method in detailed phar-
macokinetic studies. 
Apart from the above drawbacks, irreproducible colour formation in the 
Bratton-Marshall reaction due to disturbances by endogenous components 
of biological fluids has been described (Resetarits and Bates, 1979; Schäfer 
et al., 1977a). 
More sensitive, but remaining questionable with respect to interference 
by possible drug metabolites is the use of spectrofluorometry, as employed 
by Smith et al. (1976) and Brors et al. (1977) for the determination of 
hydroflumethiazide in plasma and urine, and by Hajdû and Haussier 
(1964) in case of furosemide. The same objection can be raised against the 
earliest assays of chlorthalidone, based upon ultraviolet absorption of its 
hydrolysis product (Pulver et al., 1959; Tweeddale and Ogilvie, 1974) and 
against a later one employing the carbonic anhydrase inhibitory action of 
this drug (Johnston et al., 1977). Dixon et al. (1976) reported a sensitive 
radio-immunoassay for bumetanide, and "proved" its specificity by com-
parison of the concentrations found with the values obtained by plasma 
radioactivity and ultraviolet absorption measurements, which, however, 
cannot be regarded as specific assays themselves. 
Similarly, pharmacokinetic studies using radioactive-labelled diuretic 
drugs (Anderson et al., 1961; Brettell et al., 1960, 1964; Calesnick et al., 
1966; Rupp et al., 1972; Sheppard et al., 1960) cannot be assumed to have 
provided specific information on the parent drug as long as no definite 
proof has been given that no metabolites were included in the assay. Com-
plete or almost complete absence of metabolites appears to be verified until 
now only in case of administration of hydrochlorothiazide to humans, 
where more than 95% of the dose was eliminated in unchanged form (Beer-
mann et al., 1976b). An identical situation may be expected for 
hydroflumethiazide, owing to its great structural resemblance to 
hydrochlorothiazide, see Table 2.1. The data on this drug, available so far, 
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indicated that metabolite formation accounted for not more than ca. 2% 
of the dose (Brors et al., 1978), which is in agreement with the above 
assumption. For other sulfonamide diuretics, however, no such pertinent 
information is present. On the contrary, our investigations with in-
travenously administered chlorthalidone indicate that this drug is 
metabolized in man for about 30% of the dose administered (Fleuren et al., 
1979a; Chapter 9, this thesis). A still larger percentage has been found for 
bendroflumethiazide by Beermann et al. (1977). Only when the structure of 
the metabolites has become known, it shall be possible to determine their 
influence on the analytical results obtained. At that time, several of the 
methods mentioned above, if suitably adapted, might appear very con-
venient for the purpose of pharmacokinetic studies. Until then, however, 
specific methods involving separate determination of the parent drug 
should be used. The next sub-sections will deal, therefore, with separation 
techniques, commonly employed for the assay of diuretics in body fluids, 
and the advantages and limitations of these methods will be indicated. 
Thin-layer chromatography 
Thin-layer chromatography (TLC) was the earliest chromatographic 
technique by which diuretics occurring in urine could be separated, with 
the use of ultraviolet absorption, iodine vapour and various spray reagents 
as detection tools (e.g. Maes et al., 1970; Osborne, 1972; Sohn et al., 1973). 
Only semi-quantitative information could be gathered, because the concen-
trations encountered were only slightly above the analytical limits of detec-
tion: depending upon the structure of the particular diuretic and upon the 
way of detection, absolute amounts on the plate down to 0.5-5 ¿tg could be 
visualized. 
Improvement in sensitivity was obtained by using spectrofluorometry to 
determine hydroflumethiazide (Brors et al., 1978; Garceau et al. 1974), 
hydrochlorothiazide (Schäfer et al., 1977a) and furosemide (Schäfer et al., 
1977b) down to concentrations of 20-50 ng/ml in plasma. 
High-pressure liquid chromatography 
When we look at the polar groups of the sulfonamide diuretics, some of 
which have been depicted in Table 2.1, high-pressure liquid chroma-
tography (HPLC, alternatively called high-performance liquid chroma-
tography), seems at first glance the technique of choice for determination 
of such compounds. HPLC works particularly well in the determination of 
diuretic drugs in pharmaceutical dosage forms (Butterfield et al., 1978; 
O'Hare et al., 1979; Wong et al., 1977). Also urine concentrations of 
diuretics after therapeutic doses can be readily assayed, as evidenced by 
HPLC methods for hydrochlorothiazide (Cooper et al., 1976), 
chlorothiazide (Hunt et al., 1978; Lin and Benêt, 1978; Resetarits and 
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Bates, 1979), furosemide (Carr et al., 1978; Lindström, 1974), 5-oxo-
mefruside (Little et al., 1977), bemetizide (Brodie et al., 1978) and 
metolazone (Hinsvark et al., 1972). 
Plasma concentrations of most diuretic drugs, however, are much lower 
than the corresponding urine concentrations, as discussed in the con-
cluding remarks section below. Published work dealing with assay of 
diuretics in this biological fluid indicates that at best concentrations down 
to ca. 50 ng/ml can be measured accurately, the actual levels depending on 
the ultraviolet absorptive properties of the diuretics investigated (Brodie et 
al., 1978; Carr et al., 1978; Christophersen et al., 1977; Cooper et al., 
1976; Lindström, 1974; Nation et al., 1979). 
Gas chromatography 
The main difficulty in applying gas chromatography (GC) to the assay of 
sulfonamide diuretics was that volatile derivatives of these compounds had to 
be prepared. In case of hydrochlorothiazide, neither silylation nor methyl-
ation with diazomethane gave complete derivative formation (Vandenheuvel 
et al., 1975). The same results were found during our preliminary analytical 
work with chlorthalidone (unpublished observation). Similar findings, also 
with respect to acetylation, were reported by Li et al. (1977). 
Flash-heater methylation with trimethylanilinium hydroxide, according 
to Brochmann-Hanssen and Оке (1969), led to complete conversion of 
both hydrochlorothiazide (Vandenheuvel et al., 1975) and chlorthalidone 
(Li et al., 1977) to their methyl derivatives. These authors admitted, 
however, that the molar ratio of methylation reagent over drug amount 
should be kept between rather narrow limits for successful methylation; in 
addition, the injector geometry of the gas Chromatograph proved to be a 
very critical factor. 
Most promising results have been obtained by means of extractive 
methylation. This technique, which allows better control of derivatization 
conditions than the flash-heater methylation, e.g. with regard to the reac­
tion time, is relatively new in derivative formation for GC and will be 
described, therefore, in a separate section of this chapter. GC determina­
tions of the following diuretic drugs all employed permethylation by this 
method: chlorthalidone (Ervik and Gustava, 1974; Degen and Schweizer, 
1977; Fleuren and van Rossum, 1978; this thesis. Chapter 3), furosemide 
(Lindström and Molander, 1974), hydrochlorothiazide (Lindström et al., 
1975; Redalieu et al., 1978), bendroflumethiazide (Beermann et al., 1976a) 
and mefruside (Fleuren et al., 1979b; this thesis, Chapter 4). Extractive 
methylation of the above drugs was recently re-established in a comprehen-
sive study by Fagerlund et al. (1979). These authors reported in addition 
that the technique had successfully been applied to seven other 
sulfonamide diuretics, including bumetanide and cyclopenthiazide. 
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Besides the disadvantage that volatile derivatives have to be prepared for 
gas chromatography stands the advantage that sensitive and selective detec-
tors are available. The electron capture detector (E.C.D.) has become the 
most widely used detector in gas chromatography after the conventional 
flame ionization detector. With this selective detector numerous analyses 
of pharmaceutical compounds have been performed, either directly or 
after derivatization with electron-capturing groups, see e.g. the review by 
Ahuja (1976). Accurate determination of hydrochlorothiazide and ben-
droflumethiazide with an E.C.D. was possible down to concentrations of 
5-10 ng/ml in plasma (Beermann et al., 1976a; Lindström et al., 1975; 
Redalieu et al., 1978). Although measurement of even 2 ng/ml of chlor-
thalidone in plasma was claimed by Ervik and Gustavii (1974), routine ex-
perience by other workers indicated that this statement was somewhat too 
optimistic and that, more realistically, determinations down to ca. 10-20 
chlorthalidone in plasma 
100 
relerence sample 
5 Ong/ml 
3 time (mm) 
Figure 2.2 
Gas chromalograms obtained after assay of low nanogram concentrations of chlorthalidone 
in plasma by means of a nitrogen-sensitive detector (chi. = chlorthalidone, i.st. = standard). 
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ng/ml were feasible by E.CD. (Degen and Schweizer, 1977). However, the 
E.C.D. was not very sensitive towards furosemide, of which minimum 
plasma concentrations of 0.1 μ§/ιη1 could be assayed (Lindström and 
Molander, 1974). 
Another sensitive and selective detector in gas chromatography is the 
thermionic detector using an alkali salt (nitrogen detector, phosphorus 
detector, alkali flame ionization detector). Because this detector, which in 
the nitrogen-mode selectively records nitrogen-containing organic 
substances, is still less in common use than the E.C.D., a brief summary of 
its properties and some of its applications in drug analysis will be given 
separately in one of the following sections of this chapter. Concentrations 
of both chlorthalidone and mefruside down to 5-10 ng/ml in plasma and 
urine were assayed with the nitrogen detector, see, e.g., Fig. 2.2 (Fleuren 
and van Rossum, 1978; Fleuren et al., 1979b; this thesis, Chapters 3 and 4). 
Concluding remarks 
Obviously, a specific assay of the unchanged drug is a first requirement 
in drug disposition studies.Because the plasma is the body fluid, via which 
all transport and exchange processes are mediated, concentration 
measurements in that central fluid are undispensable to obtain insight in 
the primary determinants of handling of drugs by the body, like clearance 
and volumes of distribution. For fundamental pharmacokinetic studies, 
therefore, a sensitive assay in plasma is needed too. 
Many diuretic drugs are excreted into urine as the unchanged compound 
for a considerable part of the dose (Chapter 1), implying that relatively 
high urinary concentrations occur (range ca. 0.1-15 ¿tg/ml), see for instance 
Fig. 2.3. The total volume of distribution of these drugs is, however, very 
high so that after single therapeutic doses very low plasma concentrations 
result in the terminal part of the concentration-time curves, e.g. from 5-100 
ng/ml. This circumstance indicates that the detection limit of the analytical 
method is critical for obtaining reliable estimates of the terminal plasma 
half-life of these drugs. So, if plasma concentrations of 5 ng/ml instead of 
50 ng/ml can be assayed, additional information will be available over a 
period that corresponds to ca. three times the terminal half-life of that 
drug. In the absence of this information erroneous impressions of this 
biological half-life can be found. This has been demonstrated very clearly 
in case of hydrochlorothiazide and hydroflumethiazide. While Cooper et 
al. (1976) reported a mean "half-life" of 5 hr for hydrochlorothiazide, 
based upon measurement down to ca. 100 ng/ml by HPCL, the t'/i values 
appeared to be much longer, ca. 15 hr, when measurement was performed 
down to the 10 ng/ml level by GC with E.C.D. (Beermann et al., 1976; 
Redalieu et al., 1978). Analogously, Brors et al. (1977) reported a "half-
life" of ca. 2 hours for hydroflumethiazide, but /г values of 13-25 hr were 
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chlorthalidone concentration (|ug/ml) 
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Dose- 100 mg chlorthalidone 
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time (hours) 
Figure 2.3 
Comparison of urine and plasma concentrations of the diuretic chlorthalidone after a single 
100 mg dose in man. 
found by the same authors in a later study (Brors et al., 1978) in which they 
admitted that the values obtained in their earlier communication had not to 
be regarded as the final half-lives. 
These cases may suffice to indicate that the sensitivity required is pro­
vided until now only by detectors which are available in gas 
chromatography. In high-pressure liquid chromatography there is clearly a 
need for lower limits of detection. The future will have to show us if wider 
application of e.g. fluorescence or electrochemical detectors can fulfil this 
need. 
HPCL, however, seems already very convenient for the assay of 
diuretics in urine. In a later phase of a pharmacokinetic study, therefore, 
when the full kinetic profile of the drug under study has been established, 
measurement in this or another fluid with higher concentrations could 
replace that in plasma, because the relationship between both data sets has 
then become known. We, however, dealing with the unravelling of this 
relationship, had to accept the inconvenience of derivative formation for 
GC in order to utilize the advantage of a much more sensitive detection. 
The next part of this chapter will deal with descriptions of the extractive 
alkylation technique and the nitrogen detector and their applications in the 
determination of chlorthalidone and mefruside in body fluids. 
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EXTRACTIVE METHYLATION 
By extractive alkylation is meant a combined use of ion-pair extraction 
and subsequent alkylation of the acid-anion. Much theoretical and ex-
perimental work on ion-pair extraction has been carried out since about 
1960 by Schill and coworkers (see e.g., Schill et al., 1977). A very extensive 
compilation of the literature in this field can be found in a review by 
Jonkman (1975). During the past decade, extractive alkylation has become 
a well-known derivatization technique for gas chromatographic analysis of 
a variety of weakly acidic compounds (Brandström and Junggren, 1969; 
Degen et al., 1976; Degen and Schweizer, 1977; Ehrsson, 1971; Ehrsson 
and Tilly, 1973; Ehrsson, 1974; Ervik and Gustavii, 1974; Fagerlund et al., 
1979; Fleuren and van Rossum, 1978; Fleuren et al., 1979b; Gyllenhaal and 
Ehrsson, 1975; Hartvig and Fagerlund, 1977; Hartvig et al., 1978; Lind-
ström, 1974; Lindström et al., 1975; Vessman et al., 1977). In the extrac-
tive alkylation process, acids are extracted in the anion form together with 
a positively charged counterion from a water phase into an organic phase 
having a poorly solvating ability, so that the anions possess a high reactivi-
ty in nucleophilic displacement reactions (Brandström and Junggren, 
1969). Frequently, benzene or dichloromethane containing an alkylkalide, 
e.g. methyliodide, are used in these reactions with a quaternary ammonium 
compound, e.g. tetrabutylammoniumhydroxide, providing the counterion. 
The rate of alkylation increases with increasing lipophilic character and 
concentration of the counterion (Ehrsson, 1971; Ervik and Gustavii, 1974; 
Fagerlund et al., 1979). It depends also on the concentration of the 
alkylating agent and on the reaction temperature, as was observed by Ervik 
and Gustavii (1974) in determining optimum reaction conditions for ex-
tractive methylation of chlorthalidone. The reaction can be divided into 
two steps: 
Q +
 a q + X - a q ^ Q X o r g (1) 
QXorg + CHalorg * CH3-X+ Q I o r g (2) 
where Q + aq and X—aq denote the concentrations of the cation (tetrahexyl-
ammonium ion) and chlorthalidone in an anion form, respectively, in the 
aqueous phase, and QXorg and С Н з І 0 Г ё the concentration of the ion-pair 
and methyliodide, respectively, in the organic layer. Although extraction 
of the ion-pair is not very high under equilibrium conditions, i.e. the ratio 
QXorg/X—aq is 0ПІУ 2.6, the equilibrium of step (1) is displaced to the 
right when alkylation takes place. A high methylation rate was favoured by 
choosing high concentrations of methyliodide (0.5 M in CH2CI2) and by 
working at a temperature of 50oC. Under these conditions the reaction was 
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complete after 15 minutes (Ervik and Gustavii, 1974). We verified that 
chlorthalidone had been converted to its tetramethylderivative, and that no 
hydrolysis of the isoindolin ring had taken place (Chapter 3). Quantities up 
to ca. 20 /tg of chlorthalidone can be permethylated, which is by far suffi­
cient for the assay of concentrations occurring in biological fluids. 
Mefruside was found to be dimethylated more easily, the reaction being 
complete within 5 minutes at room temperature (Chapter 4). Extensive 
descriptions of the complete analytical procedure can be found in the 
Chapters 3 and 4. 
Because we felt that some details would deserve additional explanation, 
we present now already an abbreviated version of the method for chlor­
thalidone (Fig. 2.4). According to the extraction profile shown in Fig. 2.1 
Figure 2.4 
Flow-chart for the determination of chlorthalidone in biological fluids, using extractive 
methylation and gas chromatography with nitrogen detection. 
Phase in which drug is present Procedure 
plasma (1-2 ml) 
urine (1 ml) 
red blood cells (0.1-0 2 ml) 
Add buffer of pH 7.4-pH 9 0 (0.5-2 ml) 
(in case of red blood cells· 600 mg NaCI + 100 mg NaF in 
addition) 
Add internal standard (S /tg, 0.1 ml) 
Extract twice during 20 mm with 10 ml 
methylisobutylketone/ethanol (100 2 v/v) 
Centrifuge briefly 
Transfer organic layers into another tube 
methylisobutylketone/ethanol Re-extract once with 2 ml 0.1 M NaOH during 15 mm 
Transfer alkaline layer into another tube 
0.1 M NaOH Add 50 /il of 0.1 M tetrahexylammomum-hydroxide (THA) 
Mix well 
Add 5 ml of CH3I m CH2CI2 (0.75 M) 
Shake vigorously for 20 mm at 50CC 
Centrifuge briefly 
Transfer organic layer into another tube 
CH2CI2 Evaporate to dryness to remove CH3I (40° C) 
Add 5 ml of n-hexane 
Somficate during 5-10 mm 
Centrifuge to precipitate insoluble THA-salt 
Transfer supernatant to another tube 
n-hexane Evaporate to dryness 
Re-dissolve in 50 μ\ of ethanol 
ethanol Inject 5 μ\ into gas Chromatograph with nitrogen detector 
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chlorthalidone can be extracted almost quantitatively from aqueous buf-
fers until ca. pH 9 with methyl isobutyl ketone. This holds true also for ex-
traction from plasma and urine, but not for that from red blood cells or 
whole blood, where extraction recovery is reduced due to strong binding of 
chlorthalidone to constituents in the erythrocytes, as will be pointed out in 
Chapter 3. In this case, an equal recovery as that from buffer alone was 
achieved by saturating the erythrocytes with a mixture of sodium chloride 
and sodium fluoride. Normally, we used an extraction pH of 7.4 for all 
plasma, red blood cell and urine samples, but incidentally a pH of 9 proved 
to be more advantageous, e.g. in case of bile assay (see also the Chapters 3, 
11 and 13). 
As indicated in Fig. 2.4 the 0.1 M tetrahexylammonium hydroxide solu-
tion should be added to the 0.1 M NaOH volume prior to addition of the 
dichloromethane layer. This at first sight unimportant precaution proved 
to avoid the occurrence of an enormous disturbing signal in the gas 
chromatogram, eluting immediately after the solvent peak. We ascribed 
this to decomposition of the quaternary ammonium salt to its amine, as 
this is known to occur in more concentrated solutions (Roberts and 
Caserío, 1965). Furthermore, we observed that the presence of chloride 
ions, e.g. 0.005 M in the aqueous alkaline layer negatively influenced the 
methylation of chlorthalidone, which may be attributed to competition for 
the positive counterion with respect to ion-pair extraction into the organic 
phase. This circumstance stressed the necessity of cleaning all glass tubes 
with distilled water prior to use and of avoiding contamination which could 
possibly occur by incautious transfer of the organic extracts of plasma and, 
especially, red blood cells to the next step of the procedure. Therefore, 
always brief centrifugation was carried out for good separation of these 
layers. 
The dissolution step with n-hexane was employed to get rid of the 
tetrahexyl ammonium iodide, the by-product of the extractive methylation, 
see reaction step (2), which is almost not soluble in this solvent. Removal of 
this substance is necessary prior to injection of the methylated derivatives 
into the gas Chromatograph, because of the enhanced sensitivity of the 
nitrogen detector for nitrogen-containing organic compounds (this step is, 
however, because of the iodide, also necessary in case of electron-capture 
detection, as reported by Ervik and Gustava, 1974). 
Finally, the residue was dissolved in ethyl alcohol, because n-hexane 
causes a much larger heat of combustion when introduced into the alkali 
flame ionization detector. As the operation of this detector is temperature-
dependent, as outlined in the following section, an unwanted change in 
detector sensitivity would result then. 
Despite the fact that the method consists of several steps, see Fig. 2.4, 
the overall procedure could be performed, by use of an appropriate inter-
62 
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Figure 2.5 
Repeated assay of plasma samples indicating good reproducibility of the method of deter­
mination of chlorthalidone. The investigations, of which the results are shown in this plot, are 
described in Chapter 9. 
nal standard, with a good reproducibility (5% standard deviation between 
concentrations of 10 ng/ml and 2.5 /ig/ml, Chapter 3). To illustrate this, 
Fig. 2.5 shows the results of duplicate determinations on different days of a 
series of plasma samples, obtained from two typical experiments in man. 
THE NITROGEN DETECTOR IN GAS CHROMATOGRAPHY 
The most striking property of the nitrogen detector is its ability to selec­
tively measure nitrogen over other elements in organic molecules (over car­
bon in even a 5000-fold ratio), independently of their further chemical 
class, the output signal being linearly proportional to the nitrogen content 
of the molecule (Burgett et al., 1977; Маіег-Bode and Riedmann, 1975). 
This detector belongs to the group of the so-called thermionic detectors 
using an alkali metal salt, of which the phosphorus detector is another 
variant. The detection mechanism of a nitrogen (or phosphorus) detector 
does not involve measurement of the ionization current of the eluted 
substances, as with other ionization detectors (electron capture detector, 
flame ionization detector). Instead, changes in the degree of ionization of 
an alkali metal present in the detector room (e.g. rubidium bromide) are 
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monitored. The exact nature of the response is, however, not completely 
known. Several mechanisms have been proposed, and are reviewed by Sev-
cik (1976). In general, it is believed that the background current is a result 
of the ionization of the vaporized alkali atoms (Aue et al., 1967; 
Brazhnikov, 1970; Page and Woolley, 1968; Sevcik, 1976). This ionization, 
in turn, depends only upon the temperature of the surroundings. Neither 
hydrogen nor combustion products need to be present for this ionization to 
occur. Also the presence of the flame on itself is not crucial, because 
flameless nitrogen detectors have been demonstrated to give similarly selec­
tive responses (Burgett, 1977; Kolb and Aue, 1977). In these cases, ioniza­
tion was achieved by using an electrically-heated device. 
The reactions which occur when nitrogen compounds enter the detector 
chamber are not fully understood. Mostly, it has been suggested that the 
organic nitrogen-containing molecules are pyrolyzed to form cyano 
radicals, which remove an electron from the vaporized alkali (Aue et al., 
1967; Kolb and Bischoff, 1974; Маіег-Bode and Riedmann, 1975). These 
cyanide ions then combine at the collector to form hydrogen cyanide and 
thereby generate an increased output signal. The ionized alkali returns to 
the source surface to be re-evaporized. However, as discussed by Sevcik 
(1976), also other mechanisms have been proposed. 
Regardless from the mechanism of response, the nitrogen detector has 
proven to be particularly well-suited for analysing low concentrations of 
nitrogen-containing drugs in a wide variety of chemical classes. So, deter­
minations in biological fluids have been reported on e.g. barbiturates 
(Breimer and van Rossum, 1974; Goudie and Burnett, 1973; Riedmann, 
1974), phenothiazines (Jonkman et al., 1975b; Riedmann, 1974), anti-
epileptic drugs (Goudie and Burnett, 1973), antihistamines (Bilzer and 
Gundert-Rémy, 1973; Smith et al., 1978), tricyclic antidepressants (Bailey 
and Jatlow, 1976), 5-fluorouridine (De Leenheer and Gelijkens, 1978) and 
theophyllin (Lowry et al., 1977). This encouraged us to apply the nitrogen 
detector to determination of sulfonamide diuretics (Fleuren and van 
Rossum, 1978; Fleuren et al., 1979b; Chapters 3, 4 and 5). 
The first device utilizing the thermionic principle in combination with 
gas chromatography was described by Karmen and Giuffrida (1964) for the 
detection of phosphorous and chlorinated hydrocarbons. Aue et al. (1967) 
published the first application of the alkali flame ionization detector 
towards nitrogen-containing compounds. The selectivity towards the dif-
ferent hetero-elements depends upon the nature of the alkali salt, rubidium 
bromide being favourable for detection of nitrogen (Aue et al., 1967; 
Brazhnikov, 1970). 
The Hewlett-Packard nitrogen detector employed in our investigations is 
a modified flame ionization detector, operating also with rubidium 
bromide as the alkali source. A rubidium bromide crystal has been made 
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from the molten salt and has been given a cylindrical form with a central 
bore in its longitudinal axis. This crystal fits into the cylindrical collector 
electrode. The other electrode is mounted concentrically with the burner-
jet top. The distance between the crystal and the flame can be adjusted 
mechanically. As pointed out above, the temperature of the crystal surface 
determines the evaporation rate of the alkali source and thereby the output 
signal and the selectivity. Therefore, all parameters causing a rise in 
temperature of the crystal are of influence. These include, besides the posi-
tion of the crystal, the gas flow rates (hydrogen, oxygen and carrier gas), 
detector base temperature and internal diameter of the burner-jet. Proper 
adjustment is critical for obtaining maximal sensitivity and selectivity of 
the nitrogen detector. These conditions have very extensively been describ-
ed by Maier-Bode and Riedmann (1975) for the detector type employed by 
us and are only briefly indicated, therefore, in the gas chromatographic 
sections of the Chapters 3 and 4. 
SUMMARY 
Principles of organic solvent extraction of sulfonamide diuretics in 
general and chlorthalidone and mefruside especially from biological fluids 
were discussed on basis of physico-chemical properties of these drugs, viz. 
lipophilicity and acid ionization constants. 
The literature dealing with the analysis of diuretics, starting with the late 
fifties, when these drugs were introduced, until 1979 was reviewed. Early 
colorimetic assays based upon the Bratton-Marshall reaction appeared to 
lack not only specificity but also sensitivity. Current methods of deter-
mination, employing high-performance thin-layer chromatography, high-
pressure liquid chromatography or gas chromatography equipped with 
selective detectors, were compared. It was concluded that, up to now, only 
gas chromatography with electron capture or nitrogen detection has enabl-
ed measurement of low nanogram per milliliter concentrations of 
sulfonamide diuretics in body fluids. For a few drugs showing favourable 
fluorescence properties thin-layer chromatography with fluorometric 
detection could also be employed. High-pressure liquid chromatography 
appeared to be very convenient for the assay of sulfonamide diuretics in 
urine, but the limit of detection of this technique did not suffice for study-
ing plasma kinetics of these drugs. 
After administration of single doses to humans, plasma concentrations 
of many diuretic drugs are in the very low nanogram per millimeter range, 
so that the most sensitive technique - gas chromatography with nitrogen or 
electron capture detection - is required for fundamental pharmacokinetic 
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investigations. Prior to gas chromatography, sulfonamide diuretics have to 
be converted to volatile derivatives. Complete derivatization could at best 
be achieved by means of extractive alkylation. Background and applica­
tions of this technique were described, focusing on the determination of the 
sulfonamide diuretics under study. The operation of the nitrogen detector, 
by which chlorthalidone and mefruside were determined down to 5 ng/ml 
in plasma, was outlined. 
APPENDIX 2.1 
The two proton dissociation equilibria of a dibasic acid in aqueous solution 
can be described by: 
[H+] .[A"] [HA] 
aq aq aq 1 
Ka. = or 
1
 [HA] [HA]
 +
[A-]
 1 + 1 o
P H
~
P K a i 
aq aq aq 1+10 
(Eq.2.1) 
and 
[H + ] . [ A 2 - ] [A"] 
= 22 23. or 25Ц 
[A ] [A ] + [A¿~] 
aq aq Jaq 
1 
pH-pKa2 
1 + 10 (Eq.2.2) 
where pH = — log[H + ]aq, pKaj = — logKaj, рКаг = — logKa2, and 
Kai and Ka2 are the first and second dissociation constants*, respectively. 
[HA]
a
q, [A—]
a
q and [A2—]
a
q represent the concentrations of the 
unionized, single ionized and double ionized species of the weak acid, 
respectively. 
•pKa) and pKa2 denote in this appendix the apparent acid dissociation constants, which are 
smaller than the thermodynamic dissociation constants due to the ionic strenght of the buffer 
solution used (cf. Chapter 6). 
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When a weakly acidic drug is partitioned between an aqueous and an 
organic phase, the relative amount present in the organic layer after 
equilibration will depend upon the extraction pH. For equal phase volumes 
and unsaturated solutions, the ratio of the concentration in the organic 
phase over that in the aqueous phase is called apparent partition coefficient 
(APC): 
[HA] + [A"] + [A 2"] 
дрс,
 =
 org org org 
[HA] + [ A - ] + [A ~]
 № n
 , ,ч 
a q aq aq (bq. 2.3) 
If we assume that only the unionized species enters the organic phase 
(which will be allowed in general, except e.g. in case of ion-pair 
formation), Eq. 2.3 is reduced to: 
[HA] 
org 
APC = 
[HA] + [A ] + [A 2 ] 
aq aq aq (Eq. 2.4) 
The true partition coefficient (TPC) can be regarded as a measure for the 
intrinsic lipophilicity of a drug (apart from ionization): 
[HA] 
T p c = 2£Я 
t H A ]
a q (Eq.2.5) 
To find the relationship between APC and TPC, we first have to combine 
Eq. 2.1 and Eq. 2.2 to: 
[HA] 
org 1 
[HA] + [A-] + [A2-] , „
 l n
P H
"
P K a 2 , РИ-Р^І 
aq aq aq 1 + (1+10 ) .10 
(Eq. 2.6) 
Now, it can be readily derived from Eqs. 2.4, 2.5 and 2.6 that 
TPC APC = 
pH-pKa pH-pKa. 
1 + (1 + 10 ) . 1 0 (Eq. 2.7) 
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The extraction ratio (E) can be defined as the ratio of the amount of drug 
in the organic phase over the sum of the amounts in aqueous and organic 
phases, at any pH: 
[HA] .V 
„ _ org org 
2-([HA] + [A ] + [A ] ).v + [HA] .V 
aq aq aq aq org org 
APC 
V /V + APC ,_ - „χ 
aq org (Eq. 2.8) 
By use of Eq. 2.7 we obtain 
TPC 
E = 
pH-pKa pH-pKa 
V /V (1 + (1+10 ).10 ) + TPC 
aq org 
(Eq. 2.9) 
Equation 2.9 offers a useful means for finding the TPC, once the partition­
ing of a drug as a function of the pH of the aqueous phase has been 
measured. This gives more accurate results than the calculation of TPC by 
measuring at low pH (cf. Eq. 2.5) because the ratio of [HA]
or
g/[HA]
a
q is 
very sensitive to small errors in either the aqueous or organic phase. The 
distribution curves of Fig. 2.1 were fitted to Eq. 2.9 by use of a non-linear 
least squares regression analysis program(such as FARMFIT, see Chapter 
1). At first, we attempted to fit the experimental data to a simpler form, 
which holds true as ionization of the second acid group should be negligi­
ble: 
E = T P C 
pH-pKa 
V
a q / V o r g ( 1 + 1 0 > + T P C (Eq.2.10) 
It appeared, however, that the second acid group of chlorthalidone (with 
pKa2) strongly influenced the shape of the distribution curves at a higher 
pH, so that the fits according to Eq. 2.9 were much better than those 
according to Eq. 2.10. This was judged by visual inspection, the sum of the 
squared deviations and the symmetry of residuals (cf. Chapter 6). Because 
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the pKa2 was not as accurately known as the pKaj, see Chapter 6, several 
values of pKa2 were tried until the lowest sum of squared deviations had 
been found (cf. Chapter 6). This occurred at pKa2 = 10.95. 
For a rough graphical estimation of the TPC, the following may be used. 
At the pH where half of the total amount of drug is extracted into the 
organic phase, so E = 0.5, we obtain (if pHo.5 differs by at least one half 
log unit from pKa2): 
pH,, _ = pKa. + log (TPC.V /V -1) 0.5 ^ 1 ^ ora aq 
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CHAPTER 3 
DETERMINATION OF CHLORTHALIDONE IN PLASMA, 
URINE AND RED BLOOD CELLS 
INTRODUCTION 
A sensitive and accurate assay in body fluids is necessary in order to 
determine the pharmacokinetic characteristics of a drug. Pulver et al. 
(1959) and Tweeddale and Ogilvie (1974) reported spectrophotometric 
methods for chlorthalidone, which, however, were not enough sensitive for 
the measurement of therapeutic plasma levels. The use of gas 
chromatography in the determination of chlorthalidone was delayed pro­
bably by the difficulty in forming a volatile derivative of this compound, 
which contains four polar groups (Fig. 3.1). Application of the extractive 
alkylation technique, of which a brief description has been given in 
Chapter 2, followed by gas chromatography with electron-capture detec­
tion, led to an analysis of chlorthalidone at the nanogram level, as describ­
ed by Ervik and Gustavii in 1974. However, a complete analysis of a drug 
in body fluids must include the correct way of handling the biological 
samples, especially if variations herein influence the concentration values 
found. In this chapter it will become evident that the plasma concentration 
values of chlorthalidone are to a great extent dependent upon the method 
of separation of the plasma from the erythrocytes. Therefore, a proper 
treatment of the blood samples will be emphasized, besides the gas 
chromatographic part of the analysis. Use is made of the nitrogen sensitive 
mode of the flame ionization detector, which can measure nanogram con­
centrations of chlorthalidone, as was expected because the drug molecule 
contains two nitrogen atoms (see Chapter 2). An adequate internal stan­
dard (II in Fig. 3.1) is incorporated in the extraction procedure and special 
attention is paid to a complete recovery of the drug in the red blood cell 
assay. C [ y ^ I а у ^ II 
Н ^
с
/ \ ^ х(СН2)з-ОСНз 
Figure3. J О 
Chemical structures of chlorthalidone (I) and the internal standard (II) used in the gas 
chromatographic analysis. 
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MATERIALS AND METHODS 
Apparatus 
Gas chromatographic analyses were performed on a Hewlett-Packard 
(HP, Avondale, Pa, USA) Model 5750 G gas Chromatograph, equipped 
with a dual nitrogen detector (alkali flame ionization detector, A.F.I.D., 
with a rubidium bromide crystal; HP Model 15161 A) and connected to a 
HP recorder, Model 7127 A. Column: A glass column (1.8 m χ 3 mm I.D.) 
packed with 3% GC-SE 30 on Gas Chrom Q, 100-120 mesh (Applied 
Science Labs., State College, Pa, USA) was used. Before being packed the 
glass column was cleaned with chromic acid, silanized with 5% 
dimethyldichlorosilane in toluene, rinsed with methanol and dried. The 
column was used as long as a good peak symmetry was present (usually 3-6 
months). Prior to each analysis of a series of unknown samples, several 
pre-injections of the methylated derivative of chlorthalidone, e.g. obtained 
from assay on previous days, were performed to reduce adsorption to the 
column, as evidenced by tailing of peaks in the gas chromatogram. This 
proved to be especially important in the lower concentration range, from 
10-50 ng/ml. Temperatures: Column 2650C (isothermal); Injection port 
320oC. Detector 360oC. Gas flow-rates: The carrier gas was helium at a 
flow-rate of 60 ml/min. The hydrogen flow-rate was 30 ml/min and the air 
flow-rate 180 ml/min. 
Operation of the nitrogen detector: the optimal use of an A.F.I.D. 
necessitates adjustment of constant gas flow-rates. The distance between 
the collector, containing the rubidium bromide crystal, and the flame is 
very important with respect to the sensitivity and selectivity for nitrogen-
containing compounds. Also the crystal surface has to be clean and 
smooth. At the beginning of each day the crystal surface was wiped off 
with a soft brush and the collector was lowered until the maximum ioniza­
tion current was reached (maximum recorder deflection, range 1θ2, at­
tenuation 32). The detector response was monitored by an injection of 5μΙ 
stock solution (500 ng chlorthalidone-tetramethylderivative), which gave 
full scale deflection at the recorder (range 1θ3, attenuation 32). 
A shaking apparatus (Marius, Utrecht, The Netherlands) was used for 
extractions and where shaking is indicated. Centrifugations were carried 
out in a Servali GLC2 centrifuge. For sonications a sonication bath (Bran-
sonic 220, Branson, Soest, The Netherlands) was used. 
Reagents 
Chlorthalidone (l-oxo-S-P'-sulfamoyM'-chloro-phenyO-S-hydroxy-iso-
indolin) was obtained as a gift from Ciba-Geigy, Basle, Switzerland. The 
internal standard, 4-chloro-Nl-methyl-Nl-(3-methoxypropyl)-l,3-benzene 
disulfonamide, was kindly supplied by Bayer, Wuppertal, G.F.R. 
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(courtesy of Dr. Horstmann). The purity of chlorthalidone and the internal 
standard was better than 99.5% as shown by thin-layer chromatography 
(silica gel 0.25 mm, on precoated glass plates with fluorescence indicator 
F254, Merck, Darmstadt, G.F.R.; solvent system: ethylacetatern-hexane 
= 9:1 (v/v), Rp chlorthalidone = 0.16; solvent system: methanol p.a., Rp 
chlorthalidone = 0.72. The Rp values of the internal standard are given in 
Chapter 4). Chlorthalidone stock solutions were prepared by dissolving 100 
mg in 2000 ml Sörensen phosphate buffer pH 7.4 (0.067 M), and diluting to 
the appropriate concentrations. Internal standard solutions (50 and 5 
/ig/ml) were prepared in the same buffer. Ethanol, methyl isobutyl ketone, 
n-hexane and dichloromethane (all pro analyst grade; Merck, Darmstadt, 
G.F.R.) were used without purification. Methyliodide (Riedel de Haen, 
Hannover, G.F.R.) was used without purification. Tetrahexyl ammonium 
hydrogensulphate was obtained from Labkemi, Stockholm, Sweden and 
converted to the hydroxide (0.1 M in aqueous solution) by dissolution in 
icecold 0.2 M sodium hydroxide. All inorganic chemicals used (E. Merck, 
Darmstadt, G.F.R.) were of pro analysi grade. Glassware was cleaned by 
brushing with detergent (Dubro, commercially available in The 
Netherlands), followed by thorough rinsing with tapwater, distilled water 
and ethanol. The heparin solution (Organon, Oss, The Netherlands) con-
tained 50 mg (= 5000 U) per ml. 
Determination of chlorthalidone in plasma 
Into a glass-stoppered conical tube of 50 ml capacity were pipetted 1 ml 
of plasma and 1 ml of Sörensen phosphate buffer pH 7.4 (0.067 M) con-
taining 5 /ig internal standard, and the mixture was extracted twice (20 min, 
about 250 strokes/min) with 10 ml methyl isobutyl ketone-ethanol (100:2, 
v/v) in a shaking apparatus. From plasma samples expected to contain 
concentrations lower than about 25 ng/ml, also 2 ml portions, to which 0.5 
ml of Sörensen phosphate buffer (0.5 M) and 0.1 ml of internal standard 
solution (50 ¿tg/ml) had been added, were taken for analysis. After cen-
trifugation for 5 min at 3000 r.p.m., the upper organic layers were transfer-
red with a Pasteur pipet to another conical tube and extracted with 2 ml of 
0.1 M NaOH (15 min, about 250 strokes/min). After centrifugation the 
aqueous layer was transferred to a 10 ml conical tube, equipped with a 
screw cap with a teflon-faced rubber liner. Next 50 μΐ 0.1 M tetrahexyl am­
monium hydroxide solution was added and, after mixing, 5 ml of 0.75 M 
methyliodide in dichloromethane. The tube was shaken for 20 minutes at 
50oC by means of a shaking apparatus (about 250 strokes/min) in a ther-
mostated box. After centrifugation (5 min, 3000 r.p.m.) the organic layer 
was transferred to a tube (10 ml) with a finely tapered base and evaporated 
to dryness in a stream of purified dry air (water bath 40° C); 5 ml n-hexane 
was added and the tube was sonicated for 5 minutes in a sonication bath. 
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After centrifugation (5 min, 3000 r.p.m.) the hexane layer, containing the 
chlorthalidone-and internal standard-methylderivatives, was transferred to 
another 10 ml tube with a tapered base and the hexane was evaporated to 
dryness. To the residue 50 μΐ of ethanol were added, and about 5 μΐ were in­
jected into the gas Chromatograph by means of a Hamilton syringe. Each 
sample was injected twice, by using the dual column system of the gas 
Chromatograph. 
Determination of chlorthalidone in erythrocytes 
The erythrocytes were whirl-mixed thoroughly and sonicated for 15 min, 
and a 200 μΐ volume was pipetted into a glass-stoppered tube of 50 ml 
capacity, containing 1.8 ml phosphate buffer of pH 7.4. Use was made of 
disposable Eppendorf pipettes; each pipet was washed with the buffer, so 
that no red blood cell material remained in it. Internal standard (0.1 ml, 5 
/tg) was added, and next 600 mg sodium chloride and 100 mg sodium 
fluoride, the tube contents were mixed and shaken for 15 minutes. Each 
sample was extracted and treated further exactly as described for the 
plasma samples. 
Determination of chlorthalidone in urine 
The volume and pH of each urine fraction were measured (pH meter 22, 
Radiometer, Copenhagen, Denmark) and the pH was adjusted to 8 by 
means of a few drops of 5.0 M NaOH. To 1 ml of urine in a conical tube 
were added 1 ml of 0.5 M Sörensen phosphate buffer of pH 7.4 and 0.1 ml 
internal standard solution (5 /ig). The mixture was treated further as 
described for the determination in plasma. 
Preparation of calibration graphs 
The concentrations of chlorthalidone in plasma, red blood cells and 
urine were calculated by means of calibration graphs, obtained by adding 
known amounts of the drug to blank samples containing a constant 
amount of internal standard. In order to prepare the calibration graps for 
the red blood cell assay, intact erythrocytes (0.2 ml) were incubated during 
1.5 hours at 370C in 1 ml phosphate buffer of pH 7.4 (0.067 M) containing 
known concentrations of chlorthalidone. This pre-incubation period was 
necessary to assure complete binding of chlorthalidone to red blood cells, 
as will be shown in the Results section below. 
Recovery studies 
The extraction yields of chlorthalidone from buffer and plasma into the 
organic layer were determined at three concentrations, 25 ng/ml, 250 
ng/ml and 2.5 /tg/ml, by adding known amounts to blank plasma and buf-
fer of pH 7.4. After extraction, internal standard was added and the peak 
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area ratio after derivatization was calculated (ratio I) and compared with 
the value obtained after direct derivatization of chlorthalidone and internal 
standard (ratio II). Recovery was calculated as ratio I/ratio II times 100%. 
For the internal standard the extraction recovery was determined in the 
same way. 
Taking of blood samples 
Blood (sampling volume about 7 ml) was collected in heparinized glass 
tubes (containing one drop of heparin solution) and centrifuged (3000 
r.p.m., 3 min) immediately after taking (within 5 sec). Directly hereafter 
the plasma layer was removed rapidly with a Pasteur pipet, and was centri-
fuged additionally for 20 min (3000 r.p.m.). The plasma was decanted into 
another tube. Also the red blood cell layer was centrifuged again 20 
minutes at 3000 r.p.m. The remaining supernatant was removed complete-
ly and discarded. The plasma and red blood cell fractions were frozen at 
-20oC until assay. 
In vitro incubations 
In vitro incubations of chlorthalidone were carried out by gently 
agitating freshly taken heparinized blood (hematocrit values 0.40-0.50) 
from human volunteers, obtained after overnight fasting, in a water bath 
of 370C in an open air atmosphere. The compound was dissolved either in 
a small volume of 0.1 M NaOH containing 0.3% NaCl (0.1 ml for 5 ml of 
blood) and added directly to whole blood, or first dissolved in the plasma 
and subsequently added to the red blood cells. 
Influence of hemolysis on chlorthalidone plasma concentrations 
Human blood portions, 100 ml, were taken from healthy subjects after 
overnight fasting (n = 3, age 23-26 years) under conditions preventing 
hemolysis, viz., using a wide-bore needle and carefully heparinizing the 
blood, according to Hanks et al. (1960). The blood was freshly mixed (9:1 
v/v) with chlorthalidone in 0.9% NaCl (50 /tg/ml) and incubated for 90 
min at 370C. An aliquot of this mixture was taken apart before the incuba-
tion in order to obtain blank plasma. After 60 min of incubation, a 2 ml 
blood sample was taken and hemolysed by repeated freezing and thawing 
(3 cycles). The incubated blood was divided in separate portions and to 
each of them a small volume of hemolysate was added, ranging from 0.025 
to 0.5 vol. %. After centrifugation the hemoglobin concentration in each 
plasma sample was measured relative to blank plasma by the 
cyanomethemoglobin method, see e.g. Dacie and Lewis (1975), with a 
small modification: instead of 0.02 ml of whole blood and 4 ml of reagent, 
0.5 ml of plasma was used and added to 2 ml of reagent. The chlor-
thalidone plasma concentrations were determined in duplicate. 
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Identification of the methyl derivative of chlorthalidone 
The methyl derivative of chlorthalidone was prepared in mg-scale as 
follows: 100 mg chlorthalidone was dissolved in 60 ml 0.15 M NaOH in a 
round-bottomed flask, 25 ml 0.5 M tetrahexyl ammonium hydroxide was 
added, and after mixing, 375 ml 4.4 M methyliodide in dichloromethane 
was added and the mixture was allowed to reflux at 40oC, with vigorous 
stirring, during 1.5 hours. The organic layer was separated and evaporated 
to dryness with a Rotavapor apparatus. Due to the low solubility of the 
chlorthalidone derivative in hexane (15 mg/100 ml) the residue was ex­
tracted by sonication 7 times with 100 ml portions of n-hexane, after which 
gas chromatographic detection showed insignificant amounts of product in 
the hexane extract. After centrifugation (5 min, 3000 г.p.m.) in order to 
precipitate the tetrahexyl ammonium salt, the combined hexane extracts 
were evaporated to dryness. A control extraction verified that the hexane 
layer contained only trace amounts of the insoluble tetrahexyl ammonium 
salt. The product was recrystallized from very little methanol and dried 
over P2O5 in vacuo (white crystals, m.p. 127-1280C). The reaction yield 
was at least 95% as judged by weighing and by comparison of the gas 
chromatographic peak areas with those of the microgram scale reaction. 
Mass spectrometry of the derivative formed was performed on a LKB 
9000 mass spectrometer (LKB, Bromma, Sweden), with direct inlet, and 
after gas chromatography on a 3% SE-30 column. High resolution mass 
measurements were obtained by means of a VG Micromass 70-70F ap­
paratus equipped with an on-line computer system (VG Data System 2040; 
VG, Altrincham, England). 
Nuclear magnetic resonance spectra of the methylderivative dissolved in 
d^-dmso (50 mg/ml) were obtained with a Varían 360-60-MC-NMR ap-
paratus with tetramethylsilane as internal reference. 
Infra red spectra (in KBr) were recorded by means of a Perkin-Elmer 257 
grating spectrophotometer. Ultraviolet absorption was measured with a 
Gary 118 apparatus (Varían, Palo Alto, California, USA), the compound 
being dissolved in methanol (1 mg/100 ml). 
RESULTS AND DISCUSSION 
Gas chromatography 
The alkali flame ionization detector was used successfully in the deter-
mination of chlorthalidone in body fluids, both in the nanogram and 
microgram range. Typical gas chromatograms are shown in Fig. 3.2. The 
chlorthalidone-tetramethylderivative and the internal standard dimethyl-
derivative are well-separated under the conditions used with retention times 
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Figure 3.2 
Gas chromatograms showing typical concentrations of chlorthalidone in human plasma and 
human urine. In the left part of the figure a plasma concentration of 24.8 ng/ml was measured 
100 hours after an oral dose of chlorthalidone (100 mg) to a healthy volunteer, in the right 
part an urine sample was analysed and found to contain a concentration of 5.10 /ig/ml. Use 
was made of the nitrogen mode of the flame ionization detector. Chi. = chlorthalidone, i.st. 
= internal standard (methyl derivatives). 
of 3.2 and 2.1 min respectively. Blank plasma, red blood cell and urine 
samples from normal human subjects show no peaks at the retention times 
of chlorthalidone and internal standard and thereafter; therefore, large 
numbers of samples can be injected subsequently over a short period of 
time. The detector response is linear over a wide concentration range. This 
is shown in Fig. 3.3, where a calibration graph of chlorthalidone added to 
plasma was prepared at concentrations from 20 ng/ml to 1 /ig/ml. The 
calibration graphs obtained (n = 10) were always linear and passed through 
the origin but varied in their slope about 10% between different determina­
tion days. Therefore, always two or three standard samples consisting of 
internal standard (5 ¿tg) and chlorthalidone (amount depending upon the 
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Figure 3.3A 
Calibration graph for the gas chromatographic determination of chlorthalidone in 1 ml of 
plasma with concentrations ranging from 20-1000 ng/ml. 
Figure 3.3B 
Calibration graph for the gas chromatographic analysis of chlorthalidone in red blood cells, in 
the concentration range 0.25-25 /ig/ml. 
concentration range of the biological samples, e.g. 25 ng, 100 ng and 500 
ng for plasma concentrations) were included in each series to calibrate the 
graph. This variation was not due to irregular extraction and/or derivatiza-
tion conditions as identical samples prepared in different runs, injected in 
the gas Chromatograph in the same period of time gave always identical 
responses, and the same sample could vary from day to day in peak-area 
ratios. This was attributed to somewhat different responses of the detector 
for chlorthalidone and internal standard, depending upon minor changes 
in the analytical conditions in the alkali flame ionization detector between 
different determination days (e.g. gas flows, position of the crystal). A 
similar observation on the nitrogen detector has been reported by Bilzer 
and Gundert-Rémy (1973). 
Determination of chlorthalidone in plasma 
Plasma concentrations of chlorthalidone can accurately be measured 
down to 5-10 ng/ml. The detection limit is smaller by a factor 5. Standard 
deviations were 5% at concentrations of 1 /ig/ml (n = 8) and 10 ng/ml 
(n = 8). The between-assay reproducibility (different determination days) 
was the same as the within-assay reproducibility. The extraction recovery 
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of chlorthalidone from plasma and phosphate buffer of pH 7.4 was 95% 
± 2 (n = 4) at the concentrations investigated. The addition of 2 percent 
(v/v) of ethanol to methyl isobutyl ketone was found to increase the extrac-
tion recovery of the internal standard from 80% to 95%. The extractive 
alkylation reaction necessary for the methylation of chlorthalidone, in 
which the compound is extracted as an ion-pair with the tetrahexyl am-
monium ion as the counterion and subsequently methylated with 
methyliodide, as is outlined in Chapter 2, rapidly goes to completion under 
the experimental conditions (Ervik and Gustavii, 1974). By means of gas 
chromatography-mass spectrometry, it was confirmed that also the inter-
nal standard was completely di-methylated at the nitrogen atom of the free 
sulfonamide group by this procedure (Mass spectrometric data of the inter-
nal standard can be found in Chapter 5). 
In a few occasions, plasma extracts were found to be contaminated by 
compounds of unknown origin giving rise to a broader "solvent peak" in 
the gas chromatogram than that usually observed. An excellent purifica-
tion of these samples was achieved by an additional step in the isolation 
procedure prior to the methylation, viz. the washing of the 0.1 M NaOH 
layer with a 10 ml volume of methyl isobutyl ketone-ethanol (98:2 v/v). 
This procedure was also advantageous in the determination of very low 
plasma concentrations (below 25 ng/ml) by reducing the background of the 
gas chromatogram. Previously, it had been checked that the linearity of the 
calibration graph remained intact and that the recoveries of the drug and 
the internal standard did not diminish, when this purification step was ap-
plied. 
Another possibility, which we employed incidentally (see e.g. Chapter 13), 
was extraction of plasma buffered at pH 9.0 (citrate-phosphate-borate buf-
fer, 0.1 M, Teorell and Stenhagen) followed by two washes of the organic 
layer with 2 ml of the same buffer, after which the procedure was con-
tinued further as described in the experimental section of this chapter. This 
method gave the same quantitative results as those obtained by extraction 
at pH 7.4. 
If required, additional purification of plasma extracts at a later stage of 
the procedure was achieved by washing the hexane layer twice with 2 ml of 
a saturated aqueous silver sulphate solution. The rationale behind this step 
may be that ion-pairs of tetrahexyl ammonium with endogenous 
substances in plasma (of unknown nature) are formed. Such nitrogen-
containing compounds cause a tailing base-line in the gas chromatogram 
(unpublished observation). Tetra-alkyl ammonium sulphate ion-pairs are 
very insoluble in apolar organic solvents (Tilly, 1973), so that tetra-alkyl 
ammonium ions can be removed with a sulphate containing aqueous phase 
(Ehrsson, 1974). 
82 
Determination of chlorthalidone in urine 
Preliminary experiments showed that the pH values of all urine samples 
to be extracted ranged between 7.40 and 7.45, if treated as described above. 
Calibration graphs were linear and the recovery and standard deviations 
were the same as those obtained in the plasma determination. 
Determination of chlorthalidone in erythrocytes 
Because of the strong binding of chlorthalidone to red blood cells (this 
thesis, Chapters 7 and 8), it was not possible to remove the drug quan­
titatively from this tissue by extraction with organic solvent alone. Extrac­
tion recoveries were 65% at a concentration of 10/tg/ml and only 50% at a 
concentration of 1 ^g/ml in the red blood cells, if extracted twice with 
methyl isobutyl ketone-ethanol (98:2 v/v). Complete hemolysis of 0.2 ml 
red blood cells by freezing and thawing (10 times) in 2 ml of twice-distilled 
water recovered only 85% of the amount extracted from buffer pH 7.4 at a 
red blood cell concentration of 5 μ g/ml. By exposing the red blood cells to 
salt saturation, by means of NaCl and NaF, a reliable method of deter­
mination of chlorthalidone in red blood cells was achieved. Calibration 
graphs were linear over the whole concentration range of 0-25 μg/ml, see 
e.g. Fig. 3.3, with standard deviations of 5% (n = 40). The extraction 
recovery was equal to that from plasma and urine in this procedure. At 
concentrations above 25 /ig/ml, measurements were performed after reduc­
ing the volume of the erythrocytes to e.g. 0.1 ml. In calculating the red 
blood cell concentration of chlorthalidone, the values were corrected for a 
plasma inclusion of 6 volume percent. This correction factor applies to the 
amount of plasma trapped in the packed red blood cells at the relative cen­
trifugal force and the duration of centrifugation used, see e.g. Chaplin and 
Mollison (1952). Degen and Schweizer (1977) reported that a maximum 
recovery of chlorthalidone from whole blood had been obtained by extrac­
tion with buffer of pH 5.5. We checked this for red blood cell samples. The 
concentrations of chlorthalidone, found by extracting 0.2 ml of well-
homogenized human erythrocytes at pH 5.5 (mixed with 1.8 ml of 0.25 M 
citrate-phosphate-borate buffer, Teorell and Stenhagen), were identical 
with the values from the salt saturation method at pH 7.4, so that this ex­
traction pH might be considered as an alternative for erythrocyte assay of 
chlorthalidone. 
Stability of chlorthalidone in frozen plasma, urine and red blood cells 
Upon storage at -20oC, the concentrations of chlorthalidone in plasma, 
urine and red blood cell samples from several human subjects had not 
changed after one year. 
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Taking of the blood samples and studies concerning the distribution of 
chlorthalidone between plasma and erythrocytes 
During the investigations it became apparent that the transport process 
of chlorthalidone from plasma to erythrocytes was not complete in the first 
hours after ingestion of the drug. This resulted in great differences between 
concentrations of plasma samples, which were separated from the 
erythrocytes immediately after taking the blood, and plasma concentra­
tions of the same blood samples, which had stood for a certain period of 
time. This is shown in Fig. 3.4, where plasma concentrations were deter­
mined after an oral dose of 100 mg Hygroton® (chlorthalidone) in two 
healthy human volunteers. The plasma concentrations measured after the 
chlorthalidone concentration [ng/ml) log scale 
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Figure 3.4 
Lower curves: Plasma concentrations of chlorthalidone vs time on semi-logarithmic scale in 
two healthy volunteers after an oral dose of 100 mg Hygroton®. Vertical bars connect plasma 
concentrations determined in exactly the same blood samples, only differing in the time at 
which the blood was centrifuged after vein puncture. This figure illustrates the necessity of 
rapidly separating the plasma from the erythrocytes in the assay procedure of chlorthalidone 
in order to perform reliable plasma measurements especially during the first hours after ab-
sorption of the drug. 
Upper curves: The red blood cell concentrations of chlorthalidone are 50-100 times higher 
than the corresponding plasma concentrations. Only the values obtained after direct cen-
trifugation of the blood are shown. 
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standing of the blood were invariably lower than those after immediate 
centrifugation, while the greatest differences occurred in the first ten hours 
after administration*. This phenomenon was essentially the same with the 
other subjects studied in this respect (n = 4, not shown here). 
The concentrations encountered in the red blood cells are about 50-100 
fold higher than the plasma concentrations (see Fig. 3.4). Therefore, 
relatively large changes in plasma concentrations were not expected to in­
fluence the chlorthalidone concentration in the erythrocytes significantly, 
with the exception of the very early time points (e.g. low concentrations at 
time = 1 hr of subjects L.V. and V.F. in Fig. 3.4). This was confirmed ex­
perimentally (not shown here). 
By in vitro incubations at 370C it was shown that an immediate cen­
trifugation of the blood samples minimized the exchange of chlorthalidone 
between plasma and red blood cells. Chlorthalidone was dissolved in 
plasma of fresh heparinized blood, at different concentrations. The plasma 
was mixed again with the red blood cell fraction and centrifuged either im­
mediately (within 5 sec) or at the times 5,10, 20, 30, 60, 150 min after mix­
ing, during 3 minutes at 3000 r.p.m. From the time course of equilibration 
it became clear that the distribution equilibrium was reached after 60 min 
(Fig. 3.5). Furthermore, in the plasma samples centrifuged at t = 0 always 
the initial (added) plasma concentrations were measured. This was the case 
both in the situation where a high initial gradient of plasma vs. red blood 
cell concentration exists (Fig. 3.5A) as in the more in vivo like situation, 
where the erythrocytes contain already a certain amount of drug, and con­
tinuously more drug is added to the plasma from the gastro-intestinal tract. 
This in vivo effect was achieved by adding plasma to erythrocytes, which 
had been preincubated with chlorthalidone (Fig. 3.5B). The recovery at 
t = 0 (ratio measured concentration in plasma over added concentration in 
plasma) in experiments A and В was 100% and 99% respectively. From 
four of these experiments, we concluded that in blood samples centrifuged 
immediately after the vein puncture actually plasma concentrations were 
measured, which most closely resembled the in vivo concentrations of 
chlorthalidone. No change in concentration was observed when the for 
3 minutes centrifuged plasma fraction was spun for an additional 
20 minutes, after being removed from the red blood cells. This second cen­
trifugation served to remove the buffy layer, so that clear samples were 
obtained. 
* Also in the after-distribution period (24 hours and later) small but distinct differences be­
tween directly separated and after one hour separated plasma samples were found, even if the 
blood was kept at 370C. This aspect may be of interest for the assay of plasma samples, for 
which centrifugation cannot be performed immediately, e.g. from patients outside the 
laboratory or clinic. 
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Figure 3.5 
Time course of the vitro transport of chlorthalidone from plasma to red blood cells in two in­
cubations with whole human blood at 370C. The equilibrium was complete after 60 minutes. 
The plasma concentrations were determined after immediate separation of the plasma from 
the red blood cells. In this way the measured plasma concentrations at t = 0 were equal to the 
added concentrations at t = 0 (complete recovery). For further explanation see text. 
Influence of duration of centrifugation on chlorthalidone plasma concen­
trations. 
In a separate experiment, 50 ml of blood was taken from a human sub­
ject 3 hours after a single oral 100 mg dose of chlorthalidone. Immediately 
after collection, blood was divided and centrifuged during either 1, 3, 5 or 
10 minutes (by using four laboratory centrifuges simultaneously) and 
plasma was separated immediately thereafter. Duplicate analysis of plasma 
showed that the concentration in all four samples was the same. Especially 
the finding from the 10 minutes centrifugation period might appear sur­
prising, because incubations at 37°C, see Fig. 3.5, had shown a rapid 
transport from plasma to erythrocytes during this time. The conditions of 
centrifugation differed, however, in two respects from those present during 
incubation. Firstly, erythrocytes were packed together during centrifuga­
tion, thereby strongly reducing the area of exchange with plasma. This 
seemed a plausible explanation, because plasma separated almost com­
pletely from red blood cells by a 3 min duration of centrifugation. Second-
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ly, the transport rate of chlorthalidone to erythrocytes is much smaller at 
20oC than at 37CC (see Chapter 8). (If centrifugation of blood is carried 
out at room temperature, a blood temperature close to the surrounding 
temperature is reached within a few minutes, as evident from our studies 
concerning mefruside, described in Chapter 4). 
Concludingly, the exact duration of centrifugation, if started immediate­
ly after vein puncture, is not very critical within the limits described above, 
to obtain correct plasma concentrations of chlorthalidone. In all our in­
vestigations on chlorthalidone, reported in this thesis, we used a 3 min cen­
trifugation period, because this was the shortest time to yield sufficient 
plasma for assay. 
Influence of heparin on distribution between plasma and red blood cells 
To study a possible influence of heparin on the distribution of chlor­
thalidone between plasma and erythrocytes, blood samples were drawn by 
vena punction from 4 patients using Hygroton® and every blood sample 
was divided into two portions, one being placed in a heparinized tube and 
the other in a tube which contained no anticoagulant. The blood was cen-
trifuged immediately after vein puncture. No differences between the 
plasma concentrations in heparinized tubes and those in tubes without anti­
coagulant were found. An effect of heparin was also not apparent after the 
in vitro incubations of chlorthalidone in whole blood, because of the con­
sistency of the distribution ratio at different heparin concentrations, up to 
10 fold the normal amount (0.2 ml of heparin solution on 100 ml of whole 
blood). 
Influence of hemolysis on chlorthalidone plasma concentrations 
Because the concentration of chlorthalidone in erythrocytes is 50-100 
times higher than that in plasma, see Fig. 3.4, we expected that certain 
degrees of hemolysis would influence the plasma concentrations. A pilot 
experiment proved that the calibration graph of volume percentages of 
hemolysate added to blank plasma versus the spectrophotometrically deter­
mined hemoglobin (Hb) concentrations was linear and reproducible when 
using the blank plasma as the zero point. Thus, this method is adequate for 
measuring different degrees of hemolysis. However, it must be stated here 
that the Hb concentrations obtained are not absolute, as the assumption 
that the blank plasma contains no Hb at all was not strictly proved. Never­
theless, when blood was collected under conditions preventing hemolysis, 
very low hemoglobin concentrations in plasma were found, 0.16-0.58 
mg/100 ml (Hanks et al., 1960), equivalent to 0.099-0.36 /шіоі/і. 
Hemolysis can be discerned with the naked eye if the plasma Hb concentra­
tion is above 6-12.5 /¿mol/1 (De Gowin et al., 1949). This agrees with our 
observations that the plasma samples with the lowest degree of hemolysis 
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Figure 3.6 
Relationship between the extent of hemolysis of blood and the observed chlorthalidone 
plasma concentration after an incubation of chlorthalidone in whole human blood at 37°C at 
a concentration of 5 jig/ml. The horizontal axis shows the degree of hemolysis expressed in 
two ways: as the hemoglobin concentration in plasma and as the percentual volume of the 
blood hemolysed. On the vertical axis the chlorthalidone plasma concentrations are given as 
percentage of the blank (non-hemolytic) plasma concentration, which was 220 ng/ml in this 
experiment. 
visible by the eye contained about 5 μτηοΙ/Ι of Hb in the Hb assay used. 
These considerations indicate that the Hb concentrations used (shown in 
Fig. 3.6) are not far from the absolute values (estimated maximally 5 
μτηοί/Ι lower than the absolute values). When the chlorthalidone plasma 
concentration was plotted versus the plasma concentration of Hb a linear 
increase was found, with a constant slope (5.6 ng/lO^mol in Fig. 3.6; other 
experiments yielded comparable values). In Figure 3.6 the concentrations 
of chlorthalidone are given as percentages of the blank plasma value, 
which was 220 ng/ml for this subject. The slopes were in good agreement 
with the values expected theoretically on the basis of the whole blood con­
centration of chlorthalidone, the hematocrit values and the Hb concentra­
tions of the blood portions used. On the basis of three of these experiments 
we decided to reject plasma samples with a Hb plasma concentration above 
20 /tmol/l, which corresponds to a hemolysis degree of ca. 0.12% (v/v, 
percentual volume of blood hemolysed). This degree of hemolysis could be 
very easily discerned with the naked eye as a substantial red colour; in cases 
of doubt, the Hb concentration was measured. In practice, when carrying 
out in vitro incubations of chlorthalidone in fresh blood taken the same 
day or a few days before, hemolysis seldom occurred. Mostly, the values 
for the Hb plasma concentrations after the incubation were maximally 5 
/tmol/l higher than before. Also in the 7 ml blood samples obtained 
incubation blood 37 °C 
subject Т.Н. 
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routinely for pharmacokinetic studies, hemolysis almost never amounted 
to a visible degree, although, of course, this depends upon the skill of the 
person performing the vein punctions. 
Equilibrium distribution between plasma and red blood cells in vivo 
The equilibrium distribution of chlorthalidone between plasma and 
erythrocytes in vivo was studied in a group of hypertensive patients using 
Hygroton® chronically (this thesis, Chapter 7). Blood samples were drawn 
by vena punction 24 hours after the last dose, in order to eliminate the pro­
blem of incomplete tissue distribution, which occurs in vivo during the first 
10-15 hours after ingestion of the drug (see Fig. 3.4). Taking the blood 
samples shortly after the dose would have resulted in relatively high (non-
equilibrium) plasma concentrations, see e.g. Figure 3.4. 
Identity of the chlorthalidone derivative formed in the extractive alkylation 
reaction 
In order to confirm the identity of the methyl derivative formed, electron 
impact mass spectra were recorded, and i.r., u.v. and n.m.r. measurements 
were performed. The mass spectrum shown in Fig. 3.7 was obtained after 
direct inlet into the ion source of the LKB 9000 mass spectrometer 
(temperature ion source 270oC, trap current 60 /tA, voltage 20 eV), and in­
dicates by the existence of the parent peaks m/e 394 (35ci) and m/e 396 
(37ci) that a tetramethylderivative of chlorthalidone is present (chlor­
thalidone M.W. = 338.8). The fragmentation pattern after gas 
chromatography was identical. Furthermore, high resolution mass 
measurements of the peaks m/e 363, m/e 287 and m/e 176 were performed 
by means of a VG Micromass 70-70F mass spectrometer. The elemental 
compositions in agreement with these values were: for m/e 363: 
C17H16N2O3CIS, for m/e 287: C16H14NO2CI, and for m/e 176: 
C10H10NO2. The u.v. absorption maximum was beyond 220 nm, and ben-
zophenon absorption at and around 254 nm was absent. The i.r. spectrum 
showed one strong carbonyl absorption band at 1712 cnrl (5.83 μ). By 
comparison with chemical analogues of chlorthalidone (Graf et al., 1959) 
the combined u.v. and i.r. data could be attributed to the structure 
depicted in Fig. 3.7. The n.m.r. spectra yielded values of δ = 3.02 for the 6 
methylprotons bound to the sulfonamide group, δ = 2.92 for the 3 protons 
of the methyl group bound to nitrogen in the isoindolin ring and δ = 3.16 
for the 3 protons of the methoxy group; the 7 aromatic ring protons were 
between δ = 7.5 and δ = 8.2. The integrated values were in a ratio of 6:3:3:7, 
respectively. The mass spectrum shown in Fig. 3.7 was also given by the 
peak in the gas chromatogram with the retention time of derivatized chlor­
thalidone, present in the urine of a human subject following an oral dose of 
the drug. In addition, the retention time of the methylated chemical 
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Figure 3.7 
Electron impact mass spectrum (20 eV) of the tetramethyl derivative of chlorthalidone obtain-
ed after direct inlet into the ion source of the LKB 9000 mass spectrometer 
hydrolysis product of chlorthalidone (G 32623: 4'-chloro-3'-sulfamoyl-
benzophenon-2-carboxylic acid, kindly provided by Ciba-Geigy) was 
found to be different from that of the original compound (2.8 min under 
the conditions of the GLC analysis). This product was not formed during 
the extractive alkylation of chlorthalidone. By this set of data it was con-
sidered sure that the substance determined in biological fluids is indeed in-
tact chlorthalidone, not opened in the isoindolin ring by possible metabolic 
processes. 
SUMMARY 
A sensitive and specific gas chromatographic method is described for the 
quantitative determination of the diuretic and antihypertensive drug chlor-
thalidone (Hygroton®) in plasma, urine and red blood cells. After extrac-
tive methylation of chlorthalidone and the internal standard, the methyl 
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derivatives are measured by means of an alkali flame ionization detector 
(nitrogen detector). Amounts down to 10 ng in the biological sample can be 
measured accurately, with a standard deviation of 5%. 
Because the concentration of chlorthalidone found in the erythrocytes is 
50-100 times higher than that in the plasma, the influence of hemolysis on 
the plasma concentration has been investigated. In addition, a phar-
macokinetic pilot study with human volunteers revealed that much too low 
plasma concentrations can be found (changes by more than 50%), if the 
plasma is not separated from the red blood cells immediately after the vein 
puncture. The emphasis is put on a correct handling of the blood samples, 
based upon in vitro incubations of chlorthalidone in human blood. 
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CHAPTER 4 
DETERMINATION OF MEFRUSIDE IN PLASMA, 
RED BLOOD CELLS AND URINE 
INTRODUCTION 
Mefruside (Fig. 4.1) is an effective diuretic agent (Horstmann et 
al.,1967; Meng and Kroneberg, 1967) and its biological fate has been in-
vestigated in rats and dogs (Duhm et al.,1967; Schlossmann, 1967). Very 
little information is available, however, about the disposition of this drug 
in man, as in a few instances only the sum of mefruside plus its metabolites 
was analysed by using either radioactivity measurements (Duhm et 
al.,1967) of spectrophotometry (Schlossmann, 1967). Both techniques 
have drawbacks with regard to their specificity and the latter also lacks sen-
sitivity. 
For the purpose of pharmacokinetic studies in man an accurate and sen-
sitive method for the determination of mefruside in body fluids was re-
quired. In this study, the compound was made suitable for gas 
chromatography by extractive alkylation forming the dimethyl derivative 
and was detected by the use of an alkali flame ionization detector (nitrogen 
detector), which was expected to be advantageous because of its selectivity 
for organic nitrogen-containing compounds (Sevcik, 1976; Chapter 2). A 
structural analogue of mefruside was selected to serve as an internal stan-
dard (Fig. 4.1). 
C , v^ q 
R: mefruside 
H2Ç ÇH2 
I 1 
• 'Ьо'
СИ2 
\ 
А* 0
 ч 
internal standard 
-(сн 2 ) 3 -осн э 
Fig. 4.1. 
Structures of mefruside and internal standard. 
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Because in preliminary human experiments much higher concentrations 
of mefruside in red blood cells than in plasma were found, in vitro incuba-
tions had to be performed to obtain information on the rate of distribution 
of the drug between the two blood components. Furthermore, drug parti-
tioning was studied at different temperatures because the practical cir-
cumstances of vein puncture and centrifugation of the blood, routinely at 
room temperature, appeared to introduce a considerable change in the 
distribution equilibrium of mefruside between plasma and red blood cells. 
In this way the accuracy of the analytical procedure with regard to actual in 
vivo concentrations could be established. 
MATERIALS 
Reagents 
Mefruside, 4-chloro-Nl-methyl-Nl-(tetrahydro)-2-methyl-2-furanyl)me-
thyl-l,3-benzenedisulfonamide, and the internal standard, 4-chloro-Nl-me-
thyl-Nl-(3-methoxypropyl)-l,3-benzenedisulfonamide, were gifts from 
Bayer (Wuppertal, G.F.R., courtesy of Dr. H. Horstmann). The purity of 
both compounds was larger than 99.5%, as evidenced by gas 
chromatography and by thin-layer chromatography (silicagel 0.25 mm, on 
pre-coated glass plates with fluorescence indicator F254, Merck, Darm-
stadt, G.F.R. Solvent system: toluene:ethanol:conc. acetic acid = 75:24:1 
(v/v), Rp mefruside = 0.49, Rp internal standard = 0.45). Standard solu-
tions of mefruside and the internal standard were prepared by dissolving 
50.0 mg in 1000 ml of 0.067 M Sörensen phosphate buffer of pH 7.4. Dilu-
tions of mefruside were prepared with the same buffer. Ethanol, n-hexane 
and dichloromethane (all pro analysi grade, Merck, Darmstadt, G.F.R.) 
were used without further purification. lodomethane (Riedel de Haan, 
Hannover, G.F.R.) was also used without purification. The diethyl ether 
was either freshly destilled prior to the extractions or used as delivered by 
the manufacturer (containing 7 /ig/ml of 2,6-di-tert.butyl-4-methylphenol 
as stabilizing agent, Merck, pro analysi grade), because identical results 
with the derivatization of the drug substances and no interference with the 
gas chromatographic detection were obtained for both solvent specifica-
tions. Tetrahexyl ammonium hydrogensulphate (Labkemi, Stockholm, 
Sweden) was dissolved (0.1 M) in ice-cold 0.2 M aqueous sodium hydrox-
ide. All inorganic chemicals used (Merck) were of pro analysi grade. The 
heparin solution (Thromboliquine) contained 50 mg (5000 U) per ml 
(Organon, Oss, The Netherlands). Glassware was cleaned by hand with a 
commercial detergent (Dubro), followed by thorough rinsing with tap 
water, distilled water and ethanol. 
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Gas chromatography 
A Hewlett Packard (HP), model 5750 G, gas Chromatograph with a dual 
nitrogen detector (alkali flame ionization detector), containing a rubidium 
bromide crystal (HP model 15161 A), was used in connection with a HP 
recorder, model 7127 A (HP, Avondale, Pa., U.S.A.). 
Column: glass, 1.8 m long, 3 mm internal diameter, packed with 3% of SE 
30 on Gas Chrom Q, 100-120 mesh (Applied Science Labs., State College, 
Pa., U.S.A.). 
Temperature: oven 265°C (isothermal), injection port 320°C, detector 
370oC. Gas flow rates: helium (carrier gas) 55 ml/min, hydrogen (detector 
gas) 30 ml/min, air (detector gas) 180 ml/min. 
Before being packed, the glass column was treated with chromic acid, 
silanized with 5% dichlorodimethylsilane solution in toluene, rinsed with 
methanol and dried. In order to reduce adsorption to the packed column, 
especially at concentrations below 25 ng/ml, several pre-injections (5-10 
times) of samples containing the methyl derivatives of mefruside and inter­
nal standard were necessary before each series. 
For an optimal performance of the nitrogen detector, the gas flow rates 
have to be kept constant. The distance between the collector, with the 
crystal, and the flame is crucial to obtain maximal sensitivity and selectivity 
for nitrogen-containing molecules. Also, the crystal surface must be clean 
and smooth. Therefore, the crystal was wiped, at the beginning of each 
day, with a soft brush to remove silicon dioxide deposits and the collector 
was lowered until maximum ionization current (maximum recorder signal) 
was obtained (range Ю^; atténuation 32). The detector response was 
monitored by an injection of ca. 500 ng of the dimethyl derivative of 
mefruside, which gave full-scale deflection of the recorder (range 10^; at-
tenuation 32). 
Other apparatus 
A platform shaking apparatus (Marius, Utrecht, The Netherlands) was 
used for extraction and where shaking is indicated. Centri f ugation was car-
ried out in a Sorvall GLC 2 centrifuge (Meyvis, Bergen op Zoom, The 
Netherlands). For sonication a Bransonic 22 sonication bath (Branson, 
Soest, The Netherlands) was used. The pH was measured with a pH meter 
22 (Radiometer, Copenhagen, Denmark). Haematocrit values were deter-
mined with a Hawskley micro-haematocrit centrifuge (Hawskley, Lancing 
(Surrey), England) and, after reading, corrected for a plasma trapping 
percentage of 3%, which applies to this method (England et al., 1972). 
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METHODS 
Sampling of blood and urine 
Blood samples, ca. 7 ml, were collected in heparinized glass tubes (con­
taining one drop of heparin solution) and centrifuged immediately after 
taking (within a few seconds) for 3 minutes at 3000 r.p.m. Directly here­
after, the plasma layer was removed with a Pasteur pipet and transferred to 
another tube. The red blood cell layer was centrifuged for another 20 
minutes at 3000 r.p.m. to obtain constant package of the erythrocytes 
(trapped plasma volume 6 vol. %, Chaplin and Mollison, 1952). The re­
maining supernatant was removed completely and discarded. The plasma 
layer was also spun during the same time, for practical reasons, in order to 
precipitate the buff y coat and so obtain clear samples, which were decanted 
into new tubes. The above treatment of the blood samples took place at 
room temperature (20oC) normally, with exception of parts of the parti­
tioning experiments, described below. Whole blood samples, or plasma 
and red blood cell fractions, were frozen at -20oC until assay. Prior to 
analysis the samples were well homogenized by means of a whirl-mixer. 
Blood for in vitro studies was collected in ca. 60 ml portions from 
healthy male volunteers (age 22-25 yr) after overnight fasting, under condi­
tions preventing haemolysis, by using wide-bore needles and by carefully 
heparinizing the blood (0.1 ml heparin solution on 100 ml whole blood). 
Each portion was incubated with mefruside freshly, the same day, in an 
open air atmosphere and visible haemolysis did not occur. 
After collecting human urine, the volume and pH of each fraction were 
measured the same day and an aliquot of each portion was frozen at -20oC. 
Prior to assay the pH of the urine samples was adjusted to pH 8 with a few 
drops of 5 M sodium hydroxide solution. 
Selection of derivatization time and temperature 
The concentrations of the reactants of the extractive alkylation were 
chosen analogously to those described in Chapter 3 on the permethylation 
of chlorthalidone. Mefruside was dissolved (250 ng/ml) in 0.1 M NaOH 
and 2 ml portions of this solution were pipetted into glass tubes with a fine­
ly tapered base containing 50 μ\ of 0.1 M tetrahexyl ammonium hydroxide 
solution. After mixing, 5 ml of 0.75 M iodomethane in dichloromethane 
were added and the tubes were vigorously shaken at room temperature or 
at 50oC during either 1, 5, 10, 20 or 30 minutes. After brief centri fugation 
each organic phase was transferred to another tube containing 5 /tg of the 
dimethyl derivative of the internal standard. The latter had been prepared 
by extractive alkylation at 50oC for 20 min, as a previous study had shown 
that complete derivatization had occurred under these conditions (Chapter 
3). After evaporation of the combined substances to dryness (40°C), the 
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samples were processed in the same way as described after the evaporation 
step of the analytical procedure following. 
Analytical procedure 
Depending upon the kind of biological sample, one of the four following 
combinations was pipetted into a glass-stoppered conical 50 ml tube: 
1) 2 ml of plasma and 0.5 ml of 0.5 M Sörensen phosphate buffer of pH 7.4 
2) 0.5 ml of red blood cells and 1.5 ml of 0.067 M Sörensen phosphate buf-
fer of pH 7.4 
3) 1 ml of whole blood and 1 ml of 0.067 M Sörensen phosphate buffer of 
pH7.4 
4) 1 ml of urine and 1 ml of 0.5 M Sörensen phosphate buffer (pH 7.4) 
Internal standard was added (5 /ig, 0.1 ml) and the mixture was extracted 
twice (5 min, ca. 250 strokes/min) with 10 ml of diethylether in the shaking 
apparatus. After centrifugation for 5 min at 3000 r.p.m. the organic layers 
were transferred with a Pasteur pipet to another conical tube and the drug 
was extracted into 2 ml of 0.1 M of sodium hydroxide (10 min, ca. 250 
strokes/min). After centrifugation (5 min, 3000 r.p.m.) the aqueous layer 
was transferred to a 10 ml conical tube, equipped with a teflon-faced rub-
ber liner. Next, 50 /tl of 0.1 M tetrahexyl ammonium hydroxide solution 
was added and, after mixing, 5 ml of 0.75 M iodomethane in dichloro-
methane. The tube was shaken for 15 min at 20° С by means of the shaking 
apparatus at ca. 250 strokes/min. After centrifugation (5 min, 3000 r.p.m.) 
the organic layer was transferred to a 10 ml tube with a finely tapered bot­
tom and evaporated to dryness in a stream of purified dry air (waterbath 
40°C); 5 ml of n-hexane was added and the tube was sonicated for 10 min. 
After centrifugation (5 min, 3000 r.p.m.) the hexane layer, containing the 
methyl derivatives of mefruside and internal standard, was transferred to 
another tapered 10 ml tube and the hexane was evaporated to dryness. To 
the residue 50 /tl of ethanol was added and, after thorough whirl-mixing, 5 
μΐ of the solution was injected into the gas Chromatograph by means of a 
Hamilton syringe. Each sample was injected twice. The concentrations in 
the biological samples were calculated by the use of calibration graphs, ob­
tained by plotting the mean ratio peak height mefruside/peak height inter­
nal standard against known amounts of mefruside added to blank samples 
with a constant amount of the internal standard. 
DRUG PARTITIONING BETWEEN PLASMA AND RED BLOOD CELLS 
Rate of distribution in whole blood at 20 and 37°C 
Fresh human blood (60 ml portions) was centrifuged at 3000 r.p.m. for 
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10 min. Known amounts of mefruside, 50-100 /¿g, were dissolved in 
approximately one half of the total volume of plasma and preincubated for 
30 min, either at 20 or at 370C. The remainder of the blood portion was 
homogenized again and also kept at the desired temperature by gently 
agitating the flask in open air. After 30 min the blood was reconstituted, 
and separation of plasma and red blood cells was achieved by centrifuging 
(3000 r.p.m., 3 min.) 7 ml aliquots of the incubated blood at the following 
times: t = 0 (immediately after mixing), 1=1, t = 2.5, t = 5, t = 15 min. 
Plasma and whole blood concentrations were assayed according to the 
method described in the previous section. The plasma concentration, 
theoretically present at t = 0 before mixing of the blood constituents, was 
calculated from the amount of mefruside added and the total volume of the 
plasma, present in the incubation mixture, which was accurately known 
from the total volume of the blood portion and the corrected haematocrit 
value. Prior to, and during the incubations at 37°C, all apparatus and 
glassware were equilibrated at this temperature in a thermostatically con-
trolled room. 
Influence of temperature upon the distribution equilibrium 
3 ml of mefruside solution (50 /ig/ml in physiological saline) was added 
to 80 ml of fresh human blood and the mixture was divided into four por-
tions, being placed at four different temperatures between 20oC and 370C 
(actual values in Fig. 4.7). After gentle agitation for 10 min, duplicate 7 ml 
aliquots of each portion were centrifuged (3 min, 3000 r.p.m.) and the 
plasma layers were quickly removed, the whole procedure being carried out 
at thermostatically maintained temperatures. The temperature of each red 
blood cell fraction was checked after the centrifugation step. 
The following experiment simulated the effect of handling blood 
samples at room temperature (20° C) upon the distribution of mefruside 
between plasma and erythrocytes, originally present at in vivo temperature 
(370C): 20 ml human blood portions were spiked with mefruside at varying 
concentrations, ranging from 0.25-2.0 /ig/ml (exact values in Fig. 4.8), 
warmed up and incubated for 5-10 min at 370C in a waterbath kept in a 
thermostatically controlled box. Aliquots of each portion (7 ml) were cen-
trifuged directly (3000 r.p.m., 3 min) by means of glass tubes and cen-
trifuges conditioned at 370C. Parallel to them, 7 ml aliquots were treated at 
room temperature (20°C) after the incubation. They were first drawn into 
a plastic syringe, transferred immediately thereafter to glass tubes and cen-
trifuged (3000 r.p.m., 3 min), the plasma layers being rapidly removed with 
a Pasteur pipet and put into other tubes. 
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RESULTS AND DISCUSSION 
Gas chromatography and specificity 
Figure 4.2 shows a typical gas chromatogram resulting from the assay of 
a human plasma sample, spiked with mefruside at a concentration of 12.5 
ng/ml. The retention times of the internal standard and mefruside peaks 
are, respectively, 2.8 and 4.1 minutes and no interfering peaks are present 
at their positions in normal blank plasma, red blood cells, urine or whole 
blood. The only chemical species logically interfering with this assay could 
be a potential metabolite (M) of mefruside, liberated, if existing, by 
demethylation of the methyl-substituted sulfonamide group. By using pro-
pyliodide (in analogy to the analytical procedure described for 
detector response (·/«) 
lOO-
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Fig. 4.2. 
Gas chromatogram of the methyl derivatives of mefruside and its internal standard after 
analysis of a human plasma sample of 2 ml. Use was made of a nitrogen-sensitive detector. 
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chromotographed as n-propyl-derivatives 
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Fig. 4.3. 
Left gas chromatogram: analysis of 2 ml of blank human plasma spiked with mefruside and 
normefruside (12.5 ng each). Gas chromatogram on the right side: analysis of plasma from a 
patient receiving multiple doses of mefruside; the retention time of the propylated derivative 
of normefruside (M) is marked by an arrow. 
methyliodide) the propylated derivatives of mefruside and M were 
separated on the g.c. column, with retention times of resp. 5.1 and 6.1 min 
(conditions as described under Materials). No trace of M was detected (< 1 
ng/ml) in plasma, urine or whole blood of human subjects receiving single 
or repetitive doses of mefruside, in spite of the presence of considerable 
mefruside concentrations in the plasma (19-91 ng/ml) and red blood cells 
(0.61-2.64 itg/ml) of the patients under chronic treatment (n = 17). See Fig. 
4.3. Therefore, the assay must be considered specific for the unchanged 
drug. 
Derivatization yield 
Mefruside is rapidly methylated at room temperature, the reaction being 
already complete after 5 minutes (Fig. 4.4). The structure of the methyl 
derivative was confirmed by mass spectrometry (20 eV, LKB 9000 mass 
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Fig. 4.4. 
Time course of the extractive methylation of mefruside (500 ng) at 20 0C. Organic phase: 
iodomethane, 0.75 M in dichloromethane (5 ml). Aqueous phase: tetrahexyl ammonium-
hydroxide (THA + OH-), 0.0025 M in 0.1 M sodium hydroxide (2 ml). 
spectrometer), the most predominant mass fragment (m/e 85) was at­
tributable to the 2-methyltetrahydrofuran moiety. A complete mass spec­
trum of dimethylated mefruside can be found in Chapter 5, where it was of 
help in the identification of 5-oxo-mefruside as a human metabolite. Also 
the internal standard methyl derivative was formed with a similar rate at 
room temperature, as was established in analogy to the experiment describ­
ed for mefruside. Yet, in the analytical procedure a longer reaction time of 
15 min was preferred, because it appeared that a strongly tailing substance, 
present in the methylation mixture, which eluted in the gas chromatogram 
just after the solvent peak, became reduced with longer reaction times, thus 
providing a more stable base-line, which was needed in the analysis of low 
concentrations of mefruside, below 25 ng/ml. Although the identity of this 
substance was not extensively studied, our observation that it disappeared 
completely from the gas chromatogram by washing the hexane layer with 
saturated aqueous silver sulphate solution (twice with 2 ml) points to a 
tetrahexyl ammonium salt. It is known that such a compound can be easily 
removed in this way (Ehrsson, 1974), due to the low organic phase parti­
tion coefficient of tetra-alkyl ammonium sulphate ion-pairs (Tilly, 1973). 
Extraction recovery 
The peak height ratio of mefruside and internal standard after extraction 
of mefruside from plasma or buffer of pH 7.4, followed by addition of the 
100 
recovery (0/o) 
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Fig. 4.5. 
Improvement in extraction recovery of mefruside from 2 ml of plasma (• , ·) and buffer (Δ , 
o) by two extractions with diethylether (10 ml) instead of a single one. 
internal standard prior to the methylation (ratio I), was compared with the 
ratio obtained after direct derivatization of both compounds (ratio II). The 
extraction recovery was calculated as 100% times ratio I/ratio II. After one 
extraction with diethylether a value of 98% was found at a plasma concen­
tration of 250 ng/ml, but the recovery decreased at lower concentration to 
ca. 80% at the 25 ng/ml level, see Figure 4.5. As this behaviour would not 
provide linear calibration graphs, the effect of an extra extraction was 
studied. Figure 4.5 shows that after two extractions a recovery of 
99.5±0.5% (mean±S.D., n = 8) was obtained, independently of concen­
tration , without differences in extraction yield from buffered plasma or 
buffer alone. Concludingly, solutions of mufruside in buffer can be used 
for the preparation of the calibration graph within a series of plasma 
samples. Analogously, it was established that the recovery from red blood 
cells (0.5 ml on 1.5 ml buffer) was the same as that from the buffer solution 
alone (see e.g. Figure 4.6). 
Calibration graphs and reproducibilty 
Linear calibration graphs, passing through the origin, were obtained for 
both the determination in plasma and that in urine, red blood cells or 
whole blood. Some typical results are shown in Fig. 4.6. Between different 
days, variations in slope of about 15% occurred, due to differences in 
response of the detector to mefruside and internal standard, dependent 
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Fig. 4.6. 
Typical calibration graphs for the gas chromatographic determination of mefruside in plasma 
(left part) and in red blood cells (right part). 
upon minor changes in detector operation (e.g. gas flows, height of crystal) 
at different occasions. Variations in the response of this detector have been 
observed also by others (Gough and Sugden, 1973). No fluctuations of ex-
traction and/or derivatization yields were evident as duplicate samples 
prepared in different series, but injected on the same day, always gave 
identical peak heigh ratios. Nevertheless, to check the whole procedure, 
two or three reference samples with amounts of mefruside in the expected 
range, e.g. 10, 50 and 150 ng/ml for plasma concentrations, were 
extracted, derivatized, and injected together with each series of unknown 
samples. 
The reproducibility of the analysis was relatively constant over the whole 
concentration range, with coefficients of variation ("Vo S.D.) of 3.6% 
(n= 10) at 250 ng/ml, and 4.4% (n = 8) at 10 ng/ml plasma. 
In vitro uptake rate of mefruside by red blood cells 
A very rapid transport of the drug from plasma to red blood cells was 
evident at both 370C and 20°C. Table 4.1 shows that no systematic dif-
ferences in the plasma concentrations were found within a 15 min period, 
starting from the very earliest time point (incubation time < 5 sec), the 
average ratio of red blood cell and plasma concentrations being 43.9+1.6 
(Table 4.1, left part). The exact transport rate was not measurable, due to 
the relatively long time-lag caused by the centrifugation of the blood (3 
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min). The same picture was obtained when erythrocytes were used which 
contained already a certain concentration of mefruside, thus simulating the 
in vivo situation, when during absorption of the drug from the gastro­
intestinal tract continuously more mefruside is added to the plasma and 
bound subsequently by the red blood cells: after adding a small amount of 
mefruside to the plasma of the preincubated blood portion (the one from 
the left part of Table 4.1) the drug was apparently bound with an equal 
rate, resulting in the same distribution ratio (right part of Table 4.1). Fur­
thermore, a complete recovery of mefruside from whole blood can be seen 
by comparison of the added concentrations (at t = 0) with the analysed 
values. At 20oC very similar results (not shown) with respect to the rate of 
distribution were observed. Analogous experiments (not shown) revealed 
that mefruside was also released from the erythrocytes with a comparably 
rapid rate. 
TABLE 4.1 
Rate of distribution of mefruside in human whole blood3 at 37 °C at two different initial 
mefruside concentrations in the red blood cells: 0.00 /tg/ml (left part) and 1.34 /ig/ml (right 
part). 
incubation 
time 
(min) 
Ob 
.,0„c 
1 
2.5 
5 
15 
Mean ± SD 
"0"-15min 
(n = 5) 
Cplasma 
Otg/ml) 
1.13 
0.0302 
0.0307 
0.0310 
0.0320 
0.0292 
0.0306 
±0.0010 
Cwhole 
blood 
Oig/ml) 
0.615 
0.622 
±0.014 
Cred blood 
cells 
Cplasma 
0.00 
44.4 
43.7 
43.3 
41.9 
46.3 
43.9 
±1.6 
incubation 
time 
(min) 
0b 
,.0..c 
1.5 
2.5 
5 
15 
Mean ± SD 
"0"-15min 
(n = 5) 
plasma 
(/ig/ml) 
0.0958 
0.0317 
0.0319 
0.0325 
0.0301 
0.0313 
0.0315 
±0.0009 
Cwhole 
blood 
(/ig/ml) 
0.702 
0.691 
±0.022 
Cred blood 
cells 
Cplasma 
14.0 
43.7 
43.3 
42.5 
46.0 
44.2 
44.0 
±1.3 
a. Haematocrit (corrected) 0.451 ±0.001 (mean±SD, n = 10), left part and 0.488±0.003 
(mean ± SD, η = 10), right part. 
b. before mixing the blood constituents 
с centrifugation started immediately after mixing (< 5 sec) 
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Effect of temperature change upon the distribution ratio of plasma and red 
blood cell concentrations 
When the temperature of blood portions was lowered from 370C to 
20oC a considerable decrease (together ca. 35%) of the plasma concentra­
tions of mefruside was observed, see Fig. 4.7, whereas the total blood 
concentration remained unchanged, thus indicating a change of the 
distribution ratio. This temperature-dependence of the distribution ratio 
and the very rapid rate at which the equilibrium between plasma and red 
blood cell concentrations was reached (previous section) necessitated a 
study of the quantitative changes of the plasma concentrations existing at 
in vivo temperature, caused by the decrease in temperature after treatment 
of blood samples (vein puncture, centrifugation) at routine circumstances 
(20oC). A pilot experiment had shown that after drawing 7 ml blood por­
tions of Ъ1°С into a 10 ml syringe, kept at room temperature, the 
temperature had fallen already to 31.7 ±0.3oC (mean± S.D., η = 5). After 
subsequent centrifugation for 3 minutes, the temperature of the samples 
was 27.5 ±0.4oC (mean ± S.D., η = 5). Figure 4.8 presents a comparison of 
the plasma concentrations found after such routine treatment of the blood 
samples with those present if the entire procedure was carried out at 370C. 
A linear distribution plot is apparent at both temperatures, implying a con­
stant percentual difference between the actual (in vivo) concentrations and 
the experimentally determined values, which were on an average 
85.4±2.7% of the first ones ( mean± S.D., blood portions of two human 
subjects). 
mefruside plasma concentration (ug/ml) — 
incubation in vitro 
" l ^ ^ ^ human whole blood 
τ ' 1 ' • ' ' 1 ' ' ' ' 1 • • — ' ' 1 
37 35 30 2b 20 
blood temperature C O 
Fig. 4.7. 
Temperature-dependent partitioning of mefruside between plasma and erythrocytes, evidenced 
by a decrease of plasma concentrations when going from 37 0C to 20 0C, while the total blood 
concentration remained constant (1.8 fig/ml). 
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mefruside concentration m whole blood ( jug/mi) 
Fig. 4.8. 
Plots of mefruside plasma versus whole blood concentrations at in vivo temperature and at 
the temperature reached after separation of plasma and red blood cells under routine cir-
cumstances (27.5 0C). 
Standing of blood samples after vein puncture during a certain period, 
e.g. 1 hr, results in a further lowering of the plasma concentrations, which 
was shown by in vivo experiments, in which plasma concentrations were 
determined after oral dosage of mefruside (see Fig. 4.9). Several of such 
studies (n = 4) revealed that the decrease after standing was much less 
regular than that after direct centrifugation of the blood. Therefore, a cen-
trifugation immediately after vein puncture seemed by far preferable for 
pharmacokinetic studies, realizing that plasma concentrations obtained in 
that way are constantly ca. 15% lower than those present at 370C, such 
that this treatment does not influence the assessment of plasma half-lives. 
Furthermore, it should be emphasized that plasma concentration decreases 
of this magnitude will barely influence the concentrations in the red blood 
cells if these are, which is the case (see e.g. Figure 4.10), about 30 times 
higher (an increase of only 0.5% was computed for blood of normal 
haematocrit). Therefore, plasma concentrations are a much more sensitive 
indicator for changes in the distribution ratio of this drug. 
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mefruside plasma concentration (ng/ml) 
120 
100 _ centnfugation ot blood samples immediatly after vein puncture 
0 centnfugation after standing for 
1 hour at room temperature 
20 25 
time after dose (hr) 
Fig. 4.9. 
Plasma concentrations of mefruside after a single oral 50 mg dose to subject H.B. Exactly the 
same samples were used for both curves, the only difference consisted of the duration of the 
period between vein puncture and centri f ugation. For further explanation see text. 
APPLICATION 
The present method was used to determine plasma and red blood cell 
concentrations of mefruside in man after administration of oral doses, as 
reported in Chapter 14. An example of a concentration-time curve after 
intake of a single oral dose is given in Figure 4.10. The concentrations in 
the red blood cells are about 30 times higher than those found in the plasma 
(not corrected for the constant percentual change caused by the fall of 
blood temperature, see Fig. 4.8). The time courses of the concentrations in 
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Рщ. 4.10. 
Plasma concentration and erythrocyte concentration curves on semi-logarithmic scale follow­
ing an oral dose of 50 mg of mefruside to a human subject. After a rapid absorption, a 
biphasic decay can be seen without significant difference between the terminal half-lives in the 
two blood components. The concentrations in the red blood cells are about 30 times higher 
than those in plasma. 
both blood components are exactly parallel to each other, with concen­
tration maxima occurring at 2 hours after the dose. This constant ratio of 
plasma and erythrocyte concentrations is in agreement with the linear 
distribution pattern observed in vitro (Fig. 4.8) and with the rapid rate of 
equilibration (Table 4.1). 
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SUMMARY 
A specific gas chromatographic method for the determination of the un­
changed diuretic drug mefruside in plasma, red blood cells or whole blood, 
and urine has been developed. Mefruside and an analogous internal stan­
dard are dimethylated by extractive alkylation and measured on a gas 
Chromatograph equipped with a nitrogen detector (alkali flame ionization 
detector). Concentrations down to 5 ng/ml in plasma, using 2 ml samples, 
can be assayed accurately, with variation coefficients of 4.4% at the 10 
ng/ml level and 3.6% at 250 ng/ml. 
A very rapid partitioning of mefruside between plasma and erythrocytes 
was observed upon in vitro incubations in whole blood. Linear distribution 
plots, with concentrations in erythrocytes ca. 30 times higher than those in 
plasma, were found but their slopes were strongly temperature-dependent, 
such that at 20oC ca. 35% lower plasma concentrations than at 370C 
resulted. However, if the plasma was rapidly separated from the red blood 
cells at room temperature, immediately after vein puncture, a reproducible 
and constant percentual decrease, ca. 15% different from the in vivo 
plasma concentrations, was obtained, thus making the procedure suitable 
for pharmacokinetic studies. 
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CHAPTER 5 
SEPARATE ASSAY OF MEFRUSIDE METABOLITES 
IN THE LACTONE AND OPEN ACID CONFORMATION 
INTRODUCTION 
In Chapter 4, we described a specific gas chromatographic method for 
determining mefruside in human body fluids (Fleuren et al., 1979). Because 
experiments with mefruside in man showed that less than 1 % of the dose 
was excreted into urine as the unchanged drug (Chapter 14), it seemed 
logical to continue our investigations with a search for metabolites of 
mefruside in man. 
The metabolism of mefruside in the rat was studied by Duhm and 
coworkers (1967). Two urinary metabolites, which were formed by oxida-
tion of the 5-C atom of the tetrahydrofuran ring of mefruside, constituted 
together ca. 35% of the dose in this species. These metabolites appeared to 
be connected with each other through a lactone-hydroxy acid equilibrium 
(Fig. 5.1). The reaction was shifted completely to the lactone side under 
acidic conditions, e.g. pH 2, and to the open acid side at alkaline pH, e.g. 
11, the rates of ring-closure and hydrolysis being pH-dependent (Pütter 
and Schlossmann, 1972; Schlossmann and Pütter, 1973). In aqueous buf-
fers of pH 7-8, interconversion of both compounds was unmeasurably 
slow, but it became highly accelerated by addition of rat plasma or rat liver 
homogenates. Also in vivo, in dogs, rapid turnover of the two metabolites 
has been observed (Schlossmann and Pütter, 1973). 
The possible occurrence of the above metabolites in man called our at-
tention especially, because both compounds had been reported to evoke the 
same diuretic effects as the parent drug, after i.v. administration to rats 
(Meng and Kroneberg, 1967), so might be responsible too for diuretic ac-
tivity. The aim of the investigations described in this chapter was, 
therefore, to develop an assay for these mefruside metabolites. Due to their 
particular chemical constitution, care had to be taken to avoid unwanted 
interconversion of the compounds in vitro prior to their separation. 
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Figure 5.1 
Structural formulae of mefruside, 5-oxo-mefruside and its hydroxy carboxylic acid analogue. 
MATERIALS AND METHODS 
Drugs 
5-Oxo-mefruside, 4-chloro-Nl-methyI-Nl-(tetrahydro-2-methyl-5-oxo-
2-furanyl) methyl-l,3-ben2enedisu]fonamide (Fig. 5.1), and the internal 
standard for gas chromatographic analysis (the same compound as used in 
Chapter 4) were supplied by Bayer (Wuppertal, G.F.R., courtesy of Dr. H. 
Horstmann). The synthetic 5-oxo-mefruside sample contained 1.25 wt.^o 
of mefruside, as evidenced by thin layer chromatography (system described 
in Materials section of Chapter 4, Rp mefruside = 0.49, Rp 5-oxo-
mefruside = 0.43) and by gas chromatography, according to the method 
of Chapter 4. No attempt was made to separate the lactone from mefruside 
on a preparative scale, because both compounds were well-separated on the 
gas chromatographic column (see next section). Therefore mefruside did 
not influence peak area measurement of 5-oxo-mefruside and, in analysing 
unknown concentrations, only a small correction for the weighed amount 
of the latter needed to be made. The conformation of the supplied 5-oxo-
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mefruside was checked by nuclear magnetic resonance measurements and 
elemental analysis (C, H,N)*, which yielded data confirming the lactone 
structure, and in agreement with literature (Horstmann et al., 1967). Stock 
solutions of 5-oxo-mefruside were prepared in 0 1 M aqueous HCl and in 
diethylether, in concentrations of 50 /ig/ml and dilutions thereof. 
The hydroxy acid analogue of 5-oxo-mefruside, 4-chloro-Nl-methyl-Nl-
(2-methyl-2-hydroxy-4-carboxybutyl)-l ,3-benzenedisulfonamide, was ob-
tained by dissolving 5-oxo-mefruside (50 /¿g/ml) in 0.1 M NaOH, in which 
very rapid hydrolysis, with a first-order half-life of 20-25 seconds, has been 
found (Schlossmann and Putter, 1973). Completeness of reaction was 
checked after 15 minutes by extracting ahquots (0.1 ml; 5 /ig) added to 2 ml 
of Sórensen phosphate buffer pH 7.4, twice with 10 ml of diethylether. At 
this pH, only the lactone form can be extracted (as will be shown in the 
Results section). No trace (>10 ng) was found with the gas 
chromatographic method described in this chapter, indicating complete 
formation of the hydroxy acid. 
Denvatization and gas chromatography 
With some modification, the gas chromatographic method reported for 
the assay of mefruside m body fluids (Chapter 4, Fleuren et al., 1979) could 
be used. In short, this method consists of extraction of drug and internal 
standard at pH 7.4 into diethylether, re-extraction into 0 1 M aqueous 
sodium hydroxide, and ion-pair extraction with tetrahexylammomum-
countenon into dichloromethane, under simultaneous methylation with 
lodomethane, during 15 minutes at room temperature ("extractive 
methylation", principle outlined in Chapter 2). After evaporation of the 
organic phase, the methylated derivatives are re-dissolved in n-hexane, in 
order to remove the co-extracted tetrahexyl-ammomum iodide, which is 
very sparingly soluble in this solvent, so that strong tailing of this substance 
on the gas chromatographic column is avoided. The methyl derivatives are 
thereafter concentrated in ethylalcohol, prior to injection into the gas 
Chromatograph. 
5-Oxo-mefruside and its hydroxy acid analogue were extracted as 
described in next sections of this chapter. Furthermore, the assay was 
modified with respect to the original procedure for mefruside in the 
dissolution step with n-hexane. Intensive somfication, twice for 15 mm., 
with 5 ml of n-hexane appeared to be necessary for reproducible and com-
plete dissolution of the more polar metabolites. The wash of the hexane 
layer with aqueous silver sulphate solution, by which the background 
* Performed at the Department of Organic Chemistry, University of Nijmegen, Nijmegen, 
The Netherlands 
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signal of the gas chromatogram became reduced (Chapter 4), could not be 
employed for 5-oxo-mefruside, as this step removed its methylated 
derivative almost completely. 
All reagents used, gas chromatographic equipment, and other apparatus 
were the same as described in Chapter 4. The methylated derivatives of the 
internal standard, mefruside and 5-oxo-mefruside eluted from the gas 
chromatographic column (3% SE30, 2650C) at retention times of 2.8, 4.1 
and 6.3 minutes, respectively. The derivative, formed by methylation of 
the hydroxy acid analogue of 5-oxo-mefruside had an identical retention 
time as the derivative of the latter. This was not unexpected because both 
compounds pass through an alkaline layer (0.1 M NaOH) prior to methyla-
tion, so that the lactone is transformed completely to the free acid form, 
and a common species is generated. A discussion of the structure of this 
derivative during gas chromatography will be given in the Results section 
of this chapter. 
pH-dependent distribution between aqueous and organic phases 
Lactone partitioning 
Into glass-tubes, containing 2 ml of aqueous buffers varying from pH 2 
to pH 10 (citrate-phosphate-borate, 0.1 M, according to Teorell and 
Stenhagen), were pipetted 10 ml portions of a 0.5 ¿ig/ml solution of 5-oxo-
mefruside in freshly distilled diethylether. The tubes were well-closed and 
vigorously shaken during 5 minutes. After brief centrifugation, as much as 
possible of the diethylether layer was transferred into another tube. The 
samples containing the buffers of highest pH were handled first in order to 
minimize lactone-hydrolysis. At pH 11, the half-life of lactone-hydrolysis 
is 27 min (Schlossmann and Pütter, 1973), which implies that after 5 min. 
in such solution 88% of the drug is still in the lactone form, i.e. a loss of 
12%. Because the highest pH we employed was a full pH unit lower (pH 
10), we estimated a loss of less than 5% at that pH, which should have an 
insignificant influence on the shape of the distribution curve. 
Hydroxy acid partitioning 
0.1 Ml portions of a 50 /ig/ml solution of the hydroxy acid analogue of 
5-oxo-mefruside in 0.1 M NaOH were added to 1.9 ml portions of buffer 
of pH 2-10 (same buffer as described above). After mixing, 10 ml portions 
of freshly distilled diethylether were added and the tubes were vigorously 
shaken for 5 minutes. After short centrifugation (1 min), as much as possi-
ble of the organic layers was transferred into new tubes. For samples con-
taining the buffers of lowest pH this separation was performed at once in 
order to minimize lactone formation. The half-life of ring-closure at pH 2 
is 3.3 hours (Schlossmann and Pütter, 1973), which means that 98.3% of 
drug is still in the free acid form after 5 minutes at this pH, so that the 
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observed distribution at the lowest pH values too should be a true reflec-
tion of the lipophilicity of the pure open acid species. 
Measurement of extraction recovery 
To calibrate the above partitioning studies, known amounts of lactone 
(0.1-0.5 ¿tg) and free acid (0.05-5 /tg) were dissolved in diethylether (10 ml) 
and 0.1 M NaOH (2 ml), respectively. The sodium hydroxide layers were 
used directly, the diethylether layers extracted first with 2 ml of 0.1 M 
NaOH for 5 minutes, and then used in the extractive methylation, together 
with internal standard (5 /ig in 0.1 ml of 0.1 M NaOH). The percentage of 
extraction at each pH was calculated by comparison of the ratios of the 
peak areas of drugs and internal standard. 
Procedure f or the extraction of 5-oxo-mefruside and hydroxy acid 
analogue from biological samples 
In order to determine 5-oxo-mefruside, 2 ml of plasma, 0.5-1 ml of pack-
ed red cells (1-2 ml of whole blood), or 1 ml of urine were extracted at pH 
7.4 twice with 10 ml of diethylether under the same conditions including 
addition of internal standard, as described for mefruside in Chapter 4. 
After this extraction of 5-oxo-mefruside, the same biological samples 
served to determine the hydroxy acid species. Plasma (2 ml) or urine 
(0.25-1 ml) was adjusted at pH 2 with a few drops of 2 M aqueous 
hydrochloric acid, and extracted, after renewed addition of internal stan-
dard, twice with 10 ml of diethylether for 5 min. Red blood cell or whole 
blood samples, however, extracted at pH 2, yielded a very high background 
signal in their gas chromatograms and in addition unknown disturbing 
peaks. Therefore, the hydroxy acid in these samples was converted into the 
lactone form by leaving the tubes at pH 2 for 24 hours or longer. Subse-
quently, the samples were adjusted again at pH 7.4 with solid NaHC03 
(100-200 mg/sample), internal standard and buffer of pH 7.4 were added 
until a final volume of 2.5 ml in the tube and the lactone was extracted in 
the same way as described at the beginning of this section. Previously, we 
had verified that ring-closure was completed under these conditions, by 
comparison with known amounts of 5-oxo-mefruside. (Moreover, in assay-
ing urine concentrations of the hydroxy acid, the same quantitative results 
were found from the lactone-conversion procedure as from direct extrac-
tion at pH 2.) Parallel to each series of biological samples, two or three 
standards of 5-oxo-mefruside and its hydroxy acid counterpart, added to a 
corresponding volume of pH 7.4, were extracted at pH 7.4 or pH 2, 
derivatized and submitted to gas chromatography, in order to check the 
overall procedure. For this calibration, known amounts bracketing the 
concentration range of the unknown samples were taken, e.g. 0.5, 1 and 
2.5 /tg of 5-oxo-mefruside in the urine assay. 
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Sampling of blood and urine, in vitro distribution 
between plasma and red cells 
The method of collection of venous blood from human subjects was the 
same as described for mefruside in Chapter 4. Shortly summarized, 
heparinized 7 ml blood samples were centrifuged at 3000 r.p.m. for 3 
minutes at room temperature, immediately after vein puncture, and the 
plasma was rapidly taken apart. Because the equilibration of mefruside 
between plasma and red cells was unmeasurably rapid, and the position of 
the final equilibrium temperature-dependent, the decrease in blood 
temperature inherent to routine treatment of blood samples (vein puncture, 
centrifugation) caused an altered red blood cell-plasma concentration ratio 
of this drug (Chapter 4; Fleuren et al., 1979). A similar phenomenon could 
be possible for 5-oxo-mefruside and its hydroxy acid counterpart. 
Therefore, partitioning of these two compounds between plasma and 
erythrocytes was studied in fresh human blood, according to the methods 
described in Chapter 4. Thus, the rate of distribution at 370C, and the dif-
ference between plasma concentrations present at in vivo temperature 
(370C) and those found after routine treatment of the blood (27.50C) were 
determined. A complicating factor arose from interconversion of the lac-
tone and the open acid by incubations in fresh human plasma. Although 
different in extent for each plasma sample, hydrolysis of the lactone could 
account for as much as 25% of the added amount, but ring closure of the 
hydroxy acid was always less than 5% (at plasma concentrations of 40 
¿tg/ml). This pattern was qualitatively in agreement with observations of 
Schlossmann and Pütter (1973) for the interconversion of the two species in 
rat plasma. However, because interconversion in human plasma appeared 
to be finished after 15-30 minutes, we pre-incubated the two substances 
during 30 minutes in plasma at 370C prior to the red blood cell partitioning 
experiments, and measured the concentrations of the drug under study 
both in plasma and red cells. The concentrations employed in the present in 
vitro studies are indicated in the Results section of this chapter. 
Urine from human experiments was adjusted to pH 8 with a few drops of 
5M NaOH, prior to extraction. Care was taken to mix the contents of the 
tube vigorously during pH adjustment, in order to prevent hydrolysis of 
5-oxo-mefruside. 
Comparison of presumed metabolite with synthetic 5-oxo-mefruside 
by gas chromatography - mass spectrometry 
Electron impact mass spectra of the methylated derivatives of synthetic 
5-oxo-mefruside and mefruside were compared with that of the suspected 
metabolite by means of a LKB 9000 gas chromatograph-mass spectrometer 
combination (LKB, Bromma, Sweden), at an accelerating potential of 
20eV, trap current of 60 μΑ and ion source temperature of 260oC. For gas 
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chromatographic separation a glass column (1.5 m χ 3 mm I.D.) was used, 
packed with 3% OV101 on Gas Chrom Q, 100-120 mesh (Applied Science 
Labs., State College, Pa., USA), at an oven temperature of 2550C. The 
retention times of the methylated derivatives of internal standard, 
mefruside, and 5-oxo-mefruside were 8.5 min, 13 min and 18 min, respec­
tively. 
RESULTS AND DISCUSSION 
Drug partitioning 
The distribution of 5-oxo-mefruside and its open-chain analogue be­
tween organic phase and aqueous buffer of varying pH is shown in Fig. 5.2. 
The plots indicate that the lactone can be recovered in the ether layer by a 
single extraction already with 87% yield from pH 2-8.5, similarly to extrac­
tion of mefruside, whereas the carboxylic acid can only be obtained in high 
yield (76%) below pH 3, and not at all extracted above pH 7. This latter 
β/β m organic phase 
100 
mefruside 
2 3 4 5 6 7 8 9 10 11 12 13 
pH ol aqueous phase 
Figure 5.2 
Plots showing the percentage of extraction of mefruside, 5-oxo-mefruside and the hydroxy 
acid metabolite against the pH of the aqueous phase. 
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detail was checked by separate extractions at pH 7.4 (not shown here), 
employing as aqueous phases both buffer alone, buffered plasma, red cells 
and urine. These experiments confirmed that the quantity of the open acid 
compound, recovered in the organic phase by two subsequent extractions 
with diethylether at this pH, was not detectable in our gas chromatographic 
assay, viz. < 10 ng on a total amount of 5 /tg. This means that the percen-
tage of hydroxy acid extracted at pH 7.4 is even lower than 0.2%. In this 
way, the two structural analogues were separated prior to following steps 
of analysis. 
Gas chromatographic determination of 5-oxo-mefruside and its open acid 
counterpart in plasma, red blood cells and urine 
Calibration graphs, prepared by adding known amounts of the lactone 
and the open acid to blank human plasma, urine and red cells, and plot-
ting, after gas chromatographic analysis, peak area ratios of drugs and in-
ternal standard against concentration, were linear and passed through the 
origin. The standard deviation of the whole procedure, determined from 
repeated assay of the same samples was ca. 5% (n=10) for both com-
pounds at concentrations between 0.05-10 ¿ig/sample. The lowest concen-
tration which could accurately be analysed (i.e., with the above standard 
deviation) was approximately 25 ng/sample, whereas amounts down to 
5-10 ng in biological extracts coud still be detected. The recovery of 5-oxo-
mefruside by two extractions with diethylether at pH 7.4 was 98.5 ± 1% 
(mean±S.D., η = 4) in the concentration range investigated, independent 
of the choice of buffer alone, plasma, red cells or urine as the aqueous 
phase. The corresponding figure for extraction of the hydroxy acid 
analogue at pH 2 was 9 4 ± 2 % (mean± S.D., η = 4). 
Identification of mefruside metabolites in biological samples 
The gas chromatograms, obtained by analysis of urine from human sub­
jects who had ingested an oral dose of mefruside (25 or 50 mg, as described 
in Chapter 14) showed a large peak eluting after that of mefruside itself, 
with a retention time of 6.3 minutes (Fig. 5.3), which was the same as that 
of the methylated derivative of synthetically prepared 5-oxo-mefruside. 
The peak was present already after extraction of urine at pH 7.4, but 
became larger when urine had been extracted at pH 2. This extra amount 
could also be recovered by extraction at pH 7.4, if the urine previously had 
been allowed to stand at pH 2 for several hours. 
The electron impact mass spectrum of the presumed metabolite, ex­
tracted from human urine and separated by gas chromatography, was iden­
tical with that of the pure reference compound. The mass spectra of the 
methyl derivatives of mefruside and 5-oxo-mefruside are shown in Fig. 5.4. 
The fragmentation of both compounds is consistent with the scheme of 
117 
detector response И·) -
100 τ 
5 0 
•^  л 
5-охо-
mefruside 
V 
л — г 
7 θ 
time (mm) 
Figure 5.3 
Typical gas chromatogram showing the presence of mefruside (0.15 /(g/ml) and 5-oxo-
mefrusidc (2.7 /ig/ml) in human urine, analysed S hours after intake of a SO mg dose of 
mefruside by a normal human subject (i.st. = internal standard). 
Fig. 5.5. After being split off, the tetrahydrofuran ring of both mefruside 
and its oxidized metabolite appears to be relatively stable, as the m/e 85 
and 99 fragments are very abundant. It can be seen, that a number of peaks 
in the upper panel is shifted to the right with respect to the mefruside spec­
trum with 14 m/e units, viz. 99 vs 85, 142 vs 128, and 381 vs 367, which dif-
Figure 5.5 ί 
Common mass fragmentations of the dimethylated derivatives of 5-oxo-mefruside (I, M.W. 
= 424, 3 5 CI), mefruside(II,M.W. = 410, ^5С\), andastraight-chainanalogue(III,M.W. = 
384, 35ci). 
A. Presumably formed after Η-shift from m/e 44 fragment B. Base peak 
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Figure 5.4 
Electron-impact mass spectra (20 eV) of the methylated derivatives of 5-oxo-mefruside and 
mefruside, after gas chromatographic separation. 
т / е З 1 I (A) m/e 282 , m/e 142, I 
т / е 3 6 7 П ( А ) Ì.V.m
 ( ,•' m/e 12B, Π 
т/е21 , ^ -"/e 102. DI (β) 
m/e 44 
І.П.Ш 
--''\\ С | 
НзС Л 
N ' \ о 
СНз \ „ 
т / е 325 
О , '.П.Ш , 
• s ' ' .СНз 
rí ^к/ 
О - Ν 
\ 
CHa-r^R 
m/e99 KB) 
., т/е 5 KB) 
'm/e45 Ш 
H2C С Н г 
b R = .C C - O П:Р = 
C H , 
H2C C H , I I /C ^CHJ m:R= -(сн
г
)
г
-оснз 
I о 
сн, 
119 
ferences are clearly attributable to replacement of two hydrogen atoms by 
oxygen at the C-5 atom of the tetrahydrofuran moiety. Furthermore, the 
fragmentation pattern of the two compounds is closely comparable with 
that of a structural analogue with a straight chain (III in Fig. 5.5), which is 
used as the internal standard in the gas chromatographic assay of 
mefruside and the metabolites described in this chapter. 
Only the lactone form of both occurring oxidized metabolites of 
mefruside has been drawn in Fig. 5.4. The thermodynamic equilibrium be-
tween these two species lays completely at the opened-acid side at alkaline 
pH (Schlossmann and Pütter, 1973; this chapter. Materials and methods 
section). There can be no doubt, therefore, that any derivative, formed by 
extractive methylation of either the lactone or the open acid as starting 
substance, existed in the open chain form exclusively, prior to injection in-
to the gas Chromatograph. Whether two, three or even four methyl groups 
have been introduced at that stage is not known. There is, however, besides 
the excellent agreement of the mass fragmentation pattern and molecular 
formula depicted in Fig. 5.4, another argument to favour the view that dur-
ing gas chromatography the methylated derivative possesses the structure 
shown. It is well known that, by heating, γ-hydroxy carboxylic acids and 
their ester (and even ether) derivatives are readily converted to the cor­
responding lactones (Köper, 1963). Operated at a temperature of 300 0C, 
the injection port of the gas Chromatograph must amply have provided 
such condition. It must be concluded, therefore, that both metabolites of 
mefruside, viz. the lactone and the open acid, are chromatographed as the 
same methylated derivative, with the formula depicted in Fig. 5.4. 
Duhm and coworkers (1967) have proposed N-demethylation of 
mefruside or its metabolites in the rat to account for a small fraction of 
dose, leading to carbon dioxide in expired air after administration of the 
methyl-Cl4-labelled drug. The methylation which is employed in the pre-
sent assay could have masked possible biological formation of 
Nl-demethylated 5-oxo-mefruside or its hydroxy acid congener. The 
methylated product of this metabolite would be indistinguishable from that 
originating from 5-oxo-mefruside (or open acid analogue) itself. We were 
able to exclude already the presence of detectable amounts of demethylated 
mefruside in human body fluids by the use of propyliodide as the derivatiz-
ing agent (Chapter 4; Fleuren et al., 1979). In an analogous way, we now 
carried out propylation of both urine, plasma and red cell extracts from 
several human subjects, and did not find a trace of a substance with a gas 
chromatographic retention time other than that belonging to the pro-
pylated derivative of 5-oxo-mefruside itself. In this way, the specificity of 
the assay for 5-oxo-mefruside and its open acid counterpart was considered 
to be affirmed. 
120 
red blood cell concentrat ion 
plasma concentration 
39 η 
38 
mefruside 
3 7 -
3 6 
3 5 -
3 4 -
33 
in vitro incubation 
human blood 37°C 
mefruside 3 5^jg/ml 
— ι ι 1 1 1 1 г 
1 2 3 4 5 6 7 
5 - o x o - m e f r u s i d e concentrat ion 
in whole blood (¿ug/ml) 
Figure 5.6 
Graph indicating displacement of mefruside from its red blood cell binding sites by 5-oxo-
mefruside in vitro (not included in this figure is a red cell-plasma concentration ratio of 9.4, 
measured at a lactone concentration of 30 /ig/ml in the same blood) 
In vitro distribution of mefruside metabolites between plasma and 
erythrocytes 
5-Oxo-mefruside and its hydroxy acid analogue equilibrated instan-
taneously between plasma and red cells of human blood. Thus, no dif-
ference was observed in the red cell-plasma concentration ratios at 37 0C, 
whether the blood had been centrifuged immediately after mixing red cells 
with plasma, or at 1.5, 5, 15 and 45 min after the start of the incubation. 
The lactone and the open acid differed greatly in their extent of red cell 
partitioning. While the lactone reached concentrations in erythrocytes 
which were ca. 20 times higher than those in plasma, the hydroxy carbox-
ylic acid concentrations in red cells were only one-tenth of those in plasma, 
at a whole blood concentration of 8 ^g/ml for both experiments. For this 
reason, only the red cell uptake of the lactone was subjected to further 
investigation. The red cell-plasma concentration ratio appeared to be con-
stant in the concentration range employed, 2-15 /ig/ml whole blood, and 
mean ratios of 18 and 21 were found from incubations at 370C in blood 
from two human subjects. 
When blood incubated with the lactone at 370C was centrifuged at room 
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temperature for 3 min (resulting in a blood temperature of 27.50C, as 
described in Chapter 4), the plasma concentrations of the drug were 
96.5 ± 1.5% (mean± S.D., η = 6) of the values obtained, when the whole 
procedure was carried out at 37°C. It was concluded therefore that plasma 
concentrations of 5-oxo-mefruside, found after immediate centrifugation 
of blood following vein puncture, differ by only ca. 3.5% from the concen­
trations actually present at in vivo temperature. 
Because both 5-oxo-mefruside and mefruside (Chapter 4) are rapidly taken 
up by red blood cells, we were interested to see if the binding of the 
metabolite would influence that of the parent drug. Fig. 5.6 shows that the 
erythrocyte-plasma concentration ratio of mefruside, incubated in whole 
human blood, decreases with increasing concentration of 5-oxo-mefruside. 
Although the interaction seems of little importance at whole blood concen­
trations of the lactone below 1 μg/ml, the effect visible at higher concentra­
tion might also play in vivo. Some evidence for displacement of mefruside 
from its red cell binding sites in vivo can be found in Chapter 14, which 
deals with the pharmacokinetics of mefruside in man. 
SUMMARY 
A gas chromatographic method was reported for the quantitative deter­
mination of two metabolites of mefruside, viz. 5-oxo-mefruside 
(mefruside-lactone) and its hydroxy carboxylic acid analogue, in human 
body fluids. Use was made of extractive methylation as dcrivatization 
technique, and quantitation was achieved, with help of a suitable internal 
standard, by means of a nitrogen-sensitive detector. 
Because the two metabolites were linked chemically through a lactone-
open acid equilibrium, interconversion prior to their separation had to be 
avoided. A pH-partitioning study was performed to find optimal separa­
tion conditions. The lactone could be extracted quantitatively at pH 7.4, 
without any trace of co-extracted hydroxy acid. The latter was extracted 
either at pH 2 directly (in case of plasma and urine), or after conversion to 
the lactone at pH 7.4 (in case of red cells or whole blood). Concentrations 
down to 25 ng/sample of both compounds could be analysed with a stan­
dard deviation of 5%. 
5-Oxo-mefruside and its open chain counterpart were identified as 
human metabolites by gas chromatography-mass spectrometry. The mass 
spectrum of authentic 5-oxo-mefruside was identical to that of the com­
pound present in human urine. 
The two metabolites of mefruside equilibrated instantaneously between 
red cells and plasma in vitro. At 370C, the red cell-plasma concentration 
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ratio was 20 for the lactone, but only 0.1 for the open acid compound. It 
was shown by in vitro incubations, that concentrations of 5-oxo-mefruside 
in plasma, obtained by a 3 min centrifugation of blood samples at room 
temperature, immediately after vein puncture, are ca. 3.5% lower than the 
values actually present at in vivo temperature. 5-Oxo-mefruside was able to 
displace mefruside from its red blood cell binding sites in vitro. 
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CHAPTER 6 
DIFFERENCE POTENTIOMETRIC METHOD 
FOR DETERMINING DISSOCIATION CONSTANTS 
OF VERY SLIGHTLY WATER-SOLUBLE DRUGS, 
APPLIED TO THE SULFONAMIDE DIURETIC CHLORTHALIDONE 
INTRODUCTION 
The dissociation constant of a drug is an important parameter in phar­
macokinetic and pharmacodynamic investigations. Once the pKa is 
known, the degree of dissociation of the compound at physiological pH is 
easily derived and, as it may be assumed that in general only unionized 
molecules pass readily across biological membranes (see e.g. Goldstein, 
1974), predictions concerning the access to tissue sites of interest can be 
made. Besides, the pKa has value in the estimation of the lipophilicity of a 
compound from its partitioning between an organic solvent and water: true 
partition coefficients can be calculated from the apparent values at any ar­
bitrary pH, as outlined in Chapter 2. 
Chlorthalidone contains two weakly acidic groups: one sulfonamide and 
one oxo-isoindolin (acid amide) moiety (Fig. 6.1). Although the latter was 
not expected to contribute to dissociation of the drug at acid or neutral pH, 
the former could influence back-resorption of the drug in the renal tubules, 
when urine of pH 8 is produced. In that situation a pH-dependent urinary 
excretion should become evident. This aspect gains quantitative impor­
tance, when it is realized that normally ca. 70% of an available dose of 
chlorthalidone is excreted unchanged in the urine (Fleuren et al., 1979; 
Chapter 9). The present study was undertaken because no pKa value for 
chlorthalidone was available from the literature. 
II 
о 
Figure 6.1 
Structural formula of chlorthalidone. 
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Various methods to determine dissociation constants of acids and bases 
are in common use. These were comprehensively evaluated by Albert and 
Serjeant (1962). These authors stated that both by potentiometry and by 
ultraviolet spectrophotometry, which belong to the more convenient 
methods, accurate results can be obtained, although the latter is more 
laborious. 
One of the premises for a conventional Potentiometrie titration is that 
the concentration of the weak acid or base must be so high that the amount 
of titrant, needed to titrate the solvent, is negligible in comparison with the 
amount necessary to protonate or deprotonate the dissolved compound. 
This condition could not be fulfilled at present, because the maximum 
solubility of chlorthalidone in neutral aqueous solutions was reported as 
ca. 0.12 mg/ml (Stenger et al., 1959), equivalent to 3,45.IO"4 M. In such a 
case a difference titration can be conducted, provided that the amounts of 
strong acid and base, with which the solution of the compound with 
unknown pKa and its blank (solvent alone) are titrated, are measured ac­
curately. Moreover, the pH measurement must be of high precision and 
very reproducible. In order to meet these requirements use was made of an 
automatic Potentiometrie titration equipment, containing a precisely 
operating micro-burette, motor-driven, and a high-resolution digital 
voltmeter, connected to a low drift pH meter. The apparatus has been used 
previously to determine pKa values and numbers of titratable groups of 
purified proteins (de Bruin et al., 1969; Janssen et al., 1970). 
EXPERIMENTAL 
Ал aqueous solution of 0.1 M KCl served as blank. A saturated solution 
of chlorthalidone in this solvent was prepared by vigorously stirring ca. 8 
mg of the crystalline drug in 50 ml at room temperature overnight. After 
filtration, the concentration, determined in triplicate by gas 
chromatography (Chapter 3; Fleuren and van Rossum, 1978), was 
125.2 + 0.7 /ig/ml (mean ± S.D.), equivalent to 3,695.10-4 M. Aqueous 
hydrochloric acid and sodium hydroxide solutions, 0.0604 M, were diluted 
by weighing with four volumes of distilled water and bubbled with nitrogen 
gas to remove carbon dioxide. The titrant was added stepwise by the use of 
a micro-burette (Metrohm, Zürich, Switzerland), dosing each minute 0.01 
ml with an accuracy of ± 0.1%. The titrations were conducted on the 
chlorthalidone solution (4.00 ml) and on the solvent alone (4.00 ml), at 
250C and under nitrogen, in both directions of the pH range 3.5-10.6. Two 
runs with HCl (exp. B, D) and two with NaOH (exp. A, C) were carried 
out. The actual pH ranges were: 3.47-10.28 in A, 8.55-10.58 in B, 
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8.10-10.50 in С and 6.61-10.45 in D. A pH meter in combination with a 
glass and a calomel electrode was used (all from Radiometer, Copenhagen, 
Denmark: types PHM 26, G 202 В, and К 401 resp.). A high-resolution 
digital voltmeter (type LM 1867, Solartron, Peekel, Rotterdam, The 
Netherlands) was connected with the pH meter. The pH was measured 10 
times after each addition of HCl or NaOH and the mean of these readings 
was taken. In this way very reproducible values, including the third decimal 
figure, are obtained (van Os et al., 1972). Detailed descriptions of this 
automatic Potentiometrie equipment have been published by Janssen et al., 
(1970) and van Os et al., (1972). To calibrate the pH meter, phtalate buffer 
(pH 4.008) and phosphate buffer (pH 6.865) were used. 
RESULTS AND DISCUSSION 
Typical titration curves are shown in Fig. 6.2. Equal volumes of 0.1 M 
KCl, with and without chlorthalidone, were titrated with dilute sodium 
hydroxide from pH 3.5 towards pH 10.3. A larger number of additions of 
alkali is needed to increase the pH of the drug solution in the region, where 
the drug becomes deprotonated. The difference at each pH value between 
the number of additions of the two titration runs clearly represents the 
quantity necessary for titration of the drug itself. When these differences 
are plotted versus the pH a difference titration curve is obtained. For a 
weak acid the titration curve obeyes the familiar Henderson-Hasselbalch 
equation: 
pH = pKa + l o g 1-a (Eq.6.1) 
where a represents the degree of dissociation of the acid group and pK'a its 
apparent dissociation constant, which becomes equal to the ther­
modynamic dissociation constant, pKa, at infinite dilution. At higher ionic 
strength, the following relationship is valid: 
ρώ = ρώ - log I jL
 (Eq_6_2) 
in which γΑ" and γΗΑ are the activity coefficients of, respectively, the 
ionized and unionized forms of the acid. The activity coefficients can be 
calculated according to the Debeye-Hiickel equation (see e.g.,Adrien and 
126 
pH during t i t r a t i o n 
11 • 
У 
ι / 
/ 
titration starting with equal volumes (4 ml) of 
. solvent alone (0 1M KCl m aquabidest) 
о chlorthalidone solution ( 0 3695 mM ) 
ι ·" 
0 10 20 30 4 0 50 
number ot additions of NaOH (0 01?0Θ N. 0 01 ml per addition) 
Figure 6.2 
Acid-base titration of the very slightly water-soluble drug chlorthalidone, by measurement of 
the difference in titrant between samples with and without the substance. 
Serjeant, 1962): for log γ A-/y HA a value of -0.11 was obtained. By using 
this correction, the pKa is readily obtained if the experimental value pK'a is 
known. 
When a strong base is added, an equivalent amount of protons is lost by 
the weak acid. Then α can be written as a = Z/A, where Ζ represents the 
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amount of strong base added at any moment of the titration and A the 
amount added at the titration endpoint. When polyacids are titrated, we 
will have the relation: 
η 
Ζ = Σ д . . α . 
i-1 1 1 
(Eq.6.3) 
where i denotes the identity of a specific weak acid group and η is the total 
number of classes of weak acid groups. 
Chlorthalidone contains two acidic moieties, one sulfonamide and one 
oxo-isoindolin group, potentially dissociating in the pH range under study. 
Therefore, A\ = A2 and 
Ζ = A (a. + a«) (Eq.6.4) 
By applying Equation 6.1, we can write: 
Ζ = A. 
pH-pKa 
10 
1 + 10 
pH-pKa + 
pH-pKa, 
10 
pH-pKá 
1 + 10 J (Eq.6.5) 
The titration data were analysed by means of a non-linear least squares 
regression analysis program.* In every curve-fitting procedure the correct 
assignment of independent and dependent variables is of essential impor-
tance to obtain unbiased estimates of the unknown parameters (Perrin et 
al., 1974). The pH was chosen as the independent variable, because its 
measurement was highly reproducible (see experimental section), such that 
there existed, apart from a potential calibration error, which could only in-
fluence the absolute pH scale, a very small error within each experiment. 
For the dependent variable Ζ a constant error of 0.1, expressed as additions 
of strong base, was taken as this was the read-off uncertainty of the dif­
ferences between the titration curves of the chlorthalidone solution and the 
blank, see e.g. Fig. 6.2. 
* Farmfit, a digital computer program in use at the Computer Centre of the University of 
Nijmegen. Details in Chapter 1. 
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At first, the data points were fitted according to the first term of Equation 
6.5 only, assuming that the dissociation of the second acid group was 
negligible (if pH < pK,a2, the second term approximates zero). It came out, 
however, that much better fits were obtained when also the second term 
was taken into account. For this purpose the value for pK'a2 was not left 
free in the least squares regression analysis, because a too small number of 
data points was available in the high pH region, only up to pH 10.6, which 
would introduce large errors in the estimates of the other parameters, Ai 
and pK'ai. Preset values of pK'a2 were systemically changed, until the 
minimum of the sum of weighed squared deviations had been found. The 
results of these calculations are included in Table 6.1 (рК'аг has been 
denoted k2). It has to be noticed that also for A] the best estimate was sear­
ched by the fitting procedure, because this parameter, when it would be fix­
ed at its theoretically calculated value (12.24 additions of strong base), 
would influence the pK'ai estimate with possible errors in the concentra­
tion and pipetted volume of the chlorthalidone solution and in the normal­
ity and volume of the titrant. 
Number of odditrons of strong base ( 2 ) 
pH 
Figure 6.3 
Computer-fitted difference titration curve of chlorthalidone. From four experiments the 
following estimates resulted for pK'ai: 9.228 (A), 9.287 (B), 9.210 (C), 9.235 (D), yielding a 
mean apparent dissociation constant of 9.24±0.02 ( ± S.E.M.) at 0.1 ionic strength and 
250C. 
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TABLE 6.1 
Superiority of the computer fus of difference titration curves of chlorthalidone by taking into 
account the dissociation of two weak acid groups (left part) instead of one (right part) 
Exp. 
no. 
A 
В 
С 
D 
mean 
pK'ai 
9.228 
9.287 
9.210 
9.235 
Two titratable groups 
involved 
Al 
12.15 
12.33 
13.27 
12.67 
±SEM 9.24 ±0.02 
in curve-
k2 
10 94 
11.11 
11.55 
11.95 
•fitting 
X2 
12.6 
14.3 
8.1 
6.1 
One titratable group 
involved in curve-fitting 
pK'aj 
9.35 
9.56 
9.27 
9.26 
Al 
14.43 
14.16 
14.17 
12.96 
x
¿ 
96, 
210 
67. 
11 
(η = 4) 
pK'a] = apparent first dissociation constant. A] = total amount of base at first titration 
endpoint, kj = optimally fixed value for the dissociation of the second acid group, χ^ = sum 
of weighed squared deviations of the experimental data from the fitted curve. 
χ25%, the tabulated level of significance at Ρ = 0 05, was 39,44, 40 and 37 in the experiments 
A, B, C, and D, respectively. 
The thermodynamic dissociation constant, pKaj, is larger than the pK'aj by a factor 0.11, 
due to the contribution of activity coefficients. Therefore, pKaj = 9.35 ± 0.02 (mean ± 
S.E.M ). 
Fig. 6.3 shows a typical difference titration curve, fitted according to 
Equation 6.5 (at fixed optimal pK'a2 values). The definite decision in 
favour of such fit over that based upon ionization of only one acid group 
was made by several criteria: 1) visual inspection of the plots, 2) symmetry 
of the residuals around the fitted curves, 3) calculation of the sum of 
weighed squared residuals (as χ2). Table 6.1 compares the x^-values for 
both procedures and indicates the superiority of curve-fitting according to 
two titratable groups in all four experiments. In addition, it can be seen 
that the scatter of the pK'ai estimates in the left part is much smaller than 
that in the right part. Also the estimates of Α ι at the left correspond better 
with the value calculated on the basis of the total amount of chlorthalidone 
in the titration vessel (equivalent to 12.24 additions of strong base), in­
dicating that actually one proton-donor group was dissociated completely 
at this stage. 
The variance of the four pK'aj estimates exceeds the within-experiment 
error (the computer estimated relative errors ranged from 0.0-0.1 %). This 
points to minor systematic differences between the four experiments, e.g. 
caused by the pH meter calibration. However, the differences are small 
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enough to trust upon the pK'ai (250C) = 9.24 + 0.02 (mean ± S.E.M.) as 
a reliable operational ionization constant, suitable for use as a physico-
chemical parameter in pharmacological studies. When the correction for 
ionic strength is carried out with Equation 6.2 the thermodynamic dissocia­
tion constant is calculated at pKaj = 9.35 (250C). 
Determination of dissociation constants of very slightly water-soluble 
drugs appears to be performed conveniently and reproducibly by the 
method described, and no corrections for titrant consumption by the sol­
vent need to be made. The technique was applied also to the analgesic 
Ibuprofen (pKa = 4.4, preliminary estimate) in our laboratory (van Gin-
neken, 1976), indicating that Potentiometrie difference titrations can be 
conducted in a wide area of pharmaceutical substances. 
SUMMARY 
A renewed application of Potentiometrie acid-base titrations is described, 
by which dissociation constants of practically water-insoluble drugs can be 
measured accurately. The method makes use of the difference in the 
amount of titrant between a suitable aqueous solvent and a solution of the 
drug in that solvent. Such Potentiometrie difference titrations were con­
ducted on a 3,7.10-4 M solution of chlorthalidone in 0.1 M aqueous KCl, 
in the pH 3.5-10.6 range, at 250C. Non-linear least squares regression 
analysis was applied to the data. From four determinations, a value of 
9.24±0.02 (mean ± S.E.M.) resulted for the apparent dissociation con­
stant of the first acid group of chlorthalidone. The thermodynamic 
dissociation constant was calculated at pKaj = 9.35 (250C) by using a cor­
rection for activity. 
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PHARMACOKINETICS OF CHLORTHALIDONE 
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CHAPTER 7 
BASIC PHARMACOKINETIC CHARACTERISTrCS 
OF CHLORTHALIDONE 
INTRODUCTION 
The phtalimidine derivative chlorthalidone (Hygroton®) was introduced 
in the years around 1960 as a diuretic with a long duration of action, lasting 
for up to 48-72 hours (Reutter and Schaub, 1959; Ford, 1960; Mach and 
Veyrat, 1960). The overall type of diuresis is comparable with that observ-
ed from the thiazide diuretics, i.e. chlorothiazide, hydrochlorothiazide and 
congeners (Peters and Roch-Ramel, 1969). As outlined in Chapter 1, the 
similar shape of the dose-response curves of all members of the ben-
zothiadiazine family has led to acceptance of a common mechanism of ac-
tion for them. Accordingly also chlorthalidone has been classified within 
this group. 
Despite extensive use of chlorthalidone in pharmacotherapy, very little 
was known, up to 1974, about its fate in the human body. Pulver et al. 
(1959) administered the drug to rabbits and dogs, and observed accumula-
tion and retention in renal tissue. Measurable concentrations in blood were 
found only after eight hours following oral administration. These authors 
suggested, therefore, that slow and protracted absorption would be one of 
the reasons for the long lasting effect of chlorthalidone. However, 
Beisenherz et al. (1966), using Cl4-iabelled chlorthalidone in rats, observed 
a much more rapid appearance of the drug in blood. In this species, the 
drug was extensively metabolized and excreted into the bile; the nature of 
the metabolites remained unclear. These workers were the first, who noticed 
uptake of chlorthalidone in red blood cells, in which the concentrations 
were 5-6 times higher than those in plasma. Their finding was confirmed by 
Tweeddale and Ogilvie (1974), who had modified the spectrophotometric 
assay of Pulver et al. (1959), but were unsuccessful with this method to 
measure plasma concentrations in the therapeutic concentration range. 
The above-mentioned reports were available when our studies were in-
itiated. During a preliminary study (Fleuren and van Rossum, 1975) a 
much more pronounced accumulation of chlorthalidone in human red 
blood cells was observed than that described earlier. The concentration in 
erythrocytes in vivo was at least 50 times higher than that in plasma, so that 
- in case of chlorthalidone pharmacokinetics - the erythrocytes must be 
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regarded as an important tissue compartment. An advantage of this tissue 
is that it is easily accessible, thereby providing a general model system for 
analysing the kinetics of drugs exhibiting tissue binding. 
During the course of our investigations other workers have contributed 
also to knowledge of the human pharmacokinetics of chlorthalidone. The 
results of Beermann et al. (1975), Collste et al. (1976) and Riess et al. (1977) 
were generally in agreement with our findings and will be referred to at the 
appropriate places throughout this manuscript. Some discrepancy occurred 
between our results and those from the above-mentioned groups with 
respect to the observation of the differing elimination half-lives for plasma 
and red blood cell concentrations of chlorthalidone. As described in 
Chapter 9, this divergency can be explained by a different way of handling 
the blood samples, at which point certain precautions have to be taken. We 
made considerable efforts in this respect, resulting in a reliable method for 
determining chlorthalidone plasma concentrations, as is outlined in 
Chapter 3. 
This chapter will present merely a general framework for the kinetics of 
chlorthalidone in man, especially focusing on the in vivo distribution of 
this drug between plasma and red blood cells. An attempt will be made to 
integrate the relationship between plasma and erythrocyte concentrations 
into one model, including all observed features simultaneously. 
Details of the kinetics of absorption and elimination of the drug will be 
treated in depth in the next chapters of this thesis. Thus, information on 
the rate and extent of absorption, volumes of distribution and total plasma 
clearance of chlorthalidone can be found in Chapter 9. Urinary excretion 
and renal plasma clearance after different dose levels are dealt with in 
Chapter 10. The Chapters 11 and 12 will be devoted to the processes of 
biliary and salivary excretion, respectively. Chapter 13, finally, will 
describe accumulation of plasma and red blood cell concentrations of 
chlorthalidone during multiple dosing. 
MATERIALS AND METHODS 
Chlorthalidone was given in doses of 100 or 200 mg to 10 young, healthy 
male subjects varying in age from 22-25 years. The drug was administered 
in the morning after overnight fasting in the form of a tablet (Hygroton® ). 
Blood samples were drawn by vena punction and heparinized, while 
simultaneously the urine was collected in separate portions over a period of 
at least 4 days. Plasma, urine and red cells were assayed with the gas 
chromatographic method described in Chapter 3. In vitro incubations of 
chlorthalidone in human blood were carried out by gently moving freshly 
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taken heparinized blood, spiked with the drug, in a waterbath of 370C, 
under an open air atmosphere, during 1.5 hours. A pilot study proved this 
period to be sufficient to reach equilibrium distribution, as shown in 
Chapter 3. 
RESULTS 
Time course of chlorthalidone concentration in plasma and red blood cells 
A rapid absorption of chlorthalidone into plasma was observed, with 
peak concentrations occurring at 1.5-3 hours after the dose. The decay 
thereafter was biphasic. Red blood cell concentrations of chlorthalidone 
reached their maximum much more slowly, i.e. 10-15 hours following ad­
ministration, and declined thereafter mono-exponentially. The time of the 
maximum erythrocyte levels coincided with the end of the first phase of 
disappearance of plasma concentration of chlorthalidone. At that stage, 
Chlorthalidone cone lmg/1, log scale) 
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Figure 7.1 
Pharmacokinetic profile of chlorthalidone in a human volunteer after an oral dose of 100 mg 
(Hygroton®). Concentrations were measured both in the blood plasma and in the 
erythrocytes. Plasma decay (t'/i =46 hr) was found to be considerably faster than erythrocyte 
decay (і'/г=65 hr). 
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TABLE 7 1 
Comparison of elimination half-lives in the plasma compartment with those in the 
erythrocytes in human volunteers after an oral dose of 100 or 200 mg chlorthalidone 
(Hygroton)" 
Subject 
J Bi 
J.Bi 
D Bo 
D Bo 
M.Br. 
M Br. 
H F 
V.Fl 
O L 
M R 
T S 
T S 
TS. 
JW. 
TB. 
Mean value 
Age 
(yr) 
22 
22 
22 
22 
23 
23 
25 
20 
23 
23 
22 
22 
22 
25 
24 
(SD) 
Body weight 
(kg) 
69 
69 
80 
80 
815 
815 
67 
68 
74 5 
68 5 
88 
88 
88 
65 
64 
Time period 
measured 
(hr) 
100 
80 
100 
100 
100 
200 
80 
100 
100 
100 
100 
100 
200 
100 
100 
Dose 
(mg) 
200 
100 
100 
200 
100 
100 
200 
100 
100 
100 
200 
100 
100 
100 
100 
'l/2el 
plasma 
(hr) 
36 
42 
50 
42 
45 
46 
34 
30 
39 
44 
42 
55 
42 
28 
27 
40(8) 
' l / 2 « l 
erythrocytes 
(hr) 
52 
52 
60 
64 
66 
65 
58 
51.5 
62 
68 
70 
69 
64 
50 
42 
60(8) 
"The half-life values were calculated by regression analysis, based on at least five data points in 
the terminal part of the decay curves. 
the concentrations in the red blood cells were 50-100 times higher than 
those in plasma, and this ratio increased during the elimination phase. 
Consequently, longer elimination half-lives were obtained from red blood 
cell concentrations than from those in plasma. The final phase of a typical 
drug concentration curve in plasma and erythrocytes is shown in Fig. 7.1. 
Comparative data from ten subjects, studied after administration of single 
oral 100 and 200 mg doses, are given in Table 7.1. The mean half-life in this 
group for terminal plasma decay is 40 hours, and that for erythrocyte 
decay is 60 hours. 
Urinary excretion 
A detailed account of the urinary excretion of chlorthalidone in man is 
made in Chapter 10. In short, all urinary excretion rate plots were perfectly 
parallel to the time course of plasma concentrations, implying that the 
tubular secretion mechanism, by which all sulfonamide diuretics are ex-
creted (Beyer and Baer, 1975; Chapter 1), remains far from saturated in the 
dose range employed. An example of an urinary excretion rate plot in a 
human subject is presented in Fig. 7.2. Cumulative renal excretion of un-
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Figure 7.2 
Comparison of plasma decay and urinary excretion rate of chlorthalidone versus time. In the 
two lower graphs urine production rate and pH of the urine fractions are shown. 
changed chlorthalidone amounted to ca. 25-50% of dose, as measured by 
extrapolation to infinite time after the actual period of assay. 
Distribution of chlorthalidone between plasma and red blood cells 
In the concentration range reached after oral administration of chlor­
thalidone the in vitro distribution is non-linear having an initial great rise in 
the erythrocytes/plasma ratio followed by a phase of more gradual ac­
cumulation in the red blood cells. See Figure 7.3a. A similar view is obtain­
ed from data of hypertensive patients (n = 20), who were on chlorthalidone 
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medication (Hygroton®, 100 mg/day) during 5 days or more. Despite the 
considerable scatter in this plot, which may be due to differences in the 
distribution ratio between individuals, the trend is essentially the same as 
that obtained from the in vitro experiments. See Figure 7.3b. 
Chlorthalidone cone 
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Figure 7.3a 
Relationship between plasma concentrations and red blood concentrations of chlorthalidone 
in vitro after equilibration of the drug in whole blood of a healthy volunteer The plot can be 
interpreted as consisting of a sum of two parts; the first part is saturable and obeying 
Michaehs-Menten kinetics, the second is apparently linear and indicates the value for the 
distribution ratio к
с
із/1с
с
зі of drug between erythrocytes and plasma. 
Figure 7.3b 
Relationship between plasma concentrations and red blood cell concentrations of chlor­
thalidone in 20 hypertensive patients who were receiving doses of 100 mg Hygroton® /day for 
5 days or longer (closed points) The open circles represent data from human volunteers 24 
hours after a single dose of chlorthalidone Apparently the plot consists of two phases which 
can be analysed in the same way as was done in Figure 7 3a 
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PHARMACOKINETIC ANALYSIS 
Linear approach 
The compartment models employed in current pharmacokinetic litera-
ture are mathematical descriptions of the plasma, serum or blood decay 
curves, based upon a continuous first-order exchange between the central 
compartment (generally the sampling compartment, e.g. plasma) and the 
peripheral compartments (tissues) (Dost, 1953; Gibaldi and Perrier, 1975; 
Notari, 1975; van Rossum, 1971). The factors which can be used to relate 
the concentrations in the different compartments are distribution rate con-
stants (e.g. hour-l) or transfer clearance constants (e.g. liters/hour). In this 
way, hypothetical amounts of drug in tissues or tissue concentrations can 
be simulated, provided that the plasma concentrations are known. The use 
of the ratio of the transfer clearance constants of entry into and release 
from such compartment, kc(in/kc,out> has the advantage of giving directly 
the ratio of the eventual tissue and plasma concentrations, provided that 
the state of equilibrium after absorption and distribution phases has been 
reached. 
An implication of this description by linear differential equations is, that 
if the decay curves of plasma and tissue concentrations versus time are 
compared, they always appear to become parallel to each other, in-
dependently of how fast the equilibrium is reached (linear phar-
macokinetics). This is shown in Figure 7.4 in which we brought about 
variations in the transfer rates of entry into and release from a peripheral 
compartment, and kept the ratio between them constant. The upper curves 
represent tissue compartments to which the drug is transferred preferential-
ly compared with the central compartments. If the numerical value of 
kc.out is lo w e r it takes more time to reach the point where the tissue con-
centration is maximal. For those drugs which to an appreciable amount ac-
cumulate in the erythrocytes, the erythrocytes may be considered as a 
separate compartment, that belongs either to the central or the peripheral 
compartment depending upon the rate of drug exchange between plasma 
and erythrocytes. 
Non-linear model 
The results obtained with chlorthalidone are not consistent with descrip-
tion by means of a linear distribution model, in which the decay of plasma 
concentrations and red blood cell concentrations should become parallel 
soon. Therefore, we developed a model in which the erythrocytes were con-
sidered as a compartment composed of two parts: one portion of drug is 
exchangeable with the central compartment according to the appropriate 
distribution rate constants, the other portion is more tightly bound in a 
Michaelis-Menten type of binding, assuming a saturable number of bind-
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Figure 7.4 
Theoretical plasma concentration and tissue concentration curves on semi-logarithmic scale, 
based on a central and one tissue compartment and first-order absorption following oral 
administration of a drug with a considerable tissue uptake. Upper curves represent tissue con­
centrations, lower curves plasma concentrations. The parameters used in А, В, С are: D = 
100 mg, k
c a
 = 8 1/hr, VQ = Î 1, Vi = 401 (central), V2 = 2 1 (tissue)and kcei = 7.5 1/hr. 
The ratio between kci2 and kc2i was kept constant and the absolute magnitude of these 
transfer clearance constants varied as indicated in the figure parts А, В and С In all cases the 
terminal decay curves of plasma and tissue concentrations become parallel, although this 
picture may be delayed initially by slow equilibration processes as is shown in Fig. 7.4C. 
ing sites, expressed as that concentration of drug which can be bound max­
imally. The red blood cell concentrations measured experimentally are, of 
course, the sum of these two components. 
In spite of the high concentrations found in the red blood cells with 
respect to the plasma (part of the central compartment) these two compart­
ments could not be the only ones, as judged from the absolute amount of 
drug totally present there. The red blood cell concentration was known and 
the real red blood cell volume is a reasonably constant function of 
bodyweight (see e.g. Diem and Lentner, 1968). The plasma concentration 
is also known and the volume of the central compartment (Vj) can be 
estimated reliably from the time course of plasma concentrations. Correc­
tions have to be made for the amount of drug not yet absorbed from the 
absorption compartment (Q0) and the quantity already eliminated by the 
body (Qel). The basic pharmacokinetic data from 8 experiments necessary 
for these calculations are summarized in Table 7.2. Details of the calcula­
tions are given in the Appendix 7.1. The resulting total amount, accounted 
for by the central compartment and red blood cells, was in every case 
smaller than the dose administered, for several values of biovailability e.g. 
F= 1, F = 0.5 and F = 0.25. Therefore, it was concluded that another tissue 
compartment must be present over which chlorthalidone distributes and 
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TABLE 7 2 
Pharmacokinetic data after oral administration of chlorthalidone to human subjects" 
Subject 
Τ S 
D В 
J В 
M R 
Τ В 
Dose 
(mg) 
100 
200 
100 
200 
100 
200 
100 
200 
К. 
(hr-) 
0 862 
1 385 
1 17 
1 195 
0 694 
0 990 
142 
2 07 
a 
(hr"1) 
0 392 
0 503 
0 379 
0 361 
0415 
0 595 
0 357 
0 694 
ß, 
(hr1) 
0 0123 
0 0171 
0 0139 
0 0169 
0 0165 
0 0193 
0 0165 
0 0199 
VJF 
(liters) 
253 
320 
214 
289 
312 
352 
200 
214 
VJF 
(liters) 
681 
828 
708 
740 
687 
806 
500 
728 
*« , /F 
(liters/ 
hr) 
9 67 
15 8 
12 1 
14 5 
13 6 
17 8 
8 0 
17 0 
AUC 
0-10 hr 
(mg/hter 
hr) 
1585 
2 42 
1 634 
2 79 
120 
186 
1735 
2 33 
C. af i - i a l 
/=10hr (mg/hter) 
0 100 
0 165 
0 093 
0 172 
0 082 
0 132 
0 152 
0 150 
Cjat 
Í = 1П hr 
ι — 1VJ I I I 
(mg/ 
liter) 
8 45 
114 
9 00 
13 75 
6 0 
7 20 
6 70 
7 90 
v3 
cale (liters) 
2 36 
2 36 
2 32 
2 32 
2 01 
2 01 
198 
185 
Q2 cale (% dose) 
F = 
1 
39 4 
41 1 
39 4 
39 
46 
53 
42 5 
56 8 
F= F = 
0 5 0 25 
19 4 0 
27 6 1 2 
18 6 0 
23 0 
34 10 
45 8 30 9 
29 2 2 7 
49 5 34 9 
aK
a
, a, and β are the apparent first-order rate constants for absorption, first phase of disappearance, and terminal elimination, respectively, derived 
from the chlorthalidone plasma concentrations The meaning of the other parameters shown is given in Appendix I 
DE 
У 
к Cel 
Figure 7.5 
Schematic model used to explain the different elimination half-lives of the plasma and the red 
blood cell concentrations of chlorthalidone in man after oral administradon. The absorption 
compartment has the subscript 0, volume VQ and concentration Z. The central compartment 
has the subscript 1, volume V\ and concentration x. The additional tissue compartment has 
the subscript 2, volume V2 and concentration y. The erythrocyte compartment has the 
subscript 3, volume V3 and a concentration u + DE which is the sum of the concentration of 
exchangeable drug u, and that of strongly bound drug DE; u is in equilibrium with the concen­
tration χ in the central compartment according to the first-order transfer clearance constants 
ксізапаксз!. 
where, relatively to plasma, high concentrations are reached. Expressed in 
percentages of the dose, the amount of drug calculated for this second 
tissue compartment (Q2) at 10 hours after oral administration, yielded 
mean values (n = 8) of Q2 = 44.7% (range 39-57%) in the case of complete 
absorption from the gastrointestinal tract (F=l), and for F = 0.5 and 
F = 0.25 respectively, mean values of Q2 = 30.9% (range 19-50%) and Q2 
= 10% (range 0-35%). 
The model eventually found appropriate for describing the phar­
macokinetics of chlorthalidone is shown in Figure 7.5. The differential 
equations which are valid in this non-linear three compartment model are 
given in the Appendix 7.2. The influence of the binding capacity of the 
erythrocyte compartment on the elimination half-life from this compart­
ment is shown in Figure 7.6. Three different situations were simulated, ac­
cording to this model, by means of a computerprogram in which the bind­
ing capacity, expressed as В in Appendix 7.2, was simulated to be relatively 
low, intermediate and high with respect to the total chlorthalidone contents 
of the erythrocytes. It is clear that, whereas the plasma decay half-life 
varies only to a minor extent, changes in this binding parameter have a 
much greater influence on the elimination half-life from the erythrocytes. 
<Сіз 
ксзі 
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Figure 7.6 
Plasma and tissue concentration curves computed according to the three compartment model 
of drug distribution, in which the drug is tightly bound in the erythrocytes, giving rise to a 
prolonged elimination half-life compared with the plasma decay. Three situations are plotted 
in which the magnitude of the binding capacity В of the red blood cells is varied. It can be seen 
that the elimination half-life in the plasma compartment remains fairly constant, whereas that 
in the tissue compartment increases with increasing binding capacity. The model parameters 
used here were: D = 100 mg, VQ = 5 1, V! = 2001, Vj = 2 1, V3 = 2 1, k
c l 2 = 301/h, kc2i 
= 1 І/Ь.к^з = 201/h, к
с
з] = 0.5 1/h, k^ = 8 1/h, k
c e
] = 7.5 l/h, A = 1 (mg/l)"1, B= 1 
(case а), В = 5 (case b), В = 10 (case c) (mg/l). 
Figure 7.7 shows how the experimental data after a dose of 200 mg chlor­
thalidone to a healthy volunteer do agree with the model chosen, if ap­
propriate parameters are set. The elimination half-life from the red blood 
cells is exceeding that from the plasma, while still the absorption into the 
red blood cells is reasonably fast. This picture would not be possible with 
the model shown in Figure 7.4, because in that situation, where apparently 
plasma decay is faster during the first period (e.g. Fig. 7.4c), it takes also 
more time to reach the maximum red blood cell concentration, which is not 
consistent with the experimental data. 
From the distribution plots shown in Figures 7.3a and 7.3b a first ap-
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Figure 7.7 
Chlorthalidone concentration curves in plasma and red blood cells on semi-logarithmic scale 
after an oral dose of 200 mg chlorthalidone to a healthy volunteer. The experimentally 
measured concentrations are indicated as points. The curves were calculated according to the 
three compartment model, described in the text, including non-linear tissue binding by the red 
blood cells. A good fit was obtained for plasma concentrations and red blood cell concentra­
tions simultaneously. 
proximation has been made for the parameters, describing the binding of 
chlorthalidone by the erythrocytes. These parameters were then used for 
curve-fitting according to the three compartment model shown in Figure 
7.5. A consequence of the model chosen is that, in principle, the total bind­
ing of chlorthalidone to the red blood cells is not saturable because of the 
continuous distribution ratio between plasma and red blood cells, given by 
к
с
із and к
с
зі . The stronger binding sites, defined analogously to 
Michaelis-Menten kinetics by the maximum amount of drug bound В and 
the affinity constant A, are saturable. The total concentration in the 
erythrocytes is a summation of these two binding phenomena as shown in 
Figure 7.3a. The saturable binding portion was obtained by stripping off 
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the line, which parallels the straight part of the curve and passes through 
the origin, from the original curve. The distribution ratio alone is given by 
the slope of this straight line. 
In order to obtain a good fit (see Fig. 7.7) computer simulations were 
carried out at the beginning with estimated model parameters, until there 
was, judged by visual inspection, a reasonable agreement between the 
calculated curves and the experimental measurements. Finally, use was 
made of the computerprogram FARMFIT, a non-linear least squares 
regression analysis program (Chapter 1), which can employ also differen­
tial equations, in order to give model parameters which best fitted the data 
of the concentrations in plasma and erythrocytes simultaneously. 
DISCUSSION 
Experimental evidence is presented here for the influence of non-linear 
tissue binding on the pharmacokinetics of chlorthalidone in man, giving 
rise to a disposition rate from the erythrocytes which is slower than that 
from the blood plasma. There is good evidence that in this binding the en­
zyme carbonic anhydrase is involved (Beermann et al., 1975; Dieterle et al., 
1976; This thesis, Chapter 8). In the model, the assumption is made that 
the time required for the uptake of the drug by the blood cell tissue in the 
Michaelis-Menten binding is very short compared with the transport of the 
drug to the tissue itself, governed by the distribution rate constants. This 
implies that at every moment a state of equilibrium between exchangeable 
drug and strongly bound drug in the erythrocytes is present. A similar 
theoretical model including tissue binding was given by Wagner (1971), but 
quantitative experimental measurements have not yet been described. 
Just as the term χ in the Appendix 7.2 refers to the total plasma concen­
tration, which is in fact the sum of protein-bound and free drug, refers the 
term u to that concentration in the erythrocytes, which is the sum of really 
free drug and drug which is concerned in a binding of much lower affinity 
than the strong binding characterized by the Michaelis-Menten constants. 
Therefore, this concentration behaves as an exchangeable one, just as the 
plasma concentration, and the linear distribution between them can be 
described pharmacokinetically by the ratio of the transfer clearance con­
stants к
с
і з / к
с
з і . Because the ratio к
с
і з / к
с
з і is observed to be greater 
than unity, 'binding' is also involved in this linear distribution. But this 
binding (probably to proteins within the red blood cells with lesser affinity 
for the drug, but with greater capacity, as outlined in Chapter 8) shows up 
as a linear function of the plasma concentration (see Fig. 7.3). Because of 
the fact that the plasma protein binding of chlorthalidone was found to be 
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constant (75.7% bound) over the full concentration range studied, 0.02-7.7 
/tg/ml (Dieterle et al., 1976), no further possible non-linearity due to 
plasma protein binding has to be expected. The above implies that the ex­
changeable concentration u is directly proportional to the concentration of 
really free drug in the erythrocytes, which is, of course, the only species ac­
tually in equilibrium with the strongly bound drug. Therefore, this concen­
tration u was used in the Michaelis-Menten relationship, shown in the Ap­
pendix 7.2. 
Effects of binding phenomena on elimination half-lives of drugs are of 
course only visible if the maximum amount of drug which can be bound 
and the affinity constant for the binding places are in an order great 
enough to influence the half-life, e.g. see Figure 7.6. The parameter values 
for the binding capacity В and the distribution ratio к
с
із/к
с
зі, found to 
fit adequately the experimental data in Figure 7.7, were at first estimated 
from the plots of plasma concentration vs. erythrocyte concentration (Figs. 
7.3a and 7.3b), and then adjusted by refining the fits, as described in the 
pharmacokinetic analysis section of this chapter. It became clear that the 
apparent affinity constant for the binding of drug to the red blood cells, A 
in the Appendix, should be relatively low, as at higher values a bi-
exponential decay of the erythrocyte concentrations with a slower phase 
would have been visible in the simulated plots, which was not justified by 
the experimental data. 
Ultimately, however, after a long period of time, e.g. 200 hours or more, 
according to the model shown in Figure 7.5 and the differential equations 
in Appendix 7.2, also the plasma curve tended to accept a slower phase of 
elimination with the same disposition rate as the final red blood cell con­
centration decay. Observations, confirming this ultimate behaviour, will be 
dealt with in Chapter 9. 
The solution presented in Fig. 7.7 is, however, by no means unique. This 
does not need to surprise, in view of the relatively great number of model 
parameters, as compared to the number of data points. Thus, strong 
mathematical correlation between parameter estimates results and the final 
solution depends heavily upon the adjustment of initial parameter values. 
Thus, an equally well fit to the experimental data of Fig. 7.7 was obtained 
e.g. with the model parameters: D = 200 mg, V0 = 101, Vi = 3501, V2 = 
V3 = 41, k
c e
i = 15.61/h, kCa = 201/h, kci2 = 921/h, kc2i = 11/h, к с із 
= 32 1/h, к
с
зі = 0.68 I/h, A = 0.2 (mg/l)-l and В = 9 mg/1. This in­
dicates that prior to a definite choice of any set of parameters, additional 
data are needed. Such information could be provided by the accumulation 
pattern of plasma and red blood cell concentrations during repetitive 
dosing (see Chapter 13), and/or by a detailed study of the binding of chlor­
thalidone to red blood cells in vitro. The model parameters found until 
now show a rough agreement with the values calculated on the basis of the 
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known carbonic anhydrase content and the apparent affinity of chlor­
thalidone for carbonic anhydrase in the red blood cells, as will be described 
in Chapter 8. 
In the computer fit shown to cover the experimental data in Figure 7.7 
the parameters used did neglect incomplete absorption of the drug. In fact, 
uncertainty exists about the fraction of dose that was actually absorbed 
after oral administration of chlorthalidone. However, in the case that the 
biovailability F was not equal to unity, the same fits do apply to the data 
when the volume terms and clearance constants are multiplied by F. For in­
stance, if F is 0.5 instead of 1 exactly the same plot as shown in Figure 7.7 is 
generated with the parameter values D = 100 mg, V0 = 6 1, Vj = 175 1, 
V2 = 2 1, з = 2 1, kCa = 10 1/h, kc ei = 7.8 1/h, kci2 = 40 1/h, kC2i = 
0.5 1/h, к
с
із = 20 1/h, к
с
зі = 0.5 1/h, A = 1 (mg/l)-l and В = 6 mg/1. 
These parameter values are probably closer to reality than those presented 
in Fig. 7.7, because of incomplete biovailabilty of chlorthalidone: a mean 
value of F = 0.64 was found after oral administration of 50 mg doses, as is 
described in Chapter 9. 
The first reason for the choice of an additional tissue compartment in the 
model was evident from the consideration of the total amount of drug ac­
counted for by the central compartment and the red blood cells, which 
aspect was elucidated in the pharmacokinetic analysis of this Chapter. An 
additional argument for the use of three compartments was given by the 
practice of the fitting procedure: the observed rapid decay of plasma con­
centrations in the initial period (between 3 and 10 hours after the dose) 
could be simulated with a high numerical value for the clearance constant 
к
с
і з . However, the choice of this к
с
із is limited in its upper value by the 
measured entrance rate of drug into the erythrocytes. In order to reconcile 
these observed features a second way of disappearance from the central 
compartment had to be included (k
c
i2). With respect to the diuretic action 
of the compound it is well possible that renal tissue will be a major portion 
of this compartment. 
With respect to the great central volume of distribution Vj found to fit 
the measured data, it is clear that this volume cannot represent a single 
uniform volume, but consists, besides of the plasma volume, of a compart­
ment which equilibrates with the blood plasma very rapidly relative to the 
rate of absorption of the drug. After oral administration its presence is not 
visible as an additional distribution phase in the plasma concentration 
curve. The investigations on the intravenous administration of chlor­
thalidone to human subjects, described in Chapter 9, revealed the existence 
of such a rapid phase of decay, with a mean half-life of ca. 20 min. Conse­
quently, in that study smaller values for the volume of the central compart­
ment than those found after oral administration resulted. For reasons of 
simplicity, however, this compartment was not shown explicitly in the 
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model (Fig. 7.5), but was included in the central compartment. In rat ex-
periments chlorthalidone showed a considerable liver uptake immediately 
after administration, followed by excretion into the bile (Beisenherz et al., 
1966). In view of this, the liver could be considered very well as an impor-
tant part of the central volume of distribution for this drug. 
CONCLUSION 
The non-linear pharmacokinetic model, shown in Figure 7.5, is able to 
include simultaneously all observed features of the time course of absorp-
tion, distribution and elimination of chlorthalidone in both the plasma and 
erythrocyte compartment. Numerical solutions obtained are not unique, 
however, due to a small number of degrees of freedom. It should be 
noticed in addition, that the model was constructed in the most simple way, 
by which a satisfying fit to the experimental data could be obtained. The 
binding of chlorthalidone to red blood cells, for instance, was composed of 
only two parts. This seemed justified, judged from the pattern of distribu-
tion of the drug between plasma and red blood cells (Fig. 7.3). However, as 
explained in Chapter 8, three components are actually found in red blood 
cell binding of chlorthalidone, if a more extended concentration range is 
employed. If this factor would be introduced, a still more complex non-
linear model would arise, from which naturally different parameter 
estimates, e.g. transfer clearance constants, would be found. Concluding-
ly, these circumstances cause severe limitations to the applicability of the 
non-linear model, unless its individual elements would be precisely 
specified by additional experimental data. For this reason, the model pro-
posed will be applied merely, in the following chapters of this thesis, to ex-
plain observations, which are clearly conflicting with a linear phar-
macokinetic concept. E.g. in Chapter 13 the capacity-limited binding of 
chlorthalidone to red blood cells will be shown to have a pronounced in-
fluence on its pharmacokinetics during multiple dosing. Details of the ab-
sorption and elimination phases of separate plasma and red blood cell con-
centration curves of chlorthalidone can, for the moment, with less uncer-
tainly in parameter estimates, better be described by linear differential 
equations, as used in Chapter 9. It should be realized, however, that such a 
description, although valuable of course for comparison of phar-
macokinetic parameters of chlorthalidone with those reported for other 
drugs, causes a lesser degree of understanding about the coherence and 
physiological meaning of the various compartments in the body. No doubt, 
therefore, integration of all available individual pieces into one dynamic 
system will ultimately lead to the best possible explanation of what such 
'compartments' really represent. 
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SUMMARY 
Plasma concentrations and red blood cell concentrations of chlor­
thalidone have been measured after oral administration of single doses of 
100 or 200 mg to ten human subjects. Chlorthalidone was rapidly absorbed 
into plasma, with peak concentrations occurring at 1-3 hours after drug in­
take. The transport to erythrocytes was much slower and maximum con­
centrations were not reached until 10-15 hours later. The concentration of 
chlorthalidone in erythrocytes was then 50-100 times higher than that in 
plasma. The decay of red blood cell concentrations showed a much longer 
elimination half-life (mean 60 hours) than the terminal plasma decay (mean 
40 hours). The in vitro distribution of chlorthalidone between plasma and 
erythrocytes was non-linear and similar to the in vivo distribution curve ob­
tained from patients who were in a steady-state concentration range. 
A pharmacokinetic model was developed, including non-linear binding 
of chlorthalidone by the red blood cells, which in detail could account for 
the observed time courses of drug in plasma and erythrocytes 
simultaneously. Applicability and limitations of this model were discussed 
and compared with linear pharmacokinetic analysis. 
APPENDIX 7.1 
The amount of drug totally present in all body compartments plus the 
quantity eliminated by the body equals the dose at every time t: 
Q0(t) + Ql(t) + Q2(t) + Q3(t) + Qel(t) = D 
where D = the dose of drug 
Q0(t) = the quantity of drug (e.g., mg) in the absorption com­
partment at time t 
Ql(t) = the quantity of drug (e.g., mg) in the central compart­
ment at time t. Ql(t) = Ci(t). Vj, where Сці) and Vj 
are, respectively, concentration at time t and volume of 
the central compartment. 
Q2(t) = the quantity of drug (e.g., mg) in a possibly existing addi­
tional tissue compartment at time t 
Q3(t) = the quantity of drug (e.g., mg) in the red blood cells at 
time t. Q3(t) = C3(t). V3, where C3(t) and V3 are, 
respectively, concentration at time t and volume of the 
red blood cell compartment 
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Qel(t) = the quantity of drug (e.g.,mg) already eliminated from 
the body at time t. If the elimination occurs from the cen­
tral compartment: 
t 
Q
e l ( t ) = k c e l / C l - d t = k c e l - A U C 
о 
where k
c e
i is the clearance constant of elimination (e.g. 
1/h) and AUC is the area under the plasma concentration 
vs time curve (e.g. mg.hr/1) 
Q2(t) c a n be calculated if all other quantities are known. As the plasma 
concentration curves showed a biphasic decay, these curves were fitted to a 
three-exponential equation according to a linear two compartment model, 
with first-order drug distribution and elimination after oral admini­
stration, as described in Chapter 9. The resulting pharmacokinetic data are 
given in Table 7.2. This approximation yields values for Vj/F, the total ap­
parent volume of distribution \^ 5 5 /Т, the rate constant of absorption Ka 
and the clearance constant of elimination k
c e
i/F, which is related with the 
elimination rate constant by k
e
].Vi = k
c e
i. 
Because of the fact that the fraction of dose absorbed from the 
gastrointestinal tract (bioavailability F) was not actually known, the values 
for Vj/F, Vd
ss
/F and kCel/F, shown in Table 7.2, have to be multiplied by 
F. Cumulative urinary excretion of chlorthalidone measured during 4 days 
in the subjects studied ranged between 25 and 50% of the dose, which 
indicates a minimum value for F. Estimates of Vj and kCel, necessary for 
the calculation of Q\ and Q
e
i respectively, where thus obtained using dif­
ferent values of bioavailability: F= 1, F = 0.5 and F = 0.25. 
As judged from the values for K
a
 (Table 7.2), absorption is fast and 
after 10 hours only a negligible fraction of the available dose will remain in 
the absorption compartment. Therefore, Qo was set at zero at this time and 
the calculations were carried out at t = 10 h. Сщ) and C3(t)were measured 
experimentally and are shown in Table 7.2 for t = 10 h. V3 is a function of 
bodyweight, the red blood cell volume being equal to about two liters for a 
70 kg man. The area under the curve (AUC) from t = 0 until t= 10 h was 
obtained with the trapezoidal rule and multiplied subsequently with k
c e
i to 
yield Qel at t= 10 h. Finally, Q2 was obtained for each of the three values 
of F mentioned by subtracting the other quantities from the available dose 
F.D. The results of these calculations are presented in the last three col­
umns of Table 7.2. 
152 
APPENDIX 7.2 
In the model depicted in Figure 7.5 the following differential equations 
are valid: 
d Q
o 
— - = -k .Z where Q = ν .Z (Eq.7.1) 
a t са и и 
d Q i 
— =
 k
c a -
Z
 -
 ( k
c e l + k c l 2 + k c l 3 ) · Χ + k c 2 1 ^ + k c 3 1 - U 
where Q 1 = V ^ x (Eq.7.2) 
d t = k c l 2 . x - k c 2 1 . y where Q 2 = ^2-Y (Eq.7.3) 
d Q 3 , u , d.DE 
d t с І З с З І 3 d t 
where Q 3 = V 3 . u (Eq.7.4) 
d Q
e l 
— | i - = к . . χ (Eq.7.5) d t e e l 
The boundary conditions are: 
a t t = 0 : Ζ = D/Vo x = y = u = 0 Qel = 0 
a t t = oo:Z = 0 x = 0 y = 0 u = 0 Qel = D 
The concentration DE is related to u according to Michaelis-Menten 
kinetics by means of the relationship 
where A represents the apparent association constant of the drug-
erythrocyte binding and В the maximum amount of binding sites, express­
ed as that concentration of drug that can be bound maximally. 
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The differential equation 7.4 can be transformed with the relationships 
*3,u 
dt 
dQ-, 3,u 
dt 
- "3 · Ш -
сІЗ сЗІ 
1 + d.DE/du 
d.DE d.DE du 
dt du ' dt 
k ,
 n
.x - k .,.u 
cl3 c31 
ι ι
 Α
·
Β 
2 (1+A.u) 
to 
(Eq.7.7) 
As far as we know, there is no analytical solution for this set of differential 
equations but the equations 7.1, 7.2, 7.3, 7.5 and 7.7 can be easily solved 
numerically by computer to yield simulations of Z, x, y and u as a function 
of time. DE as function of u, see Eq.7.6, is therefore also known as well as 
the sum u + DE, which was actually measured experimentally. 
A glossary of terms, not yet explained in the caption of Figure 7.5 follows: 
^
e l = the quantity of drug (e.g.,mg) eliminated per unit of time (e.g.,hr) 
dt 
keel = the clearance constant of elimination from the central compart­
ment (e.g.,liters/hr) assuming linear elimination kinetics 
D = the dose of the drug (e.g.,mg) 
QO = the quantity of drug (e.g.,mg) in the absorption compartment 
Ql = the quantity of drug (e.g.,mg) in the central compartment 
Q2 = the quantity of drug (e.g.,mg) in the second tissue compartment 
Q3,u = the quantity of drug (e.g.,mg) in that part of the erythrocyte com­
partment, which contains the exchangeable drug concentration u 
kca = the clearance constant of disappearance from the absorption com­
partment to the central compartment (e.g.,liters/hr); k
c a
 is 
directly related to the rate constant of drug absorption K
a 
(e.g.,hr-l) by k
ca
/Vo = K
a 
k
c
i2 = the transfer clearance constant of disappearance from the central 
compartment to the compartment with number 2 (e.g.,liters/hr); 
k
c
i2 is directly related to the rate constant ki2(e.g.,hr-l) by 
k
c
i2/Vi = ki2. The transfer clearance constants k
c
2l, к
с
із, 
kC3i are defined analogously, so that kc2i/V2 = k2i; kclsA^i 
= I43; kc3l/V3 = кзі. 
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CHAPTER 8 
UPTAKE OF CHLORTHALIDONE 
BY HUMAN ERYTHROCYTES IN VITRO 
INTRODUCTION 
After administration of chlorthalidone to human subjects, the concen-
tration of the drug in red blood cells is 50-100 times higher than that in 
plasma, as is described in Chapter 7. There is sufficient evidence now to 
state that the intracellular protein carbonic anhydrase is involved in this 
uptake. The drug acts as a weak inhibitor of this enzyme in vitro (Pulver et 
al., 1962; Maren, 1967). Acetazolamide, a stronger inhibitor than chlor-
thalidone, is most probably bound to the red cell enzyme (Coleman, 1975; 
Maren et al., 1960; Wallace and Riegelman, 1977), and displaces chlor-
thalidone from its erythrocyte binding sites in vivo and in vitro (Beermann 
et al., 1975). Gel chromatographic separation of red cell constituents 
revealed that chlorthalidone eluted from the column only at the retention 
time of the carbonic anhydrase fraction (Beermann et al., 1975; Dieterle et 
al., 1976). 
The mean concentration of total carbonic anhydrase in human 
erythrocytes is 140-160 /¿mol/liter (Maren, 1967; Wistrand and Baathe, 
1968; Nörgaard-Pedersen and Mondrup, 1971), but individual values may 
vary from 120-225 /¿mol/liter (Nörgaard-Pedersen and Mondrup, 1971). In 
agreement with saturation of this pool of receptors, the red blood cell bind-
ing curve of chlorthalidone shows a clear inflexion point in the same con-
centration range, as is shown in Fig. 8.1 (Experiment performed as describ-
ed in the Materials and Methods section; a similar observation has been 
made by Dieterle et al., 1976). Dieterle et al. (1976) determined the affinity 
of the drug for two isolated isoenzymes of human carbonic anhydrase 
(HCA), so called HCA-B and HCA-C. They reported one binding site per 
molecule of either isoenzyme and a K a s s = 2.4x10^ 1/mole for HCA-B and 
a K a s s = 5.7xl06 1/mole for HCA-C. The association constants were 
several orders of magnitude larger than that with respect to human serum 
albumin (K a s s = 1.2xl03 1/mole), and this difference was in agreement 
with the large erythrocyte over plasma concentration ratios of chlor-
thalidone observed in vivo. 
A discrepancy became apparent, however, between details of the report 
of Dieterle et al. (1976). Only one component of binding was discerned 
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FigureS.l 
Graphs showing the concentration of chlorthalidone in plasma and red blood cells after 
equilibration of the drug in whole blood from a normal human subject. The erythrocyte over 
plasma concentration ratio (left part) goes down from about 80 to 1.5 when the whole blood 
concentration is increased from 0.3 to 240 μg/ml. The right panel presents the concentration 
in erythrocytes as a function of plasma concentration. The saturable part of the binding cor­
responds to a red blood cell concentration of chlorthalidone of 68 /ig/ml (201 μΜ) in this ex­
periment, which is in the normal range of the total carbonic anhydrase concentration in 
human erythrocytes. 
when the mixture of HBC-B and HCA-C from erythrocytes was employed. 
This is clearly surprising because of the difference in the affinity of chlor­
thalidone for HCA-B and HCA-C and in view of the relative occurrence of 
the two isoenzymes. The quantity of HCA-C is about 6-8 times smaller 
than that of HCA-B, which means that its erythrocyte concentration lays 
between 15-25 μΜ (Nörgaard-Pedersen and Mondrup, 1971), a certainly 
significant amount. It must be expected therefore that not the total car-
bonic anhydrase pool but merely the isoenzyme with the highest affinity 
acts as the primarily saturable receptor of chlorthalidone in red blood cells. 
Some evidence for this hypothesis can be found in Chapter 7 (Fleuren and 
van Rossum, 1977), showing a small saturable component of binding in the 
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in vivo concentration range (cf. Fig. 7.3: В = 6.8 ¿ig/ml, equivalent to 20 
μΜ). Furthermore, if should be realized that the very high drug concentra­
tions employed in the in vitro experiment of Fig. 8.1 are never encountered 
in man after administration of single doses, where peak concentrations of 
about 10-15 /tg/ml are attained in red blood cells and of less than 1 ¿tg/ml 
in plasma (cf. Chapter 7). 
Because many kinetic events take place simultaneously in vivo, single 
processes are difficult to isolate. This difficulty can be circumvented by 
means of a closed system. An in vitro study with intact blood corpuscles 
was expected to approximate the in vivo situation more closely than ex-
periments with isolated proteins would do, because all components of 
binding, also those of low affinity, would be taken into account. 
Moreover, such study would provide also information on the rate of 
transport of chlorthalidone across the cell membrane. The major aim of 
this chapter was, however, to find out whether in the concentration range 
corresponding to the total amount of red cell carbonic anhydrase the two 
components of specific binding anticipated for chlorthalidone could really 
be distinguished. 
MATERIALS AND METHODS 
Drug partitioning studies 
Chlorthalidone was obtained from Ciba-Geigy (Basle, Switzerland). Its 
purity was ascertained by thin-layer chromatography as described in 
Chapter 3. All inorganic chemicals were of analytical reagent grade (E. 
Merck, Darmstadt, G.F.R.). The heparin solution contained 50 mg (5000 
U) per ml (Thromboliquine, Organon, Oss, The Netherlands). Blood por-
tions of 50-100 ml with hematocrit 0.40-0.50 were collected by venepunc-
ture from healthy human subjects, who had fasted overnight. Care was 
taken to avoid hemolysis, viz. by using a wide-bore needle and by a 
cautious heparinization of the blood (see e.g. Hanks et al., 1960), 0.2 ml of 
heparin solution being used for 100 ml of whole blood. (Heparin does not 
influence the distribution of chlorthalidone between plasma and 
erythrocytes, as reported in Chapter 3). The blood was used the same day 
or the day thereafter for incubations with the drug. These were carried out 
in glass flasks by regular and gentle agitation at 20°C or 370C. Previously, 
it had been checked that the drug was stable in whole blood or in suspen-
sions of red cells in buffer during at least 48 hours. 
The time course of equilibration of chlorthalidone between plasma (or 
physiological saline) and erythrocytes was studied by dissolving the drug in 
a small volume of 0.1 M NaOH containing 0.3% (w/v) of sodium chloride 
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and adding this to whole blood (0.1 ml on 5 ml of blood) at varying drug 
concentration (0.5-10/tg/ml). Next, separation of plasma (or physiological 
saline) and red cells was carried out as described in Chapter 3 at several 
times after the start of the incubation, see Fig. 8.2 and Table 8.1. The 
erythrocytes were assayed for chlorthalidone directly and after being wash-
ed once or twice with 0.9% (w/v) NaCl. Analogously, the rate of transport 
of chlorthalidone out of the erythrocytes was measured after suspending 
red blood cells, which had been pre-incubated with the drug, in fresh por-
tions of physiological saline. 
To study the equilibrium red cell over plasma distribution in whole 
blood, the drug was pre-dissolved in plasma (350 /¿g/ml) and aliquots of 
this solution were added to whole blood from which an equal volume of 
plasma had been removed before, so that the hematocrit remained un-
changed. The highest blood concentrations of the range 0.3-240 /tg/ml 
(Fig. 8.1) could only be achieved by repeated replacement of incubated 
plasma by a new aliquot of the stock plasma solution. A 120 min period 
was used to reach equilibrium distribution. 
Red blood cell suspensions were prepared in an isotonic phosphate buf-
fer consisting of Na2HPO4.2H20 3.674 g/l, KH2PO4 0.684 g/1 and 
NaCl 7.78 g/1. The osmolarity of this buffer was 305 mOsm/1 and its pH 
7.43 at 20°C. After collection of the blood, the plasma was separated by 
centrifugation at 3000 r.p.m. (1500 g) for 15 min, the erythrocytes were 
washed three times with four times their volume of the isotonic phosphate 
buffer, and diluted with this buffer to hematocrit 0.50. Precise 1 ml por-
tions of this suspension were added to twenty 4 ml portions of isotonic buf-
fer, containing each a known amount of chlorthalidone between 0.5 and 
250 pg (1.47-738 nmole). After incubation for 3 hours at 370C, the samples 
were centrifuged and the supernatant fluid was assayed. Erythrocyte con-
centrations were calculated from the total amounts added, the concentra-
tions in the buffer solution and the hematocrit of the cell suspension. 
The hematocrit was measured in triplicate by means of a Hawskley 
micro-hematocrit centrifuge (Hawskley, Lancing, England), and the 
readings were corrected for a fluid inclusion percentage of 3% (England et 
al., 1972). The concentration of chlorthalidone in plasma, red cells or buf-
fer was determined by gas chromatography with nitrogen detection 
(Fleuren and van Rossum, 1978; Chapter 3). 
Analysis of erythrocyte-binding sites 
At equilibrium, the concentration of unbound drug within the cells is 
assumed to be equal to the concentration of drug in the buffer solution out-
side. The total concentration of chlorthalidone in the cells (RX) can then be 
written as a function of the concentration of unbound drug (X) in the sur-
rounding buffer: 
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In this modified Scatchard equation (Scatchard, 1949) η is the number of 
classes of binding-sites assumed to be independent of each other, Nj is the 
maximum binding capacity of each class, which is the product of the con­
centration of the binding macromolecule and the number of sites on that 
macromolecule, and Kj the apparent association constant for each class. 
By means of the term кз.Х several processes are lumped together. If no 
other components of binding than those already characterized by a Ni and 
a Kj ("specific binding sites") are present, then кз = 1. If, however, also 
low affinity binding sites are involved of which no saturation is apparent 
(i.e., X is far below the dissociation constants corresponding to those 
sites), such "non-specific binding" shows up as a linear function of the 
concentration of unbound drug and кз is larger than one. 
Preliminary graphical estimation of the binding parameters according to 
the method of Rosenthal (1967) showed that either one or two specific 
binding sites were present. Both possibilities were explored by fitting the 
experimental data to Equation 8.1 by use of a non-linear least squares 
regression analysis program (Farmfit, see Chapter 1), with weights equal to 
1/(RX)2. This computer program provided also a measure for the asymp­
totic standard error in the parameter estimates. To decide between η = 1 
and η = 2, several criteria were used: 1. Visual inspection of the Scatchard 
plots for goodness of fit. 2. The distribution of the residuals around the fit­
ted curves should be as much as possible at random. 3. A statistical com­
parison of the goodness of fit by means of the f-test (see e.g. Boxenbaum, 
1974; cf. Chapter 9). This test indicates if the reduction in the total sum of 
weighed squared deviations of the data points gained by use of the more 
complicate equation (n = 2 instead of n = 1) is statistically significant at a 
certain probability level, e.g. Ρ = 0.01. 
RESULTS 
Rate of distribution of chlorthalidone between plasma and erythrocytes 
in vitro 
Chlorthalidone did not equilibrate instantaneously between plasma (or 
buffer) and erythrocytes. In fresh human blood or blood cell suspensions, 
a constant concentration ratio was attained at 370C after 90-120 minutes. 
This held true both for uptake of the drug by and release from 
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Figure 8 2 
Typical plots showing first-order rate of transport of chlorthalidone from plasma to red blood 
cells at two temperatures. At 37°C equilibrium is reached after 90-120 minutes. At lO'C the 
transport rate is much slower. 
erythrocytes. At 20oC equilibrium was not reached even after 4 hours. The 
transport rate occurred in a first-order fashion during the first part of the 
incubation period, see Fig. 8.2. Three experiments with blood of normal 
composition yielded a transport half-life of 11 + 2 min at 370C (mean value 
± S.D.). 
Washing the erythrocytes with physiological saline had a negligible effect 
upon the chlorthalidone concentration. This was the case both when the 
concentrations of the drug in plasma and erythrocytes were in equilibrium 
and during the transport of chlorthalidone from the plasma to the cells 
(Table 8.1). 
Red blood cell binding parameters 
The results of a typical experiment are presented as a Scatchard plot in 
Fig. 8.3. When two classes of specific binding were taken into account a 
much better fit was obtained than that based upon one class only. This 
visual judgement was supported by the way the residuals of the data points 
were distributed around the fitted curves and by the outcome of the f-test. 
This test indicated for all six experiments a very significant improvement 
(P< 0.005), if five instead of three binding parameters were employed. 
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TABLE 8.1 
Effect of washing of red blood cells upon erythrocyte concentrations of chlorthalidone 
Incubation 
time3 
(min) 
0 
1 
5 
10 
15 
30 
90 
150 
Plasma 
cone. 
Oig/ml) 
6.7 
5.9 
3.9 
2.2 
1.35 
0.39 
0.17 
0.17 
Red blood cell concentration 
unwashed 
— 
1.35 
7.1 
9.8 
12.1 
15.0 
15.7 
15.7 
(/ig/ml) 
washed (2 x) 
— 
1.35 
7.2 
9.8 
12.2 
14.7 
15.6 
15.7 
experiment performed at 370C 
TABLE 8.2 
Parameters characterizing the binding of chlorthalidone to human erythrocytes in vitro3 
Exp.b 
no. 
1A 
IB 
2 
3 
4 
5 
Kl 
(xlO-^M"1) 
1.08(15) 
0.% (36) 
0.92 ( 8) 
0.85 ( 7) 
1.00(22) 
1.06(12) 
N, 
(μΜ) 
151 ( 4) 
136(15) 
137 ( 4) 
204 ( 3) 
146 ( 6) 
156( 4) 
K2 
(xlO-^M-1) 
21.9(43) 
6.8 (54) 
73.5 (43) 
45.2 (32) 
10.4 (74) 
19.9 (44) 
N 2 
{μΜ) 
9.6 (42) 
34.2 (73) 
3.8 (24) 
5.3 (25) 
13.0(82) 
7.6 (47) 
k3 
3.90 (5) 
2.97 (8) 
3.22 (5) 
2.24 (9) 
3.38 (7) 
3.71 (4) 
aKi and К2 are apparent association constants, and N] and N2 maximum binding capacities; 
кз is the linear distribution parameter (relative errors of the parameter estimates in paren­
theses) 
^Numbers indicate experiments performed with red blood cell portions from different subjects 
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Figure 8.3 
Scatchard plot analysis of red blood cell uptake of chlorthalidone (exp. no. 3) indicates the 
presence of two classes of binding sites with high affinity for the drug, and an additional up­
take of low affinity. The inset represents the line of best fit if only one class of saturable bind­
ing sites was taken into account. The picture has been reproduced directly from a computer 
plot. 
Table 8.2 presents the parameter estimates obtained by fitting the ex­
perimental data according to Equation 8.1 with η = 2. 
DISCUSSION 
The observation of a transport process with an initial first-order rate 
(Fig. 8.2) can easily be explained from a fast association reaction of chlor­
thalidone with intracellular carbonic anhydrase. This binding will keep the 
free drug concentration low, so that the driving force for transport - the 
concentration gradient between the outside and the inside of the 
erythrocytes - is maintained. Also the results shown in Table 8.1 indicate 
that diffusion across the cell membrane and not formation of the drug-
protein complex is the rate-limiting step in the red cell uptake of chlor­
thalidone. Would the association reaction itself have been a slow process, 
and the diffusion rate fast, then washing of the red cells would have re-
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moved the unbound drug fraction and would have resulted in smaller con-
centrations. The rapid establishment of the binding of chlorthalidone to 
carbonic anhydrase would be in agreement with the fast protein-complex 
formation of 24 other sulfonamides, including acetazolamide, for which 
association rate constants ranging from approximately lOMo^M-l.sec-l 
have been measured (Coleman, 1975). 
During our preliminary experiments, it was noticed that the rate of 
distribution of chlorthalidone between plasma and red blood cells depend-
ed also to some extent upon the age of the blood. In whole human blood 
kept for a few days in a refrigerator a constant distribution ratio was reach-
ed after 60 min (cf. Fig. 3.5, Chapter 3), while it took 90-120 min when 
blood was incubated with the drug the day of collection itself (see e.g. Fig. 
8.2). This circumstance may be related to the slow equilibration of chlor-
thalidone between plasma and red blood cells in vivo: even after intra-
venous administration of the drug maximum red blood cell concentrations 
are not found before 6-9 hours (Fleuren et al., 1979; Chapter 9). Such a dif-
ference between the in vivo and in vitro rate of distribution in blood was 
noticed also in the rat (Beisenherz et al., 1966). The reason for this 
discrepancy is not clear, but it may be supposed that an alteration of the 
red cell membrane occurs outside the body, or that some factor acting in 
vivo, e.g. a substance competing for transport, is absent or lost in vitro. 
Scatchard plot analysis revealed the existence of two saturable classes of 
binding for chlorthalidone in the concentration range encountered after 
single doses (Fig. 8.3, Table 8.2). The molar quantity of the largest of these 
components, 136-204 /tM in six experiments is in good agreement with the 
known red cell content of one of the isoenzymes of human carbonic 
anhydrase, HCA-B, which has been reported to range from 115-220 /iM 
(Nörgaard-Pedersen and Mondrup, 1971). Also the apparent association 
constant, ІхІОб 1/mole on the average, is near the figure reported by 
Dieterle et al. (1976) on the affinity of chlorthalidone for isolated HCA-B 
( K
a s s
 = 2.4xl06 1/mole). A second possibility, however, which cannot en­
tirely be excluded is that this quantity corresponds to the concentration of 
total carbonic anhydrase in human erythrocytes, which amounts to 130-230 
/iM (Nörgaard-Pedersen and Mondrup, 1971). In this case, binding to the 
isoenzyme HCA-C would apparently be indistinguishable from that to 
HCA-B, and the binding sites characterized by K2 and N2 in Table 8.2 
would belong to a hitherto unidentified receptor. Such a hypothesis, 
however, is not supported by studies employing column chromatography 
of hemolysed red blood cells, which demonstrated no other site of ac-
cumulation for chlorthalidone than that corresponding to the combined 
carbonic anhydrase fraction (Beermann et al., 1975; Dieterle et al., 1976). 
In view of the strong mathematical correlation of the parameters K2 and 
N2, the only justified conclusion can be that the data shown in Table 8.2 do 
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not yet allow a definite statement with respect to this point, and that ex­
periments with more data points in the very low concentration range are 
needed to reduce the large errors of the estimates of K2 and N2. This is il­
lustrated also by the difference between the estimates for K2 and N2 ob­
tained from two experiments with the same blood portion, performed one 
day apart (Experiments 1A and IB in Table 8.2). 
SUMMARY 
The binding of chlorthalidone to human red blood cells was studied in 
vitro. The inital rate of erythrocyte uptake of the drug from plasma or buf­
fer was first-order (with a half-life of ca. 10 min at 370C), which was con­
sistent with a fast establishment of intracellular binding. Approximately 
90-120 minutes were needed to reach full equilibrium between the concen­
trations in plasma (or buffer) and erythrocytes. The total binding of chlor­
thalidone to red blood cells appeared to consist of three components: two 
classes of binding characterized by apparent association constants and 
maximum binding capacities, and a non-specific type of binding, showing 
up as a linear function of the unbound drug concentration. The first class 
of saturable binding sites had a maximum binding capacity of 1 SS μΜ on 
the average (six experiments, range 136-204 μΜ), and the apparent associa­
tion constant for binding of chlorthalidone was 1x1 Об 1/mole (range 
0.9-1.1x106 1/mole). These data were in good agreement with literature 
data on the molar content of and affinity of chlorthalidone for the 
B-isoenzyme of red cell carbonic anhydrase. The second class of binding 
sites could be defined less precisely: the estimates of the apparent associa­
tion constant of the drug-protein complex ranged from 7-74 χ 1θ6 1/mole 
and the maximum binding capacity from 4-34 μΜ. Due to the large uncer­
tainty in these parameter estimates, assessment of the C-isoenzyme of 
human carbonic anhydrase as the binding protein anticipated to be involv­
ed here should be regarded therefore as preliminary. 
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ERRATUM WITH RESPECT TO CHAPTER 9: 
In stead of page 177 page 184 should be read. 
In stead of page 184 page 177 should be read. 
In stead of page 185 page 192 should be read. 
In stead of page 192 page 185 should be read. 
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CHAPTER 9 
ABSOLUTE BIOAVAILABILITY OF CHLORTHALIDONE IN MAN, 
DETERMINED BY COMPARISON OF PLASMA, RED BLOOD CELL 
AND URINE CONCENTRATIONS AFTER ORAL AND 
INTRAVENOUS ADMINISTRATION 
INTRODUCTION 
In the Chapters 7 and 8, the distribution of chlorthalidone between 
plasma and erythrocytes was shown to be concentration-dependent. The 
non-linear model, which included besides first-order processes also a 
capacity-limited binding of chlorthalidone to red blood cells, enabled ex-
planation of the longer half-life of chlorthalidone concentration in 
erythrocytes compared to that in plasma. However, as described in the 
Discussion section of Chapter 7, no unique solution for the parameters of 
this model could be obtained. Therefore, we considered it more practical 
for the purpose of the present bioavailability study to describe plasma and 
red blood cell concentration decay separately, according to conventional 
linear open compartment models, of which a general description has been 
given in Chapter 1. Preliminary curve-fitting of the experimental data in-
dicated that plasma concentrations of chlorthalidone, as long as they could 
be followed by means of our assay, could be described in this way, imply-
ing that rate constants (or alternatively, time constants) of absorption, 
distribution and elimination would be obtained with good precision. 
Erythrocyte concentrations of chlorthalidone appeared to rise in a first-
order manner and, as the decline thereafter was mono-exponential (see also 
Chapter 7), a linear one compartment model sufficed for mathematical 
description of these data. Nevertheless, the non-linear approach outlined in 
Chapter 7, appeared to be of great help for meaningful interpretation of 
details of our findings, as will be shown throughout this chapter. 
The most direct way to obtain information on the bioavailability of a 
drug is by comparison of oral and intravenous doses. Although there ap-
pears to be no therapeutic need for administering chlorthalidone in-
travenously, use of this dosage form in a fundamental pharmacokinetic 
study offers many advantages. Important kinetic constants, e.g. total 
plasma clearance and volumes of distribution, can be calculated without 
the uncertainty inherent to usage of oral doses. Moreover, by measuring 
the contribution of renal clearance of chlorthalidone to total clearance, ex-
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istence of possible other routes of elimination will become established too. 
This aspect deserves attention, because e.g. the metabolic fate of chlor-
thalidone in man has been completely disregarded until now, while species 
differences have been found in laboratory animals. Whereas the rat exten-
sively metabolized the drug for ca. 70% of dose (Beisenherz et al., 1966), 
the dog excreted 90% of an oral dose unchanged into urine within 24 hours 
(Pulver et al., 1959). Some reviewers of the literature have extrapolated this 
resistance against metabolic breakdown to the human situation (Davies 
and Wilson, 1975; Swinyard, 1975), although not any actual evidence has 
been published that would justify such an assumption. 
Measurement of both plasma, red blood cell and urine concentrations 
was considered necessary for reliable estimation of the bioavailability of 
chlorthalidone. Urinary excretion of the unchanged drug had to be deter-
mined because possible changes in the balance between renal and non-renal 
clearance would obviously influence the estimate of bioavailability, if this 
was based upon plasma concentration data alone. Such variations had to 
be taken into account, due to the long biological half-life of chlorthalidone 
(see e.g. Chapter 7), which necessitated study over extended periods of time 
(several weeks). Erythrocyte concentrations had to be determined because 
the drug does not linearly distribute between plasma and red blood cells, as 
mentioned above, so that some disproportionality of the ratio of the areas 
under the curve after the two dosage modes had to be anticipated in case of 
incomplete oral bioavailability. 
Determination of faecal concentrations of chlorthalidone, finally, was 
considered advantageous for discrimination between the extent of oral 
bioavailability, i.e. the fraction of dose coming into the systemic circula-
tion, and the fraction of dose absorbed. A possible difference between 
these values should then be attributable to a first-pass effect by the liver. 
On the other hand, the amount of drug recovered in faeces after in-
travenous administration would present information complementary to 
that to be described in Chapter 11 (Fleuren et al., 1979) on the biliary route 
of excretion of chlorthalidone in man. 
The investigations described in this chapter were performed in a cross-
over design, in which intravenous and oral doses of chlorthalidone were 
administered to seven normal human subjects. 
MATERIALS AND METHODS 
Subjects and drug administration 
Seven adult human subjects (two females, five males) participated in the 
study after informed consent; personal data are given in Table 9.1. Three 
of them were healthy men (L.De, T.Ho, M.O.), who were - besides night's 
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TABLE 9.1 
Details of the subjects 
Subject 
Τ Be 
J ν Bo 
L De 
Τ Но 
A Kl 
M О 
M We 
Sex 
M 
M 
M 
M 
F 
M 
F 
Age 
(years) 
32 
29 
24 
24 
60 
28 
43 
Body 
weight 
(kg) 
69 
ПО 
73 
76 
57 
83 
62 
Plasma 
creatinine 
(μιτιοΜ) 
73 
90 
101 
90 
77 
87 
77 
Diagnosis 
ulcus 
ulcus 
healthy 
healthy 
mental distress, border-
line primary hypothyroid­
ism cholelithiasis 
healthy 
spondylitis 
Co-medication and 
daily doses during trial9 
(mg) 
aluminium hydroxide susp 
(Alummox) 4X30 ml 
Cimetidine 5 X 200 mg, diaze­
pam 3 x 5 mg 
— 
-
flurazepam 1 x 30 mg 
-
acenocoumarol 4 χ 1 mg, 
amoxycillin 3 χ 750 mg, di­
azepam 3 x 5 mg, nitrazepam 
5 mg, flucloxacillin 3 x 1000 
mg 
a
 not on first half day of studies 
rest - mainly ambulant or sitting during the trial, and carrying out their 
normal work (as students in the authors' laboratory). The four others were 
hospitalized for various reasons (see Table 9.1), but had normal clinical-
chemical values* for their serum urea, creatinine, bilirubin, alkaline 
phosphatase, G.O.T., G.P.T., hematocrit, hemoglobin, plasma proteins 
and electro-cardiogram patterns. Therefore, all subjects were normal as far 
as their kidney, liver and heart functions were concerned. 
Aseptic chlorthalidone solutions for intravenous administration were 
prepared in a concentration of 100 mg/1 by dissolving pure chlorthalidone 
(kindly provided by Ciba-Geigy, Basle, Switzerland) in 0.9% pyrogen-free 
NaCl, which had been brought to pH 8.0 with a few drops of 0.1 M NaOH. 
After sterile filtration (Millipore, pore diameter 0.21 μΐή) a known volume 
was transferred to a graduated infusion flask. The drug solutions were 
prepared the day before the intravenous experiment and kept in the 
refrigerator until use, to prevent bacterial growth; chemically chlor­
thalidone was found to be stable in these solutions for at least four weeks, 
assayed by gas chromatography, as described in Chapter 3. 
Each subject received a constant-rate infusion via a fore-arm antecubital 
vein over a period of approximately 2 hours (exact times in Table 9.3). An 
electronic drop counter (Ivac 531, I vac Corporation, San Diego, Ca., 
USA) was used to maintain zero-order infusion. The exact volume infused 
was calculated from the difference between the initial and remaining 
volumes in the flask. Five subjects received a dose of approximately 50 mg, 
one subject 60 mg and another 75 mg (exact amounts in Table 9.3), such 
that the doses applied were in the range of 0.66-0.88 mg per kg body 
weight. The infusions started in the morning at 9.00 A.M., after overnight 
fasting. The subjects took nothing except water during the first four hours 
of the study. 
In the oral study commercial tablets were used (Hygroton®, 
Ciba-Geigy). For our purpose tablets containing 100 mg were divided and 
weighed proportionally until the desired amount was obtained, so that the 
doses were equal for each subject to those employed in the intravenous 
study (exact oral doses in Table 9.4). The tablets were ingested, crushed 
with the teeth and swallowed completely with about 150 ml of tap water, 
on an empty stomach, in the morning at 9.00 A.M. No food or beverages 
except water were taken until 4-5 hours after administration of the drug. 
During the first two hours, a volume of 0.9% NaCl (w/v) equal to the 
volume of fluid given in the intravenous study (500-750 ml, depending on 
the dose) was infused in order to exclude systematic differences in the fluid 
* Determined at the Department of Clinical Chemistry, Radboud Hospital, Nijmegen, The 
Netherlands. 
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status of the subjects between the oral and the intravenous experiment. The 
order of the administrations was such that four subjects received the oral 
dose first (day nr. 1), followed by the intravenous dose (T.Be on day nr. 10, 
J.v.Bo on day nr. 11, A.K1 on day nr. 8, M.We on day nr. 10). Three sub-
jects received the intravenous dose first (day nr. 1), followed by the tablet 
(L.De on day nr. 15, M.O. on day nr. 36). 
Sampling and analytical measurements 
Venous blood samples (ca. 7 ml) were taken from the fore-arm, con-
tralateral to that of the infusion site, at the following approximate times 
(exact times were noted) from the start of the infusion: 0, 0.5, 1, 1.5, 1.75, 
2, 2.25, 2.5, 3, 4 and 5 hours. In the case of oral administration, samples 
were taken at 0, 0.5, 0.75, 1, 1.5, 2, 3 and 4 hours. For both modes of ad-
ministration sampling was continued usually at 6, 8, 12, 24, 32, 48, 56, 72, 
80, 96, 104 h after the start of the experiment, and from the subjects L.De, 
T.Ho and M.O. additional blood samples at 171, 195 and 219 h were ob-
tained. Because of frequent sampling in the first 4 hours after the dose, the 
antecubital vein was kept open by a slow-rate infusion (0.038 ml/min) of 
physiological saline, containing heparin (0.5 ml Thromboliquine, 
Organon, Oss, The Netherlands on 100 ml 0.9% NaCl), maintained by a 
Harvard infusion pump (Harvard, Millis, Mass., USA). At the times 
desired the tube was disconnected and the blood was collected directly 
from the cannula, after discarding the first 1 ml. The remainder of the 
samples was taken by vena punction. All blood samples were heparinized 
and centrifuged immediately after taking, (the detailed procedure stressing 
the importance of an immediate separation of plasma from red blood cells 
has been described in Chapter 3, Fleuren and van Rossum, 1978), and both 
fractions were frozen until assay. 
Urine was collected completely during 120 hours in separate, usually 6 
hours portions from the hospitalized subjects and in separate 12 hours por-
tions during at least 220 hours (exact times in Table 9.7) by the three am-
bulant subjects. Urine volume and pH were measured and aliquots of each 
portion were frozen until assay. The reliability of the completeness of the 
urine collections was stated from urinary creatinine excretion, and addi-
tionally by a careful supervision and personal motivation of each subject 
under trial. 
Faeces were collected in 24 hours portions during 120 hours by the 
hospitalized subjects, and during 220 hours by the ambulant subjects. The 
portions were weighed, known volumes of distilled water were added and 
the mixtures were thoroughly homogenized by the use of a Waring Blen-
dor. Aliquots were frozen until assay, or determined directly as follows: an 
aliquot (about 0.1 gram) was weighed into an extraction tube, 2 ml of 
Sörensen phosphate buffer pH 7.4 containing internal standard (5 fig, the 
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same compound as in Chapter 3) was added, the mixture was sonicated for 
10 min and the supernatant was transferred, after brief centrifugation, to 
another tube. The sample was extracted and processed further identically 
as described for the assay of chlorthalidone in plasma (see below). As a 
control, calibration graphs with blank faeces from each subject were 
prepared, which proved that the extraction recoveries were the same as 
those obtained with buffer solutions. By performing the measurements in 
duplicate a relative standard deviation of 4% for the determination in 
faeces was obtained (n = 8). 
The chlorthalidone concentrations in plasma, urine and red blood cells 
were determined by gas chromatography with nitrogen detection, as 
described in Chapter 3 (Fleuren and van Rossum, 1978). In one subject 
(M.We) the urine gas chromatograms showed two large interfering peaks, 
which we could prove to originate from the antibiotic flucloxacillin, used 
by this subject. Owing to the high water solubility of this compound, the 
interfering peaks could be removed by washing the methyl isobutyl ketone 
extracts twice with 2 ml of phosphate buffer pH 7.4, resulting in an ex­
cellent purification of these urine samples. 
Pharmacokinetics 
Preliminary graphical analyses of the plasma concentration versus time 
curves after intravenous and oral administration showed that the data 
could be described by either a two or a three compartment open model. 
Therefore the plasma concentrations were fitted to the corresponding sum 
of exponentials (Chapter 1): 
i.v. administration 
η - к . . t 
c = Σ
 V ΊΓ-Τ ( 1 - e 1 > f°rt < Τ 
i = l i ' (Eq.9.1) 
and 
η - к . ( t - T ) - к . . t 
С = Σ А. . — i — (e 1 - e 1 ) for t > Τ 
. , ι к . . Τ 
ι=1 ι 
(Eq.9.2) 
oral administration 
η - к . . t -К . t 
α = Σ Α . . ( θ 1 - e a ) 
i = l 1 (Eq.9.3) 
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In these general equations С represents the plasma concentration, t is the 
time after the start of the infusion or after the lagtime of the oral dose, Τ is 
the infusion time, the coefficients A¡ are the hypothetical intercepts with 
the ordinate, as in outlined in more detail in Chapter 1, Iq refers to the i th 
disposition rate constant (reciprocal time constant) where i = 1....П, Ka is 
the rate constant of first-order absorption into the central compartment 
and η is the number of compartments of the model employed. 
After graphical analysis had yielded initial estimates, final parameter 
values were obtained by use of the FARMFIT computer program*. A 
relative error of 5% was attributed to each datapoint (weight¡= 1/(0.05 
Ci)2), as this was the standard deviation of the assay over the entire con-
centration range. The FARMFIT program provides a measure of the error 
in a parameter estimate by dividing the asymptotic deviation of the 
estimated parameter by the computer-estimated parameter itself (times 100 
gives relative error in %). The choice of the value for the lagtime after oral 
doses was not included in the regression analysis of the computer program 
for two and three compartment models. Instead a preset value was used, 
obtained after several prior estimations with different lagtime values, 
yielding the lowest sum of weighed squared deviations, with negligibly 
small improvement upon further change of this parameter. 
Two criteria were used for each individual curve to decide between a two 
or a three compartment model: 1) A visual inspection of the goodness of 
fit, and 2) A statistical comparison of the fits by the f-ratio (Boxenbaum et 
al., 1974). This test indicates if the total weighed sum of squared deviations 
(SWSD) has been reduced sufficiently (for a certain level of significance, 
e.g. 2.5%) in going from a two to a three compartment model, by taking-
into account the degrees of freedom (df) which remain after the choice of 
the number of parameters defining the particular model (df = the number 
of datapoints minus the number of parameters). 
The biological half-life (t'/i) was calculated from the smallest rate con-
stant (k¡ = /3) by VA = 0.693/j3. 
The volume of the central compartment (Vj), the volume of distribution 
at steady state (Vd)SS) and the plasma clearance (kcei) were calculated for 
each curve directly from the coefficients and exponentials of the 
appropriate exponential equation by use of the following relationships (van 
Rossum, 1971; Wagner, 1976): 
D i.v. administration V. = ^ 1 η (Eq. 9.4) 
Σ A. 
i = l 1 
* FARMFIT, a non-linear curve-fitting program, in use at the Computer Centre of the 
University of Nijmegen. Details in Chapter 1. 
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d , s s 
c e l 
n
 2 
D. Σ A. A 
1=1 1 1 
n
 2 ( Σ A . A . ) 
i = l 1 X 
D 
η 
Σ A . A . 
i -1 1 x 
oral administration 
V l = 
F.D 
η 
F.D 
e e l η 
(Eq.9.5) 
(Eq.9.6) 
Σ (l-W.A.
 ( E q.9_7 ) 
i = l 
n
 2 
F . D . Σ ( l - k . / K )A./k7 
. , i a ι ι i = l V = 
d , s s η 
( Σ ( l - k . / K ) . A . A . ) (Eq.9.8) 
. , i a ι ι i = l 
1f1
 ( 1
-
k i / K a ) - A i / k i (Eq.9.9) 
where D is the dose, F is the available fraction, equal to the fraction of dose 
absorbed if no first-pass effect occurs, and the other symbols have the 
same meaning as explained for the Eq. 9.1, 9.2 and 9.3. As is evident from 
the Eq. 9.7, 9.8 and 9.9, only values for Vi/F, Vd ) S S/F and kCel/F can be 
obtained if F is not actually known. 
Because graphical plots of the erythrocyte concentration vs. time curves 
revealed a relatively slow and monophasic uptake of the drug into the 
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erythrocytes, both after the intravenous and the oral doses, followed by an 
apparently mono-exponential decay phase, the red blood cell concentra­
tions after both modes of administration were fitted to a one compartment 
model with first-order absorption; for this Eq. 9.3 was used with η = 1 and 
С representing here the erythrocyte concentration of chlorthalidone, and 
Eq. 9.7 yielded the volume of distribution. In case of a one compartment 
model the choice of a lagtime was made by the non-linear least squares 
regression analysis of the FARMFIT program. The maximum concentra­
tion reached in the red blood cells (C
m
ax) and the time at which this occur­
red (t
m a
x) was calculated routinely from the model parameters (Gibaldi 
and Perrier, 1975 a). 
In addition to this separate approach to plasma and erythrocyte data, 
computer simulations were performed according to a non-linear model, 
which included the concentrations in plasma and erythrocytes 
simultaneously (Fleuren and van Rossum, 1977; Chapter 7). In this way the 
theoretical influence of a variation of dose upon the elimination half-life 
from plasma and erythrocytes and upon the ratio of the areas under the 
curve of a lower and a higher dose were studied, in order to see if non-
linearities in this ratio would be apparent in the dose range encountered. 
Estimates of bioavailability, i.e. the fraction of dose coming into the 
systemic circulation, were obtained from all three sets of data, viz. plasma, 
urine and erythrocyte measurements. The apparent bioavailability derived 
from the plasma and erythrocyte concentrations was calculated as follows 
(Gibaldi and Perrier, 1975 b): 
AUG D. th. 
apparent bioavailability = ^ / ' " ' p 1 ' ^ t ^ ^ ' (Eq.9.10) 
i . V . p . o . p . o . 
where the area under the curve (AUC) was obtained by use of the 
trapezoidal rule and extrapolation to infinity from the last datapoint, using 
the half-lives (t'/z) resulting from the curve-fitting procedure. 
The renal excretion rate plots were extrapolated to infinity from the ac­
tual analytical data by use of the half-life value, which had been observed 
from the decay of the red blood cell concentrations after oral administra­
tion for each individual subject, for reasons described in the Results section 
below. The ratios of the total amount of drug excreted in the urine over in­
finite time between the two modes of administration were calculated. 
The renal clearance was calculated from each experiment by dividing the 
amount excreted in the urine during the period, that plasma concentrations 
had been measured, by the area under the plasma concentration curve 
obtained by the trapezoidal rule. 
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RESULTS 
Plasma concentrations following intravenous administration 
During the intravenous administration of chlorthalidone a regular rise in 
the plasma concentration occurred until the zero-order infusion was ter-
minated. At that time peak concentrations between 0.44 and 0.87 ¿¿g/ml 
were measured. Immediately thereafter a rapid fall was observed with an 
apparent half-life between ca. 12 and 25 minutes, passing into a slower 
phase of disappearance with a mean half-life of 3.6 hours, until finally the 
elimination phase was reached with a long t ιΛ between ca. 25 and 50 hours 
(mean 36.5 h). 
In Figure 9.1 typical plasma concentration profiles are shown. All data-
points of two subjects during and after infusion were fitted to the exponen­
tial equations for a two and a three compartment model. Visual inspection 
of the plots revealed the superiority of curve-fitting according to a three 
compartment model in five out of seven subjects; in one subject the exten­
sion of the number of compartments to three seemed doubtful (J.v.Bo) and 
in another (T.Be) no visual improvement at all was reached. The statistical 
criterion gave results in good agreement with the judgement-by-eye, as can 
be seen from Table 9.2: the f-ratio exceeded the critical value in the same 
five subjects, indicating a significant improvement in fit with the use of the 
three compartment model for them, whereas the test was negative with 
respect to the data of the subjects T.Be and J.v.Bo. 
On the basis of these criteria it was concluded that a three compartment 
model was necessary for describing the time course of the plasma concen­
trations after intravenous administration in five subjects, while a two com­
partment model sufficed in the case of the two other subjects. The model 
parameters for the seven humans are presented in Table 9.3, together with 
the calculated values for the volume of the central compartment (Vj), the 
volume of distribution at steady state (Vj
 s s
) and the plasma clearance 
(keel)· 
Plasma concentrations following oral administration 
The time course of the plasma concentrations after chlorthalidone 
tablets was in agreement on the whole with previous observations (Fleuren 
and van Rossum, 1975; ibid., 1977; Chapter 7). In the present study, peak 
plasma concentrations of 0.14-0.26 /tg/ml were measured approximately 
1-3 hours after the dose. The decline of the curve thereafter consisted of 
two phases in all subjects, the first segment had an apparent half-life of ca. 
2 h, the second part of the curve showed a decay with a mean t'A of 44 h. 
Similarly to the judgement-by-eye indicated the f-test that no improvement 
at all was obtained in the computer fits for any of the subjects when three 
compartments instead of two were used. Therefore, all data were 
calculated according to a two compartment open model, assuming first-
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D,v (mg) 
ttag (h) 
кліі-
1) 
/3(h-') 
tv, (h) 
В (mg/l) 
v d (i) 
Cmax (mg/l) 
tma, (h) 
TABLE 9.5 A 
Pharmacokinetic parameters describing chlorthalidone concentration in erythrocytes after in­
travenous administration. The data were treated according to a one-compartment open model 
with first-order absorption. (Rel. errors in parentheses) 
Subject 
T.Be 
51.3 
0.32 
(6.8%) 
0.534 
(8.9%) 
0.0176 
(4 9%) 
39.3 
9.25 
(4.6%) 
5.73 
(4.3%) 
7.97 
6.61 
J.v.Bo 
75.0 
0.37 
(4.8%) 
0.454 
(9.6%) 
0 0149 
(5.9%) 
46.7 
12.66 
(5.2%) 
6.13 
(4.7%) 
10.90 
7.78 
L.De 
50.0 
0.39 
(6.7%) 
0.470 
(10.3%) 
0.0113 
(4.1%) 
61.4 
8.61 
(4.8%) 
5.95 
(4.6%) 
7.67 
8.13 
T . H o 
51.5 
0.31 
(5.8%) 
0.56 
(6.2%) 
0.0146 
(1.7%) 
47.5 
7.44 
(2.5%) 
7.11 
(2 4%) 
6.58 
5.92 
A.K1 
50.4 
0.24 
(15.9%) 
0.445 
(12.0%) 
0.0165 
(8.1%) 
42.1 
16.02 
(6.2%) 
3.27 
(5.6%) 
13.6 
7.69 
M . O 
61.3 
0.33 
(5.6%) 
0.387 
(7.4%) 
0.0124 
(3.5%) 
55.7 
8.75 
(3.9%) 
7.24 
(3.6%) 
7.56 
9.19 
M.We 
50.7 
0.34 
(5.4%) 
0.579 
(8.5%) 
0.0215 
(3.3%) 
32.2 
15.25 
(4.0%) 
3.45 
(3.7%) 
12.9 
5.91 
TABLE 9.2 
Fit of chlorthalidone plasma concentration versus time data after intravenous administration 
to two and three-component exponential equations. Statistical analysis of the weighted sums 
of squared deviations by the f-test 
Subject 
Two- compartment 
model 
(four 
df, 
15 
17 
19 
18 
15 
18 
16 
parameters) 
SWSD, 
138.3 
38 0 
106.7 
133.1 
157 5 
80.7 
121.3 
Three-compartment 
model 
(six parameters) 
df, 
13 
15 
17 
16 
13 
16 
14 
SWSD, 
117.6 
23.7 
37.9 
36 2 
82.5 
23.5 
54.8 
f 
ratio3 
1 14 
4.52 
15.4 
21.4 
5.90 
19.5 
8.50 
Critical 
value of f 
(P=0.025) 
T.Be 
J. v. Bo 
L. De 
T . H o 
A. Kl 
M. О 
M. We 
4.97 
4.76 
4.62 
4 69 
4.97 
4 69 
4.86 
df = remaining degrees of freedom 
SWSD = sum of weigthed squared deviations 
. f = (SWSD, SWSD, 
SWSD, 
df, 
' df, - df, 
TABLE 9 3 
Open pharmacokinetic model parameters describing plasma concentration of chlorthalidone 
after intravenous administration to seven human subjects (Rel errors in parentheses) 
Dose (mg) 
Dose/weight (mg/kg) 
Infusion time (h) 
« ( h - 1 ) 
α (h"·) 
β (h-· ) 
Half-life (h) 
Ρ (mg/l) 
A (mg/l) 
В (mg/l) 
ν,Ο) 
v^d) 
к& | (l/h) 
Three compartments 
Subject 
L De 
50 0 
0 69 
2 00 
2 18 
(19 9%) 
0 217 
(37 6%) 
0 0139 
(2 6%) 
49 8 
109 
(11 8%) 
0 1 1 6 
(36 1%) 
0 106 
(4 4%) 
38 0 
366 
5 77 
Τ Но 
51 5 
0 68 
2 00 
2 12 
(15 5%) 
0 133 
(33 8%) 
0 0157 
(3 4%) 
44 2 
128 
( 1 1 0 % ) 
0 119 
(21 7%) 
0 119 
(6 0%) 
33 9 
306 
5 66 
A Kl 
50 4 
0 88 
1 85 
171 
(29 0%) 
0 124 
(58 1%) 
0 020 
(24 3%) 
34 6 
140 
(19 5%) 
0 221 
(26 5%) 
0 142 
(31 9%) 
28 6 
198 
5 19 
M О 
61 3 
0 74 
2 0 0 
185 
(18 3%) 
0 244 
(30 8%) 
0 0149 
(2 5%) 
46 7 
102 
(8 9%) 
0 154 
(33 6%) 
0 121 
(3 9%) 
47 4 
388 
6 55 
M We 
50 7 
0 82 
2 00 
3 59 
(42 9%) 
0 249 
(44 0%) 
0 0291 
(4 9%) 
23 8 
2 15 
(29 1%) 
0 224 
(41 0%) 
0 179 
(9 8%) 
198 
187 
6 63 
Two compartments 
Subject 
Τ Be 
51 3 
0 74 
1S3 
137 
(14 7%) 
0 0271 
(6 5%) 
25 5 
1 24 
(13 9%) 
0 131 
(8 3%) 
37 3 
279 
8 97 
J ν Bo 
75 0 
0 68 
2 17 
1 45 
(9 0%) 
0 0225 
(3 4%) 
30 8 
132 
(8 0%) 
0 194 
(3 7%) 
49 6 
317 
7 87 
order absorption into and first-order elimination from the central compart­
ment. 
The resulting pharmacokinetic parameters are shown in Table 9.4. By 
comparison with Table 9.3 it can be seen that the terminal Л of three sub­
jects (T.Be, J.v.Bo, A.K1) is substantially longer than that observed with 
them in the intravenous study. Furthermore, it should be noticed that the 
values for the volume of the central compartment, the total volume of 
distribution at steady state and the plasma clearance can be obtained only 
in a relative sense from oral administration data, viz. divided by the 
bioavailability (F). 
Red blood cell concentrations after intravenous and oral administration 
The rise of the erythrocyte concentrations of chlorthalidone was relative­
ly slow compared to that of the initial plasma concentrations, even after 
the intravenous dose, where maximum concentrations were not reached 
until ca. 6-9 hours after the start of the infusion. 
Upon oral administration the highest values were found between 
approximately 8 and 16 hours after the dose, similarly to earlier results 
(Fleuren and van Rossum, 1975; ibid., 1977; Chapter 7). The times at 
which the maxima occurred coincided reasonably with the end of the 
distribution phases of the plasma concentrations. 
After the top of the curves, the decline of the red blood cell level was 
mono-exponential for the oral dosage form in all seven subjects. 
Therefore, the oral data were fitted to a one compartment model with first-
order absorption and the resulting pharmacokinetic parameters are shown 
in Table 9.5 B. 
After the intravenous dose of chlorthalidone, a substantially faster decay 
than after the oral dose was observed in four subjects, three of whom had 
also shown a faster disappearance of their plasma concentrations in the in­
travenous study (T.Be, J.v.Bo, A.K1). During the ca. 100 hour-period, in 
which the blood samples had been obtained from them, no appreciable 
deviation from a straight line was apparent when the concentrations were 
plotted on a semi-logarithmic scale. A typical illustration of this 
phenomenon is given in Figure 9.2, where the upper part represents the 
concentration versus time curves in the erythrocytes and the lower part 
shows the concentrations in plasma, followed in the same subject after 
both dosage modes. It can be seen that the tVi of the oral dose did not 
change after the first 100 hour-period, judged from the concentration at 
219 h (analyzed in duplicate), which arose from the assay of the zero-point 
before the next dose (t = 0 h of the intravenous dose)*. Similarly, the late 
oral datapoints from the subjects A.K1, M.We and T.Be were located 
within a few percent of the fitted curves, based upon the first 100 hours 
only. 
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TABLE 9.4 
Pharmacokinetic parameters describing plasma concentration of chlorthalidone after oral ad­
ministration to seven human subjects according to a two-compartment open model. (Rel. er­
rors in parentheses) 
Dose (mg) 
Dose/weight (mg/kg) 
Lag time (h) 
кль-
1) 
a (h-') 
fl(b-1) 
Half-hfe (h) 
A (mg/1) 
В (mg/1) 
ν , / F (1) 
V ^ / F (1) 
kce,/F (1/h) 
Subject 
T.Be 
50.0 
0 73 
0 25 
5.79 
(22.3%) 
0.205 
(12 5%) 
00157 
(7.8%) 
44.2 
0.177 
(8.1%) 
0 0555 
(8.6%) 
221 
602 
11.5 
J. v. Bo 
75 0 
0 68 
0 35 
1.22 
(45.5%) 
0.75 
(47.1%) 
0.0144 
(5.8%) 
48.2 
1 04 
(96.0%) 
0 0940 
(5 4%) 
152 
690 
10.7 
L.De 
50 0 
0.69 
0.40 
1.53 
(21.6%) 
0 131 
(46.5%) 
0 0136 
(5 4%) 
51.1 
0 099 
(31.6%) 
0 0895 
(9.5%) 
280 
467 
6 92 
T . H o 
50.4 
0.66 
0.60 
1.51 
(11 9%) 
0 343 
(12 9%) 
0.0161 
(2.2%) 
42.9 
0.393 
(17 5%) 
0 0975 
(3.6%) 
126 
399 
7 35 
A Kl 
50 0 
0 87 
0.70 
2.73 
(10 1%) 
0.242 
(16.3%) 
0 0137 
(3 7%) 
50 5 
0 198 
(11 7%) 
0 103 
(4 5%) 
176 
402 
6.06 
M O 
60 9 
0 73 
0 40 
1 54 
(20.9%) 
0 190 
(30.0%) 
0 0145 
(2 9%) 
47.9 
0 104 
(28.4%) 
0.0764 
(5 1%) 
366 
681 
107 
M.We 
50 0 
0.81 
0.75 
1.29 
(39 0%) 
0 87 
(26.0%) 
0 0293 
(2 5%) 
23 7 
1 10 
(42 8%) 
0 0981 
(3 5%) 
no 
424 
13.6 
Footnote of page 180: 
• The concentrations in the second experiment were corrected for the remainder of the 
previous dose by subtracting an amount calculated from the zero-time concentration and the 
half-life actually observed during the next dose. This correction was no greater than 4.04,,o of 
the total area under the curve for subject J.v.Bo (1.3% T.Be, 6.7Vo A.K1, 0.4% M.We). 
Comparison of the time course of plasma and erythrocyte concentrations of chlorthalidone 
after an equal intravenous and oral dose to the same human subject. The measurements in 
both the red blood cells (upper graph) and in the plasma (lower graph) show a faster disap-
pearance of the concentrations after the intravenous dose. The pictures have been taken 
directly from computer plots, obtained by fitting the data to their appropriate phar-
macokinetic equations. 
In the intravenous study in another subject (T.Ho), from whom blood 
samples had been taken up to ca. 220 hours, a slightly faster decay was 
observed in roughly the first half of the curve, which passed over gradually 
to the same decline as that estimated after the oral dose. In two other sub-
jects where also a long sampling period was employed (L.De and M.O.) the 
time course of the red blood cell concentrations after the intravenous dose 
was apparently mono-exponential, remaining approximately parallel to the 
curve of the oral study. Examples of both kinds of decay are shown in 
Figure 9.3. 
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Figure 9.3 
Typical red blood cell concentration profiles of chlorthalidone on semi-logarithimic scale 
after approximately equal intravenous and oral doses in two human subjects. A slightly faster 
decay in the intravenous study, caused mainly by the first part of the period, was observed 
here in one subject (upper panel), whereas almost equal half-lives for both modes of ad­
ministration were found in the other (lower panel). 
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^ОНС (Ν BG/L í v n S F « CONt IN H C L P I B S I B 
C B K IH H C L П-ЯЗИЯ CÍNC IN ЛСУІ P L O S F I R 
Pharmacokinetics of chlorthalidone in plasma after a single intravenous dose in two normal 
human subjects, followed during ca. 200 hours. The upper and lower graphs show computer 
fits according to, respectively, a two and a three compartment model. The inset pictures, 
representing the plasma concentrations during the first 35 hours at an expanded scale, 
demonstrate the superiority of the three compartment fits. 
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Figure 9.7 
Cumulative urinary excretion of unchanged chlorthalidone after equal intravenous and oral 
doses to the same human subjects. From гб.З-ЗІ.вЧ о^ of dose was totally excreted after 
orally(·), and from 50.1-77.7% of dose after intravenously(o) administered chlorthalidone. 
Faecal excretion 
Measurable concentrations of chlorthalidone in human faeces (above ca. 
20 ng/sample) were present during a period varying from 4-8 days after the 
intravenous or oral dose. The peaks in the excretion mostly occurred dur­
ing the second day after intravenous administration and from 1-3 days 
after the oral dose, the actual excretion rate of each individual naturally 
being dependent upon the regularity of the defaecation pattern. The in­
dividual data are presented in Table 9.8. During the intravenous study total 
amounts of 1.3-8.5% of the dose were excreted, whereas after oral ad­
ministration 17.5-31% of the dose was found in faeces. 
DISCUSSION AND CONCLUSIONS 
As far as we know, no reports concerning the intravenous administration 
of this drug to humans have appeared in the literature. The drug was 
dissolved in physiological saline because no untoward effects were expected 
from this dosage form, when administered at a sufficiently slow rate. It 
was possible, therefore, to take a 2 hours period for the infusion of the 
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In the calculation of bioavalability, half-life differences can be handled 
by using a correction for them, based upon a constant clearance of the drug 
during both periods of measurements (Gibaldi and Perrier, 1975 b). The 
most straightforward way was to consider the clearance to be constant over 
every period of measurement, even if it was anticipated that the half-lives 
after intravenous administration would be only temporarily smaller and 
would change to larger values after the actual time of analysis, as suggested 
by the case of subject T.Ho (see Figure 9.3). The erythrocyte concentra-
tions in all subjects were therefore forced into a one compartment model, 
which seemed to be allowed because of a reasonable agreement between the 
actual data and the fitted curves, which is shown in the Figures 9.2 and 9.3, 
even with the intravenous dose in subject T.Ho, in whom the difference 
between the initial and final elimination rate was too small to permit the 
use of a more complicated model. 
The resulting pharmacokinetic parameters are presented in Table 9.5. 
Comparison with the results after the oral dose, given in the same Table, 
shows that the estimated half-lives in five subjects (T.Be, J.v.Bo, T.Ho, 
A.K1, M.We) were shorter in the intravenous study than in the oral study; 
the relatively small magnitude of the difference in two subjects (T.Be, 
T.Ho) was the overall result of a small but discernible change in elimina-
tion rate during the time of analysis, see e.g. Fig. 9.3. Table 9.5 reveals fur-
thermore that the individual values for the apparent lagtime (tiag) were 
smaller and for the absorption constant (Ka) were larger in the intravenous 
study, corresponding to the earlier times at which the maxima were reached. 
Ratio of the areas under the plasma and red blood cell concentration curves 
of oral versus intravenous doses of chlorthalidone 
Figure 9.4 shows individual plasma concentration data of chlorthalidone 
after intravenous and oral administration of this drug to six human sub-
jects (the data of the seventh subject, A.K1, have been shown in another 
context, in Fig. 2.4, Chapter 2). Comparison of the oral and intravenous 
dosage form yielded a mean apparent bioavailability of 0.61 (individual 
values in Table 9.6A), whereas a mean apparent ratio of 0.72 was found 
from the erythrocyte concentration curves (individual values in Table 
9.6B). 
Computer simulations according to a non-linear chlorthalidone model 
Calculations performed on several sets of concentration-time curves 
showed that the bioavailability assessments based upon red blood cell con-
centrations would yield about 10% too high values for the oral dose. As an 
example, when simulations with the fitting model-parameters, given in 
Chapter 7 (Fig. 7.7), were carried out (with F = 0.25 arbitrarily, the dose 
thus being 50 mg), lowering the dose to three-fourth part did not result in a 
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chlorthalKjone plasma concentration (ng/ml ) 
900 
Figure 9.4 
Plots showing the areas under the plasma concentration vs time curves of chlorthalidone after 
equal intravenous (o) and oral (·) doses. From these data, a bioavailability ranging from 
47-81% was calculated for the oral dosage form. 
area under the curve ratio of 0.75, expected in case of linear kinetics, but 
instead the outcome was 0.83, when calculated according to Eq. 9.10, while 
the tVi (32-100 h) changed only from 70 to 73 h. This non-proportional in-
crease in area under the curve was due to the capacity-limited, strong bin-
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TABLE 9 б 
Estimation of the bioavailability of chlorthalidone by comparison of the areas under the 
curves after intravenous and oral doses in seven normal human subjects Upper part (A) 
plasma concentrations. Lower part (B) erythrocyte concentrations 
Subject 
Τ Be 
J ν Bo 
L De 
Τ Но 
A Kl 
M О 
M We 
Subject 
Τ Be 
J ν Во 
L De 
Τ Но 
A Kl 
M О 
M We 
Ρ о 
ι ν 
Ρ ο 
1 ν 
Ρ ο 
1 ν 
Ρ ο 
1 ν 
Ρ ο 
1 ν 
Ρ ο 
1 ν 
Ρ ο 
1 ν 
Ρ ο 
ι ν 
Ρ ο 
ι ν 
Ρ ο 
1 ν 
Ρ ο 
1 ν 
Ρ ο 
ι ν 
Ρ ο 
ι ν 
Ρ ο 
1 ν 
Time period (t) 
measured 
(h) 
104 
96 
104 
96 
219 
219 
195 
195 
192 
80 
219 
195 
80 
104 
Time period (t) 
measured 
(h) 
104 
96 
240 
104 
219 
219 
219 
219 
192 
80 
219 
195 
264 
104 
Half-life 
(h) 
44 2 
25 5 
48 2 
30 8 
51 1 
49 8 
42 9 
44 2 
50 5 
44 6 
47 9 
46 7 
217 
2 1 8 
Half-life 
(h) 
44 6 
39 3 
58 9 
46 7 
60 0 
61 4 
50 0 
47 5 
64 1 
42 1 
52 2 
55 7 
38 8 
32 2 
AUC 
plasma 
0-t 
(h mg/1) 
3 79 
5 44 
5 56 
8 42 
6 89 
8 40 
6 78 
8 88 
7 88 
8 43 
5 58 
8 92 
3 33 
7 60 
AUC 
erythr 
0-t 
(h mg,l) 
364 
407 
708 
635 
597 
671 
415 
474 
699 
678 
397 
618 
404 
596 
AUC 
plasma 
at infinity 
(h mg/1) 
4 74 
5 79 
7 03 
9 53 
7 26 
8 78 
7 04 
9 26 
8 42 
9 89 
5 81 
9 39 
3 66 
7 92 
AUC 
erythr 
at infinity 
(h mg 1) 
457 
509 
751 
817 
653 
734 
437 
496 
810 
947 
421 
686 
407 
678 
Bioavailability 
estimate 
0 49 
0 47 
0 81 
0 80 
0 59 
0 61 
0 47 
mean (±SD) 
0 61±0 15 
Bioavailability 
estimate 
0 81 
0 73 
0 91 
0 86 
0 57 
0 66 
051 
mean (±SD) 
0 72+0 15 
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ding of chlorthalidone to erythrocytes at higher concentrations. In the con­
verse case, the plasma concentration measurements yielded smaller than 
proportional areas after the lower dose, but the difference between the 
known bioavailability (0.75) and the calculated value (0.74) was much less 
than that found with the erythrocyte concentrations. This was attributed to 
the compensatory effect of first-order elimination, taking place from the 
central compartment to which the plasma volume belongs. The tVi of the 
plasma concentrations changed only from 42 to 44 hours when the dose 
was reduced. 
Urinary excretion of chlorthalidone after intravenous and oral administra­
tion 
The urinary excretion rate versus time plots ran parallel to the decay of 
the plasma concentrations, as long as the latter could be accurately analyz­
ed (down to ca. 5 ng/ml, using 2 ml of plasma). After that time there was a 
tendency for all graphs to accept gradually the Л of the erythrocyte con­
centrations observed after oral administration. Typical examples are given 
in the Figures 9.5 and 9.6, where the urinary excretion was followed in two 
human subjects, in one during 120 hours and additionally from 215-239 
hours and in the other during 220 hours and from 292-335 hours after the 
dose. The excretion rate during the later time was in every case above the 
value expected from the regression line of the first period. The total 
amount of unchanged drug excreted at infinite time was therefore 
calculated by extrapolation with the use of this oral half-life value after the 
actual period of analysis. This was preferred firstly because very precise 
half-life values from renal excretion data can be obtained only if the urine 
samples have been collected very frequently and considerable fluctuations 
in renal clearance within and between days do not occur. These re­
quirements were not met in the present study, because urine was collected 
during 6 or 12 hour-periods and some subjects showed a remarkable varia­
tion in excretion rate, often coinciding with changes in urine flow, which is 
shown in Fig. 9.5. Secondly, according to the non-linear chlorthalidone 
disposition model (Chapter 7), the plasma concentration decay and 
therefore, under the assumption of first-order renal elimination, also the 
urinary excretion rate should become parallel ultimately to the red blood 
cell concentration decay after a period of time long enough to reach ap­
propriately low concentrations. 
Table 9.7 summarizes the urinary excretion data of all subjects after 
both modes of administration of chlorthalidone. The actual cumulative 
amounts excreted during the sampling period are given as well as the total 
calculated amounts, obtained by extrapolation to infinite time. See also 
Figure 9.7. After intravenous administration of chlorthalidone a mean 
value of 65.4% of the dose was excreted as unchanged drug at infinite time 
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and a mean value of 43.81/0 was found after the oral dose. The 
bioavailability of the oral dose was calculated as the ratio of these total 
amounts excreted, resulting in a mean value of 67%. 
Renal clearance of chlorthalidone ranged from 43.5-97.7 ml/min (Table 
9.7). Except for a rather large difference in one subject (A.K1), the values 
in the whole group of subjects were not systematically higher or lower after 
either of the two dosage modes. 
urinary excretion rate-
(mg/hr, log scale) 
Subject J ν Bo 
Dose 
73 mg CHLORTHALIDONE 
t У
г
 • 4 9 hrs 
I I I'· . 
100 200 240 
lime (hours) 
urinary excretion rate 
(mg/hr, log scale) 
2 
Subject Τ Ho 2 4 yr 7B hg 
Dose 51 5 mg CHLORTHALIDONE 
intravenously 
о 'so' ' ' юо' ' ' 'ido' ' ' гіо 
urine flow(ml/hr) 
300-, 
300 350 
- ι»-' ι ι ι ι ι ι ι ι I ' 
50 100 150 200 300 350 
time (hours) 
Figure 9.5 (¡eft panel) 
Renal excretion rate of chlorthalidone versus time. To facilitate comparison with the plasma 
concentration curve of the same subject (t'/i = 48.2 h) a regression line has been drawn based 
upon the average 24 h excretion rate during 24-120 hours, indicated as open circles. The half-
life calculated from the last point of this period and the later data-point at 227 h (t Vi ca. 57 h) 
approximates the longer t г of the erythrocyte concentrations after oral administration. In the 
lower graphs the urine flow and the pH of the urine fractions are shown. 
Figure 9.6 (right panel) 
Urinary excretion rate of chlorthalidone versus time after a single 51.5 mg intravenous dose in 
man. The excretion rate is parallel with the observed decay of the plasma concentrations in the 
subject (t'/j = 44.2), shown by regression of the averaged daily excretion rate values from 
24-220 hours (open circles). The half-life calculated from the later period of assay, 292-335 
hours, and the last point of the first period (t'/i ca. 52 h) apparently equals the iVi of the red 
blood cell concentrations after oral administration (t'/i = 50 h in this subject). The total 
amount of drug excreted unchanged at infinite time was 72 percent of the intravenous dose. 
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TABLE 9.7 
Urinary excretion of chlorthalidone after intravenous and oral administration of equal (usual­
ly SO mg) doses to the same seven human subjects. Calculation of renal clearance and estima­
tion of oral bioavailability 
Subject 
and mode of 
administration 
T.Be 
J. v. Bo 
L.De 
T. Ho 
А. И 
M. О. 
M. We 
p. о 
i. v. 
р. о. 
i. v. 
p. о. 
i.v. 
p. о. 
i. V. 
р. о. 
i. ν. 
р. о. 
i. ν. 
р. о. 
i.V. 
Time period 
measured 
(h) 
119 
119 
119 
119 
220 
216 
220 
219 
95 
95 
296 
215 
119 
119 
Cumulative excretion of chlorthalidone 
During assay 
amount 
(mg) 
22.96 
30.15 
26.83 
44.6 
22.15 
31.6 
24.81 
35.89 
15.94 
32.23 
26.39 
37.03 
12.3 
24.62 
% o f 
dose 
45.9 
58.8 
35.8 
59.5 
44.3 
63.2 
49.2 
69.7 
31.9 
64.0 
43.3 
60.4 
24.6 
48.6 
At infinite 
amount 
(mg) 
25.91 
32.85 
32.34 
48.16 
23.82 
33.65 
25.6 
37.1 
21.32 
39.2 
26.92 
38.43 
13.25 
25.40 
time3 
% o f 
dose 
51.8 
64.0 
43.1 
64.2 
47.6 
67.3 
50.9 
72.0 
42.3 
77.7 
44.2 
62.7 
26.5 
50.1 
Bioavailability 
estimate 
0.81 
0.67 
0.71 
0.71 
0.54 
0.71 
0.53 
mean (±SD) 
0.67 (±0.10) 
Renalb 
clearance 
(1/h) 
5.86 
5.29 
4.63 
4 89 
3.10 
3.70 
3.65 
3.99 
2.61 
3.67 
4.66 
4.06 
3.39 
3.20 
Urine 
flow 
(ml/h) 
73.3 
123.0 
55.7 
73.2 
65.7 
56.0 
66.7 
77.1 
65.1 
81.2 
83.7 
66.2 
103.0 
97.0 
a
 extrapolation to infinity was performed by use of the half-life of the erythrocyte concentration after oral administration. For further 
explanation see text. 
ь
 very similar renal clearance values were obtained when only the first 48-h-period was used. 
Table 9 5 В 
Pharmacokinetic parameters describing chlorthalidone concentration in erythrocytes after 
oral administration The data were treated according to a one-compartment open model with 
first-order absorption (Rel errors in parentheses) 
Dp о (mg) 
t* (h) 
К, (h-1) 
/SOi-1) 
t./, (h) 
В (mg/1) 
V d/F(l) 
Q ™ (mg/1) 
«•«(h) 
Subject 
Τ Be 
50 0 
0 34 
(2 4%) 
0 385 
(3 9%) 
0 0155 
(2 2%) 
44 6 
7 40 
(2 1%) 
704 
(1 9%) 
6 21 
8 69 
J ν Во 
75 0 
051 
(18 6%) 
0313 
(27 7%) 
00118 
(112%) 
58 9 
8 70 
(12 8%) 
8 96 
11 8%) 
7 36 
10 88 
L De 
50 0 
0 46 
(113%) 
0 180 
(115%) 
00116 
(4 9%) 
60 0 
7 95 
(6 8%) 
6 72 
(5 9%) 
6 16 
16 3 
Τ Но 
50 4 
0 64 
(6 9%) 
0316 
(24 0%) 
00138 
(7 6%) 
50 0 
6 33 
(12 9%) 
8 32 
(11 8%) 
5 26 
10 3 
A Kl 
50 0 
0 82 
(3 4%) 
0 29 
(11 1%) 
0 0108 
(6 8%) 
64 1 
8 85 
(5 9%) 
5 87 
(5 4%) 
7 50 
11 8 
M О 
60 9 
0 40 
(3 9%) 
0 195 
(8 9%) 
0 0133 
(3 9%) 
52 2 
5 98 
(6 0%) 
109 
(5 3%) 
4 59 
14 8 
M We 
50 0 
0 89 
(1 4%) 
0 437 
(7 6%) 
0 0179 
(1 9%) 
38 8 
7 04 
О 3%) 
741 
(3 1%) 
5 89 
7 62 
TABLE 9 8 
Excretion of chlorthalidone in faeces after intravenous (i.v ) and oral (p.o.) administration of 
equal (usually SO mg) doses to the same human subjects 
Subject 
Τ Be 
J ν Bo 
L De 
Τ Ho 
M О 
M We 
Time period 
measured 
(h) 
120 
120 
220 
220 
220 
120 
Cumulative amount 
(% of dose) 
Ρ о 
17 5 
21 0 
24 2 
20 9 
31 2 
η d 
ι ν 
170 
1 27 
4 14 
3 86 
3 69 
8 5 1 
η d = not determined 
volume of fluid, necessary because of the limited solubility of chlor­
thalidone in neutral aqeous solutions (Stenger et al., 1959; Chapter 6). 
Upon questioning, the subjects under study stated that no effects, except 
upon urine production, were experienced by them during and after the in­
fusion. 
Curve-fitting according to 3 versus 2 compartment models 
With respect to the plasma concentrations of chlorthalidone after in­
travenous administration a perfect agreement was noticed between the 
results of the f-test and of the visual inspection of the goodness of fit. Both 
criteria indicated the superiority of the three compartment model in five 
out of seven subjects and a serious underestimation of the terminal half-life 
would have occurred by the use of the two compartment model. Table 9.3 
shows that relatively great errors were found for the parameter estimates 
describing the first and second phase of distribution after the intravenous 
dose, due to a limited number of datapoints in these segments, despite 
reasonable visual fits, see e.g. Figure 9.1. In contrast, errors in the oral ab­
sorption rate constants obviously reflected also deviations in some subjects 
from a purely first-order absorption process, which, however, remained 
the most effective approach to include the data. Good accuracy was 
obtained for the estimates of the terminal elimination rate constants and, 
therefore, also of the terminal half-lives. Comparison of the Tables 9.3 and 
9.4 showed that the half-lives after intravenous administration were shorter 
than those after the oral dose in five of the seven humans. Simulations with 
a non-linear model indicated that differences of such magnitude were not 
expected to follow from a less tight binding of the drug to red blood cells at 
the higher concentrations reached initially with the intravenous dose. 
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Moreover, the concentration range in which the half-life differences 
became evident was practically the same for both dosage forms, see e.g. 
Figure 9.2. It is reasonable therefore to understand the shorter half-lives of 
plasma and erythrocyte concentrations as being due to an enlarged 
clearance of chlorthalidone after intravenous administration, assuming 
that the volume of distribution remained the same during both trials. In­
spection of Figure 9.5 might suggest that the faster elimination could have 
been caused by the larger urine flows, generally observed after the in­
travenous doses, see Table 9.7. Surprisingly, however, no proportional in­
crease, except in one case, in the time-averaged renal clearance was evident 
in the subjects where shorter half-lives after the intravenous dose were 
found, see Table 9.7, implying that the above difference should become 
mainly on account of increases in non-renal clearance. 
Bioavailability measurements 
For a definite statement of a greater plasma clearance after intravenous 
doses than after oral medication the exact values of the bioavailability F 
have to be known. This factor F in turn can be determined reliably from 
urinary excretion data only, if the balance between renal and non-renal 
clearance had not changed between the oral and the intravenous trials. 
Thus, this kind of a vicious circle presents a serious limitation for the exact 
interpretation of the data in some subjects. Nevertheless, the disagreement 
for two subjects between the bioavailability calculations based upon 
urinary excretion data and plasma concentrations (see Tables 9.6 A and 
9.7) could be explained by an increased non-renal clearance after in­
travenous administration, such that a greater proportion of drug was 
eliminated by another route than by excretion in the urine. Consequently 
the oral bioavailability calculated from the urinary excretion data in these 
subjects (T.Be, J.v.Bo) was too high. 
On the other hand it seemed unwise to rely upon plasma data only, 
because the semi-logarithmic plots of the elimination phase were, though 
reasonably, not perfectly linear, see e.g. Figure 9.2, indicating a decreasing 
clearance already during the measuring period, so that the model used 
should be considered only approximative in these cases. In the absence of a 
more detailed explanation for the differences in t г than described above, 
we decided not to prefer either the urinary excretion data or the plasma 
concentration data for assessment of the bioavailability of chlorthalidone, 
and when weighing equally both sets of data a mean absolute bioavaila­
bility F = 0.64 results for the oral doses. 
In contrast, the bioavailability estimate based upon red blood cell con­
centration data yields too high values, judged from computer simulations, 
and supported further by the observation that the sum of the apparently 
available dose and dose remaining in the gastro-intestinal tract after oral 
194 
administration (see Tables 9.6 В and 9.8) exceeded 100% in two subjects 
(L.De, T.Ho). 
In principle, a decreased oral bioavailability can be caused by limited ab­
sorption, by a so-called "first-pass effect" in the liver or by a combination 
of both processes. Judged from the total amounts of drug recovered from 
the faeces after oral doses, limited absorption must be the predominant 
factor here, as only minor amounts were found in the faeces after intra­
venous administration, ruling out the possibility of considerable transport 
back into the gut lumen under normal conditions. However, comparison of 
the amounts non-absorbed from the gastro-intestinal tract (by subtraction 
of the faecal amounts after i.v. doses from those after oral doses, see Table 
9.8) with the calculated bioavailability, which is the fraction of dose com­
ing into the systemic circulation, suggests that a certain degree of first-pass 
elimination, about 10-15% of the dose, is present. 
Typically, the differences in half-life between the intravenous and oral 
trial were in general the most pronounced for the hospitalized persons (see 
Tables 9.3,9.4, 9.5). Little is known of the effect of continuous bedrest per 
se on the pharmacokinetic behaviour of drugs. A report by Levy (1967) 
showed that bedrest alone had a significant influence on the disposition of 
benzylpenicillin, although the underlying mechanism was not understood. 
Our data do at least suggest that subjects with bedrest are more susceptible 
to non-renal increases in elimination rate. These changes could be due to 
the obviously higher concentrations of chlorthalidone reached initially with 
intravenous administration, making available higher free drug concentra­
tions, somehow affecting their own elimination. Only in one subject (A.K1) 
the shorter t'/z after the intravenous dose was concomitant with an increase 
in renal clearance (Table 9.7), the change thus not being of non-renal 
character. One may speculate that the underlying hypothyroidism, a 
serious metabolic disturbance (Werner and Ingbar, 1971), made this sub­
ject unable to react upon sudden increases of drug concentration by a non­
renal, e.g. metabolic, mechanism and that therefore a secondary change in 
renal clearance became evident. 
Central volume of distribution 
The volume of distribution of the central compartment (Vj) which was 
estimated from the intravenous study at a mean value of 36.4 liter (± 10.4 
S.D.) or 0.48 liter/kg body wt. (± 0.08 S.D.) (detailed data in Table 9.3) 
was still larger than the plasma volume, indicating rapid equilibration, with 
regard to the infusion rate, with well-perfused tissue. A very rapid dis­
appearance of plasma concentrations was evident shortly after the dose in 
the intravenous study, see Table 9.3 for individual data. This segment can 
be explained possibly by a strong liver uptake of chlorthalidone, which has 
been observed immediately after intravenous doses of this drug in rat ex-
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periments (Beisenherz et al., 1966). After oral administration no such 
phase of rapid decay was seen. This is not surprising because the afore-
mentioned decay showed a mean half-life of ca. 20 min, which is of about 
the same magnitude as the rate of absorption of the drug after oral admini-
stration, for which a mean half-life of ca. 19 min was measured (see Table 
9.4 for personal data). As a result, much larger apparent central volumes 
of distribution were found for the oral study, even if corrected for the bio-
availability F. Thus, the Vj/F values obtained in the oral study cannot be 
compared directly with those for Vj from the intravenous trial, because 
different models were necessary to describe the time course of the plasma 
concentrations after each dosage form. 
Plasma versus red blood cell half-lives 
The mean half-life in the present seven subjects for the terminal decay 
phase was, in the intravenous and oral study respectively, 36.5 h (± 10.5 
S.D.) and 44.1 (± 9.5 S.D.) for the plasma concentrations and 46.4 h (± 
9.9 S.D.), respectively 52.7 h (± 9.0 S.D.) for the erythrocyte concentra-
tions. A pharmacokinetic model including non-linear binding of chlor-
thalidone to red blood cells, which is able to explain in detail the observed 
half-life differences between plasma and erythrocyte decay, is described ex-
tensively in Chapter 7 (Fleuren and van Rossum, 1977). Some comment has 
to be made yet on the magnitude of the differences in the present study, be-
ing somewhat smaller than those previously reported, when an average ter-
minal V/i of 40 hours for the decay of the plasma concentrations and of 60 
hours for that of the erythrocyte concentrations was found after single 100 
or 200 mg oral doses in ten human subjects (Chapter 7). A lower dose, 
mostly 50 mg, was administered in the present experiments, consequently it 
took less time to reach the low concentrations, at which strong binding of 
drug to components of the erythrocytes becomes the predominant factor 
governing the slow transport rate to plasma. There is good evidence that 
carbonic anhydrase has an important role in this strong binding (Beermann 
et al., 1975; Dieterle et al., 1976; Chapter 8). 
An apparent discrepancy should be noticed in this context between 
recent pharmacokinetic reports on chlorthalidone by different authors. 
Our results were, shortly summarized, parallel decays of plasma concentra-
tions and urinary excretion rate, being shorter in half-life than the tVi of 
the erythrocyte concentrations during at least 100-200 hours after the dose 
(Fleuren and van Rossum, 1975, 1977; Chapter 7; this Chapter). In con-
trast, other authors estimated parallel decays of plasma concentrations, 
urinary excretion rate and red blood cell concentrations* (Riess et al., 
1977), stated that plasma concentrations "mirrored" red blood cell con-
centrations (Collste et al., 1976) or reported variable figures with relation 
to the half-life values (Beermann et al., 1975). One explanation for this 
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divergency can be found in the circumstance that methodological precau-
tions have to be taken for the precise assay of chlorthalidone plasma con-
centrations, otherwise much too low values will be found, especially during 
the first 10-24 hours after the dose (Fleuren and van Rossum, 1978; 
Chapter 3). If these conditions are not fulfilled (Beerman et al., 1975; Col-
Iste et al., 1976), or alternatively, if the concentrations during the first 24 
hours are not measured (Riess et al., 1977), the higher initial plasma con-
centrations, which contribute much to establish a faster decay phase, are 
ignored and a wrong impression of the half-life is obtained. 
Additionally, it may be argued that exact half-lives from urinary excre-
tion data are difficult to assess, if only 24 hour portions have been collected 
(Riess et al., 1977), the more so as considerable fluctuations in urinary 
clearance from day to day do occur, which can be seen by inspection of e.g. 
Figure 9.5. Nevertheless, also Riess and co-workers (1977) reported a faster 
half-life from urinary excretion data than from whole blood concentra-
tions at higher concentrations reached after chronic administration, 
although they did not comment on this observation. Analogous phar-
macokinetics, viz. a slower decay of erythrocyte concentrations than of 
those in plasma, have been reported for acetazolamide, a drug also strong-
ly bound to carbonic anhydrase in red blood cells (Maren, 1962), in both 
humans (Wallace et al., 1977) and dogs (Maren, 1962). 
It has been suggested in literature that the long biological half-life of 
chlorthalidone could be maintained by a prolonged absorption of the drug 
from the gastro-intestinal tract (Pulver et al., 1959). Evidence against this 
possibility is raised by the present faecal excretion data after oral ad-
ministration, details of which showed that 80-90% of this non-absorbed 
fraction was excreted already with the first faeces portion in most subjects, 
which was commonly produced at the first or second day. It is reasonable 
to assume that if further considerable amounts of non-absorbed drug 
would have been present in the gut lumen at later time, this had been 
reflected also in the faecal excretion during that period. This implies that 
the absorption had been terminated amply before the end of the period, in 
which the long V/i values were evident, viz. up to ten days and longer. 
Another contribution to a long half-life could theoretically have been caus-
ed by enterohepatic circulation, as chlorthalidone was found to be excreted 
in the bile of rats (Beisenherz et al., 1966). Human experiments, however, 
revealed the biliary excretion of only a few percent of unchanged drug 
* Actually measured in whole blood, but due to much higher concentrations in red blood cells 
than in plasma, a perfect resemblance between the terminal decay of whole blood and red 
blood cell concentrations can be assumed. 
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(This thesis, Chapter 11; Fleuren et al., 1979), so that the quantitative im­
portance of this possibility can be excluded. 
In conclusion, it must be stated that the long biological half-life of chlor­
thalidone is caused to an important degree by the strong binding of the 
drug to red blood cells (Beermann et al., 1975; Fleuren and van Rossum, 
1975; Collste et al., 1976; Fleuren and van Rossum, 1977; Riess et al., 
1977; This thesis, Chapters 7 and 8), and by the relatively slow exchange 
rate with that tissue, see e.g. Figures 9.2 and 9.3, together providing very 
low concentrations of unbound drug available for elimination. 
Evidence for metabolic clearance 
As the total urinary excretion of unchanged drug after intravenous ad­
ministration amounted to only 65.4 ±8.6% of the dose (mean ± S.D.) and 
only a few percent was found in the faeces (Table 9.8), while an approxi­
mately equal cumulative amount in urine plus faeces was recovered after 
oral administration (Tables 9.7 and 9.8), strong evidence exists for another 
important, presumably metabolic, route of elimination of chlorthalidone 
in man. Essentially the same information can be obtained by comparison 
of the plasma clearance (Table 9.3) with the corresponding renal clearance 
values (Table 9.7), the latter being on an average 38% lower than the total 
clearance. In agreement with metabolic degradation of chlorthalidone is 
the observation that, after oral administration of С ^ -chlorthalidone to 
humans, about 10% of the urinary radioactivity showed thin-layer 
chromatographic behaviour different from that of the original compound 
(Beermann et al., 1975). Metabolism of Cl4-chlorthalidone in the rat has 
been demonstrated by Beisenherz et al. (1966), the greatest part of the 
metabolites being excreted in the bile. A minor part of this radioactivity 
was tentatively attributed to the hydrolysis product of chlorthalidone, 
3-(4-chloro-3-sulfamoylbenzoyl)-benzoic acid. This compound was not 
found in human urine and bile (Chapter 11). Thus, the nature of the 
metabolic pattern of chlorthalidone in man has yet to be identified. 
SUMMARY 
Seven normal human volunteers received each a constant-rate infusion 
of chlorthalidone during 2 hours and an equal - commonly 50 mg - single 
oral dose on separate occasions. Concentrations of unchanged chlor­
thalidone were analyzed during 100 to 200 hours periods in plasma, red 
blood cells, urine and faeces after both dosage modes. A three compart­
ment model was necessary to describe the intravenous plasma concentra­
tions in the majority of subjects (five). A two compartment model was suf-
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ficient for the decay of the oral plasma concentrations in all seven subjects. 
The mean plasma tVi after i.v. doses was 36.5 h (± 10.5 S.D.), the mean 
plasma t'/i after oral doses was 44.1 h (± 9.6 S.D.). The mean red blood 
cell concentration VA after i.v. doses was 46.4 h ( ± 9.9 S.D.) and the mean 
red blood cell Л after the oral doses was 52.7 h (± 9.0 S.D.). The urinary 
excretion rate plots were parallel to the plasma concentration curves in all 
cases. As the faster decay after i.v. administration was not accompanied by 
an increased renal clearance, the difference had to be caused by a non-renal 
mechanism. A mean cumulative amount of 65.4 (± 8.6 S.D.) % of the in­
travenous dose was excreted in urine over infinite time, whereas a mean 
value of 43.8 (± 8.5 S.D.) % was found for the oral dose. Faecal excretion 
ranged from 1.3-8.5% of dose in the i.v. study and from 17.5-31.2% of 
dose in the oral study. The sum of the amounts present in urine plus faeces 
strongly pointed to an important metabolic route of elimination of chlor­
thalidone. Bioavailability estimates (F) were obtained from three sets of 
data: a mean F = 0.61 from plasma concentrations, a mean F = 0.67 from 
urinary excretion measurements and a mean F = 0.72 from the erythrocyte 
concentrations. Simulations with a non-linear model indicated the lesser 
validity of the estimate from erythrocyte concentrations. It was concluded 
that the average of plasma and urine data, F = 0.64, yielded the best 
estimate of the oral availability of 50 mg chlorthalidone doses in man. 
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CHAPTER 10 
URINARY EXCRETION OF CHLORTHALIDONE 
AS A FUNCTION OF DOSE 
INTRODUCTION 
Diuretics play a crucial role in current treatment of mild to moderate 
hypertension. Several recent studies have compared the antihypertensive 
effects of different dosage levels of chlorthalidone (Hygroton® ), ranging 
from 12.5-200 mg per os daily (Bengtsson et al., 1975; Carney et al., 1976; 
Materson et al., 1978; Tweeddale et al., 1977). The general conclusion was 
that with the 25 mg dose an equal or almost equal blood pressure reduction 
was achieved as with the larger amounts. 
The relationship between the natriuresis, resulting in a reduced extra-
cellular volume, and the antihypertensive effect of diuretics seems to be 
firmly established (Bennet et al., 1977; de Carvalho et al., 1977). On the 
other hand, indications exist for a dependence of natriuresis upon the ex-
cretion in the urine of the diuretic drug itself, which was demonstrated in 
the case of chlorothiazide (Beyer and Baer, 1961), hydrochlorothiazide 
(Beyer and Baer, 1975) and furosemide (Hook and Williamson, 1965; 
Homeida et al., 1977; Honari et al., 1977) by interaction studies with pro-
benecid. Some evidence for such coupling of natriuresis with urinary excre-
tion rate of chlorthalidone has been presented in Chapter 1. 
The above considerations suggested a detailed study of the involvement 
of pharmacokinetic factors, with emphasis on the urinary excretion 
parameters, in the clinical dose-response curve of chlorthalidone. 
METHODS 
Subjects and dosage 
Single oral doses of chlorthalidone were administered as commercial 
tablets (Hygroton® , Ciba-Geigy) to 17 young healthy volunteers (age 
20-32 yr, body weight 65-88 kg, 2 females, 15 males). After fasting over-
night, the subjects ingested the tablet in the morning at 9.00 a.m., crushed 
it by the teeth and swallowed it completely with about 200 ml of tap water. 
No food or beverages other than water were allowed until ca. 4 hours after 
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dosage. The 50 mg dose was received by 6, the 100 mg dose by 11 and the 
200 mg dose by 6 subjects. Three individuals in this group took both the 50, 
the 100 and the 200 mg tablet in a randomized order, each dose 1 month 
apart. In addition, 2 subjects received the same dose - 100 mg - twice, on 
separate occasions, in order to get an impression of possible intra-
individual variation in the handling of the drug. Nobody received any other 
medication at least 2 weeks prior to or during the trial. 
The influence of urinary pH upon renal plasma clearance of chlor­
thalidone was studied in a separate experiment by giving two subjects cap­
sules with sodium bicarbonate or ammonium chloride. From the second 
day after intake of 100 mg of chlorthalidone, urinary pH was adjusted 
either at pH 5.2 with NH4CI or at pH 7.5-8 with ЫаНСОз by means of 
hourly pH measurements. Subject T.Ho started with ЫаНСОз for two 
days (20 g on day 2, 13.5 g on day 3) followed by two days with NH4CI (7 g 
on day 4, 3 g on day 5). Subject M.Br made his urine acidic or alkaline in a 
different sequence (20 g ЫаНСОз o n day 2, 7 g NH4CI on day 3, 19.5 g 
ЫаНСОз on day 4, 8 g NH4CI on day 5). 
Biological samples and assay 
Urine was collected in separate or 6-12 hr portions (Chapters 7 and 9, 
respectively), in most cases during 100 hr after the dose (range 80-220 hr, 
exact time periods indicated in Table 10.1). Venous blood portions of 
about 7 ml, spread over the sampling period as indicated in the Chapters 7 
and 9, were heparinized and centrifuged immediately after collection in 
order to ensure correct values of the plasma concentrations in the way 
described in Chapter 3. The plasma and red blood cell fractions and ali-
quots of each urine portion were frozen at -20° С until assay. The concen­
trations of chlorthalidone were determined by gas chromatography with 
nitrogen detection (Fleuren and van Rossum, 1978; Chapter 3). 
Pharmacokinetic analysis 
In the present between-dose comparison of chlorthalidone data from 
subjects participating in the pharmacokinetic studies described in the 
Chapters 7 and 9 were also used. The urinary excretion rate versus time 
plots were found always to parallel the decay curves of the plasma concen­
trations of chlorthalidone. On the contrary, the elimination half-lives of 
the red blood cell concentrations , being 50-100 times higher than those in 
plasma, were considerably longer than the values obtained from the cor­
responding plasma concentrations after single 100 or 200 mg doses. A non­
linear pharmacokinetic model, proposed in Chapter 7, takes all above 
features of the time courses of both plasma and red blood cell concentra­
tions into account. Yet, it had to be expected, on the basis of that model, 
that the decay of plasma concentrations and urinary excretion rate should 
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ultimately approximate the decay of the red blood cell curves, when con­
centrations had become sufficiently low. Experiments with single 50 mg 
doses indicated that the half-life of the urinary excretion rate plots indeed 
converged to the longer half-life of the erythrocyte concentrations, when 
measurement was performed over very long time periods (200-336 hr) 
(Fleuren et al., 1979a; Chapter9). In view of this information, it was judged 
reasonable to extrapolate the urinary excretion rate plots to infinite time 
with the use of the tYi value of the erythrocyte concentrations and so ob­
tain the total amount excreted. An overestimation of this amount will 
result if the slower decay rate has not yet been reached at the time point 
where extrapolation actually begins. However, as the difference between 
the cumulative amounts, calculated by using either the Л of the red blood 
cell concentrations or the t'/z obtained from the urinary excretion rate 
plots, is relatively small (maximally ca. 10% in a few cases), the error 
possibly made herein must be even smaller, because the true value lays be­
tween these two extremes. Therefore, this method of extrapolation has a 
negligible quantitative influence on the total urinary recovery. 
The renal clearance of chlorthalidone was calculated by dividing the 
amount actually excreted in the urine during the assay period by the cor­
responding area under the plasma concentration curve. The elimination 
half-lives of plasma and erythrocyte concentrations were determined by 
non-linear regression analysis of the final straight part of the curves, using 
at least 5 data points. The areas under the concentration-time curves were 
obtained by the trapezoidal rule. 
RESULTS 
Urinary excretion rate of chlorthalidone vs time, plasma and red blood cell 
concentration decay 
A typical example, in which the absorption and distribution of chlor­
thalidone in both components of blood and its elimination into urine are 
shown, is given in Figure 10.1. Both a 100 mg and a 200 mg dose of the 
drug were administered on separate occasions to a healthy human subject. 
After a rapid absorption into the plasma, with peak concentrations occur­
ring at approximately 2 hours following the dose, the drug was transported 
relatively slowly into the erythrocytes, where maximum concentrations 
were not found before 10-15 hours. Red blood cell concentrations, ca. 100 
times higher than those in plasma, persisted during the post-distribution 
phase. The half-life of the erythrocyte concentrations was longer than the 
plasma half-life (detailed data shown in Table 10.1). The urinary excretion 
rate was parallel to the time course of the plasma concentrations. So far, 
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Figure IO J 
Urinary excretion rate, plasma (·) and red blood cell (o) concentration profiles of chlor­
thalidone following oral administration of a single 100 mg and 200 mg dose to the same sub­
ject. In the lower graphs the cumulative urinary excretion during 100 hours is shown, which 
amounted to 37.0% and 23.2% of the dose after 100 mg and 200 mg respectively. For further 
explanation see text. 
these pharmacokinetic aspects of chlorthalidone were completely consis­
tent with the observations described in the Chapters 7 and 9. The next sec­
tion deals with the total urinary recovery at different dose levels of the 
drug. 
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Cumulative urinary excretion 
The total urinary recovery of chlorthalidone is not a linear function of 
the dose (Fig. 10.2). The percentage of dose excreted in the urine was the 
same after single doses of 50 and 100 mg, 44.4% and 43.1% respectively, 
but decreased sharply to 29% after a 200 mg dose. The individual data of 
17 subjects are presented in Table 10.1 : the amount excreted at infinite time 
ranged from 16.0-25.4 mg after a 50 mg dose in 6 subjects, from 36.2-52.4 
mg after 100 mg in 11 subjects, and from 43.4-66.9 mg after 200 mg in 6 
subjects. The individual urinary recoveries of the subjects, who had receiv­
ed three dose levels of the drug (Table 10.1 : J.Bi, D.Bo, T.Sw), were entire­
ly consistent with the average pattern of Figure 10.2. 
Cumulative urinary excretion 
y g ^ of chlorthalidone (mg) 
Figure 10.2 
Cumulative amount of chlorthalidone recovered in urine after oral administration of single 
doses of different magnitude to human healthy subjects. The values shown (mean ± S.D., 
η = number of experiments) were obtained by extrapolation to infinite time from the actual 
assay period, which ranged from 80-220 hours. The average percentage of excretion decreased 
from 44.4% and 43.1 % of dose after 50 mg and 100 mg respectively to 29.0% after the 200 mg 
dose. 
Renal clearance 
A considerable interindividual variation in the renal plasma clearance of 
chlorthalidone was observed, ranging from 3.1-7.5 1/hr (52-125 ml/min) 
after the 50 mg dose, from 2.6-6.4 l/hr (43-107 ml/min) after that of 100 
mg and from 2.8-4.6 l/hr (47-77 ml/min) after the dose of 200 mg. Intrain-
dividual variation in this extent can probably be ruled out by comparison 
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TABLE 10.1 
Urinary excretion data of chlorthalidone after single oral doses of 50, 100 and 200 mg in healthy human subjects 
Dose 
(mg) 
50 
Mean ± S.D. 
100 
Mean ± S.D. 
Subject 
J.Bi 
D.Bo 
L.De 
T.HoC 
M.OC 
T.S 
(n = 6) 
J.Bi 
D.Bo 
M.Br 
M.Br 
H.v.B 
V.F1 
V.F1 
P.K 
O.L 
M.pd 
M.R 
T.S 
L.V 
(n=13) 
Assay 
period 
(hr) 
100 
100 
219 
195 
219 
100 
80 
100 
100 
200 
200 
100 
94 
100 
100 
100 
100 
100 
96 
Half-life (hr) 
plasma3 
46 
48 
51 
43 
48 
45 
42 
50 
45 
46 
45 
30 
31 
32 
39 
34 
42 
55 
29 
erythrocytes 
46 
62 
60 
50 
52 
57 
52 
60 
66 
65 
60 
51.5 
54 
59 
62 
54 
68 
69 
52 
AUC 
plasma 
(hr.mg/1) 
2.05 
2.53 
6.89 
6.73 
4.58 
3.65 
4.30 
5.75 
8.29 
14.20 
9.14 
8.19 
9.69 
12.80 
10.70 
14.30 
9.99 
6.45 
8.01 
Renal 
clearance 
(1/hr) 
6.28 
7.51 
3.10 
3.60 
4.66 
4.44 
4.93 
±1.68 
6.33 
6.43 
3.52 
3.34 
4.32 
3.72 
3.38 
2.78 
2.98 
2.56 
3.71 
4.84 
4.28 
4.02 
±1.23 
Cumulative urinary 
recovery (mg) 
during 
assay 
12.8 
19.0 
21.4 
24.3 
21.4 
16.2 
27.2 
37.0 
29.2 
47.5 
39.5 
30.5 
32.8 
35.6 
31.9 
36.6 
37.1 
31.2 
34.3 
at infinite 
timeb 
16.0 
24.5 
23.8 
25.4 
22.1 
21.3 
22.2 
± 3.4 
36.2 
47.0 
41.2 
52.4 
43.0 
36.7 
41.5 
45.2 
39.8 
44.9 
49.4 
42.1 
41.1 
43.1 
± 4.7 
TABLE 10.1 continued 
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Mean ± S.D. 
J.Bi 
D.Bo 
H.F 
OK 
J.Med 
T.S 
(η = 6) 
100 
100 
80 
185 
168 
100 
36 
42 
34 
43 
33 
42 
52 
64 
58 
60 
45 
70 
7.98 
10.00 
13.50 
22.50 
10.90 
9.78 
4.40 
4.64 
3.46 
2.81 
4.31 
4.26 
3.98 
±0.70 
35.1 
46.4 
46.7 
63.3 
47.0 
41.7 
43.4 
62.4 
64.4 
66.9 
48.3 
62.6 
58.0 
± 9.7 
a
 The urine t'/i was equal to the plasma t'A 
b The extrapolation to infinity was performed with the use of the V/z of the erythrocyte concentrations. For further explanation, see methods 
section 
c
 The subjects T.Ho and M.O received 50.4 and 60.9 mg respectively (Chapter 9). Their AUC and urinary recoveries have been standardized to 
the 50 mg dose level by multiplying the original data with 5/5.04 and 5/6.09 respectively 
d
 Subjects of female sex 
TABLE 10.3 
Effects of urinary pH and flow on renal plasma clearance of chlorthalidone 
Subject Μ.В Subject T.Ho 
Period 
after 
dose 
(hr) 
25- 37 
50- 71 
73- 95 
96-110 
Average 
urinary 
pH 
7.5 
5.2 
7.5 
5.1 
Average 
urinary 
flow 
(ml/hr) 
249 
85 
132 
123 
Average 
renal 
clearance 
(1/hr) 
5.3 
4.9 
5.4 
4.0 
Period 
after 
dose 
(hr) 
25- 39 
47- 65 
74- 88 
95-108 
Average 
urinary 
pH 
7.6 
7.8 
5.2 
5.1 
Average 
urinary 
/low 
(ml/hr) 
108 
89 
72 
69 
Average 
renal 
clearance 
(l/hr) 
4.2 
5.1 
3.8 
4.7 
о 
of the average renal clearance values in two subjects (M.Br and V.F1), who 
had received the same dose twice at different occasions (Table 10.1). A 
firm negative correlation was found between the renal plasma clearance 
and the area under the plasma concentration curve* (correlation coefficient 
R = -0.86, significantly different from zero at Ρ < 0.005), whereas there 
was no significant correlation between the renal plasma clearance and the 
total urinary recovery (R = 0.11). 
The data of the subjects (n = 3), who received each both the 50, 100 and 
200 mg doses are presented separately in Table 10.2. While the renal 
clearance in one subject did not change with dose systematically, but show­
ed variations of the same order as those in subjects administered an equal 
dose twice** (intraindividual variation), the clearance in the other two sub­
jects decreased as the doses increased from 50 to 200 mg. The mean value 
(n = 3) after 200 mg (74 ml/min) was 27% lower than that after 50 mg (101 
ml/min). Figure 10.3 represents the urinary excretion rate plotted against 
plasma concentrations of chlorthalidone, measured during 100 hr after ad­
ministration of two different doses to the same human subject. The picture 
demonstrates that the difference in the slope of both plots, viz. in the 
magnitude of the renal clearance, remained unchanged during the entire 
experimental period. 
TABLE 10.2 
Comparison of the renal plasma clearance of chlorthalidone after different single 
doses in three humans 
Subject 
50 mg 
Renal clearance (ml/min) 
100 mg 200 mg 
J.Bi 105 106 73 
D.Bo 127 107 77 
T.S 74 81 71 
Mean (η = 3) 101 98 74 
* Calculated from experiments with an equal sampling period (100 hr, n = 8, dose 100 mg, 
see Table 10.1). 
** cf. Table 10.1: subjects M.Br and V.F1. 
208 
urinary excretion 
rate (mg/ hr) 
2 
15-
0 5 
chlorthalidone ρ о 
subject D Bo,22yn80kg 
dose 100 mg (·) 
„ 200mg (») 
J 
01 02 0 3 0 4 0 5 
chlorthalidone plasma 
concentration (mg/1) 
Figure 10.3 
Two plots of the urinary excretion rate of chlorthalidone against the plasma concentration at 
the midpoints of the urine collection periods, measured during 100 hours after oral ad­
ministration of varying single doses at different occasions to the same human subject. A 
diminution of the renal plasma clearance, kc
r
, from 107 ml/min to 77 ml/min was observed 
when the dose was increased from 100 mg to 200 mg. 
Dependence of renal clearance upon urinary pH and f low 
The urinary excretion rate of chlorthalidone is subject to large fluc­
tuations. Because the decay of plasma concentrations of the drug against 
time is very regular, the profiles of plots of urinary excretion rate and renal 
plasma clearance are almost identical (Fig. 10.4). Table 10.3 shows the 
average renal plasma clearance of chlorthalidone under conditions of 
acidified or alkalinized urine production by two human subjects . The 
time-averaged clearance values appeared to depend only slightly upon 
urinary pH and not upon urine flow. Although some coincidence could be 
observed between incidental changes in flow and renal clearance for urine 
kept at constant pH, the overall pattern of excretion appeared to be 
governed by other factors. Large variations were visible which did not cor-
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Figure IO 4 
Plots of plasma concentration and urinary excretion rate of chlorthalidone against time, 
revealing large fluctuations in renal plasma clearance The time-averaged renal clearance, in­
dicated by dotted lines in the lower graph, did increase only slightly when urine pH was 
changed from 5 2 to 7 7 Black horizontal bars at the bottom indicate periods of bed rest 
During these periods a striking decrease in renal clearance compared to that by day became 
apparent 
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respond to changes in flow or urinary pH (Fig. 10.4). This held true also 
for all subjects not receiving ammonium chloride or sodium bicarbonate, 
from whom urine had been obtained in separate portions. By sampling 
urine over longer periods, e.g. 12-24 hr, excessive fluctuations became 
masked (cf., for instance, Fig. 9.6). Part of the fluctuations occurred in a 
circadian rhythm: renal clearance at night was always decreased compared 
to the clearance at day. This was the case in every subject studied (see e.g. 
Fig. 10.4). 
DISCUSSION 
Dose-dependent urinary excretion 
Several factors can be responsible for the relatively small increase in 
urinary recovery of chlorthalidone on changing the oral dose from 100 to 
200 mg: limited absorption from the gastro-intestinal tract, decreased renal 
clearance or a combination of both. No definite evidence for only one of 
these possibilities is available so far. 
In Chapter 9, we reported an absolute bioavailability of only 64%, on an 
average, after oral administration of a single 50 mg dose to 7 human sub-
jects. Because this incomplete bioavailability was mainly attributable to the 
amount of unabsorbed drug, a progressively decreasing percentage of ab-
sorption at higher oral doses would be conceivable. To clarify this point, 
we measured, as described in Chapter 9, concentrations of unchanged 
chlorthalidone in the faeces of two subjects participating in the present 200 
mg dose study. Over 7 days, 21% and 17% of the dose were found (for the 
subjects O.K. and J.Me, respectively). These data practically represent the 
unabsorbed fraction of the drug, because biliary excretion of chlor-
thalidone in man is very small (Fleuren et al., 1979b; Chapter 11). 
Therefore, compared with the single 50 mg dose, of which 17.5-31.2% was 
recovered in faeces after oral administration (Chapter 9), no dispropor-
tional change in the fraction of unabsorbed chlorthalidone has become evi-
dent after the 200 mg dose. 
The interindividual variation in the renal plasma clearance of chlor-
thalidone is in the same order as the differences found by Collste et al. 
(1976) after single 50 mg doses. The large standard deviations (Table 10.1) 
did not permit a conclusion with regard to the possible influence of dose on 
this parameter. However, in two of the three subjects in whom a clear com-
parison of three doses could be made, there was a decrease in renal 
clearance after the 200 mg dose, see Table 10.2. A similar conclusion on 
this matter can be deduced from data published by Riess and coworkers 
(1977), who found a ratio of 1:2:2.6 for the cumulative amounts of chlor-
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thalidone excreted in urine after single 50 mg, 100 mg and 200 mg doses in 
the same 6 subjects, whereas the ratio of the areas under the curve of the 
corresponding whole blood concentrations was 1:2:3.4. Also for the 
diuretic bendroflumethiazide a lesser renal clearance has been reported 
after a single 5 mg dose compared to that after a single 2.5 mg dose in 
hypertensive patients (Beermann et al., 1978). 
Renal tubular secretion is an important pathway for the elimination of 
sulfonamide-type diuretics (Beyer and Baer, 1961, 1975; Chapter 1). The 
parallel decay of plasma concentrations and urinary excretion rate plots of 
chlorthalidone (Fleuren and van Rossum, 1975; Fleuren et al., 1977, 1979a; 
Chapters 7, 9 and 10) does not support the hypothesis of a simple 
concentration-dependent decrease in tubular secretion after higher doses of 
drug. This can also be seen from Figure 10.3 where completely different 
renal clearance values were obtained after two dosage levels, while the 
range of plasma concentrations was virtually the same. If tubular secretion 
function should be involved, it must have changed in a non-competitive 
manner, because the different status of the kidney with respect to clearance 
of the diuretic remains strikingly constant during a rather long period (Fig. 
10.3). 
Fluctuations in renal plasma clearance 
The time-averaged renal plasma clearance of chlorthalidone was not 
susceptible to changes in urine flow (in the range 70-250 ml/hr). This 
confirmed similar findings described in Chapter 9. The renal clearance was 
influenced by urinary pH but the effect was small. This does not need to 
surprise, however, because the pK
a
 of chlorthalidone is 9.35 (Fleuren et 
al., 1979c; Chapter 6), which implies that the percentage of ionized drug in­
creases from 0.01% at pH 5.3 to only 3.5% at pH 7.8. Beyer and Baer 
(1975) reported an about equally small rise in renal plasma clearance of 
chlorthalidone with increasing pH in the dog. Nevertheless, as is discussed 
in Chapter 1, the pH effect indicates that also tubular reabsorption deter­
mines besides secretion the net excretion of this drug into the urine. 
Many endogenous substances are actively secreted and/or reabsorbed by 
the kidney. Among these are metabolic substrates which provide the energy 
for the tubular reabsorption of salts and water. Proximal tubular cells do 
not utilize glucose as their main energy source, but prefer lactate, α -keto-
glutarate and free fatty acids (Cohen and Barac-Nieto, 1973). These acidic 
substrates are known to compete for uptake in the renal cortex with 
sulfonamide diuretics and other drugs secreted by the renal organic acid 
transport system (Cohen and Barac-Nieto, 1973). Accumulation in prox­
imal tubules has been established also for chlorthalidone (Taugner and 
Iravani, 1965). So, it is reasonable to assume that diuretics and endo­
genous substrates utilize a common secretory pathway. The large varia-
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lions in renal clearance of chlorthalidone (Fig. 10.4) could then result from 
mutual competition for secretion. Analogously, competition for tubular 
reabsorption is conceivable for instance with uric acid which is handled 
both by active secretion and reabsorption in the kidney (Mudge et al., 
1973). Further studies are required to know which of these endogenous 
compounds or other substances (e.g. food constituents) do significantly in-
fluence the persistence of diuretics in renal tissue. The circadian rhythm in 
the renal plasma clearance of chlorthalidone might well be related to one or 
more of the many physiological changes known to occur in the kidney at 
night, e.g. the reduction of the glomerular filtration rate (Mertz, 1976). 
This issue too remains to be investigated. 
Therapeutic meaning 
OUT investigations showed a small increase in the cumulative urinary 
excretion of chlorthalidone when the dose was changed from 100 to 200 
mg. In view of the long biological half-life of the drug, see e.g. Table 10.1, 
the concentrations reached after repetitive lower doses, e.g. 50 mg/day, 
can be expected to approach those encountered after administration of a 
single 200 mg dose. In that case, the pharmacokinetic limitations described 
here may well be related to the limited or nihil gain in the therapeutic 
response of higher chronic doses, reported recently (Bengtsson et al., 1975; 
Carney et al., 1976; Materson et al., 1978; Tweeddale et al., 1977). The 
relationship between the natriuretic and antihypertensive effect of diuretics 
and their own urinary excretion after chronic administration still seems an 
unsolved problem, worthy of further investigation. 
SUMMARY 
Renal excretion, plasma concentration and erythrocyte concentration pro-
files of chlorthalidone were studied in 17 healthy human subjects during 
100-200 hours after oral administration of single doses of 50, 100 and 200 
mg. Three subjects received all three doses in a cross-over design. The other 
14 were involved in the study at one dosage level. The 50 mg dose was taken 
altogether by 6, the 100 mg dose by 11 and the 200 mg dose by 6 subjects. 
The effects of urinary pH and flow upon renal clearance of chlor-
thalidone were explicitly studied in two subjects in a separate experiment. 
The renal clearance varied considerably over time and the fluctuations were 
not attributable to changes in urinary pH or flow. 
Total urinary recovery of chlorthalidone extrapolated to infinity was 
44.4% of the 50 mg dose (22.2±3.4 mg), 43.1% of the 100 mg dose 
(43.1 ±4.7 mg), but only 29.0% of the 200 mg dose (58.0±9.7 mg; mean 
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values ± S.D.). A large interindividual variation in the renal plasma 
clearance of chlorthalidone was observed, 52-125 ml/min after 50 mg, 
43-107 ml/min after 100 mg and 47-77 ml/min after 200 mg. This variation 
correlated more with differences between subjects in the area under the 
plasma concentration curve than with those in total urinary recovery of the 
drug. The subjects who were available for a between-dose comparison of 
the renal clearance showed an average decrease in it of 27%, in going from 
the single 50 mg to the 200 mg dose, suggesting a causal relationship with 
the limited urinary recovery of the drug at the higher dose. 
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CHAPTER 11 
BILIARY EXCRETION OF CHLORTHALIDONE IN HUMANS 
INTRODUCTION 
In man, chlorthalidone (Hygroton® ) is eliminated for the greater part 
by excretion into urine in unchanged form (Chapters 9 and 10; Fleuren et 
al., 1979). Following oral administration, urinary recovery measurements 
alone are not sufficient to proof an additional route of elimination, 
because the missing part of the dose could have resulted from incomplete 
absorption in the gastro-intestinal tract. However, after intravenous doses 
of 50 mg of chlorthalidone, only a mean total of 65% of the dose was 
recovered in urine (Chapter 9), so that elimination via the liver, either by 
biliary excretion or by metabolism, should account for the remainder 35%. 
When Cl4-chlorthalidone was given to rats, radioactivity concentrated not 
only in the kidneys but also in the liver, which was followed by excretion of 
label into the bile (Beisenherz et al., 1966). The present study was perform-
ed to elucidate biliary excretion of chlorthalidone in man. The drug was 
given orally to cholecystectomized patients with normal (or nearly normal) 
liver function. T-tube drainage was used to collect bile from the common 
bile duct, and chlorthalidone concentrations in bile and urine were 
analysed. 
EXPERIMENTAL PROCEDURE 
Patients 
Four female and two male subjects gave informed consent for this study. 
All patient? had undergone cholecystectomy and choledochotomy because 
of cholelithiasis*. Liver and renal function had been judged by routine 
laboratory tests (S.G.O.T., S.G.P.T., bilirubin, alkaline phosphatase, 
L.D.H., total protein, hemoglobin, serum electrolytes, plasma creatinine 
and ureum). Detailed patient data are shown in Table 11.1. 
The study started 3 to 4 days postoperatively, when the patients had 
• Operations performed at the Department of Surgery, Radboudhospital, Nijmegen, The 
Netherlands. 
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TABLE 11.1 
Cholecystectomy patients3. Clinical-chemical data*3 
subject 
M.A. 
A.E. 
E.K. 
A.L. 
MM. 
R.V. 
normal 
values 
age 
(yr) 
59 
61 
42 
60 
28 
49 
— 
body 
weight 
(kg) 
61 
82.5 
57 
56 
54 
61 
— 
creatinine 
plasma 
ОшіоІ/1) 
77 
90 
71 
66 
76 
79 
60-100 
ureum 
plasma 
Oxmol/l) 
5.73 
4.92 
4.65 
4.21 
5.62 
5.43 
3.0-6.0 
total 
bilirubin 
(μτηοΐ/ΐ) 
<10 
<10 
< I 0 
<10 
<10 
<10 
<10 
sGOT 
(U/1) 
10 
10 
8 
11 
30 
14 
<15 
sGPT 
(U/1) 
4 
8 
8 
6 
41 
16 
<15 
alkaline 
fosfatase 
(U/1) 
86 
86 
79 
78 
122 
220 
<120 
LDH 
(U/1) 
— 
128 
136 
— 
— 
— 
<175 
diagnosis of 
liver function 
normal 
normal 
normal 
normal 
slightly disturbed 
almost normal 
a. Subjects M.A. and A.E. were males, the others females. 
b. Determined pre-operatively; all patients were normal in their plasma albumin, total protein, hemoglobin, electrolytes and E.C.G. pattern. 
again a normal food and fluid intake. Each subject received a single oral 
dose of 100 or 200 mg of chlorthalidone (Hygroton®, Ciba-Geigy, Basle, 
Switzerland), as indicated in Table 11.2, after an overnight fast. Food or 
fluid, except water, were not given until about 4 hours after the tablet. No 
co-medication was used during the trial. Urine and bile were collected in 
24-hours portions during 3 to 7 days after the dose (exact sampling periods 
given in Table 11.2. Bile was obtained by gravity drainage, via a T-tube, of 
the common bile duct. 
Chlorthalidone assay 
The volumes of the urine and bile samples were measured and an aliquot 
of each portion was kept frozen until determination, at -20oC. The concen-
tration of unchanged chlorthalidone in urine was assayed as described in 
Chapter 3. For analysis of bile the following minor modification was found 
suitable: 0.1 ml of a well-homogenized bile sample was added to 2 ml of 
buffer of pH 9.0 (0.1 M, citrate-phosphate-borate, Teorell and Stenhagen), 
containing the internal standard, and extracted twice with 10 ml of 
methylisobutylketone-ethylalcohol (MIBK:ALC 98:2, v/v). The combined 
organic layers were washed twice with 2 ml of the above buffer, transferred 
into a new tube, and re-extracted with 2 ml of 0.1 M aqueous NaOH. In 
the alkylation reaction and following steps the alkaline extract was treated 
identically as described in the original procedure (Chapter 3). Calibration 
graphs were prepared by the use of blank bile, obtained from each patient 
prior to administration of the drug. They proved to be linear and to pass 
through the origin, while the extraction recovery was the same as for an 
equal volume of buffer without bile. Standards of chlorthalidone, in the 
10-250 ng/sample range, were used for each analysis of unknown samples. 
Bile from each patient was treated with 0-D-glucuronidase from 
Escheria coli (strain K12, Sigma, St.Louis, Mo., USA) by incubating 0.1 
ml, mixed with 1 ml of 0.067 M phosphate buffer pH 6.5 (Sörensen), with 
1000 Fishman units of enzym during 16 hours at 370C. Analogously, β-Ό-
glucuronidase with arylsulfatase activity from Helix pomatia (2000 
Fishman units, same manufacturer) was incubated with 1 ml of 0.1 M 
acetate buffer pH 5.2 (Walpole), containing 0.1 ml of bile. Afterwards the 
pH was brought to pH 9 with a few drops of 5 M aqueous sodium hydrox­
ide, and the sample was analysed for chlorthalidone as described above. 
In order to detect in bile and urine the chemical hydrolysis product of 
chlorthalidone, 3-(4-chloro-3-sulfamoyl-benzoyl)-benzoic acid (compound 
A), which has been tentatively indicated as a metabolite of chlortha­
lidone in rats (Beisenherz et al., 1966), bile and urine samples (0.1 ml 
and 1 ml, respectively) were extracted at pH 2, both directly and after 
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treatment with glucuronidase/sulfatase. The conditions of incubation were 
similar to those described above, except for omittance of acetate buffer 
because the acetate anion, extracted as acid at pH 2, interfered with the ex-
tractive alkylation reaction. Instead, the pH was adjusted to pH 5.2 with 
dilute HCl and checked after the incubation. A good separation of com-
pound A and chlorthalidone on the gas chromatographic column (3% SE 
30) was obtained by lowering the oven temperature to 240oC. The other 
conditions of analysis, as described in Chapter 3, remained unchanged. 
The methylated derivatives of the internal standard, compound A and 
chlorthalidone eluted at retention times of 3.7, 4.8 and 6.2 minutes, respect-
ively. 
RESULTS 
Chlorthalidone is excreted into human bile. Figure 11.1 shows 
concentrations of unchanged drug in 24-hours bile from six cholecystec-
tomized patients, followed during 3 to 7 days after oral administration of 
single 100 or 200 mg doses. Biliary concentration was 11-44 times smaller 
than that in urine, on a subject-averaged basis. The values depicted in 
Figure 11.1 represent in fact amounts excreted per day, when a liver bile 
flow of 1000 ml/24 hr is assumed (see section Discussion). Thus, the biliary 
excretion rate was seen to be a small fraction of the urinary excretion rate 
in each subject and the total biliary recovery of chlorthalidone ranged from 
0.6-1.4% of the dose, see Table 11.2. When the amounts in bile and urine 
were compared directly, from equal sampling periods, 2.5-4.7% and 
2.5-5.7% of the quantities found in urine were excreted into bile after doses 
of 100 and 200 mg of chlorthalidone, respectively (Table 11.2). 
Glucuronidase and sulfatase treatment of the individual bile samples did 
not increase chlorthalidone concentrations. Measurable amounts (> 5 
ng/sample) of 3-(4-chloro-3-sulfamoylbenzoyl)-benzoic acid as a human 
metabolite of chlorthalidone in bile or urine were not found. 
DISCUSSION AND CONCLUSIONS 
Only part of the liver bile can be collected by drainage of the common 
bile duct. The remainder is lost into the duodenum via the second way of 
the T-tube. Therefore, the volume of bile recovered indicates a minimum 
only for the actual bile production by the liver. Liver bile now in healthy 
humans may vary from 250-1200 ml/day, with an average of 800 ml/day 
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Figure ¡I. I 
Concentration in bile and urinary excretion rate of chlorthalidone in 6 cholecyslectomized pa-
tients, following an oral dose of 100 or 200 mg. Concentration in bile is numerically equal to 
biliary excretion rate at a bile flow of 11/day. The lower graph shows daily volumes of actual-
ly collected bile, by means of T-tube drainage of the common bile duct. 
(see, e.g., Rein, 1971). The present cholecystectomized patients were 
selected on the basis of a normal or almost normal liver function, thereby 
excluding cholestasis of significant extent (Sherlock, 1975). By the T-tube 
drainage, however, parts of the bile pool were withdrawn from these sub-
jects. It is well-known that any interruption of the normal enterohepatic 
circulation of bile acids leads to a marked reduction in total liver bile now 
(Wheeler, 1975a), so that our patients most probably were different in this 
respect from normal healthy subjects. On the other hand, many examples 
of active biliary secretion of organic compounds have .been found 
(Schanker, 1968), implying that the excretion of such drugs is not 
necessarily dependent upon bile flow. 
In fact, Pratt and Aikawa (1962) reported that the total biliary recovery 
of the related sulfonamide-diuretic hydrochlorothiazide did not increase 
above controls, when bile flow was stimulated by secretin or by brom-
sulphalein, in dogs. If an analogous situation would apply to chlor-
thalidone, the biliary concentrations encountered in patients undergoing 
cholecystectomy and subsequent T-tube drainage, should be even higher 
Sdbj R V 
dose 200mg 
I subj M Д 
] dose lOOmg 
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TABLE 11.2 
Cumulative excretion of chlorthalidone into bile and urine of patients undergoing common 
bile duct drainage after cholecystectomy and choledochotomy. 
Subject Dose Assay period Urinary Estimated biliary 
(mg) (days) recovery recovery3 
urine bile (mg) amount Щц of urinary 
(mg) recoveryb 
M.A. 
A.E. 
E.K. 
A.L. 
M.M. 
R.V. 
100 
100 
100 
200 
200 
200 
4 
5 
4 
7.5 
6 
7 
4 
5 
4 
3 
6 
7 
24.6 
31.6 
36.5 
62.8 
46.3 
58.1 
0.62 
1.12 
1.70 
2.66 
1.18 
2.75 
2.5 
3.5 
4.7 
5.7 
2.5 
4.7 
a. Under assumption of a bile flow of 1000 ml/day 
b. Based upon time period during which both bile and urine had been collected. 
than those in healthy subjects, because the excreted amounts concentrated 
in smaller volumes of bile. Therefore, by assuming a bile flow of 1000 
ml/24 hr (see Table 11.1), the estimated cumulative amounts are to be con­
sidered as maximum values. It must be concluded that biliary excretion is 
not a preferred route of elimination of chlorthalidone in man, accounting 
for only a few percent of the dose. These quantities are consistent with the 
1.5-8% of the dose found in the faeces of humans after intravenous ad­
ministration of chlorthalidone (Chapter 9), indicating that this amount did 
result indeed from excretion into the bile. 
The extent of biliary excretion of chlorthalidone appears to be in the 
same order as that known from other sulfonamide-type diuretics. 
Although more than 40% of an i.v. dose of C14-labelled chlorothiazide 
was excreted into bile in the nephrectomized dog, this percentage diminish­
ed to almost zero under normal physiological conditions (Baer et al., 1959). 
From a patient, receiving С ^ -chlorothiazide and тЗ-hydrochlorothiazide 
simultaneously, only 4.4% and 2.4% respectively, of the radioactivity of 
both drugs was recovered in the bile during 6 days (Calesnick et al., 1961). 
This figure corresponds with the total recovery of hydrochlorothiazide 
Cl4-label in human faeces after intravenous administration, which 
amounted to 1 and 4% of the dose in two healthy subjects (Beermann et 
al., 1976). 
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Biliary excretion by active transport has been demonstrated by Hart and 
Schanker (1966) for chlorothiazide in dogs. Preliminary evidence for such 
a process can be gained from a high bile/plasma concentration ratio of un-
bound drug. Although the plasma concentrations of chlorthalidone were 
not determined in the present study, they can be estimated indirectly from 
urinary excretion data, because the relationship between both parameters is 
known: in our investigation reported in the Chapters 9 and 10 and in that 
of Riess et al. (1977) a renal plasma clearance of ca. 50-100 ml/min was 
measured for chlorthalidone. By means of the equation dQr/dt = kcr-Cpi 
(where dQr/dt denotes urinary excretion rate, kcr renal plasma clearance, 
and Cpi plasma concentration), plasma concentrations of approximately 
0.07-0.14 mg/1 are found at an urinary excretion rate of 10 mg/24 hr 
(which can be considered as a typical value, see Figure 11.1.). After correc-
tion for a protein binding of 75% (Dieterle et al., 1976; Collste et al., 1976), 
free drug concentrations in plasma are estimated at roughly 0.02-0.04 
mg/1. The corresponding concentrations of chlorthalidone in bile are clear-
ly much higher, see Fig. 11.1. Because human bile contains almost no pro-
tein (Wheeler, 1975 b), total drug concentration in it can be assumed to be 
closely equal to the concentration of unbound drug. A free drug concentra-
tion ratio of bile: plasma = 20:1 approximately, can then be deduced by 
inspection of Figure 11.1. While the demonstration of this concentration 
gradient alone is not sufficient as proof, it may well serve as first evidence 
for active secretion of chlorthalidone in bile. 
The total recovery of chlorthalidone in urine in the present group of pa-
tients (Table 11.1) lays in the same order as the values we found in Chapter 
10 after single 100 and 200 mg doses in healthy volunteers. This indicates a 
similar disposition of the drug in both groups. Doses of different 
magnitude, 100 and 200 mg, have been employed in this investigation, 
because of dose-dependence in the renal excretion of chlorthalidone: after 
oral adminstration of single 50 and 100 mg doses an average fraction of 44 
and 43% of dose, respectively, was recovered in human urine, whereas this 
figure decreased to 29% after the 200 mg doses. The available evidence 
pointed to a decrease in renal clearance, rather than a limited absorption at 
the higher dose level (Chapter 10). These findings had left open the 
possibility of a compensatory biliary pathway at higher concentration. 
However, no disproportional increase in biliary amount of chlorthalidone 
after the 200 mg doses became evident (Table 11.2). This might implicate a 
greater participation of metabolism in the elimination of such doses. After 
the smaller doses of chlorthalidone, usually 50 mg, employed in Chapter 9, 
metabolic clearance has been estimated by us as responsible for removal of 
ca. 30% of the drug. 
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SUMMARY 
A single oral dose of the diuretic chlorthalidone (100 or 200 mg) was 
given to six cholecystectomized patients with T-tube drainage of the com­
mon bile duct, and the 24 hours bile and urine were collected during 3-7 
days. Urinary recovery of chlorthalidone was 23-37% of the dose, which is 
in the range of that in healthy volunteers. Chlorthalidone concentration in 
bile was 11-44 times lower than urinary concentration in corresponding 
periods, and biliary recovery was only 0.6-1.4% of the dose. The same 
relative amount of drug was found in bile, whether the 100 or 200 mg dose 
had been given (viz., a fraction of 2.5-4.7% and 2.5-5.7% of correspon­
ding urinary amounts respectively). It was concluded that excretion into 
bile constitutes only a minor route of elimination for unchanged chlor­
thalidone. Bile samples treated with glucuronidase and sulfatase showed no 
increase of chlorthalidone concentration. The open acid analogue of chlor­
thalidone, 3-(4-chloro-3-sulphamoylbenzoyl)-benzoic acid, was apparently 
not formed as a human metabolite, as evidenced by gas chromatographic 
analysis of both urine and bile. 
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CHAPTER 12 
SALIVA CONCENTRATIONS OF CHLORTHALIDONE 
INTRODUCTION 
A study of the relationship between plasma and saliva concentrations of 
chlorthalidone was considered worthwhile, because saliva has been sug-
gested as a satisfactory alternative for routine determination of phar-
macokinetic parameters (Dvorchik and Vesell, 1976; Graham and 
Rowland, 1972; Groth et al., 1974; Koysooko et al., 1974; Horning et al., 
1977). Use of saliva as the sampling fluid precludes the discomfort of 
venipunctures, while still information would be provided for the adjust-
ment of dosage regimens. Moreover, saliva concentration was suggested to 
be closely related to free drug concentration in plasma and might, 
therefore, show a better correlation with therapeutic effects than total 
plasma concentration. A comprehensive review of the literature on saliva 
levels of some 30 drugs was given by Danhof and Breimer (1978). They 
concluded that good correlations between plasma and saliva concentra-
tions had been reported for only a few drugs (e.g., for phenytoin, 
primidone, carbamazepine and antipyrine), mostly during chronic medica-
tion. In single dose studies, very often irregular saliva over plasma concen-
tration ratios (S/P ratios) had been found. This variability was explicable 
in part by changes in the pH of saliva, which can rise from 6.5 for resting 
saliva to 7.4 by stimulation of salivary flow, causing differences in the 
degree of ionization of weakly acidic or basic drugs. Killmann and Thaysen 
(1955) and Grüneisen and Witzgall (1974), using stimulated saliva, 
reported very nice correlations between the pKa values and saliva over 
plasma water concentration ratios of a series of closely related sulfonamide 
antibiotics. The distribution between saliva and plasma could fully be ex-
plained here according to pH-partitioning theory only. However, Feller 
and Le Petit (1977), employing several drugs of different chemical classes, 
demonstrated that also lipid solubility and molecular size determined, as 
could be expected, the rate of transport into saliva, which they deduced 
from differences in the S/P ratios between resting and stimulated saliva. In 
addition, also active transport processes have been proposed for some 
drugs, e.g. penicillin, to operate in the salivary glands (see the review by 
Danhof and Breimer, 1978). 
In this chapter, our studies on the excretion of the diuretic chlor-
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thalidone into saliva are described. A single dose of chlorthalidone was ad­
ministered to three healthy human subjects by the intravenous route, so 
that contamination of saliva, which forms a possible risk in oral ad­
ministration studies, was avoided, and plasma and saliva concentrations of 
the drug were followed for a 100 hours period. 
METHODS 
Three healthy young males, aging 24-28 yr, weighing 73-83 kg, were ask­
ed to collect mixed saliva (spit) into glass vials at regular times (indicated in 
Table 12.1) during and after a 2 hr-infusion of a chlorthalidone solution, 
which contained 50.0, 51.5 and 61.3 mg of the drug for L.De, T.Ho and 
M.O. respectively. The study was performed during participation of the 
subjects in a bioavailability experiment with chlorthalidone, described in 
Chapter 9 (Fleuren et al., 1979), where the exact times of blood sampling 
can be found. No artificial means of saliva stimulation was applied. The 
volumes of the saliva samples ranged from ca. 2-8.5 ml, with an average of 
4.2 ml for L.De, 2.8 ml for T.Ho, and4.1 ml forM.O.; the mean saliva pH 
was 6.65 for L.De, 7.21 for T.Ho and 6.77 for M.O. (Detailed data in 
Table 12.1). Saliva samples were frozen at -20° С until assay. 
Chlorthalidone concentration in saliva was assayed by gas 
chromatography with nitrogen detection, as described in Chapter 3 for the 
the determination of plasma concentration (Fleuren and van Rossum, 
1978), with small adaptations. After centri f ugation, to remove cellular 
debris, 2-4 ml portions of saliva were extracted twice at pH 7.4. Almost no 
background signal was found in the gas chromatograms of blank saliva 
specimens, so that determinations down to ca. 1-2 ng/ml could be perform­
ed using 4 ml portions. Extraction recovery (95%) and reproducibility (5% 
S.D.) were the same as observed when using equal volumes of buffer solu­
tion alone. 
RESULTS AND DISCUSSION 
The time courses of saliva (S) and plasma (P) concentrations of chlor­
thalidone are compared in Fig. 12.1. Although a rough parallellity was ap­
parent in the terminal parts of the plots, there was a very irregular S/P 
ratio over the whole period (Table 12.1). The low S/P ratios observed in 
the three subjects at ca. 1 hr after the start of the chlorthalidone infusion 
may be attributed to incomplete equilibration between plasma and saliva, 
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Figure 12.1 
Plasma and saliva concentration profiles of chlorthalidone, followed for ca. 100 hours after a 
single intravenous dose to three healthy human subjects. Note the considerable fluctuations in 
saliva concentration, causing large variability in the saliva over plasma concentration ratios. 
but no definite explanation can be given for the remainder of the varia­
tions. It is not likely that these originated from analytical errors, because 
the standard deviations of the plasma and saliva determinations would 
allow a possible error in this ratio of only 10%. There was no correlation 
between the S/P ratios and either the volume or the pH of saliva collected 
for any of the subjects. This observation on pH was not unexpected, 
because the pKa, of chlorthalidone is 9.35 (Chapter 6), so that pH changes 
around pH 7, which were very small besides (Table 12.1), barely influence 
the ionization degree of the drug. 
The protein-binding of chlorthalidone in human plasma is ca. 75% 
(Collste et al., 1976; Dieterle et al., 1976), without great differences be­
tween individuals in the extent of binding (range 73-76%, Collste et al., 
1976). Moreover, percentual protein-binding is the same over the 0.02-7.7 
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TABLE 12.1 
Relationship between plasma and saliva concentrations of chlorthalidone in three humans 
Subject 
L.De 
T.Ho 
M.O 
mean3 
(±SD) 
meana 
(±SD) 
mean3 
(±SD) 
Volume 
(ml) 
8.7 
4.3 
3.7 
2.5 
4.2 
3.9 
3.4 
3.0 
4.5 
4.2 
(±1.8) 
2.2 
3.2 
2.4 
2.3 
3.6 
2.8 
3.7 
2.9 
2.2 
2.9 
2.8 
(±0.6) 
3.9 
3.2 
2.5 
5.3 
5.0 
4.2 
4.5 
4.2 
4.1 
(±0.9) 
Saliva 
pH 
6.75 
6.60 
7.10 
6.95 
6.40 
6.55 
6.63 
6.35 
6.48 
6.65 
(±0.25) 
7.25 
7.15 
7.42 
7.22 
6.90 
7.36 
7.12 
7.18 
7.35 
7.12 
7.21 
(±0.15) 
6.60 
6.70 
6.77 
6.75 
7.08 
6.82 
6.77 
6.70 
6.77 
(±0.14) 
Sampling 
time 
(hr) 
1.25 
2.1 
3.2 
8.0 
25 
32 
49 
72.5 
104 
1.0 
2.3 
2.65 
4.0 
8.0 
12.0 
25.3 
49 
73 
97 
0.83 
1.9 
2.9 
6.8 
12.0 
24.8 
48.5 
96.5 
S/P 
ratio 
0.062 
0.13 
0.13 
0.30 
0.45 
0.53 
0.43 
0.36 
0.50 
0.35 
(±0.16) 
0.029 
0.14 
0.14 
0.12 
0.21 
0.23 
0.50 
0.25 
0.27 
0.20 
0.23 
(±0.12) 
0.043 
0.13 
0.12 
0.13 
0.18 
0.10 
0.097 
0.089 
0.12 
(±0.03) 
3saliva samples obtained at ca. 1 hr were not included in the calculation of the mean saliva 
over plasma concentration ratios 
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pg/ml range (Dieterle et al., 1976), so that the concentration of the drug in 
plasma water can be safely assumed to be approximately one-quarter of the 
total plasma concentration shown in Fig. 12.1. 
Other factors obviously caused the large inter- and intrasubject dif-
ferences in the S/P ratio of chlorthalidone. By analogy with other ex-
cretory organs active transport processes might be involved also in the 
salivary glands, as they are known to operate for sulfonamide diuretics in 
kidney and liver (Beyer and Baer, 1961; Schanker, 1968). In this case en-
dogenous substrates would compete with the drug for transport and 
thereby could cause an irregular excretion rate. On the other hand, it is 
conceivable that the molecular volume of chlorthalidone (MW 338.8) did 
not facilitate rapid transport across the glandular membrane, which could 
be in agreement with a relatively slow transport rate through the red blood 
cell membrane (Chapter 8). Also the high abundance of carbonic 
anhydrase in parotid salivary glands (Maren, 1967) could have been of in-
fluence because chlorthalidone strongly binds to carbonic anhydrase in 
vitro (Dieterle et al., 1976; Chapter 8). Acetazolamide, however, the only 
other sulfonamide diuretic of which literature data on saliva levels were 
available (Wallace et al., 1977), showed a much more consistent correlation 
between its plasma and saliva concentrations, which could be due to its 
smaller molecular weight (222.2). 
In conclusion, it has to be stated that the mechanism of salivary excre-
tion of chlorthalidone, like that of several other drugs (see the review by 
Danhof and Breimer, 1978) is badly understood. Regardless this 
mechanism, however, a consistent relationship between saliva and plasma 
concentrations of chlorthalidone does apparently not exist (although a 
change in this situation after multiple dosing cannot be excluded). We have 
to conclude, therefore, that saliva measurements constitute no useful 
means for obtaining reliable pharmacokinetic parameters of chlor-
thalidone in single dose studies with this drug. 
SUMMARY 
Saliva and plasma concentrations of chlorthalidone were determined in 
three healthy human subjects during 100 hours following single in-
travenous doses of 50-60 mg. There was a large inter- and intraindividual 
variation in the saliva over plasma concentration ratio. The subject means 
were: 0.35 ±0.16 S.D. (range 0.13-0.53), 0.23 ±0.12 S.D. (range 
0.12-0.50), and 0.12±0.03 S.D. (range 0.09-0.18). It was concluded that 
saliva measurements are not suitable for pharmacokinetic single dose 
studies with chlorthalidone. 
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CHAPTER 13 
PHARMACOKINETICS OF CHLORTHALIDONE 
DURING CHRONIC ADMINISTRATION 
INTRODUCTION 
Diuretic drugs need to be administered in general over long periods of 
time, especially if used in antihypertensive therapy. Chlorthalidone may be 
regarded as one of the most widely prescribed drugs in this field, certainly 
in The Netherlands, where its share in treatment of mild to moderate 
hypertension was estimated at about 70% of the total number of prescrip-
tions of drugs*. A detailed study of the accumulation kinetics of chlor-
thalidone in man was, therefore, considered to be of major interest. 
When linear pharmacokinetic processes prevail, accumulation of drug 
concentration until steady-state, can be predicted from the pharmacokinetic 
constants obtained in single dose studies (van Rossum and Tomey, 1970, 
van Rossum, 1971). Such situation implies that no alterations in plasma 
clearance and volumes of distribution occur, when single dose kinetics are 
extrapolated to higher concentration. Some exceptions to linear kinetics 
have been reported until now. The clearance of the analgesic salicylic acid 
in man proceeds via saturable metabolic pathways, giving rise to concen-
tration-dependent elimination rate in the therapeutic dose range (Levy et al., 
1972; van Ginneken et al., 1974). Analogous phenomena have been 
reported for ethanol (e.g. Wagner and Patel, 1972), ethylbiscoumacetate 
(van Dam, 1968), 7-hydroxybutyric acid (van der Pol et al., 1974) and 
Phenytoin (e.g. Arnold and Gerber, 1970). More examples from literature 
were cited in publications by Wagner (1973) and by van Rossum and co-
workers (1977). 
Another type of non-linearity can be found in saturable binding of drugs 
to plasma proteins or cellular constituents. Despite the fact that the 
theoretical possibility of occurrence of such phenomena had already early 
been recognized (Krüger-Thiemer, 1964; Wagner, 1973), only very few ex-
perimental examples have been provided up to now. Plasma concentrations 
of phenylbutazone (Burns et al., 1953) and warfarin (Kekki et al., 1977) did 
not increase linearly with increasing dose, but with less than the propor-
'Unpublished data over 1975 and 1976 obtained from a representative population of ca. 
300.000 sick-fund insured subjects. 
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tional amount, indicating relatively reduced plasma protein binding at 
higher concentration. Capacity-limited binding to extravasal tissue has 
been proposed, tentatively, in case of a diazepam metabolite, 
N-desmethyldiazepam, to account for the much higher concentration of 
this metabolite attained in plasma after the second dose, as compared to 
the first one (Korttila et al., 1975). 
These few cases may, however, suffice to indicate that non-linearities in 
either an upward or downward direction can show up from a multiple of 
causes. Therefore, for unequivocal explanation of non-linear pharmacoki-
netic behaviour always additional information should be available, which 
can be derived from, e.g. isolated liver perfusion, autoradiographic study, 
or in vitro protein binding. In vitro uptake of chlorthalidone by erythro-
cytes has been analysed in Chapter 8. Our findings pointed to occurrence 
of binding-sites with limited capacity, in the concentration range reached 
after therapeutic doses. Binding to intact red blood cells was approximately 
in agreement with the affinity constants and numbers of binding sites per 
molecule of two isoenzymes of carbonic anhydrase, as reported by Dieterle 
et al. (1976). The non-linear pharmacokinetic model of chlorthalidone, 
described in Chapter 7 (Fleuren and van Rossum, 1977), included this satu-
rable binding in order to explain the time course of plasma and red blood 
cell concentrations after single doses in man. A decisive test for the validity 
of any hypothetical model is difficult to obtain, but a useful approach may 
be found in looking at what the model predicts. The model indicated that, 
after repetitive administration of chlorthalidone, red blood cell concentra-
tion would rise considerably less than expected from linear kinetic analysis 
of concentration-time curves, found after single doses. A comparison be-
tween steady-state levels, according to a linear and a non-linear accumula-
tion process, is shown in Fig. 13.1. 
For this purpose, hypothetical red blood cell concentration vs time data 
were generated by means of the non-linear chlorthalidone model, described 
in Chapter 7 by the differential equations of Appendix 7.2 and by the 
schematic drawing of Fig. 7.5. (Numerical values of the model parameters 
used here are given in Appendix 13.2 at the end of this chapter). The con-
centrations of the single dose curve of this hypothetical data set were subse-
quently regarded as if they would have been obtained in a real experiment. 
In that case, we could analyse these data according to linear phar-
macokinetic equations. With the model parameters calculated we could 
simulate accumulation again, but now of course according to first-order 
processes only. This was done, and resulted in a higher plateau, as in-
dicated in Fig. 13.1. It should be noticed that the difference between the 
two curves in the single dose phase is so small, that it would not be 
distinguished experimentally. This is in agreement with our observation, 
that separate concentration-time curves after single doses of chlor-
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Figure 13 1 
Accumulation of red blood cell concentrations of chlorthalidone during multiple dosing ac-
cording to two different pharmacokinetic models. The upper plateau (100%) was reached by 
superposition of single dose curves, when purely first-order processes were assumed The 
lower plateau concentration (71% for the example chosen) was found when capacity-limited 
binding of chlorthalidone to erythrocytes was taken into account For further explanation see 
text 
thalidone, can be described very well by linear pharmacokinetic equations, 
as outlined in Chapter 9. Not withstanding this, it can be seen that a signifi-
cant difference arises between the two approaches during repetitive ad-
ministration. 
The present study was undertaken to verify non-linear binding of chlor-
thalidone to red blood cells in the chronic situation. At first, the kinetic 
profile after administration of single doses had to be determined in order to 
obtain basic pharmacokinetic parameters, necessary for predicting steady-
state concentration. The study was performed at two dosage levels in the 
same human subject in order to assure a wide concentration range. 
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EXPERIMENTAL 
Drug administration 
A young, well-motivated male human subject (J.Se, 28 yr, 77 kg) with mild 
essential hypertension (pretreatment blood pressure, systolic/diastolic: 
140/100 mm Hg, both in supine and standing position; average of two 
visits to the clinician) and no further disease, took part in the study after 
informed consent. The first part of the study consisted of a 50 mg dose 
schedule, in the second part a 100 mg dose regimen was used. The two trials 
were separated by an interval of 1 month. Details of the protocol are shown 
in Fig. 13.2. Commercial chlorthalidone tablets of 100 and 50 mg were ad-
ministered (Hygroton® , Ciba-Geigy, Basle, Switzerland). On the first day 
of each trial, the tablet was taken together with about 200 ml of tap water 
at 9.00 A.M., after overnight fasting. No food or fluid, except water, was 
taken until 3-4 h after the dose. During chronic administration, the tablets 
were ingested once a day, usually at 9.00 A.M., and, although abstinence 
from food during several hours was, of course, not imperatively prescrib-
ed, subject J. Se was used to consume no breakfast in the morning. No 
other medication was used during both trials and during at least 1 month 
preceding them. 
Protocol 
single dose 
kinetics 
50 mg 
accumulotion elimination 
repetitive dos« ' kinetics 
50 mg ƒ day J I 
single dose | 
kinetics 
100 mg 
accumjlation 
repetitive doses 
100 mg / day 
eliminaton 
kinetics 
0 
- 21 days — •^ 10 days •* 
-*· 14 days —" 
Symws ( A 0 1 blood 
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я
 24 помп 
\jrnc ропюп 
Figure ¡3.2 
Protocol of chronic pharmacokinetic study with chlorthalidone. 
Sampling and analytical measurement 
In the single dose studies, venous blood samples of ca. 7 ml were taken, as 
described in Chapter 3, at the following approximate times (exact times 
were noted): 0, 1, 2, 3, 5, 7 and 24 hours and at 2, 3, 4, 7, 8 and 9 days after 
administration. During the period of repetitive doses, blood samples were 
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obtained mostly at 9.00 A.M., prior to intake of the next dose. In addition, 
on some days, which are indicated in Fig. 13.2, more than one sample was 
taken, viz. at noon (12.00 h) and at 5.00 P.M. (17.00 h). Urine was col-
lected completely, in 24 h portions, during 10 days in the steady-state of 
each dose regimen, as depicted in Fig. 13.2. 
The concentration of chlorthalidone in plasma, red blood cells and urine 
was determined as described in Chapter 3, with the exception that plasma 
was extracted at pH 9 instead of at pH 7.4, because the gas chromatograms 
from subject J. Se showed, occasionally, small interfering peaks of un-
known origin, which were avoided by extracting the drug at higher pH than 
that usually employed (cf. Chapter 3). Creatinine in plasma and urine was 
determined with a modified Jaffé reaction, by using continuous flow 
analysis with dialysis and reaction with alkaline picrate (see, e.g. Henry et 
al., 1974). 
Pharmacokinetic analysis 
Plasma concentrations of chlorthalidone after administration of single 
doses were fitted to the exponential equation, according to a linear two 
compartment open model after oral administration, described in Chapter 
1. Red blood cell concentrations were fitted according to a one compart-
ment open model, with first-order absorption, see also Chapter 1. Plasma 
clearance and volumes of distribution (Vj and Vdss) were calculated as 
described in Chapter 1. Under the assumption of linear, i.e. first-order pro-
cesses, plasma concentration during repetitive doses, with constant dosage 
interval ΔΙ, can be described by the following general equation (van 
Rossum and Tomey, 1970): 
, -
J A t / T i - t/T. 
._. ι -at/τ. 
1 - 1
 1-е 1 (Eq. 13.1) 
where С represents plasma concentration at any time after the start of ther­
apy, η is the number of compartments of the body plus gastrointestinal 
tract, Ai is the ith coefficient, T¡ the ith time constant (reciprocal rate con-
stant), and j the number of doses that have been administered, while t is the 
time after administration of the jth dose. When the dosage interval is not 
exactly constant, simulations can more easily be performed by numerical 
integration by means of a suitable computer program. Details of the pro-
cedure are described in Appendix 13.1 at the end of this chapter. A similar 
approach was used for generation of the curves shown in Fig. 13.1. 
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RESULTS 
Single dose kinetics 
The time course of plasma concentrations of chlorthalidone was 
biphasic, and could accordingly be described by means of a linear two com­
partment model with first-order absorption, in agreement with the results 
obtained from other human subjects, which have been dealt with in the 
Chapters 7, 9 and 10. Peak concentrations of chlorthalidone in red blood 
cells were reached at about 10 h after the dose in both single dose trials. At 
that time, concentrations were ca. 100 times higher than those in plasma. 
Similarly as described in Chapter 9, the red blood cell concentrations were 
fitted according to a linear open one compartment model with first-order 
absorption. 
Some important pharmacokinetic parameters for subject J. Se, obtained 
from this linear analysis of plasma and red blood cell concentrations after 
both dose levels, are shown in Table 13.1. 
TABLE 13.1 
Pharmacokinetic parameters of chlorthalidone, characterizing the time curves of plasma and 
red blood cell concentration following administration of a 50 and a 100 mg single dose in the 
same human subject, prior to multiple dosing of chlorthalidone. 
Dose (mg) 
AUC (h.mg/1) 
at infinite time 
м
а (% S.D.) 
Vdss/F О 
k
c e
|/F (1/h) 
Plasma concentration 
50 
5.10 
38.3 
(8.1%) 
474 
10.2 
100 
11.20 
35.3 
(3.0%) 
446 
9 36 
Erythrocyte concentration 
50 
438 
46.1 
(1.7%) 
7.73 
0 116 
100 
935 
42.6 
(1.8%) 
6.64 
0.108 
Multiple dose kinetics 
The height of the plateau level, predicted by using the first-order kinetic 
parameters from the single dose experiments, was not reached. Figs. 13.3 
and 13.4 compare the simulated accumulation with actual measurement. 
During the 50 mg dosage regimen, minimum steady-state concentration 
was 86% and 57% of the expected levels in plasma and erythrocytes, 
respectively. Following 100 mg doses, the difference was even more pro­
nounced, the minimum plasma and red blood cell concentrations during 
steady-state being 59% and 50% of the predicted values, respectively. 
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chlorthalidone concentration in 
red blood cells (/ug/ml; log. scale) 
predicted. 15. 5 i jg/ml 
, \ found 8 9;ug/ml 
Subject: J. Se, 29yr, 77kg 
Dosage. Chlorthalidone ρ о, 
50 mg/day 
time (days) 
chlorthalidone concentration in 
plasma (/jg/ml; log scale) 
predicted- 0 14^jg/ml 
0 12;Lg/ml 
Subject. J Se,29yr, 77kg 
Dosage. Chlorthalidone ρ о 
50 mg / day 
time (days) 
Figure 13.3 
Plasma and red blood cell concentrations of chlorthalidone, on semi-logarithmic scale, after 
both single and multiple 50 mg oral doses. The concentrations measured after administration 
of the single dose were fitted to linear pharmacokinetic model equations and the parameters 
obtained were used to simulate concentration-time curves during steady-state and thereafter. 
Whereas a reasonable agreement was found, at this dosage level, between predicted and 
observed plasma concentrations, much lower chlorthalidone concentrations than predicted 
were found in the red blood cells, indicating reduced uptake of this drug in the erythrocytes at 
higher concentration. See also text at Fig. 13.4. 
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chlorthalidone concentration in 
red blood cells t/ug/ml, log scale) 
predicted 34 3 ^ g / m l 
found 17 1 jug/ml 
Subject. J Se , 29yr, 7 7 kg 
Dosage. Chlorthalidone ρ о 
100 m g / d a y 
time (days) 
chlorthalidone concentration 
in plasma (дід/ml, log scale) 
predicted О 34 jug/ml 
v » \ found 0 2 0 ^ j g / m l 
Subject J Se.29yr, 77kg 
Dosage Chlorthalidone ρ о 
100 mg / day 
time (days) 
Figure 13.4 
Comparison of observed and predicted steady state concentration of chlorthalidone during 
daily doses of 100 mg in man. The continuous lines represent concentration-time curves, 
predicted on basis of curve-fitting of the single dose data according to first-order kinetics. The 
broken lines connect plateau concentrations measured just before intake of the next dose and 
correspond therefore to minimum steady-state levels. Judged from the total profile of plasma 
concentrations during steady-state (including a few peak concentrations, see lower panel), a 
somewhat smaller difference between predicted and observed values might become apparent, 
if the average steady-state plasma concentration could be calculated exactly. Accumulation of 
red blood cell concentration of chlorthalidone, however, was obviously not in agreement with 
linear binding to red blood cell constituents. Compare with text at Fig. 13.3. 
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Urinary excretion during steady-state 
The 24-hours cumulative amounts of chlorthalidone in urine, during 10 
days of both steady-state periods, are presented in Table 13.2. A mean 
total of 38.1% of dose was recovered during the 50 mg dosage regimen, 
and a mean of 47.1% of dose during the 100 mg dose schedule. This dif-
ference was statistically significant (p < 0.025, Wilcoxon's signed ranks 
test). 
The different urinary recoveries were not correlated with renal plasma 
clearance of creatinine: urinary amounts of creatinine were 17.2 (± 0.7 
S.D.) mmol/24 hr (n = 10) and 17.0 ( ± 0.9 S.D.) mmol/24 hr (n = 10) dur-
ing the 50 and 100 mg trial respectively. The mean plasma creatinine con-
centration was 72.3 (± 3.7 S.D.) /¿mol/l (n = 7) and 73.1 (± 3.5 S.D.) 
/imol/l (n = 7) during the 50 and 100 mg dosage regimen, respectively, so 
that a creatinine clearance resulted of 165 ± 7 ml/min (mean ± S.D., 
η = 7) and 159 ± 11 ml/min (mean ± S.D., η = 7) during repetitive ad­
ministration of 50 and 100 mg chlorthalidone respectively. Also the in-
TABLE 13.2 
Urinary excretion of chlorthalidone during 10 consecutive days of steady-state3 under two dif­
ferent dosage regimens, in the same human subject. 
50 mg chlorthalidone dailyb 
Urine 
flow 
(ml/24 h) 
1360 
1375 
1065 
1265 
1090 
1145 
1240 
1075 
1250 
1420 
Urine 
pH 
(average) 
6.38 
5.96 
6.35 
6.48 
6.33 
5.88 
6.16 
6.37 
6.22 
6.00 
24-hours 
urinary 
amount 
(% of dose) 
44.7 
37.2 
35.6 
38.2 
37.6 
32.9 
30.5 
38.0 
47.7 
39.3 
mean(±S.D.) 
38.2(±5.1) 
100 mg chlorthalidone dailyb 
Urine 
flow 
(ml/24 h) 
2180 
1580 
1720 
1500 
1440 
1700 
1120 
1000 
2100 
1430 
Urine 
PH 
(average) 
7.21 
6.50 
6.55 
6.50 
6.95 
6.62 
6.59 
6.41 
7.00 
6.95 
24-hours 
urinary 
amount 
(% of dose) 
43.0 
55.1 
50.8 
42.7 
49.6 
51.2 
50.4 
51.2 
41.4 
39.8 
mean(±S.D.) 
47.5(±5.3) 
a = first collection on day no. 12 of multiple dosing 
b = creatinine clearance during 50 mg/day: 165(±7 S.D.) ml/min; during 100 mg/day: 159 
(±11 S.D.) ml/min. Difference not significant. 
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dividual daily excreted amounts of creatinine and chlorthalidone showed 
no correlation. 
Renal plasma clearance of chlorthalidone could be calculated only ap­
proximately, because most blood samples had been taken at the ends of the 
urine collection periods, so that the complete time course and, therefore, 
the exact areas under the plasma concentration curves during steady-state 
were not known. Upper estimates, obtained by using the average minimum 
plasma concentration, resulted in values of, at most, 6.63 1/h (111 ml/min) 
and 9.9 1/h (165 ml/min) for the 50 mg and 100 mg dose regimen, respect­
ively. 
Therapeutic effect 
Regular blood pressure recordings indicated no significant decrease in 
blood pressure for the subject under study. Representative values at the 
end of both treatment periods were: 126/94 and 126/100 mm Hg after 50 
mg repetitive doses, and 142/88 and 148/96 mm Hg following 100 mg 
dosage of chlorthalidone (recorded in supine and standing position respect­
ively). 
DISCUSSION 
Blood pressure response 
Despite considerable concentrations of chlorthalidone in blood, no or 
hardly any reduction in blood pressure was achieved. The young age of the 
subject (28 yr) may have been a factor here, as failure of young hyperten­
sive patients to respond to diuretic treatment has been described (Gordon 
et al., 1977). In that report it was indicated that young people have a 
greater ability to compensate for the diuretic-induced loss in plasma 
volume by homeostatic mechanisms, e.g. mediated by a larger vascular 
flexibility as compared to that in older patients. 
Absorption during chronic administration 
If linear differential equations would adequately describe the phar­
macokinetic behaviour of chlorthalidone, steady-state concentration 
would be determined solely by the dose (D), the dosage interval ( At) and 
the plasma clearance (keel) (van Rossum, 1971): 
с
 F
-
D 
p i , s s k C e l . A t ( E q i l 3 _ 2 ) 
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The oral bioavailability, F, is in principle unknown, therefore, also its in-
fluence on the steady-state concentration attained. Therefore, prior to 
drawing conclusions on non-linearity of drug distribution, some remarks 
concerning drug absorption have to be made. As is described in Chapter 9, 
about 70-80% of the dose is absorbed from the gastro-intestinal tract after 
administration of single 50 mg doses of chlorthalidone. A similar percen-
tage of absorption after single 100 mg doses was indicated by the findings 
of Chapter 10, showing that cumulative urinary excretion of chlor-
thalidone increased linearly with dose up to the 100 mg level. Although no 
urine was assayed in the single dose phase of the present study, the areas 
under the curves of plasma and erythrocyte concentration after the 50 and 
100 mg dose were approximately in a ratio 1:2 (see Table 13.1). This con-
firms that large variation in the degree of absorption between the two dif-
ferent single doses in subject J. Se did not occur. 
During chronic administration of chlorthalidone, a mean daily amount 
of 38.1% and 47.5% of dose was recovered, in the 50 mg and 100 mg 
schedule, respectively, see Table 13.2. These figures fell in the range of 
total urinary amounts encountered after single doses in normal human 
volunteers: 44.4 ( ± 6.8 S.D.)% of dose after 50 mg and 43.1 ( ± 4.7 S.D.)% 
of dose after 100 mg of chlorthalidone (Fleuren et al., 1979; Chapter 10). 
Suppose, however, that the lower steady-state concentration, being even 
ca. 50% of the expected value (Fig. 13.4), would still have been caused by 
an absorption degree, which was systematically reduced as compared to the 
single dose situation. In that case, the theoretical cumulative urinary 
amount, expected for that single dose experiment, would have been twice 
as high as the daily amounts found during steady-state, i.e. 76% (50 mg) 
and 94% (100 mg) of dose. Such high values have never been observed 
after oral administration of single doses, see Chapter 10, or the report by 
Riess et al. (1977). Concludingly, a different degree of absorption during 
chronic administration must be considered as a highly improbable cause 
for the reduced steady-state blood levels of chlorthalidone. 
Red blood cell binding 
Our observations can better be explained on basis of capacity-limited 
binding of chlorthalidone to red blood cells. Ever since its introduction, 
chlorthalidone was known as an in vitro inhibitor of red cell carbonic anhy-
drase, although the concentration at which 50% inhibition was observed, 
was about 10 times higher than that of acetazolamide (Maren, 1967; Pulver 
et al., 1962). In agreement with this, Beermann et al. (1975) demonstrated 
that chlorthalidone was attached to the carbonic anhydrase fraction of the 
red blood cell proteins; the drug could be displaced from its erythrocyte 
binding sites by acetazolamide, both in vivo and in vitro. 
Carbonic anhydrase is a metallo-protein of molecular weight ca 30000, 
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containing one zinc atom per molecule, which occurs, so far as 
erythrocytes are concerned, exclusively in cell water. The enzyme has a 
wide-spread distribution over mammalian tissues, especially high concen­
trations being found, besides in red blood cells, in kidney cortex, stomach 
parietal cells, eye lens and retina, parotid salivary glands, and the choroid 
plexus of the brain. More information on its occurrence, physiological 
function and biochemical properties can be found in the extensive reviews 
by Maren (1967) and Carter (1972). Some points of interest for the present 
investigation have to be mentioned here. Two major isoenzymes of human 
red cell carbonic anhydrase, so-called HCA-B and HCA-C, have been 
isolated. Besides in physicochemical properties, these isoenzymes differ 
greatly in their catalytic efficiency. HCA-C possesses a carbon dioxide 
hydratase activity, which is 20-40 times that of HCA-B on a molar basis. 
The high activity isoenzym has on the other hand a much lower abundance 
than the low activity isoenzym. The intracellular concentration of HCA-C 
was reported as ca. 20 /tM, versus ca. 140 μΜ for HCA-B, see also 
Wistrand and Baathe (1968). Furthermore, it was observed that HCA-C 
function was inhibited by smaller concentrations of acetazolamide and 
other sulfonamide inhibitors than those needed for inhibition of HCA-B. 
Correspondingly, higher association constants were measured for the bind­
ing of carbonic anhydrase inhibitors to the HCA-C isoenzyme (Maren, 
1967). 
The binding of chlorthalidone to the pure isoenzymes was determined by 
Dieterle et al. (1976). The association constant was 5.7χ1θ6 1/mole for 
HCA-C and 2.4x106 1/mole for HCA-B. The in vitro binding of chlor­
thalidone to intact red blood cells, described in Chapter 8 of this thesis, was 
in qualitative agreement with the above data. The amount of drug involved 
in the strongest binding might correspond with the known molar amount 
of the isoenzyme HCA-C. So, we proposed that this small HCA-C fraction 
would represent the binding sites of limited capacity in the non-linear phar­
macokinetic model, described in Chapter 7 (Fleuren and van Rossum, 
1977). The prediction made according to this model with respect to ac­
cumulation of chlorthalidone concentration during multiple dosing, ap­
pears to be fulfilled, at least qualitatively, by the experimental data shown 
in Figs. 13.3 and 13.4. 
In addition, it can be observed from Fig. 13.4 that not only the steady 
state concentration in erythrocytes but also that in plasma was smaller, 
during the 100 mg dose regimen, than expected if no other factors than the 
distribution of the drug between plasma and red cells were in play. An ob­
vious co-determinant of the concentration in plasma is the renal plasma 
clearance. It should be noticed in this context that the renal plasma 
clearance of chlorthalidone during repetitive administration of the 100 mg 
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doses was larger than in the 50 mg dosage period. This aspect is discussed 
separately in the following section. 
Renal clearance 
We can offer no definite explanation at present for the elevated renal 
clearance of chlorthalidone during the higher - 100 mg - dose regimen as 
compared to the lower - 50 mg - one. This effect was possibly secondary to 
the combination of higher urine pH and flow, observed in the latter study 
(Table 13.2). In turn, this average 24-hours urine pH of 6.7 could have 
been caused by a certain degree of renal carbonic anhydrase inhibition at 
higher doses (see below). On the other hand, the maximum capacity of 
distal kidney tubular cells to reabsorb the drug might be approximated dur-
ing this dose schedule. In single dose studies with chlorthalidone, describ-
ed in Chapter 10, a decrease in the percentual urinary excretion and also, in 
so far as a comparison could be made, in renal clearance occurred with in-
creasing dose. Unfortunately, we have no data at hand to compare the 
single with the multiple dose situation in the present study. It is, however, 
conceivable that the physiological status of the kidney during chronic 
medication is very much different from that in the beginning, e.g. with 
regard to homeostatic mechanisms, so that extrapolation from the single 
dose situation, as proposed in the discussion section of Chapter 10, would 
be complicated by additional factors. More experimental work with chlor-
thalidone and other thiazides is needed with respect to the renal handling of 
diuretics during chronic administration. 
Therapeutic meaning 
Maren (1963) and also Wistrand and Baathe (1968) have pointed out that 
a very large excess of carbonic anhydrase activity in relation to the physio-
logical need, at least 100-fold, is apparent in many tissues, including red 
cells and kidney. Therefore, a fractional inhibition of more than 99.5% or, 
equivalently, an almost complete receptor occupancy, would be required to 
achieve only a 50% inhibition of the in vivo enzyme function. This would 
explain why severely toxic effects of carbonic anhydrase inhibitors are not 
encountered normally in diuretic therapy. Undesirable side-effects, how-
ever, attributed to carbonic anhydrase inhibition, do frequently occur 
during long term treatment with sulfonamide diuretics. Although it is a 
general opinion nowadays, that renal carbonic anhydrase does not play the 
first role in the biochemical mechanism of action of diuretic agents (Meng 
and Loew, 1974; Peters and Roch-Ramel, 1969; see also Chapter 1), in-
hibitory effects appear following higher doses of these drugs. Tweeddale et 
al. (1977), for instance, compared the antihypertensive and biochemical ef-
fects of different daily doses of chlorthalidone, ranging from 25-200 mg. 
While maximum blood pressure reduction was achieved already with 25 or 
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50 mg doses in two third of the patients, side-effects, e.g. the decrease in 
serum potassium concentration, strongly increased with dose. Minimal 
biochemical changes were observed with daily doses of 50 mg or less. 
To account for these findings, we would like to suggest the following. 
The strong binding sites of chlorthalidone in red blood cells, tentatively 
associated with one of the isoenzymes of carbonic anhydrase, HCA-C, as 
described in Chapter 8, act as a depot and keep free concentrations low. 
When their capacity is exceeded, e.g. above daily doses of 50 mg, 
disproportionally higher amounts of drug become available to the kidneys. 
It is tempting to speculate in this context that the height of the red blood 
cell concentration of chlorthalidone operates merely as an indicator for the 
probability, that side-effects of this drug are going to occur. Further 
monitoring of red blood cell concentrations in relation to diuretic effects 
will be required to support this view. 
SUMMARY 
A young, mildly hypertensive subject received single and multiple oral 
doses of chlorthalidone, according to both a 50 and a 100 mg dosage 
regimen. Each trial took 45 days, which were separated by a 1 month inter-
val. At first, plasma and red blood cell concentrations were followed dur-
ing 10 days after the single dose, in order to obtain pharmacokinetic model 
parameters for prediction of steady-state levels. Thereafter, the drug was 
administered once a day during three weeks. In this period urinary excre-
tion of chlorthalidone was also determined. After cessation of repetitive 
dosing, the decline of plasma and red blood cell concentrations was 
measured over 14 days. The average 24-hours urinary excretion of un-
changed chlorthalidone, at steady state, was 38.2 (± 5.1 S.DJ'Vo of dose, 
and 47.5 (± 5.3 S.D.)% of dose, during the 50 and 100 mg dosage 
regimens respectively. This difference was statistically significant, but not 
correlated with creatinine clearance. 
Steady-state concentrations of chlorthalidone in plasma, and especially 
those in red blood cells, were lower than the values predicted by use of a 
linear pharmacokinetic model with parameters obtained from the single 
dose studies. The difference between the expected and observed values 
became more pronounced at the 100 mg dose level. Thus, during the 50 mg 
dosage regimen, a minimum steady-state plasma concentration of, on an 
average, 0.12 /ig/ml was observed, while 0.14 /ig/ml had been predicted. 
For erythrocytes a value of 8.9 ¿ig/ml was found, instead of the predicted 
15.5 /ig/ml. During the 100 mg dosage regimen, a minimum steady-state 
concentration of 0.34 /ig/ml in plasma had been predicted, while only 0.20 
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/tg/ml was found. In erythrocytes a value of 34.3 /ig/ml had been 
predicted, but only 17.1 ¿ig/ml, on an average, was observed. 
It was concluded that capacity-limited binding of chlorthalidone to red 
blood cells, probably to an isoenzyme of carbonic anhydrase, was responsi-
ble for this non-linear increase of chlorthalidone concentration during 
chronic administration. 
APPENDIX 13.1 
The following first-order differential equations describe the time course 
of plasma and red blood cell concentrations, according to a open two- and 
a one compartment model, respectively. 
Plasma concentration 
d Qo 
d Q i 
—
 = r a - Q o - ( r e l + r 1 2 , - Q 1 + r 2 r Q 2 
d t r l 2 - Q l ~ r 2 1 ' Q 2 
Red blood cell concentration 
d t - = - r a Q o 
d t " = r a - Q o - r l e r Q l 
In these equations Qo, Qi and Q2 denote the quantities of drug in the ab-
sorption compartment, central compartment (Vj), and peripheral com-
partment, resp.; ra, ri2. Γ21 and ri ei are first-order rate constants of ab­
sorption, transfer from central to peripheral compartment and vice versa, 
and elimination from the central compartment, respectively. 
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During the 50 mg dose schedule, plasma concentration was simulated with: 
r
a
 = 12.99, nel = 2.51, ri2 = 8.51, Γ21 = 2.21 (all in days -1), and Vi = 
97.7 1. Red blood cell concentration with: r
a
 = 7.10, ri
e
i = 0.361 (both in 
days -1), and Vj = 7.73 1. 
During the 100 mg dose schedule, plasma concentration was simulated 
with: r
a
 = 15.85, n
e
i = 1.284, i\2 = 7.23, тц = 4.66 (all in days-1) and 
Vj = 174.9 1. Red tjlood cell concentration according: r
a
 = 4.70, ri
e
] = 
0.391 (both in days-l) and Vi = 'ξ&Ιϊ., 
In addition, the following functions \Vere used: 
Q
o
(0) = dose; Q = Qi/Vi 
Q0(t + h) = Qo(t) + I 
I = dose for t<Tj<t + h; h = 0.005 day (step width) 
I = 0 for t<Tj<t + h 
Tj = Σ Ati(from i = l....j), where j = 1 21; T21 = 30 days 
Ati = 10 days; t^lday for i Φ 1, At[ = dosage interval 
APPENDIX 13.2 
The plot of erythrocyte concentrations of chlorthalidone vs time, shown 
in Fig. 13.1, according to the non-linear model of Chapter 7, was simulated 
with the following model constants: D = 100 mg, VQ = 5 1, Vj = 1751, V2 
= 1.31, V3 = 2.71,k
c
i2 = 40I/hr,k
c
2i = 0.5 1/hr, к
с
із = 201/hr,k
c
3i 
= 0.5 1/hr, k
c a
 = 10 1/hr, kCel = 7.8 1/hr, A = 0.15 (mg/l)-l, В = 6 
mg/1. The meaning of these parameters can be found at the original 
description of the model in Chapter 7. 
For generation of the levels during steady-state, a procedure analogously 
to that described in Appendix 13.1 was employed, but now of course by use 
of the differential equations for the non-linear model, as described in Ap­
pendix 7.2 in Chapter 7. 
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CHAPTER 14 
ABSORPTION, DISTRIBUTION, METABOLISM AND 
EXCRETION OF MEFRUSIDE IN MAN 
INTRODUCTION 
Since its introduction in 1967 (Horstmann et al., 1967) the sulfonamide 
diuretic mefruside (Baycaron® ) has been established as a diuretic with an 
intermediate duration of action (Brogden et al., 1974; Schwab and Im-
mich, 1967; Wilson and Kirkendall, 1970). The pharmacokinetic 
background of these clinical observations was, however, until now unclear. 
Although the distribution and metabolism of mefruside in rats and dogs 
have been well-described (Duhm et al., 1967; Schlossmann and Pütter, 
1973), kinetic data of this drug in man remained very scarce. In one human 
study (Schlossmann, 1967) the use of a spectrophotometric assay allowed 
measurement only of the sum of mefruside plus metabolites. In another 
report (Duhm et al., 1967), C^-mefruside was administered to a single 
subject, and, after fractionation of urinary radioactivity, a parallel was 
drawn, tentatively, with the metabolic pattern in rats. In short, these 
animal studies had shown that oxidation of the tetrahydrofuran ring of 
mefruside accounted for the largest part of metabolites (Duhm et al., 
1967). The main product, 5-oxo-mefruside, alternatively called mefruside-
lactone, existed in equilibrium with its open acid analogue. See Fig. 14.1. 
Interconversion of the two metabolite forms was strongly catalyzed in 
vivo, so that the open acid form constituted an important secondary 
metabolite (Pütter and Schlossmann, 1972; Schlossmann and Pütter, 
1973). 
In the Chapters 4 and 5 gas chromatographic methods were described for 
the specific determination of mefruside and both oxidized products in 
human plasma, red blood cells and urine, and these two compounds were 
identified as metabolites of mefruside in man (Fleuren et al., 1979a, 
1979b). Simultaneous analysis of mefruside and metabolites seemed to be 
relevant, because the lactone and the open acid compound have been 
reported to give the same diuretic effect as the parent drug (Meng and 
Kroneberg, 1967). Moreover, preliminary experiments had indicated that 
both metabolites were excreted into human urine (Chapter 5; Fleuren et al., 
1979b), suggesting that they might be very important for diuretic action. 
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Figure 14.1 
Structural formulae of mefruside, 5-oxo-mefruside and its open acid analogue. 
MATERIALS AND METHODS 
Drug administration and sampling of blood and urine. 
Eight young male volunteers took part in the study. They were aged 
21-24 yr, and weighed 61-84.5 kg (detailed body weight data included in 
Table 14.1). AH were healthy and took no other medication for at least one 
month before or during the study. Each subject received a single oral dose 
of 25 or 50 mg of mefruside as commercial tablets (Baycaron® , 25 mg, 
Bayer) together with about 250 ml of tap water at 9.00 A.M., after an over­
night fast. A 25 mg dose was taken by two, and a 50 mg dose by six sub­
jects, as indicated in Table 14.1. 
Blood samples of ca. 7 ml were drawn by venepuncture from an 
antecubital vein, usually at the following approximate times after the dose 
(exact times were noted): 0, 0.5, 1, 1.5, 2, 3.5, 5.5, 8, 14, 24, 32, 48 and 56 
h. All blood samples were heparinized and centrifuged immediately after 
collection, followed by rapid separation of plasma from red blood cells, as 
described in the Chapters 4 and 5. Both blood fractions were kept frozen at 
-20oC until assay. Urine was collected completely in separate portions, 
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usually for 56 h. Times of voiding were noted, urine volumes and pH were 
measured, and aliquots of each portion were frozen until determination. 
Assay of mefruside and metabolites 
Concentrations of mefruside, mefruside-lactone and its open acid 
analogue were determined separately in plasma, red blood cells and urine 
by gas chromatography with nitrogen detection (Chapters 4 and 5). From 
plasma samples, expected to contain a very low mefruside concentration, 
i.e. ca. 2.5-7.5 ng/ml, 3 ml portions of plasma were used for assay. The 
distribution of mefruside and metabolites between plasma and red blood 
cells is temperature-dependent, so that irregular concentration-time curves 
can be found, if no precautions in the analytical procedure are taken 
(Fleuren et al., 1979a, 1979b). By employing a 3 min centrifugation at 20CC 
starting immediately after collection of the blood samples, the plasma con­
centration of mefruside was found to be constantly ca. 15% lower than 
that present at 370C. Therefore, estimates of half-lives were not influenced 
by this procedure (see Chapter 4). In the present study, the uncorrected 
plasma concentrations were used for pharmacokinetic calculations. 
Glucuronidase treatment of urine was carried out by incubating 1 ml 
portions of urine with 2000 Fishman units of/3-D-glucuronidase containing 
arylsulfatase activity from Helix pomada (Sigma, St. Louis, Mo., USA) 
during 16 hours at 370C. Before incubation, urine samples had been ad­
justed to pH 5.2 with a few drops of dilute aqueous HCl and buffered with 
1 ml of 0.1 M Walpole acetate buffer (pH 5.2). 
Pharmacokinetic analysis 
Plasma concentration vs. time data of mefruside were fitted according to 
exponential equations, corresponding to linear open compartment models 
with first-order absorption, similarly as described in Chapter 9 for phar­
macokinetic studies with chlorthalidone (Fleuren et al., 1979c). Because 
preliminary graphical estimation indicated that the data could be described 
by either a one or a two compartment model, decision in favour of the 
most appropriate model equation for each subject was made by the f-test 
for goodness of fit (see e.g. Boxenbaum, 1974) which resulted in choice of 
a two compartment model for five subjects and a one compartment model 
for three, as reported in the Results section. 
For curve-fitting the computer program FARMFIT* was used, which 
yielded the exponential terms, i.e. K
a
, α, β, and the coefficients A and В of 
the model equations. This program provided also a measure of the relative 
* FARMFIT, a non-linear curve-fitting program in use at the Computer Centre of the Univer­
sity of Nijmegen. Details are given in Chapter 1. 
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error in the parameter estimates, by dividing the asymptotic standard 
deviation of the estimated parameter by the computer-estimated parameter 
itself (times 100 gives relative error in %). A relative error of 4% was taken 
into account for each concentration value Q: weightj = 1/(0.04 Ci)2, 
because this was the mean standard deviation of the gas chromatographic 
assay. Terminal half-lives were calculated as tVi = 0.693//3, where /3 
represents the smallest rate constant (reciprocal time constant) for each fit­
ted curve. The plasma clearance (kcd)» ^ е v o l u m e of the central compart­
ment (Vi) and the volume of distribution at steady state (V^ss) were ob­
tained directly from the coefficients and exponentials of the fitted model 
equations, similarly as described in Chapter 9. It should be noticed that 
these parameters can be calculated from oral administration data only as 
Vj/F, Vdss/F and kcel/F. a s indicated in Table 14.1, because the 
bioavailability F, i.e. the fraction of dose coming into the general circula­
tion, is not actually known. 
In one subject, F.So., irregular absorption of mefruside did not allow 
use of a curve-fitting procedure for obtaining pharmacokinetic parameters, 
as will be shown in Figure 14.5 in the Results section. Instead, the terminal 
half-life was found by non-linear regression analysis of the final straight 
part of the curve, and the plasma clearance and the total volume of 
distribution (divided by F) were calculated as D/AUC and D//3.AUC, 
respectively, where D represents the dose and AUC the area under the 
plasma concentration vs. time curve, extrapolated to infinity from the last 
data point. The AUC had been obtained by use of the trapezoidal rule. 
The renal plasma clearance of mefruside was measured by dividing the 
amount of drug excreted in urine by the corresponding area under the 
plasma concentration curve during the period that the plasma concentra­
tion could be accurately analysed, i.e. down to ca. 5 ng/ml using 2 ml of 
plasma (Fleuren et al., 1979a; Chapter 4). 
The apparent terminal half-lives of 5-oxo-mefruside and its open acid 
analogue were calculated by non-linear regression analysis of the final part 
of the concentration-time curves and urinary excretion rate vs. time plots. 
The plots of urinary excretion rate vs. time were extrapolated to obtain the 
total urinary recovery of mefruside and metabolites at infinite time. 
RESULTS 
Pharmacokinetics of mefruside in plasma 
Mefruside was rapidly absorbed with peak plasma concentrations of 
68-128 ng/ml reached at 1.5-5.5 h (mean 2.6 h) after oral doses of 50 mg in 
six subjects. In the two subjects, who had received a 25 mg dose, peak con-
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centrations of 76 and 84 ng/ml occurred at 2 and 2.5 h, respectively. After 
the top the concentration-time curves were biphasic in five subjects. In the 
three other subjects terminal elimination was so fast with respect to 
distribution, that initial decay, viz. the first phase of disappearance visible 
in the afore-mentioned five subjects, could not be distinguished in them as 
a separate phase. To illustrate this difference between subjects, typical 
plasma concentration vs. time curves on semi-logarithmic scale are shown 
in Fig. 14.2. Considerable inter-individual variaton in /г, over a 4-fold 
range, was found. The pharmacokinetic parameters, obtained by fitting 
the data according to either a one or a two compartment open model, are 
given in Table 14.1. It can be seen from this table that the variation in ter­
minal half-life, from 2.9-12.5 h, is reflected mostly in differences in the 
plasma clearance (kcel)>which ranges from 22.5-1291/h, whereas intersub-
ject differences in the total volume of distribution (Vdss) are much less pro­
nounced, ranging from 314-518 liters. 
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Figure 14.2 
Computer-fitted plasma concentration curves of mefruside, on semi-logarithmic scale, after 
oral administration of single 50 mg doses to three human subjects. A ca. 4-fold intersubject 
difference in elimination half-lives was observed. 
255 
in 
ON 
TABLE 14.1 
Open pharmacokinetic model parameters describing plasma concentration of mefruside after oral administration to eight healthy human subjects 
(Rel. errors in parentheses) 
Dose (mg) 
Dose/weight (mg/kg) 
Lag time (h) 
Ka (h"1) 
α (h"1) 
ß (h"1) 
Half-life (h) 
A (mg/1) 
В (mg/1) 
Vl/F(l) 
VdSS/F (1) 
k C e l /F (1/h) 
One compartment 
J.C1 
50 
0.78 
0.38 
2.97 
(38%) 
0.204 
(6.4%) 
3.4 
0.171 
(10.4%) 
314 
64.1 
Subjects 
J.Da 
50 
0.68 
0.01 
1.01 
(9.9%) 
0.158 
(3.2%) 
4.4 
0.138 
(6.5%) 
428 
67.4 
S.Si 
50 
0.60 
0.23 
1.40 
(12%) 
0.249 
(2.3%) 
2.9 
0.117 
(5.7%) 
518 
129 
H.Ba 
50 
0.61 
0.10 
0.685 
(52%) 
0.458 
(63%) 
0.0978 
(7%) 
7.1 
0.521 
(294%) 
0.076 
(18%) 
210 
351 
47.9 
Two compartments 
K.Ko 
25 
0.41 
0.4 
1.20 
(107%) 
0.951 
(138%) 
0.0554 
(9.2%) 
12.5 
0.210 
(528%) 
0.062 
(23%) 
243 
391 
22.5 
Subjects 
P.Pe 
25 
0.35 
0.35 
1.16 
(51%) 
0.832 
(76%) 
0.0664 
(4.5%) 
10.4 
0.306 
(183%) 
0.046 
(7.8%) 
194 
436 
33.1 
A.Ro 
50 
0.59 
0.25 
0.791 
(90%) 
0.522 
(124%) 
0.0611 
(5.3%) 
11.4 
0.323 
(471%) 
0.0980 
(9.9%) 
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431 
29.6 
F.Soa 
50 
0.77 
-
-
-
0.101 
6.9 
-
0.078 
-
487 
49.2 
vd/3 calculated instead of ^
а 5 for subject F.So, see text for further explanation 
Uptake of mefruside in red blood cells 
Mefruside concentration in erythrocytes was 20 to 40 times higher than 
corresponding plasma concentration. Peak concentrations, 1.83-3.53/tg/ml 
after 50 mg doses, and 1.49 and 2.50μ%/χη\ after 25 mg of mefruside, were 
reached at the same times as those at which peak concentrations in plasma 
had been found. The time-averaged ratio of red blood cell concentration 
over plasma concentration was closely equal to 30 in five subjects. Mean 
ratios (± S.D.) were: 29.4 (±3.0) in subject H.Ba, 29.9 (±6.7) in subject 
J.C1, 29.7 (±3.5) in subject A.Ro, 28.9 (±2.5) in subject S.Si, and 29.9 
(±5.1) in subject F.So. In the subjects J.Da, K.Ko and P.Pe, the mean 
ratios were 35.5 (±3.7), 36.2 (±3.9) and 20.1 (±2.6), respectively. 
At and around the top of the concentration time curves, the red blood 
cell over plasma concentration ratio was systematically ca. 10-15% lower 
than the time-averaged value in each subject. The ratio became constant, 
however, after this time, so that a parallel terminal decay of the concentra­
tion in both blood fractions resulted. Figure 14.3 shows red blood cell con-
J S 1Ú IS 20 25 30 35 40 4S 50 
П И Е IN nai'fls 
Figure 14.3 
Red blood cell concentrations of mefruside are ca. 30 times higher than corresponding plasma 
concentrations and provide virtually the same information on elimination rate as plasma data 
from the same subjects, as can be seen by comparison with Fig. 14 2 The picture has been ob­
tained directly from a computer-plot. 
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TABLE 14.2 
Some pharmacokinetic parameters describing red blood cell concentration of mefruside in 
humans after single oral 25 and 50 mg doses 
Subject 
H.Ba 
J.C1 
J.Da 
K.Ko 
P.Pe 
A.Ro 
S.Si 
F.So 
Dose 
(mg) 
50 
50 
50 
25 
25 
50 
50 
50 
C-max 
(mg/l) 
3.01 
3.32 
2.92 
2.51 
1.49 
3.53 
1.83 
2.32 
'max 
(h) 
2.0 
1.0 
2.0 
2.1 
2.0 
3.5 
1.2 
5.5 
f/iel 
(h) 
7.2 
3.5 
4.1 
12.1 
10.7 
11.3 
3.0 
6.7 
centration vs. time data, taken from the same three subjects, from whom 
the plasma concentrations appeared in Fig. 14.2. Terminal half-lives, 
calculated by regression analysis of the final straight part of erythrocyte 
concentration curves in eight subjects are presented, together with max-
imum concentrations (Cmax) and times of these maxima (tmax), in Table 
14.2. No differences with the tVi values resulting from plasma measure-
ment were found, cf. Table 14.1. 
Urinary excretion of mefruside 
The urinary excretion rate plots of mefruside were parallel to the decay 
curves of plasma concentration in all subjects and no great dependence of 
urinary excretion rate upon either flow or pH of urine was observed. A 
typical plot is shown in Fig. 14.4. Only a very small proportion of the dose, 
ranging from 0.3-1.1% in eight subjects, mean 0.49%, had been excreted 
at infinite time. Detailed pharmacokinetic data are presented in Table 14.3. 
Renal plasma clearance of unchanged mefruside was very low, from 
2.5-5.4 ml/min, see Table 14.3. 
Concentration of mefruside metabolites in plasma and red blood cells 
The concentration of 5-oxo-mefruside and its open acid analogue in 
plasma remained below the limit of detection of the analytical method, i.e. 
ca. 5 ng/ml. In red blood cells, 5-oxo-mefruside was measurable from the 
earliest sample, collected at 0.5 h, until at least 50 h after the single oral 
dose of mefruside. The open acid metabolite could be followed in red 
blood cells during 24-30 h, after which concentration became too low for 
accurate determination. Figure 14.5 shows red blood cell concentrations of 
the two metabolites in subject F.So, together with the concentrations of 
unchanged mefruside in plasma and red cells. The absorption pattern of 
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Figure 14.4 
Urinary excretion rate and cumulative urinary excretion of mefruside in a human subject after 
a single oral 50 mg dose of mefruside, plotted vs time. The urinary excretion rate was precisely 
parallel to the time course of plasma concentrations. Only 0.434Ό of dose was excreted as the 
unchanged drug over infinite time. In the two lower graphs pH and flow of urine portions are 
shown. 
mefruside, being irregular in this subject, is closely reflected, after some 
delay, by the formation of metabolites. Maximum metabolite concentra­
tions were reached ca. 10 h post-dose. The ratio of lactone concentration 
over open acid concentration was about 10 in the final part of the decay 
curves, although it had been lower, ca. 6-8 initially, see Fig. 14.5. 
Similar data resulted from the erythrocyte concentrations in the three 
other subjects. Peak concentrations of the lactone metabolite were: 1.05 
Hg/ml, 2.34 pg/ml and 0.83 /ig/ml in the subjects H.Ba, J.C1 and S.Si, 
respectively. The corresponding maximum concentrations of the open acid 
metabolite were: 0.176 /ig/ml, 0.54 /tg/ml and 0.11 /tg/ml, respectively, at­
tained at 5-8 h after intake of mefruside. Terminal half-lives of the two 
metabolites could be calculated only approximately, especially that of the 
open acid compound, due to limited numbers of data points, but the Wi 
values were clearly longer than the half-life of mefruside itself, in each sub-
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Figure 14.5 
Concentration-time curves of mefruside and main metabolites after oral administration of a 
single 50 mg dose of mefruside in man. 5-Oxo-mefruside (mefruside-lactone) and its open acid 
analogue were eliminated more slowly than the parent drug, as seen from the red blood cell 
concentration. The plasma concentration of the two metabolites was too low to be detectable. 
ject. In the subjects H.Ba, J.CI, S.Si and F.So the red blood cell concentra-
tion of 5-oxo-mefruside declined with VÁ values of 13 h, 10 h, 14 h and 
12.5 h, respectively. 
Urinary excretion of 5-oxo-mefruside and its hydroxy carboxyiic acid 
analogue. 
Typical urinary excretion rate vs. time plots on semi-logarithmic scale 
are shown in Fig. 14.6. After intake of mefruside an abundant excretion of 
the two metabolites was seen, with high urinary excretion rates persisting 
during up to ca. 10-15 h after the dose. The cumulative urinary excretion 
(extrapolated to infinite time after actual analysis) amounted to mean 
values of 13.1% of dose and 46.2% of dose, respectively, for the lactone 
and the open acid metabolite. Detailed excretion data from four human 
subjects are given in Table 14.4. The terminal VA of the lactone ranged 
from 10-14 h, and that of the open acid compound from 9-12.5 h. 
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TABLE 14.3 
Urinary excretion of unchanged mefruside after oral administration of single 25 or 50 mg doses in man 
Subject 
H.Ba 
J.C1 
J.Da 
K.Ko 
P.Pe 
A.Ro 
S.Si 
F.So 
Dose 
(mg) 
50 
50 
50 
25 
25 
50 
50 
50 
Time period 
measured 
(h) 
52.6 
13.5 
22.0 
30.6 
32 
28.3 
18.9 
24.7 
half-life 
(h) 
7.2 
3.4 
4.5 
12.5 
10.4 
10.6 
3.1 
6.2 
Cumulative excretion of mefruside 
during assay 
amount Чч of 
(mg) dose 
0.214 0.43 
0.130 0.26 
0.109 0.22 
0.229 0.92 
0.133 0.53 
0.303 0.61 
0.135 0.27 
0.145 0.29 
at infinite ι 
amount 
(mg) 
0.215 
0.139 
0.113 
0.271 
0.155 
0.354 
0.138 
0.152 
mean 
time 
% of 
dose 
0.43 
0.28 
0.23 
1.08 
0.62 
0.71 
0.28 
0.30 
0.49% 
clearer 
(1/h) 
0.198 
0.197 
0.151 
0.267 
0.195 
0.317 
0.325 
0.155 
ice 
(ml/min) 
3.30 
3.20 
2.52 
4.45 
3.24 
5.29 
5.40 
2.58 
TABLE 14.4 
Urinary excretion of two oxidized metabolites of mefruside, viz. mefruside-lactone and carboxylic acid analogue, after oral administration of single 
50 mg doses of mefruside to four healthy human subjects 
Subject 
H.Ba 
J.CI 
S.Si 
F.So 
Time period 
measured 
(h) 
55.4 
56.1 
55.4 
55.5 
Elimination 
half-life (h) 
lactone 
14 
11.5 
10 
10 
open acid 
9.5 
11 
8 
12.5 
Cumulative excretion of lactone 
during 
amount 
(mg) 
6.79 
6.30 
5.84 
6.21 
assay 
% o f 
dose 
13.6 
12.6 
11.7 
12.4 
at infinite time3 
amount 
(mg) 
7.25 
6.51 
5.99 
6.37 
mean 
Щ of 
dose 
14.5 
13.0 
12.0 
12.7 
13.1«7o 
Cumulative excretion of open 
during 
amount 
(mg) 
20.5 
16.9 
27.0 
25.7 
assay 
of 
dose 
41.0 
33.8 
54.0 
51.4 
acid 
at infinite time3 
amount 
(mg) 
21.0 
17.3 
27.1 
27.0 
mean 
Щ of 
dose 
42.0 
34.6 
54.2 
54.0 
46.2% 
a
 Calculated by extrapolation from plots of urinary excretion rate vs time 
O O O É cDMOiO 
О О 
Figure 14.6 
Urinary excretion rates of 5-oxo-mefruside, the hydroxy-carboxylic acid analogue thereof, 
and mefruside, plotted on semi-logarithmic scale against time. The subjects J.CI and F.So ex­
creted 34.6% and 54% of dose respectively, as the open acid metabolite, and 13% and 12.7% 
of dose respectively, as the lactone metabolite. Only 0.28% and 0.30% of dose respectively 
was excreted as unchanged mefruside. The elimination half-lives of the metabolites of 
mefruside were approximately the same for each subject, ranging from 10-12 h. 
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Judged from the urinary excretion rate plots neither of the two 
metabolites responded much to changes in urine flow or urine pH, but the 
profiles of excretion of the two compounds were strikingly parallel to each 
other, see e.g. Fig. 14.6. 
Urinary excretion of conjugated metabolite 
After treatment of urine with glucuronidase an additional amount of the 
hydroxy carboxylic acid metabolite, corresponding to 5-15% of dose, was 
recovered over a ca. 55 h period (exact periods the same as indicated in 
Table 14.4). The figures were: 3.0 mg for subject H.Ba, 5.3 mg for subject 
J.C1, 2.3 mg for subject S.Si and 6.9 mg for subject F.So. 
In a pilot experiment it was checked that spontaneous hydrolysis of this 
conjugated metabolite did not occur in human urine at measurable rate. 
Thus, when urine samples obtained from two human subjects 4 h after in­
gestion of 50 mg of mefruside, were extracted at pH 2 immediately after 
voiding, values identical with those analysed after standing of urine for 1 
day at room temperature were found. This implies that no in vitro libera­
tion of the open acid metabolite of mefruside from its conjugated form had 
taken place. 
DISCUSSION AND CONCLUSIONS 
Pharmacokinetic parameters 
The plasma concentration versus time curves of mefruside were well-
fitted according to the appropriate model equations, see Fig. 14.2, and the 
terminal tVi values could be measured accurately (Table 14.1). Estimates 
of the absorption rate constant, K
a
, and the parameters α and A, were ob­
tained with less precision in case of two compartment kinetics, because 
relatively few data points were available during the early distribution phase 
of each curve. These uncertainties did, however, not seriously influence 
estimation of plasma clearance and total volume of distribution, which was 
verified by calculating these parameters (divided by the bioavailability F) as 
D/AUC and D//3.AUC, respectively, where D represents the dose and 
AUC the total area under the curve after extrapolation to infinite time. 
Plasma clearance values very close to the keel values presented in Table 
14.1 were found. Similarly, the total volume of distribution by area, i.e. 
Vdß, was generally comparable in magnitude to the Vdss values, although 
each Vdß was systematically larger than the corresponding Vjss, which is 
in agreement with theoretical expectation, see, e.g., Wagner (1976). Con-
cludingly, the important pharmacokinetic constants of Table 14.1 can be 
regarded as essentially model-independent parameters. 
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The large total volume of distribution, 314-518 liters equivalent to 5-7.5 
liter/kg body weight, implies extensive tissue binding of mefruside. In rat 
experiments high levels of radioactivity were found, besides in red blood 
cells, in kidney and liver, already shortly after i.v. administration of 
mefruside (Duhm et al., 1967). So, it is reasonable to assume that the large 
Vdss in man reflects binding to these tissues, and of course, as evidenced by 
our data, to red blood cells. 
Binding to red blood cells 
A linear distribution of mefruside between plasma and red blood cells 
was observed in vitro, and the rate of equilibration was unmeasurably 
rapid (Fleuren et al., 1979a; Chapter 4). Consequently, a constant ratio of 
mefruside concentration in plasma over its concentration in erythrocytes 
could have been expected for the present study. This turned out in general, 
see the Results section. Yet, at the top of the concentration time curves the 
ratios were somewhat lower than those present during the absorption and 
elimination phase, which could be due to competition of metabolites of 
mefruside for binding sites at higher concentration. This was in agreement 
with the observation that red blood cell binding of mefruside in vitro 
decreased with increasing concentration of 5-oxo-mefruside (Fleuren et al., 
1979b; Chapter 5). However, as the red blood cell over plasma concentra-
tion ratio was constant in the terminal part of the plots, perfect agreement 
between terminal half-lives of mefruside concentration in plasma and red 
blood cells resulted. Therefore, red blood cell concentrations being ca. 30 
times higher than those in plasma or, alternatively, whole blood concentra-
tions constitute a comfortable means for measuring elimination half-lives 
of mefruside in man (see Table 14.2). 
The observation that the open acid metabolite of mefruside was 
measurable in the red cell fraction of blood but not in plasma (Fig. 14.5) is 
surprising, as in vitro experiments indicated only a small degree of 
erythrocyte uptake of this anionic substance (Chapter 5; Fleuren et al., 
1979b). In contrast with 5-oxo-mefruside, which accumulated in red blood 
cells with a concentration about 20 times higher than that in plasma, the 
concentration of the carboxylic acid metabolite in erythrocytes was only 
one-tenth of that in plasma. In view of the ability of fresh human plasma to 
convert the lactone to the open acid (Chapter -5), an artefact in the in vivo 
observation due to the experimental procedure cannot be excluded. So, it is 
possible that the apparent red cell concentration of the open acid 
metabolite resulted from in vitro hydrolysis of 5-oxo-mefruside in the small 
volume of plasma trapped between the red blood cells after centrifugation 
of the blood. (In turn, 5-oxo-mefruside must have come there by diffusion 
out of the red cells because no trace of it was detectable in plasma). 
The nature of the binding of mefruside by red blood cells has not yet 
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been established. In order to go into some more detail, we incubated 
mefruside in fresh human blood, as described in Chapter 4, for 60 min at 
370C in the presence of varying amounts of acetazolamide, a drug most 
probably strongly bound to the carbonic anhydrase fraction of red blood 
cells (Maren et al., 1960; Wallace and Riegelman, 1977). At a mefruside 
whole blood concentration of 3.5 /¿g/ml, the following erythrocyte over 
plasma concentration ratios were found at acetazolamide concentrations of 
0.0, 6.25, 26.8 and 53.5 /ig/ml, respectively: 38.5, 27.8, 7.0 and 2.5. From 
this displacement by acetazolamide we conclude tentatively that binding to 
carbonic anhydrase plays a role in the accumulation of mefruside in red 
cells. This would be in accordance with the weak inhibition of red cell car-
bonic anhydrase activity by mefruside in vitro (Wilson and Kirkendall, 
1970). 
Intersubject difference in elimination of mefruside 
The 4-fold difference between human subjects with regard to the 
elimination rate of mefruside, see Figs. 14.2 and 14.3 and Tables 14.1 and 
14.2, must be explained by variation in the rate of metabolism, because 
renal clearance of unchanged drug accounts for removal of less than ca. 
1% of the dose (Table 14.3). Intersubject variation of this magnitude has 
been observed with some other drugs, which are known to be metabolized 
by hepatic microsomal oxidation and it is believed that such differences are 
determined both by genetic and environmental factors (Sjöqvist et al., 
1976a). At least, 60-65% of an oral dose of mefruside is oxidatively 
transformed in man, as judged from the sum of 5-oxo-mefruside and its 
open acid analogue in urine, see Table 14.4. Therefore, the kinetic 
behaviour of mefruside forms no exception as far as being caused by such 
oxidative processes. 
Relationship between pharmacokinetics and diuretic effect 
Many-fold interindividual differences in elimination half-life will be no 
advantage for a drug in general, because of concomitant variation in 
therapeutic response to be expected. The pharmacokinetic profile of 
mefruside, however, seemed to contradict a direct correlation with its 
biological action. Thus, especially in subjects with half-lives of only a few 
hours, an early cease of the diuretic effect of mefruside would be expected. 
On the contrary, a slow onset of water and salt diuresis has been found 
after single oral doses of 25 to 100 mg of mefruside in man, with peak ef-
fects observed at 4-12 h by Wilson and Kirkendall (1970) and at 6-12 h by 
Schwab and Immich (1967). Diuresis continued up to ca. 20-24 h after the 
dose (Brogden et al., 1974; Schwab and Immich, 1967; Wilson and Kirken-
dall, 1970). 
Both 5-oxo-mefruside and the carboxylic acid metabolite of mefruside 
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possess intrinsic diuretic properties, similar to those of mefruside, which 
has been demonstrated by intravenous studies in rats (Meng and 
Kroneberg, 1967; cf. Chapter 15). The half-life of the two metabolites in 
humans, 10-14 h for each subject, would provide effective concentrations 
of diuretic agents for a longer time than that predictable from the variable 
kinetics of the parent drug. Therefore, the time course of blood concentra-
tion and urinary excretion rate of the oxidized metabolites of mefruside, 
see Fig. 14.6, appears to be much more compatible with the above duration 
of diuretic effects. 
For many classes of drugs the concentration in plasma is believed to be 
an adequate measure of biological effects (McDevitt and Shand, 1975; 
Schneider and Ruiz-Torres, 1977; Sjöqvist et al., 1976b), although the ac-
tual relationship can sometimes be complex, as for the tricyclic anti-
depressants (Editorial, 1978). On the contrary, as discussed in Chapter 1, 
evidence is growing that the effects of diuretic drugs might correlate better 
with the urinary excretion rate of the active principles than with their 
plasma concentration. This is supported by the observation that each 
sulfonamide diuretic, from which data are available, is excreted into urine 
for a large part of the dose (Table 1.3, Chapter 1). Thus, both the time 
course and the extent of urinary excretion of 5-oxo-mefruside and its car-
boxylic acid analogue lead to the conclusion that these metabolites of 
mefruside are the active principles of this drug in man. 
SUMMARY 
Single oral 25 or 50 mg doses of mefruside were administered to eight 
healthy human subjects and plasma, red blood cells and urine were assayed 
during up to 50 h. In four of these subjects, the concentrations of two ac-
tive metabolites of mefruside, 5-oxo-mefruside (mefruside-lactone) and its 
hydroxy carboxylic acid analogue, were also measured. 
Mefruside was rapidly absorbed into plasma, with a mean half-life of 0.5 
h. A 4-fold interindividual difference in elimination half-life was observed, 
ranging from 2.9-12.5 h. The decay was biphasic in five of the eight sub-
jects. In the three others having the shortest Л values initial distribution 
was not visible as a separate phase, so that a monophasic decay resulted. 
The variation in Л was reflected in a large variation in total plasma 
clearance between subjects (22.5-1291/h). The total volume of distribution 
ranged from 314-518 liters. Mefruside distributed instantaneously between 
plasma and red blood cells. The concentration in red blood cells was about 
30 times higher that that in plasma and the terminal decay was parallel to 
that of plasma concentration. Also the urinary excretion rate of mefruside 
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was parallel to the plasma concentration curves. Only a mean total of 
0.49 % ( ± 0.30 %, S.D.) of dose was excreted in urine over infinite time as 
the unchanged compound. 
Measurable concentrations of 5-oxo-mefruside were observed in the red 
blood cell fraction already in the first samples, i.e. at 0.5 h. The carboxylic 
acid metabolite reached red blood cell concentrations ca. 10 times lower 
than those of 5-oxo-mefruside. The plasma concentrations of these meta­
bolites were not detectable, but high concentrations were found in urine. 
Total urinary excretion of the lactone metabolite over infinite time ranged 
from 12.0-14.5 % of dose (mean ± S.D., 13.0±1.1 %), and that of the 
open acid metabolite was 34.5-54.3 % of dose (mean ± S.D., 46.2±9.6 
%). Another 5-15 % of the dose was recovered in urine as conjugate of the 
open acid metabolite. 
Urinary excretion rate of both main metabolites became maximal be­
tween approximately 5-10 h after administration of mefruside, and the 
decrease thereafter showed much less intersubject variation in t '/2 than that 
observed with the parent compound. A mean tVi of 11.9 h (± 1.7 h, S.D.) 
was measured for the lactone, and a mean tVi of 10.5 h (± 1.6 h, S.D.) for 
the acid metabolite. Approximately the same Л resulted from red blood 
cell measurement. 
It was concluded that the urinary excretion profile of both metabolites 
corresponded very well with the clinically known duration of action of 
mefruside, and that the metabolites instead of the parent drug must be con­
sidered as the actual therapeutic principles in man. 
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CHAPTER 15 
DIURETIC EFFECTS OF MEFRUSIDE AND ITS MAIN METABOLITES 
IN THE ISOLATED PERFUSED RAT KIDNEY 
INTRODUCTION 
Studies on the metabolism of mefruside showed that the major metabolites 
were formed by oxidation of the 5-carbon atom of the tetrahydrofuran ring in 
both rats (Duhm et al., 1967) and humans (Fleuren et al., 1979; Chapter 14). 
The primary metabolite, the so-called 5-oxo-mefruside or mefruside-lactone, 
appeared to exist in equilibrium with its free acid analogue. Both species were 
found in urine, accounting together for ca. 35% of the dose in rats (Duhm et 
al., 1967) and for ca. 60% in man (Fleuren et al., 1979; Chapter 14). Meng and 
Kroneberg (1967) compared the pharmacodynamic properties of mefruside 
and these metabolites by intravenous studies in rats. No differences between 
the three compounds were found with regard to their diuretic effects, as 
evidenced by identical dose-response curves. These findings suggested that the 
diuretic activity of mefruside was attributable to its metabolites, because the 
parent drug itself was almost completely metabolized, with less than 147ο of the 
dose being excreted unchanged into the urine (Duhm et al., 1967; Fleuren et 
al., 1979; Chapter 14). This would be in agreement with the observation that 
all sulfonamide diuretics show a considerable degree of urinary excretion of 
their active principles. So, as discussed in Chapter 1, evidence has arisen that in 
the first place the extent of urinary excretion of diuretic drugs determines their 
effectiveness rather than the height of their plasma concentration. 
A detailed study of the interconversion of the two metabolites in vivo and in 
vitro was made by Schlossmann and Pütter (1973). The formation of the lac-
tone from the free acid and, on the other hand, the hydrolysis of the lactone 
appeared to be unmeasurably slow in aqueous buffers in the pH 7-8 range. Rat 
plasma and rat liver microsomes, however, markedly catalyzed the inter-
conversion of both metabolites. When the lactone was administered in-
travenously to dogs, it was rapidly transformed into the free acid and the same 
was found for the formation of the lactone from the free acid. Moreover, both 
the lactone and the free acid were detected in the plasma of dogs, already 3 
minutes after an intravenous injection of mefruside (Schlossmann and Pütter, 
1973). 
In the light of these observations, the pure diuretic effect of the two 
metabolites could have been obscured, because it had been measured during 
269 
several hours (Meng and Kroneberg, 1967). This period should be sufficient by 
far for a considerable interconversion, and for this reason it was considered of 
interest to re-assess the diuretic properties of both metabolites. Evidently, an 
unequivocal conclusion on the intrinsic diuretic action of mefruside and the 
two metabolites can be drawn only when conversions by metabolism are ruled 
out. 
The isolated perfused rat kidney seemed to fulfil this requirement, as the 
kidney has a relatively small drug metabolizing capacity compared with the 
liver (see e.g., Jones et al., 1979). Use was made of a perfusion technique 
developed by Siegers and coworkers (1979), by which the functional 
characteristics of the kidney, viz. reabsorption of sodium, potassium, glucose 
and water, are kept in good condition for at least one hour or longer. 
Although, as in any presently known isolated kidney preparation, loss of func-
tion occurs with time, the detoriation in the present technique is moderate, e.g. 
the mean fractional sodium reabsorption decreases only 0.35% per 5 minutes 
over a 90 minutes period (Siegers et al., 1979). This enabled us to study in this 
system the influence of drugs with a presumed diuretic activity on the water-
and electrolyte excretion. For this purpose, the drug effects were compared 
with the values from control kidney perfusions, in which perfusate without 
drug had been used during an equal period. The study described in this chapter 
was aimed to give a first qualitative impression of the diuretic properties of 
mefruside and its metabolites, not distorted by in vivo metabolic factors. 
MATERIALS AND METHODS 
Drugs 
Mefruside and 5-oxo-mefruside (mefruside-lactone) were obtained from 
Bayer (Wuppertal, G.F.R., courtesy of Dr. H.Horstmann) (Horstmann et 
al., 1967). The purity of mefruside was better than 99.5%, as described in 
Chapter 4. The mefruside-lactone sample contained about 1.25% of 
mefruside (see Chapter 5), but no attempt to separate the lactone from its 
parent drug on a preparative scale was made. The small percentage of con-
tamination did not justify such an effort, in view of the qualitative com-
parison of this study aimed at. The same was judged to apply to a 3% por-
tion of the open acid form in the crystalline lactone sample, found by 
analysis of a solution of the sample in phosphate buffer of pH 7.4, im-
mediately after dissolution. Quantitative determination of the concentra-
tions of the lactone and its open acid analogue was performed as described 
in Chapter 5. The open acid was formed from the lactone by dissolving the 
latter in 0.1 M aqueous sodium hydroxide. This solution was allowed to 
stand overnight prior to the perfusion experiment. Mefruside and both 
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metabolites were dissolved in the perfusion fluid (10 and 50/tg/ml) shortly 
before the kidney perfusions. The composition of the perfusion fluid is 
described in the next section. 
The isolated perfused rat kidney 
Male Wistar rats, weighing approximately 200-250 g, were used. A 
detailed description of the surgical procedure of the rat kidney isolation 
and the methods and equipment used in the perfusion has been given by 
Siegers and coworkers (1979). Some aspects, considered relevant with 
respect to the subject of the present investigation, will be dealt with in 
short. The perfusion method is in essence a modification of that published 
by Nishiitsutsuji-Uwo et al., 1967). However, a completely artificial perfu-
sion fluid is used instead of a semi-synthetic one, and the perfusate is not 
recirculated. 
After anaesthesia with pentobarbital (45 mg/100 mg body wt) and 
heparinization (500 I.U./rat), the right kidney and ureter are carefully 
dissected free of adhering tissue and the ureter is cannulated. A metal can-
nula, which is continuously flushed with the perfusion fluid, is introduced 
via the mesenteric artery into the renal artery and tied. To direct the venous 
outflow, a cannula made of glass is put into the vena cava with the tip at 
the place where the renal vein is entering and ligated. A schematic drawing 
of the ligatures made is presented in Fig. 15.1. After the kidney has been 
dissected completely free, it is carefully placed into a perspex perfusion 
a. mesenterica 
Figure 15.1 
Schematic representation of the ligatures made in the isolated perfused rat kidney. The can-
nulas were entered at places marked by X. Reproduced, with permission, from Siegers and 
coworkers (1979). 
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chamber. The temperature of the perfusion fluid is kept at 37.5CC, just 
before entrance into the kidney. A constant perfusion flow of 15.1 ml/min 
is used, which results in a renal perfusion pressure of 120 mm Hg. The per­
fusion fluid has the following composition: 
Electrolytes (mM): NaCl 124, KCl 5.2, СаСІ2 1.0, MgCl2 0.3, NaHCOa 
25, Na2HP04 0.84, and KH2PO4 0.24 
Substrates (mM): glucose 5, Na-pyruvate 1.99, Na-glutaminate 1.2, Na-
acetate 1.2, Na-propionate 2.1, and Na-lactate 1.0 
In addition: urea 0.4 mM, alanine 5.0 mM, inosine 1.0 mM, in­
sulin 4 I.U./liter, aldosterone 2 /tg/liter, anti-diuretic 
hormone 10"2 I.U./liter, and angiotensin II 15 ng/ml 
Plasma expander: pluronic F108 (Wyandotte Chem. Corp., through 
BASF, Ludwigshafen, G.F.R.) 
The pH of the perfusate is 7.4, when it is gassed with 5% CO2 and 95% O2 
(v/v) and its osmolarity is 310 mOsmol/liter. The plasma expander 
pluronic F108 is a polymer of polyoxyethylene and polyoxypropylene with 
a molecular weight of 16250. It is electrically neutral, stable in solution, 
and biologically inert (Geyer, 1970). Physiological and morphological 
studies of Franke et al. (1975) have shown that better results are obtained 
during kidney perfusion with pluronic F108 than with dextran or haemacel. 
Vitamin B12 (cyanocobalamin) was added to the perfusion fluid, in a 
concentration of 20 mg/liter, as a marker for glomerular filtration rate. 
Previously, Siegers and coworkers (1979) had established that the ratio of 
the clearance of vitamin B12 over the clearance of 14c.¡nuiin w a s almost 
equal to unity in their system, viz. 1.025 + 0^)12 (mean ± S.E.M., η = 23) 
and that renal handling of sodium, potassium and water was not impaired 
by the concentration of vitamin B12 used. The modified kidney prepara­
tion possesses, particularly under influence of the composition of the per­
fusate, a high reabsorbing capacity for electrolytes, glucose and water. E.g. 
over a 90 min. period, a fractional reabsorption of 96% for sodium has 
been achieved, whereas this lays in the order of 70% for potassium on an 
average (Siegers et al., 1979). 
The kidney perfusions were performed in 90 minutes periods, divided 
into two sections. The first 45 minutes served as a control period (perfusion 
fluid alone). From 45 to 90 minutes the kidney was perfused with the perfu­
sion fluid, which in addition contained one of the drugs in a concentration 
of 10 or 50 μg/ml. Urine samples were collected over 5 minutes periods and 
their volumes were measured by weighing. Vitamin B12 concentrations in 
perfusate and urine were determined spectrophotometrically at 546 nm. A 
flame photometer was used to measure urinary sodium and potassium con­
centrations. 
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Calculation 
Fractional reabsorption of sodium and potassium was calculated as: 
GFR.c - U.V ,„.„ % r e a b s
·
 =
 —ш^ — ·
 100% 
urine cone. vit. в 
GFR = — — . V 
p e r f u s a t e cone. v i t . В 
where GFR = glomerular filtration rate; с and U concentrations of Na or 
К in perfusate and urine respectively, and V = urine now rate 
RESULTS 
The urinary excretion of sodium and potassium together with urine flow 
in two typical experiments is shown in Fig. 15.2. The isolated rat kidney 
was perfused with fluid of normal composition during a control period of 
45 minutes. Thereafter, perfusate to which drug had been added was used. 
Information on the performance of the individual kidneys was obtained 
from a number of renal parameters in the control period, viz. fractional 
reabsorption of sodium and potassium, and concentrating capacity. The 
data are presented in Table 15.1. By comparison with values found in a 
previous study by Siegers et al. (1979), it can be seen that the parameters in 
the present study fell in the normal range for those of such kidney prepara­
tions. 
Diuretic effects were calculated as the percentual change of electrolyte 
excretion and urine formation with respect to a previous control period. 
The results are given in Table 15.2. Because every isolated kidney prepara­
tion looses salts and water with time, also when it has not been exposed to 
any diuretic drug, the changes obtained in perfusions without drug are also 
shown. Compared to the controls, only the perfusions with the open acid 
exhibited a consistent diuretic response. The lactone failed to be effective 
in one of the two experiments. Mefruside showed no increase in water and 
salt excretion at all. 
DISCUSSION 
The information on electrolyte excretion in control perfusions, in which 
no diuretic drug was added to the perfusate (Siegers et al., 1979), has been 
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Figure 15.2 
Diuretic effects of the two main metabolites of mefruside in the isolated perfused rat kidney. 
Arrows indicate times, at which the normal perfusion medium without drug was replaced by 
one, in which the lactone or the free acid had been dissolved. 
an essential pre-requirement for interpretation of our results. This provided 
a reference for the normal variation in losses of water and salt from the 
isolated kidney preparation. These always occur with time though to a 
variable extent (See Table 15.2). By comparing the diuretic parameters 
after the drug with the values from the control experiments, diuretic effects 
were observed for both metabolites of mefruside, but not for mefruside 
itself. The latter detail is surprising, because of the great structural similari­
ty of the parent compound and the lactone. Apparently, the larger 
hydrophilicity of the metabolites as compared to mefruside (cf. Fig. 5.2, 
Chapter 5) favours diuretic action in this series of compounds. However, it 
cannot be excluded that higher concentrations of mefruside in the perfu­
sion fluid would elicit any diuretic response. Moreover, the tacit assump­
tion that drug metabolism would be insignificant in an isolated kidney 
preparation appeared to be not completely justified. Mefruside itself was 
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TABLE 15.1 
Kidney perfusion parameters in control period (40-45 min) 
Experiment 
no drug2 
mefruside 
lactone 
carboxylic acid 
Drug 
concentration 
(/ig/ml) 
— 
10 
50 
10 
50 
10 
50 
Fractional reabsorption 
sodium 
95.8 ± 2.4 
96.3; 97.4 
97.9 
96.3 
97.6 
96.4 
97.1 
№ 
potassium 
89.8 ± 6.6 
92.9; 94.4 
91.0 
78 
94.3 
82 
88.8 
Water 
conserving 
capacity1 
10.7 ± 2.1 
10.1; 10.8 
11.5 
11.4 
12.1 
11.3 
11.8 
1
 Calculated as the ratio of the vitamin B|2 concentrations in urine and perfusate 
^Mean values ± S.D., taken from Siegers et al. (1979) 
TABLE 15.2 
Changes in diuresis, and excretion of Na and К after the control period' 
Experiment 
no drug2 
mefruside 
lactone 
carboxylic acid 
Drug 
concentration 
(/ig/ml) 
— 
10 
50 
10 
50 
10 
50 
urine flow 
29 ± 
10; 51 
33 
186 
38 
98 
152 
22.5 
% change 
E x N a 
64 ± 52.5 
29; 119 
98 
581 
115 
312 
445 
Ехк 
122 ± 100 
13; 145 
216 
372 
237 
249 
714 
' Calculated by comparison of the average values during 45-70 min with those from the 
25-45 min section of the control period 
^Mean values ± S.D., taken from 7 perfusions (Siegers et al., 1979) 
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not metabolized during perfusion, judged from the absence of its main 
metabolites in pooled urine. Also the hydroxy carboxylic acid metabolite 
underwent the procedure apparently unchanged. On the contrary, after 
perfusion with 5-oxo-mefruside the open acid compound was present in 
urine in a concentration of ca. 10% of that of the lactone, indicating an in 
vitro conversion process. So, a possible influence of the open acid on the 
observations with the lactone cannot be disregarded at this stage. 
A definite assessment of a difference in diuretic potency between the two 
metabolites of mefruside would demand perfusion experiments employing 
a broad concentration range. These studies would have to be performed at 
the expense of several kidneys at each concentration, due to biological 
variations in response (cf. Table 15.2). Therefore, any conclusion in this 
respect cannot be drawn at present and the positive evidence for intrinsic 
diuretic activity of the open acid metabolite of mefruside and also, but less 
unequivocally, of the lactone metabolite should be interpreted merely in a 
qualitative sense. These findings support the observations of the diuretic 
activity of both metabolites in the intact rat (Meng and Kroneberg, 1967), 
and thereby indicate the usefulness of a pharmacokinetic study of these 
compounds as the relevant diuretic principles of mefruside in vivo (cf. 
Chapter 14). 
SUMMARY 
Isolated rat kidneys were perfused with an artificial perfusion fluid con­
taining mefruside, 5-oxo-mefruside or the hydroxy carboxylic acid 
analogue thereof. Diuretic effects were determined from the excretion of 
sodium and potassium and from water diuresis. The open acid compound 
exhibited a consistent diuretic response in two experiments. 5-Oxo-
mefruside was active in one experiment, but not in the other. Mefruside 
failed to show diuretic action in all three experiments. These preliminary 
data can be regarded as support for the view that active metabolites of 
mefruside are the determinants of the in vivo diuretic effect of this drug. 
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SAMENVATTING 
Dit proefschrift is gewijd aan de farmacokinetiek van sulfonamide-
diuretica in de mens. Hoewel deze groep geneesmiddelen reeds in de zes-
tiger jaren geïntroduceerd werd, was zij tot voor kort in farmacokinetisch 
opzicht nauwelijks onderzocht, mede door het ontbreken van adequate 
chemische analysemethoden. 
Het hier beschreven onderzoek is dan ook in eerste instantie gericht geweest 
op het ontwikkelen van specifieke en gevoelige bepalingen van diuretica in 
biologische vloeistoffen. Om een aantal redenen werden speciaal chloorta-
lidon en mefruside als onderwerp van studie gekozen, ni. a) beide middelen 
worden frequent toegepast in de medicamenteuze therapie ter bestrijding 
van hypertensie en oedemen; b) vergeleken met de benzothiadiazines, 
waaraan chloortalidon en mefruside qua werking nauw verwant zijn, 
waren er bij aanvang van het onderzoek juist over deze verbindingen bij-
zonder weinig gegevens; c) tijdens vooronderzoek bleek dat beide stoffen in 
vivo in hoge mate door rode bloedcellen worden opgenomen. Deze accu-
mulatie in een gemakkelijk toegankelijk lichaamsweefsel bood mogelijk-
heden voor de modelmatige beschrijving van weefselbinding van genees-
middelen in het algemeen. 
Het proefschrift is onderverdeeld in vier secties. Sectie I bevat een alge-
mene inleiding tot de sulfonamide-diuretica en een overzicht van hun far-
macokinetische eigenschappen. Sectie II beschrijft de voor het kinetisch 
onderzoek aan chloortalidon en mefruside ontwikkelde analysemethoden. 
Sectie III behandelt de humane farmacokinetiek van chloortalidon 
(Hygroton®), en sectie IV die van mefruside (Baycaron®). 
Sectie I: Diuretica en farmacokinetiek (hoofdstuk 1) 
In HOOFDSTUK 1 worden de verschillende typen sulfonamide-
diuretica gekarakteriseerd qua werking, aangrijpingspunten in de nier en 
wijze van transport vanuit de bloedbaan naar de urine. Het belang van het 
renale anion-transportsysteem bij de tubulaire secretie van diuretica wordt 
onderstreept, en de bijdragen van de processen van glomerulaire filtratie en 
tubulaire terugresorptie worden aangegeven. Na een inleiding tot de farma-
cokinetiek, waarin de mathematische verwerking van concentratie-
tijdscurven met behulp van lineaire en niet-lineaire compartimentenmodel-
len aan bod komt, en waarin belangrijke parameters als klaring en ver-
delingsvolume worden gedefinieerd, worden de farmacokinetische eigen-
schappen van sulfonamide-diuretica onderling vergeleken. Voor wat betreft 
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chloortalidon en mefruside wordt hierbij vooruitgelopen op de resultaten 
vermeld in de volgende hoofdstukken van dit proefschrift en voor wat de 
overige diuretica aangaat, wordt geput uit recente literatuur. 
De potente lis-diuretica furosemide en bumetanide blijken zich in sterke 
mate te onderscheiden van de thiazides (waartoe ook chloortalidon, mefru-
side en andere heterocyclische verbindingen gerekend worden). Het totale 
verdelingsvolume van de twee eerstgenoemde stoffen is ongeveer 10-15 liter, 
hetgeen gering is ten opzichte van dat van de thiazides dat varieert van 
100-500 liter. De grootte van het verdelingsvolume is duidelijk gecorreleerd 
met de mate van accumulatie van deze stoffen in nier- en leverweefsel en in 
rode bloedcellen. Het verschil in de totale klaring van sulfonamide-
diuretica onderling is in het algemeen gering. Er wordt dan ook geconclu-
deerd dat de korte half waardetijd van verbindingen als furosemide en bu-
metanide louter het gevolg is van hun kleine verdelingsvolumina. Binnen de 
hele groep van sulfonamide-diuretica vertoont de duur van het diuretisch 
effect een sterke samenhang met de lengte van de halfwaardetijd. Litera-
tuurgegevens en eigen experimenten wijzen erop dat niet de plasmaconcen-
tratie van diuretica maar veeleer hun urinaire excretiesnelheid als maatstaf 
voor hun biologische werking beschouwd kan worden. 
Sectie II: Analytische methoden (hoofdstukken 2-6) 
In HOOFDSTUK 2 worden de principes van vloeistof-vloeistof extractie 
van sulfonamide-diuretica besproken op basis van de fysisch-chemische 
eigenschappen van deze verbindingen. Uit een overzicht van de analytische 
literatuur sedert 1960 blijkt dat de eerste bepalingen, gebaseerd op de 
Bratton-Marshall reactie, niet alleen als aspecifiek maar ook als ongevoelig 
gekenmerkt moeten worden. Van de huidige technieken, te weten dunne-
laag chromatografie, hoge druk vloeistofchromatografie en gaschromato-
grafie, is alleen de laatstgenoemde voorzien van voldoende gevoelige en 
specifieke detectoren om de uiterst lage plasmaconcentraties van de meeste 
sulfonamide-diuretica te kunnen meten. Hoge druk vloeistofchromato-
grafie kan wel worden toegepast op de bepaling van deze verbindingen in 
urine, omdat de concentraties hierin een factor 50-100 maal hoger zijn dan de 
plasmaconcentraties. Voorafgaande aan gaschromatografische analyse van 
sulfonamide-diuretica is wegens hun polariteit derivatisering noodzakelijk. 
Principe en toepassingen van de in ons onderzoek gebruikte extractieve 
alkyleringstechniek worden besproken, alsmede de werking van de thermi-
onische alkalizout detector, de z.g. stikstof detector. 
De gaschromatografische analyse van chloortalidon in plasma, urine en 
rode bloedcellen wordt beschreven in HOOFDSTUK 3. De gepermethy-
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leerde derivaten van chloortalidon en zijn interne standaard worden ge-
meten door middel van een stikstofdetector. Hoeveelheden van de stof tot 
een benedengrens van 10 nanogram per biologisch monster kunnen be-
paald worden met een nauwkeurigheid van 5% (relatieve standaarddevia-
tie). 
Aangezien chloortalidon sterk in erythrocyten accumuleert, en het even-
wicht van de concentraties in plasma en erythrocyten in vivo pas tussen de 
10 en 15 uur na toediening van het geneesmiddel wordt bereikt, vindt ook 
na bloedafname transport van chloortalidon naar de erythrocyten plaats. 
Door dit in vitro proces kan de oorspronkelijke plasmaconcentratie met 
meer dan 50% verminderen. Een dergelijk artefact wordt vermeden door 
het bloedmonster onmiddelijk na de venepunctie te centrifugeren en het 
plasma snel te verwijderen. In verband met de hoge concentratie van 
chloortalidon in erythrocyten is eveneens de invloed van hémolyse op de 
plasmaconcentratiemetingen onderzocht. 
HOOFDSTUK 4 is gewijd aan de kwantitatieve bepaling van mefruside 
in lichaamsvloeistoffen. Extractieve methylering bij kamertemperatuur ge-
durende 5 minuten resulteert in een volledige omzetting van mefruside tot 
het dimethylderivaat. Met behulp van een analoge interne standaard wordt 
voor concentraties tussen 10 en 250 nanogram per milliliter een meetnauw-
keurigheid verkregen van 4% (relatieve standaarddeviatie). 
Ook mefruside wordt in sterke mate in erythrocyten opgeslagen, doch de 
hiermee samenhangende analytische complicaties zijn van andere aard dan 
in het vorige hoofdstuk beschreven. Het evenwicht van de plasma- en de 
rode bloedcelconcentraties van mefruside wordt praktisch momentaan in-
gesteld, waarschijnlijk wegens de grote lipofiliteit van mefruside. De lig-
ging van dit evenwicht is echter temperatuur-afhankelijk. In bloed van 
20oC zijn de plasmaconcentraties van mefruside ca. 35% lager dan in bloed 
van 370C. Dit gegeven resulteert in een daling van de plasmaconcentraties 
van mefruside ten opzichte van de vivo waarden, indien bloedmonsters on-
der routine-omstandigheden worden afgenomen. De meting van de biologi-
sche half waardetijd van mefruside wordt echter niet beïnvloed , omdat de 
plasmaconcentratie op reproduceerbare wijze met een constant percentage 
afneemt. 
HOOFDSTUK 5 behandelt de identificatie en de kwantitatieve analyse van 
twee hoofdmetabolieten van mefruside in de mens. Deze metabolieten, het 
lacton 5-oxo-mefruside en de open-zuur analoog daarvan kunnen afhanke-
lijk van de pH van de oplossing in elkaar overgaan. Om ongewenste in 
vitro omzetting te vermijden werden optimale scheidingscondities bepaald 
door middel van een pH-partitie studie. 
Bij een pH van 7.4 wordt het lacton geëxtraheerd zonder een spoor van 
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het hydroxy-carbonzuur. Vervolgens wordt het open zuur ofwel, uit 
plasma en urine, rechtstreeks geëxtraheerd bij pH 2 ofwel, in geval van rode 
bloedcellen of volbloed, eerst omgezet tot het lacton en daarna neutraal 
geëxtraheerd. De verdere procedure is, op kleine modificaties na, analoog 
aan die beschreven voor mefruside. 
Door middel van gaschromatografie-massaspectrometrie werden beide 
stoffen als humane metabolieten van mefruside geïdentificeerd. 5-Oxo-
mefruside blijkt evenals mefruside te accumuleren in erythrocyten. 
In HOOFDSTUK 6 wordt een potentiometrische verschiltitratiemethode 
beschreven ter bepaling van de pKa van chloortalidon. Deze methode is al-
gemeen toepasbaar op farmaceutische verbindingen met een zeer geringe 
wateroplosbaarheid. Vier experimenten met chloortalidon leverden voor de 
schijnbare zuurdissociatieconstante in 0.1 M KCl een gemiddelde waarde 
van 9.24 ±0.02(± S.E.M.) bij 20oC. De thermodynamische dissociatie-
constante werd, rekening houdend met ion-aktiviteitscoëfficiënten, be-
paald op pKai = 9.35. 
Sectie Ш: Farmacokinetiek van chloortalidon (hoofdstukken 7-13) 
Het accent in HOOFDSTUK 7 ligt op de verdeling van chloortalidon 
over plasma en erythrocyten in vivo. Na orale toediening wordt de stof snel 
uit het maagdarmkanaal opgenomen en de plasmaconcentraties zijn maxi­
maal tussen 1 en 3 uur. Het transport van chloortalidon naar de rode 
bloedcellen verloopt echter traag: piekconcentraties worden eerst tussen 10 
en 15 uur na inname van de dosis waargenomen. De concentratie in rode 
bloedcellen is dan 50 tot 100 maal hoger dan die in plasma. De eliminatie-
halfwaardetijd van de erythrocytenconcentratie van chloortalidon is langer 
dan die van de plasmaconcentratie, gemiddeld respectievelijk 60 en 40 uur 
na doses van 100-200 mg aan tien proefpersonen. Een niet-lineair farmaco-
kinetisch model was noodzakelijk om deze concentratie-tijdscurven te kun­
nen beschrijven. In dit model is het element van capaciteitsbeperkte bin­
ding van chloortalidon aan rode bloedcellen ingebouwd. De toepasbaar­
heid en de beperkingen van deze benadering worden besproken en vergele­
ken met de conventionele analyse volgens een lineair compartimenten 
model. 
Ter ondersteuning van het in hoofdstuk 7 ontwikkelde farmacokinetische 
model, wordt in HOOFDSTUK 8 de binding van chloortalidon aan rode 
bloedcellen nader geanalyseerd door middel van in vitro experimenten. In 
het therapeutische concentratiegebied zijn voor intacte menselijke erythro­
cyten twee klassen van bindingsplaatsen aantoonbaar. De grotere compo-
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nent heeft een totale bindingscapaciteit van ca. 150-200/imol/liter en de schijn­
bare associatieconstante van chloortalidon is ІхІОб liter/mol (0.9-1.1x106 
1/mole). Voor de kleinere component werden waarden gevonden van 4-34 
/¿mol/liter voor de totale bindingscapaciteit, en waarden van 0.7-7x107 
liter/mol voor de schijnbare associatieconstante. De onzekerheid in de 
parameter schattingen van deze laatste component was echter groot. Der-
halve kon de identiteit van dezebindingsplaats, die op grond van literatuur-
gegevens geassocieerd zou kunnen worden met het C-isoenzym van carbo-
anhydrase, niet vastgesteld worden. De bindingsparameters van de grotere 
component daarentegen vertonen een goede overeenkomst met de bekende 
molaire concentratie van het B-isoenzym van carboanhydrase in humane 
erythrocyten en de affiniteit van chloortalidon voor het gezuiverde isoenzym. 
In HOOFDSTUK 9 wordt de absolute biologische beschikbaarheid van 
chloortalidon tabletten vastgesteld aan de hand van een vergelijking met de 
intraveneuze (i.v.) toedieningsweg. Chloortalidon concentraties in plasma, 
rode bloedcellen, urine en faeces werden gemeten gedurende 100-200 uur 
na toediening van beide dosisvormen - in een sterkte van 50 mg - aan zeven 
proefpersonen. De eliminatie-halfwaardetijd (t'/z) van de plasmaconcen-
traties na i.v. dosering was 36.5 (±10.5 S.D.) uur, en die van de erythrocy-
tenconcentraties 46.4 (±9.9 S.D.) uur. De gemiddelde t'/z na orale toedie-
ning was langer: 44.1 ( ± 9.6 S.D.) uur voor de plasmaconcentraties en 52.7 
(±9.0 S.D.) uur voor de concentraties van chloortalidon in rode bloedcel-
len. Aangezien de kortere i.v.-halfwaardetijd niet gepaard ging met een 
toegenomen renale klaring, werd aangenomen dat een niet-renaal proces 
hierbij een rol speelde. Ook de som van de hoeveelheden, die als onveran-
derd chloortalidon in urine en faeces werden uitgescheiden, wijst sterk op 
de aanwezigheid van een niet-renale en waarschijnlijk metabole eliminatie-
route: na i.v. toediening wordt gemiddeld 65.4% (±8.6 S.D.) van de dosis 
in urine en 1.3-8% in faeces uitgescheiden. Na orale toediening: 43.8% 
(±8.5 S.D.) in urine en 17.5-31.2% in faeces. Het laatste gegeven is vrijwel 
uitsluitend toe te schrijven aan onvolledige resorptie van chloortalidon uit 
het maagdarmkanaal. 
Voor de biologische beschikbaarheid van de orale dosis (F) wordt een 
gemiddelde waarde van 61% gevonden, indien de plasmaconcentratie-
metingen als maatstaf worden genomen. Uit urinemetingen resulteert een F 
van 67%, en uit meting van de rode bloedcelconcentraties een F van 72%. 
Met behulp van berekeningen volgens het in hoofdstuk 7 beschreven niet-
lineaire chloortalidon-model wordt aannemelijk gemaakt dat de schatting 
van F systematisch zo'n 10% te hoog uitvalt bij gebruik van rode bloedcel 
gegevens. Derhalve is het gemiddelde van de plasma- en urinemetingen, 
F = 64%, als de meest betrouwbare waarde te beschouwen. 
283 
De uitscheiding van chloortalidon in de urine wordt in detail besproken 
in HOOFDSTUK 10. Na orale toediening van enkelvoudige doses van 50 
mg aan zes, 100 mg aan elf, en 200 mg aan zes proefpersonen verloopt in 
alle gevallen de renale excretiesnelheid van chloortalidon als functie van de 
tijd parallel aan de plasmaconcentratiecurve. Dit impliceert dat er geen 
concentratie-afhankelijke verzadiging van het tubulaire secretiesysteem 
van de nier is opgetreden. Overigens is de urinaire excretiesnelheid onder-
hevig aan grote fluctuaties over de tijd. Deze zijn echter niet toe te schrij-
ven aan veranderingen in urine-flow of urine-pH, omdat de renale klaring 
van chloortalidon van de urine-flow niet, en van de urine-pH nauwelijks 
afhankelijk blijkt te zijn. 
Het totale percentage van de dosis dat als onveranderd chloortalidon in 
de urine wordt uitgescheiden is dosis-afhankelijk: 44% (±7 S.D.) en 43% 
( ± 5 S.D.) na toediening van 50 en 100 mg respectievelijk, en 29% ( ± 5 
S.D.) na 200 mg. Een verminderd resorptiepercentage van de hoogste dosis 
werd op grond van faeces-analyses onwaarschijnlijk geacht. De andere 
mogelijke oorzaak, een verandering van de renale klaring, kon niet met 
zekerheid vastgesteld worden aan de hand van de hele groep proef-
personen, wegens de grote interindividuele variatie in deze parameter, bijv. 
43-106 ml/min na de 100 mg dosis. Bij twee van de drie proefpersonen ech-
ter, die zowel 50, 100 als 200 mg chloortalidon hadden ontvangen, was de 
gemiddelde renale plasmaklaring van chloortalidon na de 200 mg hoeveel-
heid meer dan 25% lager dan die waargenomen na de 50 en 100 mg doses. 
Mogelijke implicaties van deze observatie worden bediskussieerd. 
De uitscheiding via de galwegen als aandeel in de totale klaring van 
chloortalidon wordt behandeld in HOOFDSTUK 11. Zes galsteenpatiënten 
met ongestoorde nier- en leverfunctie ontvingen, 3-4 dagen na operatieve 
verwijdering van hun galblaas, een eenmalige dosis van 100-200 mg. De 
renale excretie van chloortalidon in deze groep was volledig vergelijkbaar 
met die gevonden in normale proefpersonen. De uitscheiding van het genees-
middel in de gal was zeer gering, nl. 0.6-1.4% van de dosis gedurende 3-7 
dagen. De conclusie luidt dat bij de mens galuitscheiding normaal gespro-
ken geen belangrijke eliminatieroute voor onveranderd chloortalidon is. 
Behandeling van gal- en urinemonsters met /3-glucuronidase en arylsulfa-
tase gaf geen verhoging van de daarin aanwezige chloortalidonconcentra-
ties. Ook de open-zuur analoog van chloortalidon, die in de literatuur als 
metaboliet was gesuggereerd, bleek niet aantoonbaar te zijn. 
HOOFDSTUK 12 heeft de relatie tussen de concentraties van chloor-
talidon in speeksel en plasma als onderwerp. Na toediening van een intra-
veneuze dosis van 50-60 mg aan drie proefpersonen, werden plasma- en 
speekselmonsters verzameld gedurende 100 uur. De verhouding van speek-
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sel- (S) en plasmaconcentraties (Ρ) bleek niet constant te zijn. Zowel tussen 
de individuen als binnen iedere proefpersoon waren de variaties groot: de 
per persoon gemiddelde S/P ratio's waren: 0.35 (±0.16 S.D.), 0.23 (±0.12 
S.D.) en 0.12 (±0.03 S.D.). De conclusie luidt dat speekselvocht niet als 
vervanging kan dienen van bloedmonsters ter verkrijging van farmacokine-
tische gegevens van chloortalidon, althans niet na enkelvoudige dosering. 
De farmacokinetiek van chloortalidon bij chronische medicatie staat 
centraal in HOOFDSTUK 13. De proefopzet was de volgende: aan een 
patiënt met lichte hypertensie werden achtereenvolgens enkelvoudige en 
herhaalde doses van zowel 50 als 100 mg chloortalidon toegediend, over 
een totale tijdsduur van 90 dagen. Het experiment met de enkelvoudige do-
ses was nodig ter verkrijging van kinetische basisparameters om de accu-
mulatie van de concentraties na chronische toediening te kunnen voorspel-
len. Conform de concentratie-afhankelijke verdeling van chloortalidon 
over plasma en erythrocyten, zoals die beschreven is in de hoofdstukken 7 
en 8, mocht verwacht worden dat de werkelijk gemeten concentraties tij-
dens de steady-state beduidend lager zouden zijn dan de volgens een lineai-
re kinetische analyse voorspelde waarden. De resulterende gemiddelde mi-
nimum steady-state concentraties (Cmin ss) waren: tijdens de periode 
waarin 50 mg chloortalidon per dag werd toegediend: plasma Cm¡n,ss 
voorspeld 0.14 /tg/ml, gevonden 0.12 /tg/ml; erythrocyten Cm jn > s s voor-
speld 15.5 /tg/ml, gevonden 8.9 jwg/ml. Tijdens de periode met 100 mg 
chloortalidon per dag: plasma Cmin,ss voorspeld 0.34 /tg/ml, gevonden 
0.20 μg/nú·, erythrocyten Cmin>ss voorspeld 34.3 /tg/ml, gevonden 17.1 
¿tg/ml. Deze waarnemingen zijn volledig in overeenstemming met een capa-
citeitsbeperkte binding van chloortalidon aan erythrocyten. 
Op het concentratieplateau bedroeg de 24-uurs urineuitscheiding van 
chloortalidon gemiddeld 38.2% (±5.1 S.D., n=10) van de dosis tijdens 
het doseringsschema van 50 mg per dag, en 47.5% (±5.3 S.D., η = 10) 
tijdens toediening van 100 mg per dag. Mogelijke oorzaken voor dit signifi­
cante verschil worden aangegeven. 
Sectie IV: Farmacokinetiek van mefruside (hoofdstukken 14 en 15) 
De opname in het lichaam, de verdeling erover, de metabole omzetting 
en de renale uitscheiding van mefruside zijn de onderwerpen van de studie, 
die beschreven is in HOOFDSTUK 14. Deze processen werden geanaly­
seerd door middel van plasma-, rode bloedcel- en urineconcentratiemetin-
gen na orale toediening van een dosis van 25 of 50 mg aan acht normale 
proefpersonen. Bij vier personen uit deze groep werden bovendien de con­
centraties van twee aktieve metabolieten van mefruside gemeten, namelijk 
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van 5-oxo-mefruside (mefruside-lacton) en van de hydroxy-carbonzure 
structuuranaloog daarvan. De resultaten laten zich als volgt samenvatten: 
Mefruside wordt snel uit het maagdarmkanaal opgenomen met een ge­
middelde absorptie-t!/2 van 0.5 uur. De eliminatiesnelheid van mefruside 
verschilt sterk van individu tot individu: de t Vi -waarden varieerden van 
2.9-12.5 uur. Deze variatie weerspiegelde zich in de totale plasmaklaring, 
waarvoor waarden van 20-130 liter/uur werden gevonden. Het totale ver­
delingsvolume van mefruside daarentegen vertoonde minder spreiding 
(300-500 liter). Dit grote verdelingsvolume kan voor een belangrijk deel op 
rekening geschreven worden van de binding van mefruside aan erythrocy-
ten. De erythrocytenconcentraties van de stof zijn gemiddeld 30 maal hoger 
dan de plasmaconcentraties. De instelling van het evenwicht tussen de con­
centraties in beide bloedfracties geschiedt praktisch momentaan, zodat uit 
de concentratiemetingen van mefruside in plasma en erythrocyten dezelfde 
eliminatie-halfwaardetijd resulteert. Ook de renale excretiesnelheid van 
mefruside als functie van de tijd verloopt in alle gevallen parallel aan de 
plasmacurve. De totale hoeveelheid die als onveranderd mefruside in de 
urine wordt uitgescheiden is echter gering, namelijk gemiddeld 0.5% ( ± 0.3 
S.D.) van de dosis. 
De metaboliet 5-oxo-mefruside was al kort na toediening van mefruside 
meetbaar in de rode bloedcellen. In plasma waren noch 5-oxo-mefruside 
noch de open-zuur metaboliet detecteerbaar, maar hoge concentraties van 
beide stoffen werden aangetroffen in urine. In totaal werd ca. 70% van de 
dosis als metaboliet in de urine teruggevonden, waarvan gemiddeld 46% 
(35-54%) als het hydroxy-carbonzuur, 13% (12-14.5%) als het lacton en 
5-15% als conjugaat van het open zuur. De renale excretie van het lacton 
en het open zuur werd maximaal tussen 5-10 uur na toediening van mefru­
side. De eliminatie-halfwaardetijd van beide metabolieten was langer dan 
de і г van mefruside en er was nagenoeg geen interindividuele variatie in 
deze grootheid: det!/2 van het lacton was gemiddeld 11.9 uur (± 1.7 S.D.), 
en de VA van de open zuur metaboliet 10.5 uur (±1.6 S.D.). 
Er wordt geconcludeerd dat het renale excretiepatroon van beide meta­
bolieten zeer goed correspondeert met de diuretische werkingsduur van 
mefruside bij de mens en dat niet het mefruside zelf maar zijn metabolieten 
als de therapeutisch werkzame verbindingen beschouwd moeten worden. 
HOOFDSTUK 15 beschrijft enige inleidende onderzoekingen naar de 
diuretische aktiviteit van de in hoofdstuk 14 aangetoonde hoofdmetabolie-
ten van mefruside. Geïsoleerde rattenieren werden geperfuseerd met een 
kunstmatige perfusievloeistof die hetzij mefruside, dan wel 5-oxo-mefruside 
of de hydroxy-carbonzure analoog daarvan bevatte. De open-zuur verbin-
ding gaf een consistent diuretisch effekt in twee experimenten, 5-oxo-
mefruside was aktief in één van de twee proeven, maar mefruside was in 
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geen van de drie experimenten effektief. Deze voorlopige gegevens 
ondersteunen de bevinding dat aktieve metabolieten van mefruside het 
diuretisch effekt van deze stof bepalen. 
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STELLINGEN 
I 
In tegenstelling tot hetgeen bij andere groepen geneesmiddelen het geval 
is, is de biologische werking van sulfonamide-diuretica niet zozeer van 
de hoogte van de plasmaconcentratie als wel van de mate van renale 
excretie van deze verbindingen afhankelijk. 
Dit proefschrift. 
II 
Het natriuretisch effekt van mefruside bij de mens wordt niet door de 
stof zelf, maar door aktieve metabolieten veroorzaakt. 
Dit proefschrift. 
III 
De gebruikelijke dosering van een aantal in Nederland veel voor-
geschreven diuretica ter bestrijding van hoge bloeddruk kan, mèt 
behoud van de therapeutische werking en met vermindering van bij-
werkingen, op z'n minst gehalveerd worden. 
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Uit educatief oogpunt verdient het gebruik van tijdsconstantes in farma-
cokinetische studies de voorkeur boven de in de literatuur frequent 
gehanteerde snelheidsconstantes. 
ν 
Het boek van Smith over de galexcretie van farmaca zou aan waarde 
hebben gewonnen indien bij de evaluatie van de humane studies de 
afwijkende fysiologie van galsteenpatiënten in aanmerking zou zijn 
genomen. 
Smith, R.L.: The excretory function of bile. London: Chapman and Hall 
1973. 
VI 
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VII 
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het bestaan van twee of meer onafhankelijke bindingsplaatsen gehan­
teerd mag worden. 
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Greenlee, D.V., Van Ness, P.C., Olsen, R.W., Life Sci. 22, 1653-1662 (1978). 
VIII 
Evenals dit bijvoorbeeld voor een geschiedschrijver geldt, kan ook een 
biochemicus zich beter onthouden van een opzienbarende bewering, die 
bij nader onderzoek niet steekhoudend blijkt te zijn. 
Anderson, R.E., Maude, M.В., Arch. Biochem. Biophys. 151, 270-276(1971). 
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IX 
Gezien de klinische effekten van diazoxide, te weten water- en zout-
retentie, en gelet op de experimentele condities van het onderzoek van 
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χ 
De lever wordt ten onrechte nog te vaak bestudeerd als een systeem dat 
geïsoleerd kan worden van neuronale sturing vanuit de hersenen. 
Sawchenko, P.E., Friedman, M.I., Am. J. Physiol. 236 (1), R5-R20 (1979). 
XI 
De poging van Campbell et al. het diureticum Indapamide als anders 
dan andere sulfonamide-diureticate classificeren op grond van het renale 
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Campbell, D.B., Taylor, A.R., Hopkins, Y.W., Williams, J., Curr. Med. Res. 
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XII 
Aan sommige plasmacurves valt geen τ vast te knopen. 
XIII 
Wachtkamers van ziekenhuizen en tandartsenpraktijken zouden minder 
afschrik wekken, indien bij de inrichting ervan meer kennis van de 
kleurenpsychologie was toegepast. 
XIV 
De spelling van het woord oligarchie lijkt wel verouderd. Beter ware: 
oliegarchie. 
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